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The protracted duration of standard tuberculosis (TB) therapy suggests the inadequacy of current first-
line TB drugs to eliminate the causative agent Mycobacterium tuberculosis (Mtb). Among multiple 
potential causes, this may be due to poor distribution of TB drugs into the pulmonary lesions in which 
the bacilli reside. In attempting to explore this possibility, the study described here aimed to assess 
selected novel compounds (phenoxazine, artemisinin, and decoquinate derivatives) proposed to 
induce redox-cycling in efficacious combinations, as well as their distribution to TB-relevant lesions, 
for potential clinical use against TB.  
To this end, specific in vitro absorption, distribution, metabolism, and excretion (ADME) assays were 
performed to predict the abilities of the compounds to penetrate different TB microenvironments. 
Penetration into murine blood and organs was assessed via pharmacokinetic (PK) profiling. 
Complementary analyses involving murine epithelial lining fluid allowed for more detailed analyses of 
the potential of these novel compounds to penetrate the deeper recesses of the lung. In order to gain 
a greater understanding of the potential efficacy of the compounds in an intracellular environment, 
THP-1 macrophage-like cells were infected with Mtb, treated with anti-TB agents, and sampled at 
different time-points. Samples were analyzed via liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) assays and drug concentrations were determined and related to efficacy measurements 
using colony forming unit counts. Promising combinations of novel drugs were identified in a two-
dimensional synergy assay; these combinations showed synergistic activity in the infected 
macrophage model.  
The compounds showed marked differences in their abilities to accumulate within infected 
macrophages. Differential uptake was also indicated by the results of the PK studies involving murine 
blood and organ uptake, and the in vitro ADME assays. These results enable PK modelling on the 
putative drug target to be carried out, allowing for the determination of more accurate dosing. In 
addition, results indicate the need for further studies, including investigations of the impact of 
macrophage structural organisation (three-dimensional model) on compound efficacy and in vivo 
studies in a relevant mouse model of TB disease. The identification of a potentially efficacious two-
drug combination which might penetrate to the site of pulmonary TB supports the utility of this 
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1. Literature review - drug discovery at the unit of infection 
1.1 Understanding the unit of infection in the context of drug discovery 
1.1.1 Introduction  
Tuberculosis (TB) remains a leading cause of death owing to an infectious disease1 despite the 
existence of multiple front-line and second-line drugs2 that are active against Mycobacterium 
tuberculosis (Mtb), its etiological agent.3,4 Accordingly, the World Health Organisation (WHO) has 
taken a strong stance against TB, aiming to eliminate the disease by 2035, necessitating an annual 
decrease in TB disease of 17%, from the current value of 1.5%.5–7 This task is made particularly 
challenging in the South African context with approximately only 53% of individuals who have TB 
acquiring successful treatment, indicating the lack of implementation of existing policies in diagnosis, 
treatment initiation, and subsequent treatment completion.8,9 A critical limitation of the current anti-
TB regimen is that it involves a minimum of six months of combination therapy, a requirement thought 
to reflect the inability of the existing drugs to sterilize bacilli located in different host 
microenvironments and in variable metabolic states, often resulting in clearance of bacilli from 
sputum followed by subsequent disease relapse.10–12 Consequently, rational approaches to addressing 
this problem are urgently needed as they might offer the prospect of elucidating (at least partially) 
the reasons for the often described difficulty in translating compound potency in vitro into drug 
efficacy in vivo13 – and, in turn, could inform the choices of chemical properties and screening assays 
to be prioritized in the critical-path algorithms that drive medical chemistry efforts as part of new TB 
drug discovery.14 
A seminal review15 highlighted the absence of knowledge about the distributions of widely used anti-
TB agents into the pulmonary lesions in which infecting bacilli are sequestered and, therefore, the 
need to understand how individual compounds distribute into the different host cell 
environments.16,17 In order to reach its mycobacterial target, an anti-TB antibiotic must penetrate 
complex host lesions and lesion compartments comprising multiple cell types.14,15,18 For intracellular 
bacilli, the drug must also overcome the barrier of the host cell wall and, in many cases, an 
encapsulating vesicular membrane, as well as potential sequestration by the different organelles and 
intracellular bodies within different cell types.19,20 The occupation of discrete host loci21–23 presents an 
additional confounder (Figure 1.1), in that individual bacteria from a clonal infecting population are 
characterized by different physiological states, and this can impact drug susceptibility,19,24,25 and the 
ability of the drug to penetrate the complex mycobacterial cell wall,26 as well as subverting the active 





Figure 1.1. The complexity of targeting M. tuberculosis bacilli in an infected host. After administration 
of drug to a patient, the drug passes from the bloodstream into the lung tissues, diffusing into the lung 
fluid. The drug must then penetrate the granulomatous structure and enter the various cellular 
microenvironments in which bacilli can be sequestered. There are a number of processes that affect 
drug efficacy in this microenvironment including, but not limited to: (i) drug metabolism and 
biotransformation, (ii) binding to various cellular components and lipids, (iii) differences in local 
cellular drug concentrations giving rise to potential drug-resistant bacteria, (iv) compound-specific 
differences in the permeation of drug into the macrophage or cellular environment, (v) bacterial- and 
cell-mediated drug efflux, and (vi) differences in intracellular pH leading to in-/activation of the drug 
 
As if that were not already sufficiently complex, host-mediated29,30 and/or mycobacterium-
mediated31,32 biotransformation may further complicate the passage of drug from ingestion by the 
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patient to its intrabacillary target.15 Although some guiding principles have been inferred from both 
pre-clinical and clinical observations in TB as well as other diseases, the physico-chemical and 
pharmacological properties that enable drugs to navigate this complex delivery pathway, avoid host 
metabolism, and penetrate the bacillus remain poorly understood.14,15,33 It is not surprising, therefore, 
that active compounds selected (and optimized) for potency in a handful of in vitro assays often fail 
to demonstrate activity in vivo in the infected host.34 
Therefore, the initial intent of this thesis was to obtain a thorough understanding of how drug 
concentrations affect Mtb within the intracellular environment and moreover, how we could 
accurately measure these target site concentrations. This is discussed in the initial part of the literature 
review in the context of anti-TB drug discovery. Of equal importance, is the need to provide the most-
appropriate drug or combination of drugs for the particular Mtb-associated microenvironment. For 
this reason the second thrust of this thesis was to use the knowledge of the various intracellular 
subtleties associated with Mtb to develop a treatment regimen which potentiates antimycobacterial 
activity. This was investigated using compounds which exert their anti-Mtb activity utilizing the 
proposed ubiquitous mechanism of action of reactive oxygen species (ROS) upregulation. This is 
discussed in the second portion of the literature review.  
During the last decade we have seen considerable efforts towards developing accurate methods 
(Table 1) to measure drug levels directly in Mtb-infected tissues.35–37 Through the application of 
advanced chromatographic, mass spectrometry (MS), and imaging techniques including high 
performance liquid chromatography (HPLC) coupled to tandem MS (LC–MS/MS) and matrix-assisted 
laser desorption ionization mass spectrometry imaging MALDI–MSI, the quantification of tissue and 
lesion distribution of known and experimental anti-TB drugs in animal models and clinical samples has 
become increasingly attainable, primarily through the work of Veronique Dartois and 
colleagues,11,15,16,36,38 thus offering the prospect of informing a systems pharmacology approach to the 
design of antimycobacterial therapy.39 In addition to the well-established appreciation that TB drugs 
can be differentially active against bacilli in different metabolic states,40–42 these new analytical 
techniques have demonstrated that those same drugs can also possess distinct lesion-penetrating 
abilities.14,15,17,26 Moreover, in many cases, tissue penetration appears to correlate well with the 
demonstrated activity of specific drugs in vivo,17 for example, the ability of pyrazinamide (PZA) to 
diffuse through the necrotic areas at the center of mature granulomas is consistent with its sterilizing 
ability in the TB regimen.15 This is a critical observation, which prompted the prediction that “the next 
major step towards curing TB and preventing the development of resistance will come from a 
combination of complementary drugs, each of which preferentially distributes in the lesion or lesion 
compartment where its most vulnerable target bacterial population resides.”15 That is, future 
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combination therapies for TB should be based on multidrug regimens optimized according to the 
specific activities and tissue distributions of each constituent drug. 
Table 1.1 Methods to measure intracellular drug concentrations 







analysis to quantify 
fluorescence signals 
from molecules or 
compounds 
Allows temporal and 
physiological studies of 
drugs in various 
microenvironments 
Few drugs fluoresce above 
background detection limit; 
incorporation of 
fluorescent tag or “click 
chemistry”-enabled 
fluorescent derivatization 
not always feasible 
Raman microscopy 48–50 Light scattering 
through change in 
polarization potential 
or vibrational energy 
Shortened data 
collection time for high-
throughput analyses; 
can provide indications 
of the cellular state of 
Mtb and host cells 
Can only be applied to 
biological systems with 
lower excitation energy  
Nuclear microscopy 51–53 Uses ion microbeam 
with particle-induced 
X-ray emission 
Used as a quantitative 
standard to 
complement MRI in 
animal or human 
studies where tissues 
may be removed after 
imaging 
Not widely accessible 





Exposure or tagging 
using radiolabel and 
confocal microscopy 
Coupling this technique 
to fluorescence in situ 
hybridization allows 




material and extensive 






collides with local 
electron, produce 
photons and these are 
detected by ƴ-
detectors 
Can be coupled to other 
techniques such as 




Expensive owing to 




Analysis by mass 




MS analysis coupled 
to HPLC 
Allows for intracellular 
drug concentrations to 
be calculated using PK 
approach 
Long sample processing 
times and extensive 
optimization steps, bulk 
analysis can cause loss of 










Allows temporal and 
spatial resolution of 
drug distribution in 
different organs 
Difficulty in determining 
whether analyte is truly 
absent or simply below 




1.1.2 Probing the unit of infection: the Mtb-infected macrophage 
Developing comprehensive rules for targeted TB drug delivery necessitates concerted research efforts 
to elucidate the various factors that influence host tissue penetration and bacillary permeation. From 
a drug discovery perspective, the ability to assess rapidly whether a putative hit compound possesses 
the required characteristics would profoundly impact the efficiency of development pipelines by 
ensuring that medicinal chemistry, pharmacology, and biology resources and expertise are applied 
only to the most promising candidates. However, as noted elsewhere,15,65 this is critically dependent 
on the development of medium-throughput in vitro assays for intralesional (e.g., necrotic foci or 
caseum,19 intrabacillary,41 and intra-macrophage66) PK determinations that can be readily integrated 
into lead compound discovery and lead compound optimization campaigns. 
Mtb is sequestered in multiple different host compartments during infection,10,17,37 including cellular 
granulomas, in which bacilli are located predominantly within macrophages but also in some 
extracellular niches, necrotic granulomas, where they are extracellular in the caseous centers and 
considered metabolically quiescent,67 and the inner surface of open cavities, where bacilli occur within 
multiple cell types while some are extracellular,68,69 an environment in which they are protected from 
the immune system and able to replicate freely.70 There is even evidence that bacilli can reside in cells 
in distal loci of the lung71 and in other organs.72–74 These observations corroborate the suggestion that 
TB disease should be treated as a polymicrobial infection,75 and simultaneously reinforce the 
complexities inherent in determining the factors that might be essential to ensure optimal drug 
exposure for extended durations. From a drug development perspective, they also highlight a major 
obstacle to defining the optimal pre-clinical assays to be used in selecting compounds for 
advancement through the discovery pipeline. 
How does the microenvironment in which Mtb persists influence compound penetration and 
permeation? Current anti-TB chemotherapy may cause bacilli to revert to a drug-tolerant phenotype, 
which may explain the difficulty in achieving complete bacterial clearance.76,77 Therefore, more 
research is needed to understand the mechanism(s) by which exposure to these compounds might 
force the exposed bacilli into a different metabolic state.78 It is well-established that a biphasic 
reduction in bacterial load is observed under current anti-TB therapy,40 a phenomenon that has been 
explained by two models: (i) the killing of actively dividing bacilli in an initial rapid killing phase, 
followed by the gradual decrease in the persistent population of bacteria, or (ii) the lack of treatment 
of bacterial populations due to the inaccessibility of bacteria within granulomas.79 Adding a further 
layer of complexity is the fact that bacteria exist within both intra- and extracellular environments,80 
an observation that is exacerbated by the knowledge that these lesions are very heterogeneous, often 
differing even within the same patient.11,22 
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As noted elsewhere,81 the immunological lifecycle82 of TB disease involves multiple stages at which 
the interaction between host macrophage and invading pathogens might be critical to the outcome 
of infection.10,67,83 That is, the ability of Mtb to survive and replicate within the macrophage is a 
defining feature of mycobacterial pathogenesis.84 This observation has motivated a longstanding 
interest in understanding the dynamics of the host-pathogen interaction within this phagocytic 
cell,38,80,83,85 as well as efforts to understand the factors that might undermine therapeutic 
outcomes.25,86 It has also underpinned the use of alternative screens to identify compounds active 
against bacilli in this intracellular environment,87–90 as well as approaches to understand the impact of 
the intracellular environment on drug partitioning and how this knowledge might be exploited for 
rationale drug and drug regimen design.66,91–93 The perceived centrality of the host macrophage in 
infection outcomes94–96 has also been key to the use of standard mouse models as distinct from the 
“Kramnik” or C3HeB/FeJ model37,97 in pre-clinical efficacy assessments.98 Therefore, while cultured 
cells in vitro do not fully replicate the specialist functional properties of differentiated macrophages 
in vivo,10,99 with their diverse ontogenies and differential trajectories of activation and development,100 
the utility of the macrophage model in inferring disease-relevant mycobacterial physiological and 
metabolic adaptations, as well as innate host defense strategies, seems convincing.10,81,101 This notion 
is perhaps best summarized in the concept that the Mtb-infected macrophage represents the 
“minimal unit of infection”,80 a term that encapsulates critical concepts in immunometabolism 102 and 
pathometabolism.103 
The concentration that any drug achieves within its target (myco) bacterial cell is a function of multiple 
factors, including passive or active uptake, pathogen-mediated metabolism, active drug efflux, and 
cell growth.104 Mycobacterial drug uptake is generally encapsulated in the concept of “permeation”. 
The complex mycobacterial cell wall is thought to function as an impermeable barrier to most 
compounds and undergoes dynamic architectural modifications during infection that correlate with a 
switch from active replication to a persistent state.26,105 Moreover, the mechanisms that enable many 
of the known anti-TB drugs (in particular, small hydrophilic compounds like isoniazid (INH), 
ethambutol (EMB), and cycloserine to permeate the lipid-rich mycobacterial cell wall remain 
unknown.106 Mtb also possesses an expanded complement of efflux pumps33,107,108 that have been 
implicated in intrinsic resistance to applied drugs in vitro109,110 and in experimental models of 
infection.111 Moreover, growth within THP-1 and J774 macrophages has been shown to induce Mtb 
efflux pump activity,112 resulting in tolerance to rifampicin (RIF) and other drugs mediated by the efflux 
transporter Rv1258c.112,113 As highlighted elsewhere,15 this is an important observation since it 
supports the need for in vitro assays to determine (and ultimately predict) drug distributions within 
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immune cells such as macrophages, as well as the sub-cellular organelles in which the bacterium might 
be contained. 
 
1.1.3 The prevailing drug discovery paradigm 
It is generally acknowledged that, in order to understand how a drug will respond in the human body, 
the PK/pharmacodynamic (PD) parameters in various tissues and cells must be understood fully.11,38,75 
The propensity for Mtb to occupy different microenvironments at the same time within an infected 
host21–23 makes it essential that new combination regimens comprise partner drugs that are active in 
the various microenvironments and, potentially, have the ability to modulate permeability of the 
mycobacterial cell.114 
Anti-TB drug discovery often begins with a basic screen against replicating Mtb, followed by 
subsequent cytotoxicity screens to determine the compound selectivity against the pathogen.45 This 
allows high-throughput screening whilst identifying potential candidates with initial activity against 
replicating bacteria,45 but neglects aspects such as intracellular compound activity, membrane 
permeability, involvement of efflux, and metabolism of the compound.115 The use of a standard 
growth medium alone ignores the metabolic changes that Mtb undergoes when in the host cell 
environment, and could influence compound efficacy:116 the evidence is strong that the metabolic 
status of the bacterium is a function of the host environment.81,117 Therefore, the active compounds 
that emerge from in vitro screens are likely to be active only under specific conditions.118 For example, 
amikacin displayed potent activity in initial screens against extracellular bacteria, but little to no 
activity against intracellular Mtb.119 
Next, the PK parameters of the compounds are assessed using in vitro or in vivo absorption, 
distribution, metabolism, and excretion (ADME) studies. In the simplest sense, the ADME parameters 
for a compound in combination with the dose of the drug determine the time course, concentration 
in serum, and consequently, the tissues and fluids. The PD parameters relate drug concentration with 
the observed antimicrobial effect. The PK/PD characteristics of a drug have implications for dosing, 
clinical efficacy, and the combinatorial drug classes that can be used to treat TB.120 Summary exposure 
parameters, such as area-under-the-concentration-time-curve (AUC) and peak concentration (Cmax), 
are often used in combination with PD parameters, such as minimum inhibitory concentration (MIC). 
The PK/PD relationship for TB drugs is established in the literature between AUC or Cmax (adjusted for 
MIC) and/or time above a certain concentration threshold (T>MIC), with many of the first-line TB drugs 
described by AUC/MIC and some of the newer compounds best described by T>MIC.30,121 Convincing 
arguments can be made to justify using AUC/MIC to allow for penetration in the lesions or other “hard 
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to reach” compartments/tissues in the body, or saturation of efflux pumps. Similar arguments can be 
made for the use of T>MIC to avoid the concentration falling below the threshold at which Mtb is able 
to start replicating, possibly leading to resistance if low drug concentrations are present.  
As discussed, for TB the PK/PD relationship is complicated by the fact that the PK is generally measured 
in plasma in clinical trials, but the majority of bacilli are sequestered in other compartments into which 
the drugs may not readily penetrate. Therefore, the PK profile in these regions is likely to be different 
from that measured in plasma. A reasonable PK/PD modeling approach in such cases is to use a 
hypothetical "effect compartment"122,123 mimicking the concentration at the site of action which, 
while dependent on the concentration in plasma, is “delayed” by the drug traversing through the 
numerous layers of biological tissue, thus significantly smoothing out peak and trough concentrations. 
Also, the time over a certain concentration would be very different in this effect compartment. The 
best proxy for concentration at the site of action is plasma AUC since the ratio between the average 
concentrations would remain the same, and AUC is closely related to average concentrations in the 
plasma. In the literature, some results from clinical and in vitro data report the superiority of Cmax/MIC 
versus AUC/MIC for prediction of clinical efficacy,124,125 however this should be interpreted with care 
since it is very difficult to discriminate which of these PK exposure parameters is most closely related 
to outcome in the clinic - especially when the only available data are derived from observational 
clinical studies where all patients are on a similar dosing regimen. Without targeted studies of dose 
fractionation (when the same total dose is given in a single or multiple dosing events), Cmax and AUC 
are generally strongly correlated and difficult to separate.126 Comparing the two parameters, Cmax data 
can also be variable, even on a daily basis, and this should also be considered when interpreting PK/PD 
results. The variability will result in a Cmax that fluctuates considerably as the determination of this 
parameter is based on a single sample. AUC may also change but is generally more stable due to the 
parameter being determined by an entire PK profile. Therefore, the use of AUC/MIC might better 
predict the outcome of clinical efficacy in diseases such as TB which have sites of action that are 
disparate from the plasma. Although the best PK/PD values would be derived from target site 
concentrations, these are often difficult to access.127 
 Importantly, drugs display varied and distinctive PK/PD relationships that can influence their 
activity.128,129 The main patterns include bacterial killing based on maximum drug concentration 
(Cmax/MIC), total exposure over a certain time period (AUC/MIC), or time above MIC (T>MIC).130 
Notably, these parameters have been experimentally determined using multiple approaches, 
including the ex vivo hollow fibre model, which allows for the recapitulation of the different bacterial 
populations and their corresponding PK/PD responses. Applying this technique, Gumbo and 
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colleagues were able to predict the inability of moxifloxacin (MXF) used at WHO-recommended doses 
to improve clinical outcomes significantly in a series of drug trials. 131–136 
 
1.1.4 Potential for a paradigm shift 
Many anti-TB drugs were discovered before the routine use of PK/PD analyses, a problem that 
continues to impair correct drug dosage today, as exemplified by the case of RIF,137 for which recent 
studies are highlighting the benefits of using a larger dose than has been employed in the last decades. 
Although plasma and tissue PK analyses are routinely used in drug discovery,138 they may not reveal 
the entire picture owing to the complex nature of TB lesions and the difficulty faced for a drug to 
access, and then penetrate, the infecting bacilli. This is further complicated by the avascular nature of 
necrotic lesions, where the relationship between plasma and target site drug concentrations is even 
more difficult to predict.15 PK within the human setting can be spatially unique and the heterogeneous 
nature of both the bacterial and lesion phenotypes leads to increased complexity.139 
This complexity is shown in the use of RIF in first-line anti-TB therapy. The current dosing of RIF (10 
mg/kg daily) is sub-optimal for TB, with some studies suggesting that significantly higher doses are 
needed for more effective treatment.140 Moreover, the problem persists in vulnerable population 
groups, with Sub-Saharan individuals (primarily in South Africa and Malawi) displaying reduced drug 
exposure.121,141 This often places individuals below the recommended target concentrations, 
potentially exposing them to increased burden of disease, the development of resistance, and risk of 
mortality.142,143 Many of the problems associated with RIF stem from a poor underlying understanding 
of dosing requirements in combination with other first-line treatments. Interestingly, MXF has been 
shown to be antagonistic with most antibiotics, including RIF and pretomanid.144,145 This knowledge, 
in conjunction with the deficiency of MXF in penetrating different lesions types,35,146 could explain the 
recent failed drug trials.147,148 Given the cellular concentrations of these first-line drug combinations, 
it may have been possible to predict their efficacy before commencement of the trials. 
A series of studies conducted between 1950 and the 1980’s showed that concentrations of INH and 
RIF are far lower in TB lesion homogenate than in the plasma of infected patients,149,150 a finding that 
was confirmed in MALDI studies.35 Despite the increasing appreciation that the activity of antibiotics 
depends on their ability to reach and accumulate in lesions, there is a continued reliance on blood and 
plasma levels to drive drug discovery.151,152 In various other diseases, target areas and plasma levels 
are often quite closely related, which leads to predictable and reliable plasma PK/PD values, even 
when using plasma exposure as a PK target.153 However, owing to the complex nature of TB pathology, 
blood supply is often absent and free drug has difficulty in entering the different lesion compartments 
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homogeneously. Drug PK/PD relationships are therefore extremely difficult to determine, particularly 
for newer drugs. So, while plasma PK measures still offer some value for many diseases, these 
determinations need to be repositioned in the TB drug discovery pipeline and factored in with new PK 
analyses at the target site. Using the technologies available today (Table 1), it is possible to evaluate 
PK/PD properties at the cellular level.139  
The use of in vitro macrophage culture to represent Mtb’s intracellular environment has shown some 
success with the identification of compound Q203.118 Similar assays have been undertaken in various 
cell types including mouse-derived macrophages and epithelial cells, with a limited number of studies 
having used cell lines such as the human-derived THP-1 macrophage-like cells.90,154,155 Progress in the 
use of metabolomics to obtain PK/PD information from treated mycobacterial cells156,157 has been 
especially useful in determining the systems-level impact of drug treatment on Mtb physiology, and 
has the capacity to provide key insights into the mechanisms of action of new156,158 and even 
known157,159,160 anti-TB drugs. However, while the effective intra-bacterial concentration is critical to 
efficacy, for most drugs the identity of the active metabolite(s) remains unknown. It is likely, therefore, 
that in addition to revealing intracellular modes of action of known drugs, analyses of active drug 
metabolites generated via host- or Mtb-mediated biotransformation could identify new targets.15 
Metabolism alone does not always account for the disappearance of drug during PK/PD analyses: 
instead, this can be a multifactorial phenomenon, involving the binding of drugs to macromolecules 
such as plasma proteins161 and binding to lower molecular-weight targets such as the oxidative stress 
protectants glutathione (GSH) and mycothiol (MSH).162 The phagolysosome in which these molecules 
must function undergoes significant pH changes in response to interferon gamma (IFNƴ)-dependent 
macrophage activation, decreasing from a pH of 6.2 to approximately 4.5,163,164 a shift that has the 
potential to limit the activities of acid-labile drugs while elevating the efficacy of drugs such as PZA, 
which function optimally at low pH.165  
 
1.1.5 Drug discovery at the target site 
The importance of determining lesion-specific drug concentrations stems from various sources. 
Mitchison and Coates (2004) described a model explaining the relationship between the different 
microenvironments in TB and current first-line TB drug efficacy.166 In their model, actively growing 
bacilli were killed by INH, semi-dormant bacilli were killed by RIF, intracellular bacilli were targeted by 
PZA in the acidic phagolysosome, while dormant persisters were found in hypoxic environments, 
making them harder to treat using standard therapies.166,167 
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Pioneering work by Kjellsson et al., 2012 allowed scientists in the TB drug discovery environment to 
start looking at the target site of pulmonary TB in far more detail.16 Using a combination of New 
Zealand White rabbits, imaging MS, three first-line anti-TB drugs (INH, RIF, and PZA), and the 
fluoroquinolone MXF, the group demonstrated that drug plasma concentration was indeed a poor 
proxy for drug concentration in TB lesions.16 The lack of data on how this might translate into humans 
combined with the absence of cellular protein binding data were acknowledged as weaknesses by the 
authors. Nevertheless, this work prompted a growing appreciation of the need to include permeation 
studies in their drug development pipeline.2,24,168 
In a later study, Prideaux et al., 2015 provided a compelling extension of this work by taking advantage 
of a small set of resected lung samples from drug-resistant TB cases.35 In this case, the patients 
received a steady-state dose of RIF, INH, MXF, and PZA at intervals ranging from 2-24 h pre-surgery, 
and lung samples were analyzed using imaging MS. This revealed that RIF and PZA were able to 
penetrate lesions, with RIF accumulating to steady-state levels in the caseum.35 Although multiple 
dosing was not investigated, patients had been receiving these drugs for several weeks/months. A 
controlled trial involving infected, drug-naïve patients would be necessary to confirm these findings 
and control for drug levels. This work could potentially correlate clinical trial data with lack of efficacy 
and motivate earlier inclusion of such studies in a pre-clinical setting.169 
The influence of caseum binding on the permeation of compounds into the deeper recesses of the 
granuloma was the next object of study.19 Exploiting a very large sample set which covered the 
molecular space using 64 parameters and over 200 compounds, it was observed that a compound’s 
cLogP value best described penetration into the granuloma.19 The use of surrogate caseum was also 
investigated: while it was acknowledged that the surrogate failed to reproduce the full composition 
of the in vivo material, and so required further development to mimic patient-derived lesions more 
accurately, the results supported the prospect for this assay to be standardized, thereby allowing 
more in-depth in vitro assays to take advantage of this methodology. 
Another recent study investigated the mystery of EMB’s clinical efficacy despite its modest potency 
against non-replicating Mtb.38 Using the Mtb-infected rabbit model, along with microdissection and 
LC-MS/MS, the group determined that EMB partitions into the caseous lesions with great efficiency, 
potentially explaining its efficacy and again motivating for permeation studies to be conducted in early 
pre-clinical drug development.38 This work was followed up by a further study using the infected rabbit 
model, where ex vivo minimum bactericidal concentration (MBC) measurements were taken in 
caseum for several first-line TB drugs.24 The Wayne170 and Loebel171 models for non-replicating 
persistence failed to predict the extent to which resistance was being generated in the caseous 
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environment, whilst also indicating that PZA has activity in the caseum, a fact that the current non-
replicating models would have missed. This motivates for the use of an in vitro assay that closely 
mimics the in vivo situation. 
 
1.1.6 Challenges and perspectives 
Incorporating findings from these recent studies into the model by Mitchison and Coates40 has 
revealed interesting correlations with, and departures from, their original ideas. For example, Dartois 
and others suggested that drug accumulation within granulomas may not simply follow the binary 
‘in/out’ dichotomy.35,172 Instead, four distinct patterns of drug accumulation were identified including: 
(i) rapid and homogeneous distribution with no accumulation appearing over time (INH/linezolid 
(LZD)), which may explain the predominant killing of extracellular bacteria by INH; (ii) rapid and 
heterogeneous distribution with accumulation in the cellular rim rather than the caseum 
(fluoroquinolones and oxazolidinones); (iii) slow distribution with gradual accumulation of drug over 
time (RIF) explaining the intracellular killing of Mtb; and (iv) rapid distribution with massive 
accumulation in the cellular layers and poor diffusion into the caseum (clofazimine (CLZ) and 
bedaquiline (BDQ)).35,172 
From a translational perspective, knowledge about the permeation of current first-line drugs and 
novel drug candidates into TB microenvironments is clearly essential. In addition to elucidating 
reasons for therapeutic failure that do not simply invoke patient non-adherence, the potential to 
inform combinations inferred from high-order drug interactions145 with this information promises a 
route to mitigate the criticisms often levelled at in vitro-derived compound synergies. This enables the 
rational design of new regimens that incorporate knowledge about drug permeation into the 
heterogeneous TB microenvironments. Towards this end, a number of factors may have to be 
considered in ensuring clinical relevance, including: 
1) Is there a quantifiable and agreed measure of “cure” that can be evaluated in an in vivo 
model? 
2) What host-pathogen relationships can be effectively modelled in a non-clinical setting? 
3) Is there a way to model bacterial physiology, pathogenesis, and drug susceptibility effectively 
to allow better understanding of these aspects in patients? 
4) What critical PK/PD relationships can be modelled using in vitro/in vivo systems and how 
might these be applied in clinical trial settings? 
13 
 
5) Can dosing regimens be altered according to data emerging from in vitro/in vivo experiments 
employed in the pre-clinical setting? 
In this context, it is worth noting the parallel development and application to Mtb infection studies of 
increasingly sophisticated systems for three-dimensional cell culture173–177 since these might offer a 
useful intermediate in bridging the in vitro/in vivo divide.178–182 Importantly, these models have already 
stressed the significance of the multi-celled, granuloma organization and the regulatory roles of 
extracellular matrix183,184 in granuloma formation.    
In summary, there is increasing evidence that the incorporation of the efficacy of drugs in the 
microenvironments must be assessed early on in pre-clinical development to allow correct dosing in 
further in vivo experiments. A better understanding of target site drug concentrations, rather than 
plasma concentrations, is needed, particularly for a complex, multi-faceted disease such as TB. The 
aim of novel drug discovery programs should be to target populations of bacilli with the most effective 
drugs, which should be most proficient at reaching relevant sites in the human body. In driving this 
concept of target site drug concentrations, it is hoped that the translational link between the lab bench 
and clinic can be strengthened, allowing expedited and “smarter” drug discovery and, by implication, 
enhanced therapeutic regimens. 
 
1.2 Developing a novel drug combination- rationale for compound selection  
1.2.1 Reactive oxygen species  
To address the aim of achieving concentrations at the target site of the most-appropriate drug, tool 
compounds which are proposed to achieve antimycobacterial activity by the upregulation of ROS 
production within Mtb were chosen. It is therefore important for us to discuss ROS and their 
associated activity against Mtb within the human host. ROS (Figure 1.2) are an important by-product 
of aerobic respiration in the cellular environment and are responsible for the maintenance of redox 
homeostasis. Aerobic respiration is the process by which oxygen is converted to water and carbon 
dioxide to produce adenosine triphosphate, a product necessary for cellular metabolism.185 The 
process reduces oxygen to both non-radical and reactive radical species. The radical known as 
superoxide (OO.-) is generated by a single electron transfer to the oxygen by the electron transport 
chain (ETC) or nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX).186 Superoxide 
damages iron-sulfur (Fe-S)187 proteins which, in turn, release Fe(III) into the extracellular environment 
causing the inactivation of the Fe-S proteins.188 Superoxide undergoes dismutation to hydrogen 
peroxide (H2O2) catalyzed by the superoxide dismutase (SOD) family of enzymes.189 Hydrogen peroxide 
is a reactive molecule, interacting with functional groups including the thiol of cysteine-containing 
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proteins to form sulfenic acids. These acids can be oxidized by hydrogen peroxide or equivalents to 
sulfinic and sulfonic acids which result in permanent deactivation of protein function.190 
Hydrogen peroxide is further reduced by metals (predominantly Fe(II) and Cu(I)) to form hydroxyl 
radical (.OH) through the Fenton reaction.191 Hydroxyl radical directly interacts with DNA causing 
irreversible oxidative damage and mutations by reacting with the sugar backbone and 
nucleobases.192,193 Hydroxyl radical is also able to oxidize sulfide residues in proteins to the 
corresponding sulfoxides, again resulting in protein inactivation. In addition, by abstraction of 
hydrogen atoms from unsaturated lipids, the hydroxyl radical generates carbon-centered lipid radicals 
that, via reaction with oxygen, in turn generate hydroperoxyl or organoperoxy radicals which have the 
potential to damage lipids through oxidation and peroxidation reactions catalysed by 
lipoxygenases.188,194 Hydrogen peroxide is catalytically converted by myeloperoxidase (MPO) to 
hypochlorous acid (HOCl) which is far more reactive towards biomolecules than is hydrogen peroxide; 
it oxidizes cysteine residues and tyrosine residues to cysteine sulfenic acid and dityrosine, 
respectively.191 The different forms of ROS have different diffusion capabilities with superoxide 
segregated to its site of generation whilst each of hydroxyl radical and hydrogen peroxide, as neutral 
species, may diffuse away from their sites of generation. Thus, hydrogen peroxide is able to cross 
various membranes making it more versatile in both cell signalling195 and as an antibacterial agent.196 
Importantly, the build-up of ROS via multiple mechanisms is collectively termed oxidative stress 
(Figure 1.2) and serves multiple purposes.190,191,193,197 As an example, the enhanced production of ROS 
induced within macrophages upon infection with pathogens provides a means to combat the 
infection. Thus, intracellular levels of H2O2 above 1 mM required to overcome bacterial antioxidant 
pathways induce bactericidal effects in Mtb.198–200 ROS also mediate key cell signalling processes, 
where different ROS levels can induce cell proliferation or survival responses.197 These levels are tightly 
regulated by antioxidant thiols and enzymes with aberrant levels implicated in various 
pathologies.201,202 ROS based therapeutic strategies certainly hold promise and have generated great 
interest within the scientific community, with the focus placed on ROS-generating molecules which (i) 
abrogate the antioxidant systems, (ii) become involved in the transfer of electrons thereby generating 






Figure 1.2. Summary of the reactive oxygen species production and management mechanisms 
employed in the human body  
 
1.2.2 Reactive oxygen species and reactive nitrogen species (ROS/RNS) in Mtb 
The potential roles of hypoxia and redox stresses on Mtb have attracted considerable attention. This 
interest stems from many different perspectives, one of which concerns the effects of hypoxia. If the 
pathogen is exposed to sudden hypoxic conditions, a lethal response is seen, yet if oxygen is slowly 
removed from the system,203 Mtb is able to induce a non-replicating phenotype that can persist for 
decades by thickening its cell wall, elongating itself, and acquiring increased resistance to TB 
drugs.170,204,205  
During the infection of a human host, Mtb encounters many such host-mediated stresses, 
predominantly associated with macrophages (Figure 1.3).206 Macrophages produce reactive oxygen 
and reactive nitrogen species (ROS/RNS, Figure 1.2) via the action of NADPH oxidase (NOX) and 
inducible nitric oxide synthase (iNOS).162,207,208 Macrophages employ numerous enzymes to generate 
various stresses in an effort to eliminate the pathogen.209 These enzymes include NOX, various 
hydrolases, and myeloperoxidases. Importantly, NOX are the only known enzymes dedicated solely to 
the generation of ROS.210 The action of NOX involves transfer of two electrons from NADPH through 
enzyme prosthetic groups such as FAD and/or heme to an oxygen molecule to generate superoxide 
radical and hydrogen peroxide.211 NOX differ in their modes of activation and products of reaction but 
all require the presence of membrane bound proteins for activity.212 In the context of pulmonary TB, 
the isoforms predominantly expressed in the lungs are NOX 2, NOX 4, and the NOX isoform dual 
oxidase (DUOX) 1 and 2.210,213,214 Superoxide radicals are formed by a reaction sequence involving 
proton transfer and reduction mediated by SOD and are later transformed into hydrogen peroxide 
H2O2. The latter reacts with endogenous transition metal ions to provide hydroxyl radical (HO.).215–217 
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Hydrogen peroxide and hydroxyl radical both have bactericidal and inhibitory effects on the growth 
of Mtb.218 This bactericidal activity is derived from the ability of ROS to damage cellular components 
including lipids, DNA, and proteins.115  
 
Figure 1.3. Formation and biotransformation of ROS in Mtb-infected macrophage; O2•-, superoxide 
radical; SOD superoxide dismutase; MSH mycothiol; MSSM oxidized mycothiol; MSH-P mycothiol 
peroxidase; MtR, mycothiol reductase; HO• hydroxyl radical; R• secondary carbon centered radical; 
ROO• peroxy radical; ROOH organic hydroperoxide; NADPH reduced nicotinamide adenine 
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In vitro experiments using a model for ROS deficiency involving macrophages deficient in phagocyte 
oxidase (p47phox), a gene which controls the ability of phagocytes to produce superoxide using NADPH 
oxidase, suggest that wild-type Mtb has developed resistance to oxidative burst. Mice deficient in this 
particular gene are not able to control Mtb infection early on in the infection process, suggesting a 
role for ROS in the early stages of Mtb infection.219,220 Furthermore, iNOS-deficient mice or mice given 
NOS inhibitors showed rapid progression of Mtb infection with a significantly higher mortality 
rate.221,222 Inhibitory experiments revealed that inhibition of tumor necrosis factor alpha (TNFα), a 
cytokine involved in the modulation of iNOS, caused the reactivation of latent bacilli in both the 
murine and human diseases.223,224  
Although the exact role of nitric oxide (NO) has not been identified, evidence supporting its action in 
the protection against infection has come from various sources, including reported levels in human 
granulomas, its association with infection control, the production of endothelial NOS by lung epithelial 
cells in response to infection, and the presence of nitrotyrosine, a compound that is produced and 
accumulates within macrophages.221 Moreover, the ability of a macrophage to moderate Mtb 
infection is related to the accumulation of iNOS within the cell as demonstrated by healthy patient 
cells subsequently infected with Mtb.222 When extrapolated to the granuloma, this finding could 
explain the bacteriostatic225,226 and bactericidal221 effects of RNS observed in the human lung in vivo. 
The production of both ROS and RNS seems only partially redundant in host protection.221,227 This is 
further supported by the lack of overlap in responses when cultures were exposed to NO or H2O2 and 
analyzed by gel-electrophoresis.228 
It has been proposed that ROS activity is encompassed in the activity of almost every antibiotic 
currently in use for the treatment of TB, pointing to a common mechanism of action.200,229 The 
involvement of ROS in bacterial killing has been debated by several sources due the non-specific action 
by which ROS acts, making the actual contribution of ROS to bacterial control difficult to 
determine.187,230 The measurement of ROS, predominantly using hydroxyphenyl fluorescein (HPF), has 
also come under some criticism.229 HPF is a non-fluorescent molecule which, upon oxidation by ROS 
species such as hydroxyl radicals, produces a fluorescein molecule, causing an increase in fluorescence 
and indicating the presence of ROS. However, the reaction seems to be less specific than first thought. 
Both redox-active metal ions and varying levels of auto-fluorescence from cells at different times in 
their respective metabolic states particularly following drug treatment, lead to confounding 
results.231,232 Subsequent studies using alternative methods have re-confirmed the contribution of 
oxidative stress to antibacterial activity.233–237 Caution needs to be maintained when using agents 




1.2.3 Mtb oxidative stress homeostasis mechanisms  
The literature cited above provides clear evidence that Mtb is exposed to various stresses, including 
ROS, RNS, and hypoxia, of all which require active perceptive and modulatory sensors to allow the 
pathogen to adapt to changes throughout its infective life cycle. These redox sensors are present in 
other bacteria and include the oxygen regulon (OxyR)239–241 in Salmonella and Escherichia coli (E. coli), 
the nitrogen fixation regulon (FixL)242–244 in Rhizobium, the redox sensing regulon (SoxR),245,246 
fumarate/nitrate reduction regulator (FNR),247,248 and the transmembrane histidine kinase sensor 
(ArcA)249,250 in E. coli.  
 Although Mtb lacks any of the above classical redox sensors, it does possess the heme-based sensors 
or “dormancy survival” regulator proteins, DosS, DosR, and DosT, which comprise the Dos RST two-
component regulatory system.251 Briefly, the system functions via DosS under hypoxia or ROS/RNS 
stress undergoing autophosphorylation.251 In doing so, DosS transfers a phosphate to DosR, a DNA-
binding protein that controls the latency of Mtb. DosT, a second sensor thought to be involved in gas 
sensing activated by the binding of NO or CO, controls the degree of the dormancy response mediated 
by DosR. This binding of phosphorylated DosR to DNA causes the activation of approximately 50 genes 
associated with dormancy.251 The Dos R/S/T system has also been shown to be well established in vivo 
and is associated with local hypoxic conditions adding to the relevance of this approach for Mtb.252,253 
As demonstrated, Mtb is well-equipped to sense the ROS/RNS stresses it is exposed to within the host. 
The sensing of redox activity is the first step to dealing with the host defenses.  
The continual exposure of aerobes to oxidative stress forces these cells to develop antioxidant 
counter-measures against such pressure.191 Small molecule thiols such as cysteine and GSH are the 
most important components of this anti-oxidant defense system, along with various other antioxidant 
proteins which maintain the redox state.190 E. coli is one of the most well-studied bacteria due to its 
sensitivity to ROS and diminished antioxidant capacity.191 E. coli and other bacteria cope with the 
reduced oxygen species superoxide through the action of SOD which catalyze the dismutation of 
superoxide into hydrogen peroxide and oxygen. The hydrogen peroxide is reduced to water by GSH 
peroxidase enzymes.190,254 Other bacterial counter-defenses include the protective enzymes catalase 
(KatG) and alkyl hydroperoxidase (AhpC), which neutralize redox build-up, particularly of hydrogen 
peroxide. Trace levels of metal ions react with hydrogen peroxide to generate hydroxyl radical,255 
which in turn reacts with thiols cysteine and GSH. MSH is the mycobacterial equivalent of GSH and is 
the main thiol in Mtb. During macrophage infection, Mtb is able to downregulate the production of 
both ROS and antioxidant molecules.256,257 The effects of this were shown in the depletion of ROS in 
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SOD deficient E. coli mutants during aerobic conditions which resulted in increased sensitivity to ROS, 
with similar sensitivity being observed in catalase deficient mutants exposed to hydrogen 
peroxide.258,259  
The bioenergetic and redox homeostasis mechanisms of Mtb have been shown to be inextricably 
linked, with both processes synergistically contributing to the survival of Mtb in both macrophages 
and mice, and importantly, contributing to the sensitivity of Mtb to oxidative stresses induced by drug 
treatment.260–262 This was demonstrated through use of respiratory extracellular flux analysis in MSH 
and ergothionine (EGT)-deficient mutants when tested against several first line drugs.260,261 The 
importance of EGT, modulated by the redox- and pH- responsive protein, WhiB3, was highlighted in 
this study as a potentially novel redox antioxidant component. EGT has roles both distinct to, and 
overlapping with those of, MSH.260,263 The results overall indicate the sensitivity of Mtb to these 
compounds. The results also show a significant alteration in the bioenergetic profile of the mutants, 
suggesting likely dysfunction of the electron ETC.260,261 The work also tied together the importance of 
central carbon metabolism in the different environments in which Mtb is able to survive, indicating 
the importance of different carbon sources for redox homeostasis and bioenergetics. 
Mtb infection potential can then be summarized in the ability of the bacillus to overcome host 
oxidative stress mechanisms. The generation of imbalances in the redox homeostasis mechanisms 
employed by Mtb seems to be a viable approach for drug discovery endeavors due to the unique anti-
oxidative stress mechanisms which Mtb employs.264 Exposing bacteria to elevated levels of ROS, by 
either the upregulation of ROS through mechanisms such as flavin or flavoprotein ROS-
generation265,266 or the abrogation of bacterial antioxidant systems such as catalase259 could prove 
successful in treating TB.191    
 
1.2.4 Proposed treatment regimen 
The novel therapeutic approach that will be investigated in this study comprises, in part, a combination 
of two drugs that work by creating an imbalance in the redox regulatory pathways in Mtb. Studies 
indicate that Mtb may be vulnerable to redox-cycling drugs that are able to permeate the phagosomal 
environment and bacteria.261,267 These drugs are then able to elevate endogenous ROS levels and 
perturb the delicate redox homeostasis within the pathogen. In addition, the healthy human cell is 
more tolerant of increased ROS levels than diseased cells, as shown in cancer-related studies, 
potentially creating a targeted anti-TB approach.268,269 Thus, MDR and XDR strains of Mtb display 
exceptional sensitivity to increased ROS/RNS generated by redox-active drugs such as CLZ, RIF, and 
some nitroimidazopyrans.270,271 Importantly CLZ is equipotent in vitro against both MDR and drug 
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sensitive Mtb, likely due to its activity on the Mtb type II NADH:quinone oxidoreductase (Mtb NDH-
2),272 where it induces the formation of ROS via redox cycling that is associated with the increased 
consumption of NADH.273 CLZ-like compounds are ideal for inclusion in this regimen as both MDR and 
drug sensitive TB patients could be treated using similar treatment regimens.    
 
The combination proposed in the study displays both redox and oxidant activity. The redox component 
of this combination consists of a redox molecule that is converted to its reduced conjugate by reduced 
flavin cofactors of flavo-enzymes such as MR, Mtb NDH-2, and decaprenylphosphoryl-beta-D-ribose 
oxidase (DprE1)274,275, involved either directly in regulating oxidative stress, or in other important 
intracellular processes.276 Oxidation of the reduced conjugate by oxygen restores the parent redox 
molecule, whilst at the same time, the oxygen is reduced to produce ROS. The newly re-generated 
redox molecule is then reduced by the reduced flavin cofactor, resulting in redox cycling and build-up 
of ROS. On the other hand, the oxidant drug component impedes the electron transfer chain by 
abruptly oxidizing reduced flavin cofactors. An example of this has been shown in the context of 
malaria, in the reduction of artemisinin-based drugs to the by-product deoxyartemisinin, and could 
theoretically be applied to Mtb to subvert control of redox homeostasis within the bacillus.277 These 
two effects cause the uncontrollable production and build-up of ROS in the bacteria (Figure 1.4), 
resulting in its destruction.277 However, these effects are abrogated after the exhaustion of 
artemisinin, resulting in resumption of redox homeostasis in Mtb.277,278  
 
 
Figure 1.4. Intracellular reactive oxygen species (ROS) generation (top) and proposed artemisinin-
based generation of ROS (bottom); G6PD glucose-6-phosphate dehydrogenase; NADPH nicotinamide 
adenine dinucleotide phosphate; FAD flavin adenine dinucleotide; MSH, mycothiol; MSSM, oxidized 




The redox component of the combination ensures that the generation of ROS is not diminished after 
artemisinin exhaustion (Figure 1.5). The enzyme disulfide reductase catalyzes the reduction of 
methylene blue (MB) by NADPH. The resulting leucoMB (LMB), is then rapidly oxidized by oxygen.276,279 
Each reaction cycle, catalyzed by the MB-enzyme ensemble, leads to the consumption of NADPH and 
oxygen and the production of ROS.280   
 
  
Figure 1.5. Intracellular reactive oxygen species (ROS) generation (top) and artemisinin/methylene 
blue (MB)-based ROS production; G6PD glucose-6-phosphate dehydrogenase; NADPH nicotinamide 
adenine dinucleotide phosphate; FAD flavin adenine dinucleotide; MSH, mycothiol; MSSM, oxidized 
mycothiol (adapted from Haynes et al., 2010a and Haynes et al., 2010b)  
 
Novel compounds were selected for this proposed combination approach based on their effects on 
TB. Redox active agents may include CLZ, used clinically, or the methylene blue (MB) analogue PHX 1 
(Haynes et al., unpublished), along with other classes of compound that meet the study criteria. These 
will be coupled with an artemisinin derivative, such as Coco compounds 296 and 298, which have 
shown synergistic activity in malaria, and are hypothesized to achieve similar synergism within Mtb.277 
The emergence of drug resistance is a crucial consideration and, as such, the WHO has maintained 
that two novel components should be coupled with at least one other known anti-TB compound to 
enhance efficacy and suppress resistance to the new regimen.281 These could include INH derivatives, 
such as DPINH, or a derivative of quinolone, which is known to be active against Mtb.282 The 
compounds listed in Table 1.2 were selected from a large series based on their favorable in vitro 
activities against Mtb and the potential to synergize in a combination promoting the production of 
ROS (minimum inhibitory concentrations: 0.194 to 80 μM against H37Rv). All compounds also 
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displayed selectivity indices for Mtb of 10 or greater. Values were calculated using the Chemicalise 
function (ChemAxon, MA, USA). 
 
Table 1.2. Chemical properties of selected compounds 
Compound  PHX 1 DPINH RMB 041 RMB 043 RMB 073 Coco-296 Coco-298 
MW 456.59 303.33 504.67 503.68 520.67 488.71 556.83 
cLogP 1.48 2.58 1.32 4.80 3.59 5.68 6.6 
PKa -0.11 3.12/9.81 14.3 8.2/14.6 14.34/13.56 8.45 8.45 
tPSA 39.54 78.54 97.33 100.13 117.56 43.4 45.4 
 
 
The ultimate goal of these new combinations is to: (i) shorten the treatment regimen for both drug-
sensitive and MDR-TB by inducing futile ROS cycling within the bacillus, (ii) pair novel compounds to 
induce maximum ROS production, and (iii) reduce the burden of drug resistance by targeting MDR-TB 
whilst simultaneously preventing the formation of new cases of drug-resistant TB via the inclusion of 
drugs that target multiple populations of Mtb.  
 
1.2.5 Compound structures and background information 
a. Redox active compounds 
Phenoxazine derivatives  
The PHX series (Figure 1.6) is a set of phenoxazine derivatives, a class of compounds present in various 
insect pigments283,284 and in actinomycins produced by bacteria.285 Phenoxazines are a group of N-
heterocyclic compounds comprising tricyclic structures incorporating nitrogen and oxygen atoms. The 
derivatives are more accurately classified as benzo(a)phenoxazines with their characteristic angular 
ring system arrangement.284 These phenoxazines and related compounds show diverse biological 
activities,286,287 which has sparked great interest particularly in the treatment of Mtb, resulting in the 
design and synthesis of new phenoxazine compounds to explore their biological activities.288–293 
Historically, phenoxazine derivatives have been investigated by various groups and have shown potent 
anti-tubercular activity, although mainly in bovine strains of TB.294,295 The compounds were first 
reported by Goldstein and Ludwig-Semelitch in 1919296and were tested further to determine their 
anti-TB properties by Crossley and colleagues.294,295 This was documented in the 1962 United States 
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Patent Office application by Andre Girard, in which guinea pig survival and lesion development was 
monitored for a period of over 100 days. The protective effect of these compounds against Mtb 
infection was then shown.297 In this patent application, the author also alluded to the reason many 
groups have avoided the study of such compounds: some possess the ability to stain dermal and organ 
tissues temporarily, making this a difficult and ultimately stigmatizing treatment for patients to 
endure. The ability to interact with various protein, carboxylic acids, and DNA molecules is what allows 
the compound to stain cellular constituents so effectively and has been used to probe biological 
systems with great proficiency.298–300    
 
 
Figure 1.6. Chemical structures of the phenoxazine nucleus (box) and the phenoxazine derivatives PHX 
1, PHX 6, and PHX 8 
 
The mechanism of action of these compounds remains unknown, but particular emphasis is placed on 
the ring nitrogen, which should be free to partake in oxidation-reduction reactions. It is hypothesized 
that the quinone-like moiety of these agents is reduced to a semi-quinone and hydroquinone moiety 
and in the presence of molecular oxygen, these reduction products are able to generate ROS by the 
process of redox cycling.301,302 Some of the quinone compounds such as doxorubicin and actinomycin 
D have shown proclivity towards non-specific DNA cleavage, resulting in high levels of cytotoxicity in 
human cells, an effect which was not seen in this study against human cell lines.303 PHX 1 is particularly 
active against H37Rv, with an MIC90 of 0.196 µM.    
It was thought that a compound possessing this structure was destined to have poor drug-like 
properties due to its low solubility in water.304 More recently however, advances in formulations and 
chemical modifications have allowed these potentially poorly soluble compounds to gain greater 
recognition as drug candidates against malaria, TB, and cancer.291  
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The antimicrobial activities of the closely related phenothiazines, of which methylene blue (Figure 1.7) 
is an example, have been widely reported, particularly that against TB and malaria.305,306 This is 
demonstrated in the ability of phenothiazines to inhibit oxygen consumption in both Mtb and 
Mycobacterium smegmatis (Msm).307 Coupled to this is the ability of the compound to potently inhibit 
the mycobacterial type 2 NADH:quinone oxidoreductase (Mtb NDH-2), which plays a central role in 
the respiratory metabolism of bacteria, and membrane succinate dehydrogenase culminating in a 
significant decline in intracellular ATP concentrations in Mtb and a decline in Msm redox potential, a 
finding that was supported by transcriptional profiling of various respiratory gene clusters.307 These 
compounds have also demonstrated synergistic interactions with other anti-TB agents, indicating 
great promise for inclusion in drug treatment regimens. The inclusion of phenoxazine derivatives 
should potentiate similar redox active potential in this treatment regimen.    
 
 
Figure 1.7. Chemical structure of methylene blue (MB) 
 
INH derivatives 
INH (Figure 1.8) has been part of the Mtb drug treatment regimen for the past 60 years, primarily due 
to its potent activity against Mtb. This activity is derived from the interference of INH with the 
synthesis of mycolic acid, a major component of the Mtb cell wall.308 As a prodrug, INH exerts its anti-
TB activity after activation by the Mtb enzyme KatG, which oxidizes INH to the isonicotinoyl radical, 
after which the oxidation product reacts with NAD(H) to form the active metabolite, an INH-NADH 
adduct that inhibits the enzyme InhA, which is involved in the production of mycolic acids.309 Recently, 
an escalation in resistance to INH has been reported, with approximately 9.5% of people infected with 
TB experiencing resistance to INH.310 INH resistance has been identified as the most common form of 
TB drug resistance amongst first-line drug users, with nearly 13% of these patients resistant to INH, 
resulting in significantly poorer clinical outcomes than that in patients with drug-sensitive TB.311,312 
INH resistance is caused by mutations in the KatG gene, specifically the Rv1910c-furA intergenic 
region, furA-katG intergenic region, and mabA (fabG) inhA regions,1 often resulting in Mtb mutants 
that are unable to oxidize INH.313,314 Patients with INH mono-resistance are also more likely to develop 




Figure 1.8. Chemical structure of INH 
 
The potential loss of INH, a compound with a relatively low risk of adverse events and potent early 
bactericidal activity,315 from the current first-line treatment regimen has generated interest in the 
drug discovery field, with many investigators combining INH with other active groups. A degree of 
success has been achieved with the discovery of LL-3858 (Figure 1.9), an INH-pyrrole derivative 
currently in phase II clinical trials.316  
 
 
Figure 1.9. Chemical structure of LL-3858, an INH derivative 
 
DPINH (Figure 1.10), another INH derivative, derives its structure from the incorporation of the INH 
structure into a di(2-pyridyl)ketone. Many dipyridine structures are redox active, mainly exerting 
activity by interruption of the ETC in Mtb.317 INH itself is also able to generate NO during the process 
of INH oxidation by katG, with NO shown to have antimicrobial properties against Mtb. In any event, 





Figure 1.10. Chemical structure of DPINH 
 
1.2.6 Oxidant drugs  
a. Artemisinin derivatives  
Artemisinin (Figure 1.11), isolated from the plant Artemisia annua, is currently used in the treatment 
of malaria.318 It has been noted that artemisinin has a proclivity towards the inhibition of non-
replicating persistent bacteria (NRP) in Mtb.25,319 NRP is characterized by a decrease in mycobacterial 
metabolism, caused by host and environmental pressures, resulting in a drug-tolerant phenotype that 
enables the bacillus to survive within the host for decades, leading to the prolongation of TB 
treatment.170,171  
 
Figure 1.11. Chemical structure of artemisinin 
 
The Abramovitch group has presented evidence that artemisinin is able to impede Mtb persistence 
possibly by its interaction with the heme moiety present in the DosS and DosT sensor kinases, oxidising 
the ferrous heme and creating heme-artemisinin. These oxidation reactions of the kinases are similar 
to the naturally occurring oxidation reactions common in oxygen-rich environments that cause the 
bacterium to maintain its replicative state.319     
Artemisinin shows very low activity against Mtb (200-2000 µM against H37Rv) compared to current 
first-line treatments. However, the addition of iron-chelating siderophores such as mycobactin, and 
various other modifications320 such as the addition of cholesterol 321 to the artemisinin core, increases 
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activity against Mtb.322–324 Numerous studies aiming to understand mycobacterial iron acquisition 
have been conducted, including work on iron chelators, heme-mediated iron acquisition, and iron 
transport and utilization pathways.325–327 Significant upregulation of the genes encoding siderophores 
and iron importers has been reported under low iron conditions, suggesting that Mtb favors iron 
uptake during disease states, thus adding to the attractiveness of developing conjugating drug-like 
compounds. The activity reported for these mycobactin-artemisinin and cholesterol-artemisinin 
conjugates provides evidence that artemisinin is active against Mtb provided it can make access the 
cytosol. However, other mechanisms of improving compound permeation into the mycobacterial 
cytosol are available, such as the addition of lipophilic side groups that increase compound efficacy.328–
330        
In addition, it has been suggested that artemisinin may promote Fenton reactions and act as an 
indiscriminate oxidant.307,319 In this regard, Coco-296 and Coco-298 (Figure 1.12) are to be included in 
this study. These compounds retain the core artemisinin structure whilst incorporating a long alkyl 
chain to increase lipophilicity and subsequently allow permeability through numerous cellular layers 
to reach Mtb at the target site in the lungs. Coco 296 and 298 are significantly more active against Mtb 
(18 and 89 µM, respectively) than artemisinin; they may perform an integral role in the ROS-
generating regimen, ensuring that intracellular ROS production is initiated. It is vital that the 
compounds are not degraded to dihydroartemisinin (DHA) as the compound shows little to no activity 
against Mtb (Haynes, unpublished data). 
 




1.2.7 Third partner drug  
a. Decoquinate derivatives 
Decoquinate (DQ), an anticoccidial quinolone, has been used in poultry feed for more than 50 years.331 
Since the discovery in 1962 of the first quinolone, nalidixic acid, the quinolones have been used to 
treat a variety of pulmonary infectious diseases.332 Subsequent development of newer quinolones 
resulted primarily from substitution at the C-6, C-7, and C-8 positions, with compounds acting on 
mycobacterial DNA gyrase and topoisomerase IV.333,334 The addition of fluorine at position C-6 is one 
such example, giving rise to the class of compounds known as the fluoroquinolones, which are active 
against Mtb and have been included in treatment regimens since 1984.335 The emergence of 
fluoroquinolone resistance has created the need for novel quinolone structures.169,310  
A series of compounds derived from DQ,336 (Figure 1.13) was prepared in the Centre of Excellence for 
Pharmaceutical Sciences at North-West University. The primary use of DQ is in the veterinary 
treatment of coccidiosis.337 DQ has little to no activity against Mtb, primarily due to its inherently poor 
solubility. DQ was therefore used as a backbone to which polar groups were attached to produce 
quinolone derivatives with the goal of improved solubility and activity. The recently synthesized RMB 
041, RMB 043, and RMB 073 were the most promising of the derivatives in the series (Figure 1.13). 
 
Figure 1.13. Chemical structure of decoquinate molecule, associated carbon numbering on the core 
quinolone structure (box), and the decoquinate derivatives RMB 041, RMB 043, and RMB 073  
 
1.3 Summary of proposed compound combination 
The compounds included in this study have been specifically selected for their potential to upregulate 
ROS production in Mtb. In addition to this, it is necessary to show that these compounds will possess 
favorable pharmacological properties to allow for further development of combination therapies 
which are cheaper, more effective, and which are better able to permeate into the various host 
microenvironments than compounds currently used in anti-TB therapy.   
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2. Aims and objectives 
2.1 Rationale 
TB is an infectious disease caused by the pathogen Mtb. The progression of Mtb infection relies upon 
the relationship between the bacillus and various cells in the immune system. As discussed, this 
relationship and subsequent disease progression involves the continual response and adaptation of 
the infecting mycobacterium and its human host in different microenvironments, with multiple 
studies highlighting the critical role of ROS in determining bacillary fate. Overexpression of ROS caused 
by the abrogation or upregulation of certain chemical pathways could hold the key to effectively 
eradicating TB in these different microenvironments. For this reason, a series of compounds 
hypothesized to upregulate ROS production when used in combination were to be tested in a number 
of pre-clinical in vitro and in vivo assays. 
Furthermore, the treatment of TB is made more difficult by the ability of the bacillus to exist in diverse 
microenvironments within the human host, an aspect often overlooked by various drug discovery 
programs. A testing cascade aiming to understand whether the complexity of compound penetration 
and efficacy at the target site is an appropriate strategy to ensure more efficacious drugs and regimens 
was therefore evaluated.        
 
2.2 Aims 
This study was designed to: 
1. Investigate whether the compounds displayed initial selective activity against Mtb  
2. Determine whether the compounds possessed appropriate physicochemical properties to 
penetrate the microenvironments in which Mtb is able to survive 
3. Through the use of a murine model, identify whether the physicochemical properties were 
able to sufficiently explain the accumulation of the compounds in a number of host 
microenvironments, including the blood, various organs, epithelial lining fluid, and associated 
cell types within the lungs 
4. Investigate whether, once at the unit of infection, the compounds were able to penetrate an 
infected macrophage environment and maintain the efficacy displayed within standard Mtb 
culture screens.  
5. Identify combinations of novel compounds that could potentiate ROS production and 




1. Identify and select compounds that could potentiate ROS and redox cycling in Mtb 
2. Assess the in vitro anti-Mtb activity of the selected compounds in H37Rv 
3. Assess the ADME drug-like properties of the compounds in the context of penetration into 
Mtb-relevant microenvironments via the following in vitro assays: kinetic solubility, 
lipophilicity, metabolic stability, membrane permeability (PAMPA), plasma protein binding, 
microsomal protein binding, and blood-to-plasma partitioning 
4. Assess the compounds’ 48 h oral and IV PK profiles in a murine model 
5. Evaluate drug distribution in various murine organs (brain, heart, lungs, spleen, kidneys, and 
liver) and lung fluid constituents 24 h after oral administration 
6. Identify compounds that potentiate synergy within an extracellular environment using a 2-D 
checkerboard assay in H37Rv 
7. Confirm whether specific compound/compound combinations can maintain their activity 
within an intracellular Mtb-infected macrophage environment. An in vitro platform was 
developed to test the permeability of novel compounds into human THP-1 macrophage-like 
cells, including: 
- Optimization of the assay using uninfected cells 
- Assessing compound permeation in this model 
- Optimization of the assay using green fluorescence protein (GFP)-expressing Msm 
- Optimization of the assay using mCherry-expressing M. tuberculosis H37Rv 







3.1 In vitro screening 
3.1.1 Cytotoxicity assay (CHO, VERO, and THP-1 cells) 
A standard operating procedure, prepared by the Division of Clinical Pharmacology at the University 
of Cape Town (UCT), was followed. Chinese hamster ovarian (CHO), VERO, and THP-1 cells were 
routinely maintained as adherent monolayers in 75-cm3 culture flasks in complete medium consisting 
of Dulbecco’s Modified Eagles Medium (DMEM, Highveld Biologicals, Lyndhurst, South Africa) and 
Hams F-12 medium (1:1, Sigma, St Louis, MO, USA), supplemented with 10% heat inactivated fetal 
bovine serum (FBS, Highveld Biologicals, Lyndhurst, South Africa). The cells were incubated in a 5% 
CO2, humidified atmosphere at 37°C. The culture medium was changed every 3 days when the cells 
were sub-cultured. Mosmann’s MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay was used, with minor modifications to determine cell viability.338 This is a reliable method to 
measure the metabolic activity of cell cultures in vitro for the assessment of growth characteristics, 
50% inhibitory concentrations (IC50), and cell survival rates.339 The assay distinguishes living cells from 
dead by measuring the formation of a water-insoluble purple formazan product, from yellow water-
soluble tetrazolium salt that is metabolized by living cells. The absorbance of the formazan product is 
measured by a BioRad iMark™ Microplate Absorbance Reader (CA, USA) and is proportional to the 
metabolic activity and number of cells in each microplate well.  
Vero cells derived from the African green monkey (Cercopithecus aethiops) were grown to confluence 
(> 90% viability). Cells were added (1 x 106 cells/well) to a 96-well plate and incubated for 24 h at 37 
°C/5% CO2.340    
After the addition of the compounds at a starting concentration of 50 µM (serial diluted to 5 mM) 
each well received MTT at a concentration of 5 mg/mL in phosphate buffered saline (PBS), with blank 
samples receiving only medium and MTT. Each compound concentration tested in this study was 
completed in triplicate. The plates were incubated for 4 h at 37°C, before centrifuging for 10 min at 
500 g, and removing the supernatant from the wells without disturbing the formazan crystals. 
Dimethyl sulfoxide (DMSO) was added to each well and the plate was shaken for 5 min on vortex to 
dissolve the crystals. The absorbance of the formazan salt was measured at 540 nm. The following 





Equation 3.1 Cell viability in CHO cells 




Non-linear dose response curves were constructed using GraphPad Prism 4 software and Microsoft 
Excel. 
 
3.2 In vitro activity 
3.2.1 In vitro minimum inhibitory concentration drug susceptibility testing 
The M. tuberculosis H37Rv MA341 and the mutant strain carrying the pMSP12::mCherry fluorescence 
reporter342 were cultured in Middlebrook 7H9 medium supplemented with 10% oleic acid-albumin-
dextrose-catalase (OADC, Difco) at 37°C for approximately 3 days. These cells were further sub-
cultured until a 600 nM optical density (OD600) of 0.5 was obtained. The cell suspension was added 
to the plate at a final concentration of 1 x 108 cells/mL. The medium was supplemented with 25 mg/mL 
hygromycin during the growth of the mCherry reporter strain. 
The drugs’ minimum inhibitory concentrations (MIC) were determined using the broth microdilution 
assay in round-bottom 96-well plates. Drugs were diluted in 7H9 medium using two-fold serial 
dilutions, and Mtb was added to each well at a final inoculum of 105 cells/mL (final volume in each 
well:100 µL). Sterile water was added to each outer well of the plate to reduce the effects of 
evaporation. Plates were incubated at 37°C for 8 days. Following the addition of resazurin, the plates 
were incubated for a further 3 days to allow a color change from blue to pink, associated with bacterial 
growth. Samples were read at 560 nm using the Spectramax multi-mode plate reader (Molecular 
Devices, CA, USA). The MIC90 is the concentration at which 90% of cell growth is inhibited, and at which 
this color conversion is prevented.  
 
3.3 ADME 
3.3.1 Kinetic solubility 
Stock solutions of each compound were spiked into a 96-well plate in duplicate into a phosphate buffer 
(pH 7.4) to give a final sample concentration of 200 µM. The individual compounds were also prepared 
in duplicate at three concentrations, 11, 100, and 220 µM, that was used to produce a calibration 
curve which was then subsequently used to determine the concentration of the solubility test 
samples. The plate was agitated for 2 h using a plate shaker (500 rpm, 22°C). The supernatant (150 µL) 
was pipetted from the samples into a 96-well analysis plate, and the compounds were analyzed via 
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high-performance liquid chromatography with diode array detector (HPLC-DAD, Agilent Rapid 
Resolution HPLC).  
 
3.3.2 Lipophilicity 
This shake-flask assay was used to determine the partition coefficient between buffer (pH 7.4) and 
octanol for each compound. The compounds were added to a 96-deep-well plate at a concentration 
of 1 µg/mL. The organic solvent octanol was added to the compounds before the addition of 
phosphate buffer (pH 7.4, 1:1 v:v), and the plate was then placed on a plate shaker (500 rpm, 2 h, 
22°C). The buffer and organic layers were removed separately and plated into a 96-well analysis plate. 
The samples were submitted for HPLC-DAD (Rapid Resolution HPLC) analysis. The different layers were 
analyzed to obtain HPLC peak areas. These were then used to calculate lipophilicity values for each 
compound by dividing the peak area of the octanol sample by the peak area of the buffer sample. The 
logarithm of this value was then calculated to obtain a LogD value. 
 
3.3.3 Parallel artificial membrane permeability assay (PAMPA) 
The permeability of the compounds was assessed via an artificial membrane partitioning assay using 
a 96-well multiscreen filter plate (0.4 μM pore size). The filter plate was coated with 5% hexadecane 
in hexane and was allowed to dry before starting the assay. In each well containing test compound, a 
membrane integrity marker, Lucifer yellow, was added to the apical side of the filter plate. Each 
compound was added to the apical portion of the PAMPA plate (donor plate) at a final concentration 
of 1 μg/mL in a phosphate buffer (pH 7.4). The bottom portion (acceptor plate) was filled with blank 
buffer (pH 7.4). The plates were then slotted into each other and placed on a plate shaker at 80 rpm 
for 4 h at 22°C. The samples from both donor and theoretical equilibrium wells were matrix matched 
with blank pH 7.4 phosphate buffer. Each sample received acetonitrile (ACN) containing internal 
standard (IS) (carbamazepine at a concentration of 0.0236 µg/mL) and was then submitted for LC-
MS/MS analysis (Agilent Rapid Resolution HPLC and AB Sciex 4500 MS). A portion of the sample 
containing Lucifer yellow was analyzed on a BioRad iMark™ Microplate Absorbance Reader (BioRad, 
CA, USA) (excitation 490 nm, 510-570 nm emission) and used to determine the Papp value of each well 






Equation 3.2. Calculation of Lucifer yellow permeability value (Papp) 




Where C is calculated using Equation 3.3.  
 
Equation 3.3. Calculation of permeability factor (C) 
𝐶 =  
𝑉𝐷 𝑥 𝑉𝐴
(𝑉𝐷 + 𝑉𝐴) 𝑥 𝐴 𝑥 𝑡
 
Where VA is the volume of the acceptor compartment (0.25 cm3), VD is the volume of the donor 
compartment (0.15 cm3), A is the accessible filter area (0.024 cm2), and t is the incubation time in 
seconds.  
 
The peak areas of the LC-MS/MS samples were used to determine the Papp of each compound. This 
was completed using Equation 3.4. 
Equation 3.4. Calculation of compound permeability value (Papp) 
𝑃𝑎𝑝𝑝 =  𝐶 𝑥 − ln (1 −
𝐴𝑐𝑐𝑒𝑝𝑡𝑜𝑟 𝑤𝑒𝑙𝑙𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
𝐷𝑜𝑛𝑜𝑟 𝑤𝑒𝑙𝑙𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 
) 
Where C is calculated using equation Equation 3.3.  
 
3.3.4 Metabolic stability 
A metabolic stability assay was performed in duplicate in a 96-deep-well plate. Compounds (10 mM) 
were incubated separately with mouse, human, and rat microsomes with a final microsomal 
concentration of 0.4 mg/mL at 37°C using the cofactor nicotinamide adenine dinucleotide phosphate 
(NADPH, 1 mM). This assay is a turnover microsomal stability assay and compounds are assessed at 
two time-points (0 and 60 min). The reaction was stopped using ice-cold ACN containing 
carbamazepine as the IS (0.0236 μg/mL).The samples were analyzed using LC-MS/MS (Agilent Rapid 
Resolution HPLC coupled to an ABSciex 4000QTRAP MS).  
The in vitro half-life (t1/2), intrinsic clearance rate (Clint), and hepatic extraction ratio were predicted 
using results from this assay by following the disappearance of compound and the using the following 
equations:  







 = ln 2 +
0.5[𝑆]𝑡=0
𝐾𝑀𝑎𝑝𝑝
       
Where, ln 2 ≥ 
0.5[𝑆]
𝐾𝑀𝑎𝑝𝑝
; assuming one t1/2 has passed, VM is the rate of maximum metabolism, [S] is the 
concentration of the substrate, and KMapp is the apparent rate of metabolism.  
     
Equation 3.6. Clint calculation 






 ) ( 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 (𝜇𝐿)
𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝜇𝑔)
 )     
Where, t1/2 is calculated in minutes. 
 





Where, EH is hepatic extraction ratio, Fu is fraction of unbound drug in the plasma, and QH is blood 
flow to the liver. 
 
3.3.5 Protein binding and microsomal protein binding 
The plasma and microsomal protein binding properties of compounds were assessed by adding each 
compound to a 96-deep-well plate at a final concentration of 1 μg/mL in pooled human plasma which 
was sourced with informed consent and ethics according to the UCT Human Research Ethics 
Committee ((HREC) 783/2016). Equal sample volumes were then transferred in duplicate to: (i) a total 
concentration plate, which was immediately quenched with 0.0236 µg/mL carbamazepine in ACN; (ii) 
a degradation control, with samples placed in the water bath at 37°C for 4 h; and (iii) ultracentrifuge 
tubes, before ultracentrifugation for 4 h at 37°C and 30 000 g. The reaction was stopped for all three 
sample types by the addition of ACN containing 0.0236 μg/mL carbamazepine, and the samples were 
submitted for LC-MS/MS analysis. Percentage plasma protein binding was determined by dividing the 
peak area ratio (peak area of compound/divided by the peak area of the IS) of the ultracentrfuged 
samples to the peak area ratio of the total concentration samples and multiplying this value by 100. 
Compound degradation was monitored in this assay by dividing the peak area ratio of the degradation 
control samples by the peak area ratio of the total concentration samples and multiplying this value 
by 100. The acceptable value for percentage degradation was set at 85% for this assay.  
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3.3.6 Plasma stability 
Plasma stability was assessed in a 96-deep-well plate. Compounds were added to human plasma (UCT 
HREC 783/2016) at a concentration of 10 mM. The five separate deep-well plates (one per time-point) 
were incubated at 37°C and the reactions were stopped at set time-points (0, 5, 30, 60, and 120 min) 
using ice-cold ACN containing carbamazepine as the IS (0.0236 μg/mL). The supernatant from each 
plate was analyzed using LC-MS/MS. The percentage stability was determined by dividing the peak 
area ratio of each of the time-point samples by the peak area ratio of the time-point 0 min samples 
and multiplying by 100 to obtain several percentage remaining values. These values were then used 
to construct a percentage time versus Ln percentage remaining graph for each compound. The plasma 
t1/2 was then calculated using Equation 3.8.   




   
   
3.3.7 Blood plasma partitioning ratio 
Freshly drawn aliquots of human (HREC 783/2016) and murine blood (UCT Animal Ethics Committee 
(AEC) number 013/032) were obtained. Plasma was obtained in triplicate by centrifuging blank whole-
blood at 1000 g. A mean haematocrit value was calculated by determining the amount of plasma 
removed from the sample and subtracting this value from the total whole-blood volume. These 
samples were subsequently used as the reference plasma samples. The whole-blood samples not 
centrifuged were subsequently used as the whole-blood samples. 
Each whole-blood and reference plasma sample was spiked with compound to obtain a final 
concentration of 500 nM (final volume of 2mL per sample). The samples were incubated at 37°C for 2 
h. At each time-point, 200 μL whole-blood or plasma was transferred to new Eppendorf tubes at 0, 
10, 30, 60, and 120 min post spiking. The samples were immediately centrifuged (1000 g) for 5 min 
and 50 μL of plasma (from the whole-blood samples and reference plasma samples) was transferred 
to a new Eppendorf tube for extraction. The plasma samples were kept on ice until extraction, with 
200 μL ACN containing IS. An aliquot of 100 μL of sample supernatant was submitted for LC-MS/MS 
analysis.   
Calculations were completed using the area ratios obtained by measuring the concentration of the 
drug from an equilibrating whole-blood sample relative to a carefully defined reference plasma 




Equation 3.9. Blood plasma partitioning ratio calculation 






− 1) + 1 
Where H = haematocrit, Iref-Pl = instrument response from the reference plasma, and IPl = instrument 
response from the equilibrating plasma.  
 
3.4 Partial method validation of PK LC-MS/MS assays 
3.4.1 Compound stability  
Compounds were spiked in triplicate into mouse whole-blood at low (10 ng/mL) and high (4000 ng/mL) 
compound concentrations. These samples were tested under various conditions pertinent to the 
experiment, including (i) bench-top stability on ice over 2 h, (ii) freeze-thaw stability (3 cycles) after 
freezing at −80°C and thawing to room temperature (25°C), and (iii) auto-sampler stability at the set 
auto-sampler temperature (10°C) for 48 h. These conditions replicated the (i) extraction procedure on 
bench, (ii) the freeze-thaw cycles of samples post-animal sample collection, and (iii) on instrument 
stability. The percentage stability represents compound loss due to instability and was determined by 
comparing the above samples to freshly spiked samples at the respective low and high concentrations.  
Similarly, formulation stability (both oral and intravenous) was assessed at 25°C for 2 h. The 
compounds were spiked in triplicate into either an IV formulation (1:3:6 v/v solution of 
dimethylacetamide (DMA), polyethylene glycol (PEG), and polypropylene glycol (PPG)) or oral 
formulation (100% hydroxypropyl methylcellulose (HPMC)) at a single high concentration (4000 
ng/mL). This experiment aimed to represent the time taken between compound formulation and 
animal dosing. The percentage stability was then determined by comparing freshly prepared sample 
LC-MS/MS peak areas to the sample peak areas of samples exposed to the various experimental 
conditions. 
 
3.4.2 Matrix effects (ME) 
This experiment was completed in triplicate at low (10 ng /mL) and high (4000 ng/mL) compound 
concentrations. ME were assessed by spiking compounds into a (i) pre-extracted mouse whole-blood 
sample (extracted using ACN), which was compared to (ii) a sample spiked directly into injection 
solvent (mixture of 1:1 H2O:ACN (v:v, containing 0.1% FA)). The difference in LC-MS/MS response 
between the samples is then assumed to be due to interference by the matrix (mouse whole-blood). 
ME were calculated by dividing the normalized peak area response of the analyte spiked into injection 
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solvent by the normalized peak area response of the analyte spiked and extracted from the pre-
extracted matrix and multiplying by 100 to obtain a percentage.  
 
3.4.3 Recovery from mouse whole-blood 
This experiment involved the preparation of a sample that was spiked into a pre-extracted matrix 
(extracted using ACN), which was compared to a sample that was spiked into mouse whole-blood and 
subsequently extracted. This experiment was completed in triplicate at low (10 ng/mL) and high (4000 
ng/mL) compound concentrations. The difference in LC-MS/MS response is assumed to be due to 
differences in the ability of the extraction method to remove compound from mouse whole-blood 
compared to the pre-extracted solution. The recovery percentage is calculated by dividing the 
normalized peak area of the spiked and extracted matrix sample by the normalized peak area of the 
pre-extracted sample and multiplying by 100 to obtain a percentage.  
 
3.4.3 Intra assay validation statistics  
The intra-assay validation statistics were calculated by preparing stock solutions (1 mg/mL) of each 
compound. Working stock solutions of each compound were used to prepare serial diluted 
concentrations of compound which were spiked into murine whole-blood (20 µL) to generate 
calibration curve samples (0.98 – 4000 ng/mL) and quality control smples (2 to 3200 ng/mL) in 
triplicate for each compound. Blood proteins were precipitated from murine whole-blood samples 
using 150 µL ACN containing IS (carbamazepine, 1 µg/mL). The samples were then subjected to 
vigorous vortexing for 1 min. Samples were centrifuged at 5590 g for 5 min, where-after 100 µL of the 
supernatant layer was removed from each sample and added to the analysis plate. The supernatant 
layer received 50 µL injection solvent (1:1 volume H2O:ACN) and was injected onto the LC-MS/MS 
system. These samples were used to generate calibration curves and quality control (QC) samples. The 
intra-assay validation statistics were then calculated according to the following principles: 
(i) Accuracy 
The intra-assay percentage accuracy was calculated by comparing the calibration curve and QC 
samples prepared in triplicate to the nominal value generated using the calibration curve. An 
acceptance criteria which should not deviate by more than 20% from the true value or nominal value 
presented as a percentage (%NOM) was applied to the calibration and QC samples. 
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(ii) Precision  
The intra-assay precision was calculated by comparing the same calibration and QC samples prepared 
in triplicate to the nominal value generated using the calibration curve. The acceptance criteria used 
in this study allowed a degree of variation between QC replicates of the same concentration, 
presented as the percentage coefficient of variation (%CV) of 20%, was used to determine precision 
of the assay.  
(iii) Selectivity             
The intra-assay selectivity was measured in this study by comparing the peak area response of the 
lowest limit of quantitation (LLOQ) samples extracted from murine whole-blood. The peak area 
response for the LLOQ samples was required to discern the peak of interest from background matrix 
components and other compounds using an automated quantitation algorithm.      
(iv) Sensitivity  
The method sensitivity was determined by comparing LLOQ replicate sample concentrations to the 
nominal concentration values. The %NOM and %CV values for the LLOQ were assessed by an 
acceptance criteria which did not allow deviation of more than 20% for either value.343  
 
3.5 Pharmacokinetics 
3.5.1 Murine blood pharmacokinetics 
Animal housing 
All study procedures were conducted with prior approval from the UCT AEC (013/032). Healthy male 
C57BL/6 mice, 12 to 16 weeks old, weighing approximately 30 g were maintained at the animal facility 
of UCT. Mice were fed a standard laboratory diet and water was available ad libitum. Mice were 
housed in 27 cm x 21 cm x 18 cm cages, under controlled environmental conditions (26 ± 1°C with 12 
h light/dark cycles). Mice were acclimatized to their experimental environment for 4 days before the 
experiment started.   
Oral (PO) drug administration  
Compounds were dissolved in 100% HPMC. The drug was administered by oral gavage at a dose of 20 
mg/kg (n = 3). The total volume administered per mouse was approximately 200 µL (dosed per 
bodyweight). Blood samples, approximately 20 µL, were collected via tail bleeding at 0.5, 1, 3, 5, 8, 10, 
24, and 48 h after dosing. The samples were collected on ice in lithium-heparinized micro-vials to 
prevent blood coagulation and immediately stored at -80°C.  
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Intravenous (IV) administration 
The IV doses (5 mg/kg) were formulated in a 1:3:6 v/v solution of DMA, PEG, and PPG and injected 
into the murine penile vein (n = 3). The total volume per drug administration was approximately 80 μL 
(dosed per bodyweight). Blood samples were collected via tail bleeding at 0.083, 0.5, 1, 3, 5, 8, 10, 24, 
and 48 h post dose on ice in heparinized micro-vials to prevent coagulation and immediately stored 
at -80°C. 
Sample processing and analysis  
Samples were processed using quantitative LC-MS/MS assays developed at UCT, Division of Clinical 
Pharmacology (described further in Chapter 5). Blood proteins were precipitated from 20 µL whole-
blood sample using 150 µL ACN containing IS (carbamazepine, 1 µg/mL). The tubes were then 
subjected to vigorous vortexing for 1 min. Tubes were centrifuged at 5590 g for 5 min, where-after 
100 µL of the supernatant layer was removed from each sample and added to the analysis plate. The 
supernatant layer received 50 µL injection solvent (1:1 H2O:ACN) and was injected onto the LC-MS/MS 
system. In order to determine compound concentration in blood samples, compounds were serially 
diluted into blank mouse whole-blood to generate calibration curve samples (0.98 to 4000 ng/mL) and 
quality control samples (2 to 3200 ng/mL). These samples were then extracted using the same ACN 
extraction procedure. The calibration curves constructed using the results from these samples were 
best fitted with quadratic regression using a weighting factor of 1/x. 
Chromatographic separation was performed using an Agilent 1200 Rapid Resolution HPLC system 
comprising a binary pump, degasser, and auto-sampler (Agilent, Little Falls, Wilmington, USA) coupled 
to an AB Sciex 4000 QTrap hybrid triple quadrupole linear ion-trap mass spectrometer (AB Sciex, 
Framingham, MA, USA). Reversed-phase HPLC columns, as detailed in Chapter 5, were used along with 
mobile phases comprising various solvent combinations. The mobile phases were delivered with 
different gradients. The column was kept at 20°C in a column compartment. Auto-sampling was 
completed with an Agilent 1200 series auto-sampler, injecting 5 μL into the analytical column. Samples 
were cooled to 4°C whilst awaiting injection in the auto-sampler.   
 
3.5.2 Organ distribution 
Animal housing 
Animals were kept in one group for oral dosing. Prior to dosing, drugs were prepared and formulated 
appropriately according to mouse weight. Animals were maintained in an appropriate group 
environment (wood shavings, paper towel for nesting material, red perspex mouse house) for the 




Compounds were prepared in theoretical fixed volumes for the average weight as determined above. 
Dose volumes ranged from 200 to 300 µL for oral dose (according to animal weight). Animals (n = 4) 
were dosed at 10 mg/kg, and three animals were dosed with vehicle control (100% HPMC) in order to 
obtain blank organs for calibration curves, and remained in the group environment after dosing.  
Procedure 
Mouse (M) 1 and 2 were anesthetized via intraperitoneal injection (IP) of ketamine/xylazine (75-100 
mg/kg + 10 mg/kg) at pre-determined time-point 1 (T1). Depth of anesthesia was monitored by the 
absence of the pedal withdrawal reflex. The area of M1 and M2 (thorax to abdomen) was shaved and 
washed before dissection along the mid-ventral line of the animals to expose the organs. Euthanasia 
via exsanguination was performed on M1 and M2 in order to confirm death and to ensure that the 
majority of the vascular blood had been cleared from the body. Both femoral arteries were cut and 
approximately 20 mL of saline injected into the aorta to rinse the circulatory system of blood, which 
continued until the organs took on a pale color. The organs were then dissected out, weighed, and 
flash-frozen in liquid nitrogen, and stored at -80°C. This was repeated for M 3, 4, 5, and 6. To obtain 
blank matrix for calibration curves in order to determine concentrations of drug in the organs, the 
process was repeated in the other three mice that did not receive any compound.  
Sample processing 
Organ samples were homogenized using an Omni Bead Ruptor (Omni, Georgia, USA). The programed 
settings for each organ are presented in Table 3.1. Briefly, organ samples were diluted 1:1 with PBS 
solution and homogenized according to the specific setting for each organ type. Blank homogenate 
samples were pooled in order to maximize organ volume for standard curve preparation.  
 
Table 3.1. Homogenization parameters for organ experiments 
Parameter Liver Kidney Lung Spleen Brain Heart 
Speed (m/s) 5 5.2 6 6 5 6 
Cycle time (s) 30 30 30 30 30 30 
Number of cycles 2 1 3 2 2 3 





After homogenization, organ samples (30 µL) were extracted using a liquid-liquid extraction method 
(LLE) using ethyl acetate (250 µL) and a 0.1 M Britton Robinson buffer (50 µL) prepared at pH 4 for 
PHX 1 and pH 10 for RMB 041 containing 1 µg/mL IS (carbamazepine) solution. Samples were vortexed 
(1 min) and centrifuged at 10621 g (5 min). Thereafter, 200 µL of the sample supernatant was removed 
and dried down under nitrogen. Samples were reconstituted in 150 µL of injection solvent (1:1 H2O: 
ACN) before being submitted for LC-MS/MS analysis. 
Serial dilutions of each compound were spiked into blank murine organ homogenate to generate 
calibration (3.9 - 4000 ng/mL) and quality control (10 – 3200 ng/mL) samples (n = 3), which were 
extracted using the same extraction procedure as above and submitted for LC-MS/MS analysis. LC-
MS/MS analysis was performed using the same methods used for murine PK concentrations. Briefly 
an Agilent 1200 Rapid Resolution HPLC system comprising a binary pump, degasser, and auto-sampler 
(Agilent, Little Falls, Wilmington, USA) coupled to an AB Sciex 4000 QTrap hybrid triple quadrupole 
linear ion-trap mass spectrometer (AB Sciex, Framingham, MA, USA) was used for sample analysis. A 
reversed-phase HPLC column with different mobile phase combinations were delivered using the 
same gradient as for the murine PK samples (as presented in Chapter 5). The calibration curves 
generated were then used to quantitatively determine the concentration of each analyte in the 
respective murine organ samples. 
 
3.5.3 Bronchoalveolar lavage (BAL) fluid analysis 
Animal housing 
Animals were kept in one group for oral dosing. Prior to dosing, drugs were prepared and formulated 
appropriately according to mouse weight. Animals were maintained in an appropriate group 
environment (wood shavings, paper towel for nesting material, red Perspex mouse house) for the 
duration of the exposure period.  
Dosing 
Compounds were prepared in theoretical fixed volumes for the average weight as determined above. 
Dose volumes ranged from 200 to 300 µL for oral dose. Animals (n = 6) were dosed at 10 mg/kg (based 
on weight) and three animals were dosed with vehicle control (100% HPMC) in order to obtain blank 
BAL fluid for calibration curves, and remained in the group environment after dosing. 
Procedure 
M1 and M2 were anesthetized via IP of ketamine/xylazine (75-100 mg/kg + 10 mg/kg) at a pre-
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determined time-point 1 (T1). Depth of anesthesia was monitored by the absence of the pedal 
withdrawal reflex. A blood sample (15 µL) was taken 10 min before the BAL procedure from M1 and 
M2 via tail tip bleeding. This sample was immediately spun down (5 min, 10621 g) to obtain plasma. 
This was done to compare the circulating concentration of compound in the plasma to the 
concentration within the lung fluid at the time of the BAL fluid extraction procedure. M1 and M2 were 
then prepared for the surgical procedure by shaving and washing of the neck area. Dissection of the 
tissue from neck to expose trachea to allow a small incision into the trachea was completed to allow 
passage of 23 gauge IV catheter into trachea. The wash fluid containing PBS was introduced into the 
lungs of the animals via the lavage tube, aspirated inside of the lung and was then removed using the 
same syringe. The trachea of each animal was stabilized with forceps throughout. The procedure 
consisted of four washes per animal, collected on ice, and the total volume collected was recorded. 
Each wash was introduced at a volume of 100 µL. Exsanguination of the animal was the mode of 
euthanasia used immediately post-procedure (cardiac puncture). The process was repeated for the 
remaining M3, M4, M5, and M6 at the relevant time-points. In order to obtain blank BAL fluid, the 
process was also repeated for mice (n = 3) which were dosed with vehicle control. Blood from these 
mice was immediately spun down (5 min, 10621 g) and the plasma was removed.   
Sample processing 
BAL samples were assessed for cell number using a trypan blue staining method and a TC-20 
automated cell counter (BioRad, CA, USA). The dye exclusion test determines the number of viable 
cells present in a suspension. In this test, a sample containing cells (10µL) was mixed with the same 
volume of dye and the number of cells which take up or exclude dye was measured. In the protocol 
presented here, a viable cell will have a clear cytoplasm whereas a non-viable cell will have a blue 
cytoplasm.344 BAL samples were then processed by initially spinning down (5 min, 10621 g) the 
aspirate to pellet any remaining cells, followed by removal of the aspirate supernatant.   
ELF volume determination 
BAL supernatant was analyzed using the colorimetric Quantichrom urea assay kit DIUR-500 (BioAssay 
systems, CA, USA). Calibration samples were prepared (in triplicate) in a 96-well format by serially 
diluting a urea stock solution (1 mg/mL) in PBS solution, to cover the range from 0.39 µg/mL to 100 
µg/mL. Samples were analyzed by the addition of 200 µL of a proprietary “working solution” to 5 µL 
of each calibration, ELF, and plasma sample and left to incubate for 20 min at room temperature. The 
optical density of each sample was read using a BioRad iMark™ Microplate Absorbance Reader 
(BioRad, CA, USA). A calibration curve was constructed using these readings and quantitative 
estimations of urea concentration in both the plasma and BAL were determined using this calibration 




Equation 3.10. Determination of ELF volume in murine BAL fluid  
VELF= VBAL X [urea]BAL/[urea]plasma 
      
Sample processing leading to LC-MS/MS analyses 
Cellular, plasma, and lung fluid samples were processed by the addition of 150 µL of ACN containing 
1 µg/mL of IS (carbamazepine) to 20 µL of sample, followed by vortexing (1 minute) and centrifugation 
(5 min, 10621 g). Supernatants were then removed and dried down under nitrogen and reconstituted 
for LC-MS/MS analysis using injection solvent.  
Standards and QC samples were prepared in each matrix (pooled blank murine matrices) in triplicate 
and were extracted using the same ACN protein precipitation method as above. LC-MS/MS analysis 
was performed using the same methods used for murine PK concentrations. Briefly an Agilent 1200 
Rapid Resolution HPLC system comprising a binary pump, degasser, and auto-sampler (Agilent, Little 
Falls, Wilmington, USA) coupled to an AB Sciex 4000 QTrap hybrid triple quadrupole linear ion-trap 
mass spectrometer (AB Sciex, Framingham, MA, USA) was used for sample analysis. ELF 
concentrations were subsequently calculated for each mouse using Equation 3.11 below.  
Equation 3.11. Concentration of drug in ELF 
[Compound]ELF= [Compound]BAL × VBAL/plasma 
 
3.6 Microbiology 
3.6.1 Uninfected macrophage assay 
Tamm-Horsfall Protein 1 cells (THP-1) were adhered to plastic 24-well plates over the course of 24 h 
using 0.1 µM phorbol 12-myristate 13-acetate (PMA). The cells were then supplemented with Roswell 
Park Memorial Institute (RPMI) medium containing 10% fetal calf serum (FCS). The cells were grown 
at 37°C in 5% CO2.  
RPMI containing 20X Mtb MIC90 of the drugs (compound specific) was added to the cells in a volume 
of 500 µL in triplicate. The cells were allowed time to equilibrate before removal of the medium. This 
was followed by washing of the cells using 300 µl RPMI medium and was repeated thrice. The addition 
of 200 µL ethylenediaminetetraacetic acid (EDTA) for 5 min caused the detachment of the cells from 
the surface of the plate. The cell numbers were determined using a trypan blue staining method and 
a TC-20 automated cell counter (BioRad, CA, USA) as mentioned above, in section 3.5.3.  
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The cells were then lysed using 100 µL of the ACN (0.1% Triton X100) solution containing compound-
specific deuterated IS (1 µg/mL) for the known anti-TB compounds and carbamazepine (1 µg/mL) and 
the sample was removed from the well. The samples were then stored at -80°C overnight before 
further processing. Samples were vortexed (1 minute) and centrifuged (5 min, 10621 g). Supernatants 
were removed and dried down under nitrogen and reconstituted for LC-MS/MS analysis using 
injection solvent.  
The samples were thawed and transferred into a 96-well analysis plate, and dried under a gentle 
stream of NO2 gas to concentrate. The sample was then reconstituted in a mixture of 1:1 H2O:ACN 
(containing 0.1% FA, v:v). An equal volume of solution at a final 1000 ng/mL in ACN was added to the 
reconstitution mixture before analysis via LC-MS/MS. Samples were processed using quantitative LC-
MS/MS assays developed Samples were processed using a quantitative LC-MS/MS assays as described 
in Chapter 5 for the novel compounds and several clinically-used assays (Division of Clinical 
Pharmacology, UCT) were modified for use in this study. Chromatographic separation was performed 
using an Agilent 1200 Rapid Resolution HPLC system consisting of a binary pump, degasser, and auto-
sampler (Agilent, Little Falls, Wilmington, USA) coupled to an AB Sciex 4000 QTrap, hybrid triple 
quadrupole linear ion trap mass spectrometer (AB Sciex, JHB, South Africa). Chromatographic 
separation was performed using an Agilent 1200 Rapid Resolution HPLC system consisting of a binary 
pump, degasser, and auto-sampler (Agilent, Little Falls, Wilmington, USA) coupled to an AB Sciex 4000 
QTrap, hybrid triple quadrupole linear ion trap mass spectrometer (AB Sciex, JHB, South Africa).  
Blank cell lysates (lysed using ACN (0.1% Triton X)) were spiked in triplicate with serially diluted 
compound concentrations to generate the calibration (2 - 5000 ng/mL) and quality control (6 – 4000 
ng/mL) samples. These samples were extracted using the same procedure above and were used to 
construct calibration curves to quantitate the amount of analyte in each respective intracellular 
sample. Extracellular concentrations were determined by spiking serially diluted concentrations of 
compound into media removed from the untreated cells to generate calibration and quality control 
samples, which were then extracted using the same procedure as above and used to quantitate the 
amount of compound in each extracellular sample. 
 
3.6.2 Fluorescence microscopy and flow cytometry 
Fluorescence microscopy 
THP-1 cells were seeded in a 24-well plate containing a single pre-treated (poly-L-lysine) cover slip at 
5 x 105 cells/well. After PMA maturation for 24 h, the cells were infected with a log-phase culture of 
GFP-expressing Msm (OD = 0.6) at a multiplicity of infection (MOI) of 5. The infection was allowed to 
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continue for 30 minutes after which the wells were washed with fresh RPMI medium. RPMI medium 
containing 1 µg/mL of each drug was added to each well, in triplicate. The experiment was allowed to 
progress for an additional 2 h before the wells were again washed with RPMI medium. The cover slips 
were carefully removed from each well and adhered to a microscope slide containing a single drop of 
paraformaldehyde. Microscope slides were then examined using an Axio Scope A1 microscope and 
images were captured using a Zeiss 1 MP monochrome camera (Carl Zeiss, Germany). Samples were 
exposed to the same exposure settings for respective channels for image acquisition. Green 
fluorescence from the GFP bacteria was detected using a 488 nm excitation filter and a 510 nm 
emission filter set. Red fluorescence from the compounds was detected using a 587 nm excitation 
laser filter and 610 nm long-pass emission filter. Finally, bright-field imaging was used to detect the 
position of the bacteria within the macrophage cells. 
Flow cytometry 
In addition, flow cytometry was used to isolate Msm-infected THP-1 cell populations whilst 
simultaneously monitoring PHX 1 accumulation in the allophycocyanin (APC) channel (red 
fluorescence, 650 nm excitation and 660 nm emission wavelength). 
THP-1 cells were seeded at a concentration of 5 x 105 cells/well. After PMA maturation for 24 h, the 
cells were infected with a log-phase culture of GFP-expressing Msm at a multiplicity of infection (MOI) 
of 5. The infection was allowed to continue for 30 minutes after which the wells were washed with 
fresh RPMI medium. RPMI medium containing 1 µg/mL of drug was added to each well. The 
experiment was allowed to progress for an additional 2 h before the wells were again washed with 
RPMI medium. Cells were detached using 200 µL of EDTA (5 mM). Samples were left unfixed as fixation 
agents may have caused cell lysis and loss of drug. Sorting was completed using the FACS Jazz™ cell 
sorter instrument for 10 000 events per samples (BD, NJ, USA). Gating was initially based on forward 
and side scatter (size of macrophage) to differentiate debris and undifferentiated cells, followed by 
further gating based on the live/dead stain SYTOX® (used according to manufacturer’s instruction). 
Samples were analyzed and further sorted based on GFP fluorescence, providing both uninfected and 
infected populations of cells. Results were analyzed using the FlowJo software package.  
 
3.6.3 M. tuberculosis-infected macrophage assay 
A modification of a previously described protocol (section 3.6.1) using the THP-1 cell line was used as 
seen in Figure 3.1. The human acute monocytic leukemia cell line THP-1 was grown in RPMI medium 
containing 10% FCS at 37°C in 5% CO2. Cells were seeded and differentiated according to the above 
protocol for 24 h using PMA. 
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M. tuberculosis (H37RvMa) cells were grown to mid-LogPhase (cultured according to protocol 3.2.1) 
in 7H9 medium. THP-1 cells were infected at an MOI of 5:1. Three hours were allowed for infection to 
occur, followed by washing with RPMI medium to remove extracellular bacteria and dead cells. RPMI 
medium containing a pre-determined concentration of compound was added to each well (except 
drug-free controls) in a volume of 500 µL, in triplicate. The solution was allowed to equilibrate for 30 
min. In addition, three wells for each compound were left without drug treatment (following Mtb 
infection) and served as untreated controls, whilst an additional three wells of THP-1 cells were left 
uninfected and were used as uninfected controls.   
Thereafter, at each time-point, cells were washed (three times with 300 µL RPMI medium). This was 
followed by the addition of 200 µL EDTA (5 mM), after which 5 min was allowed for the cells to detach. 
Trypan blue-stained cells were counted using the automated cell counter, as before, in uninfected 
cells (section 3.5.3). The remaining supernatant (150 µL) was added directly to an Eppendorf tube 
containing chloroform:methanol (3:1, v:v) and 1µg/mL of compound specific IS (deuterated IS for 
known anti-TB compounds and carbamazepine for novel compounds). An aliquot of 5 µL of the 
remaining supernatant was added to 90 µL RPMI medium and 10 µL of this solution was streaked onto 
hygromycin-containing 7H10 plates and placed at 37°C, followed by counting 21 days following 
plating.  
After the collection of samples at the remaining time-points, the samples were surface-
decontaminated and stored at -80°C overnight. Samples were removed from the BSL III laboratory and 
processed (according to section 3.6.1). The samples were thawed and transferred into a 96-well 
analysis plate, and dried down under a gentle stream of NO2 gas to concentrate. The samples were 
then reconstituted in a mixture of 1:1 ACN:H2O (containing 0.1% FA, v:v) before analysis via LC-MS/MS. 
Samples were processed using quantitative LC-MS/MS assays as described in Chapter 5 for the novel 
compounds and several clinically-used assays (Division of Clinical Pharmacology, UCT) were modified 
for use in this study. Chromatographic separation was performed using an Agilent 1200 Rapid 
Resolution HPLC system consisting of a binary pump, degasser, and auto-sampler (Agilent, Little Falls, 
Wilmington, USA) coupled to an AB Sciex 4000 QTrap, hybrid triple quadrupole linear ion trap mass 
spectrometer (AB Sciex, JHB, South Africa).  
Blank infected cell lysates (lysed using chloroform:methanol) were spiked in triplicate and extracted 
using the same procedure above to generate compound specific standard and quality control samples. 
These were then used to construct calibration curves which were subsequently used to quantitate the 
amount of analyte in each respective sample. Extracellular concentrations were determined by spiking 
serially diluted concentrations of compound in triplicate, into media removed from untreated THP-1 
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cells to generate calibration and quality control samples, which were then extracted using the same 
procedure as above and used to quantitate the amount of compound in each extracellular sample.  
 
 
Figure 3.1. Experimental layout for the M. tuberculosis-infected macrophage assay 
 
3.6.4 Synergy assay 
Drug interactions were assessed by checkerboard dilution in a 96-well format with slight modifications 
to the method described by Chen et al., 2006.345 The first column contained drug-free control cells and 
the last column contained control drug giving maximum inhibition. Compound A (PHX 1) was pipetted 
at starting concentrations 100-fold higher than those in the 96-well plate along the x-axis (column 3-
11) and compound B was pipetted at starting concentrations 50-fold higher than in the 96 well plate 
(from row B to H). Column 1 and column 12 contained maximum inhibitory concentrations of drug (no 
bacterial growth) and media containing only Mtb (maximum bacterial growth), respectively. Row A3-
A11 contained only PHX 1 and column B2-H2 contained only Coco 296, which allowed for the 





Figure 3.2. 96-well plate layout for 2-D synergy assay 
 
Mtb were overlaid (100 µL) onto the drug containing wells at a concentration of 1 x 108 cells/mL (OD-
0.6). Plates were incubated at 37°C for 8 days. Following the addition of resazurin, the plates were 
incubated for a further 3 days to allow a color change from blue to pink, associated with mycobacterial 
growth and read at 560 nm on a Spectramax multi-mode plate reader (Molecular Devices). Synergy 
was determined by the fractional inhibitory concentration index (FICI) in Equation 3.12.  
 
Equation 3.12. FICI ratio determination 






   
Where CAcomb and CBcomb are the concentrations of drugs A and B which are the iso-effective 
concentrations (combinations of each drug which produced a level greater than their respective 
MIC90). 
FICI values for which the FICI ≤ 0.5 represented synergy, FICI > 4 antagonism, and any value between 








In this chapter, the use of the absorption, distribution, metabolism, and elimination (ADME) screening 
cascade (Figure 4.1) is described and used to identify a group of anti-TB compounds with suitable in 
vitro properties. Compound triage followed the identification of several compounds showing selective 
in vitro activity against Mtb H37Rv. The results of experiments described in this chapter allowed us to 
determine the in vitro ADME properties of the selected set of compounds. We investigated the most 
relevant drug-like properties of the compounds including solubility, lipophilicity, forms of protein 
binding, metabolic stability, and various other properties. The ADME data were subsequently used to 
generate in vitro/in vivo correlations and dose predictions to support the testing of compounds in a 
murine pharmacokinetic (PK) model.   
 




4.2.1 ADME screening cascade 
A chemical compound can only be a drug if it is able to perform a specific set of actions in the human 
body.347 However, it is important to appreciate what is required of a drug once it is ingested so that it 
may be able to exert its designated effect. The drug needs to pass from the alimentary canal into the 
bloodstream before making its way in sufficient concentration to the site of action, usually a tissue or 
cellular environment. To accomplish this journey, a drug needs to dissolve, endure a vast pH range 
and survive enzyme degradation, cross membranes, and avoid accumulating in undesired locations. 
The study of this process is collectively termed drug metabolism and pharmacokinetics (DMPK). The 
measurement of ADME properties is important for predicting whether or not a compound will be 
clinically successful.  
The establishment of in vitro ADME assays that are logical, high-throughput, and allow for the accurate 
prediction of some of the vital pharmacological properties of drug candidates in vivo have filled this 
niche in the pre-clinical setting.348 As with most assays used in isolation, ADME assays do not have 
especially useful predictive power when considered alone. Assays comprising a screening cascade are 
far more powerful, as together the assays can be adapted and reworked to suit most drug discovery 
challenges.  
The success of an assay can be measured using a strict set of properties, which include reproducibility, 
predictive strength, turnaround time, and costs associated with the setup and running of the assay.349 
These screens may be carried out in any particular order, depending on what is required of them. 
However it has been suggested that in the early stages of discovery, the so-called hit-to-lead stage, 
certain assays should be used in a pre-determined order to give medicinal chemists an idea of some 
of the basic drug-like properties of the compounds. These particular properties include solubility, 
lipophilicity, liver microsomal stability, and permeability.350  
The results obtained through these assays offer insight into which compounds could potentially move 
forward along the pipeline. Because of their significant anti-TB activity and minimal cytotoxicity 
(providing a selectivity index, by dividing the cytoxicity value by the activity value, of > 10), solubility, 
lipophilicity, and permeability properties of the compounds were investigated. The tier 1 assays 
determine whether the compounds will potentially permeate further into the organs, tissues, and cells 
of TB pathology. Solubility is an extremely important factor in this decision as many of the ADME tests 
that follow are completed at a pH of 7.4. If the compound has poor solubility at this pH, future tests 
become difficult to interpret as false positives and negatives are difficult to separate from accurate 
results. In addition, the likelihood of obtaining reliable PK data is reduced because of the erratic 
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solubility of the compound in solution. The assays also become costly as we move from tier 1 to tier 2 
and 3 assays, making this decision even more important from a drug development perspective.  
Following completion of the tier 1 assays (solubility, lipophilicity, and permeability) a decision point is 
reached. Using these tier 1 data, we can decide whether the compound should be tested in the more 
specific tier 2 and tier 3 assays. Tier 2 and tier 3 assays allow us to answer more specific questions as 
we move towards murine pharmacokinetic experimentation. The protein binding and microsomal 
stability assays give us a greater understanding of how the drug might behave within the in vivo murine 
model and, therefore, were deemed more relevant to this study, placing them in the slightly more 
important tier 2 assay category. The tier 3 assays of blood-to-plasma partitioning (BPP) and plasma 
stability are used mainly to supplement the human dose prediction of the data and were deemed less 
crucial to compound progression and decision-making.      
With the use of this screening cascade, most of the important drug-like properties are measured. 
Exceptions to this include the cytochrome P450 and Caco-2 assays, which were deemed too 
specialized for an initial ADME screen; it was decided that these would be carried out if it turned out 
that exceptionally high levels of metabolism or permeability were to be observed.   
 
4.2.2 ADME in TB drug discovery 
In early drug discovery programs, priorities often center on the in vitro potency of hits, with PK 
parameters often considered later in development. With hit compounds needing to penetrate the 
various microenvironments in which Mtb resides, compounds need to possess properties that allow 
them to reach these sites of infection. This places anti-TB compounds in a very distinctive and varied 
chemical space compared to drugs acting against other infectious or non-infectious diseases.34 
Moreover, even the most active hits will be largely ineffective if these do not possess favorable ADME 
properties required for penetration into the site of action. This was emphasized in a recent review in 
which it was stated that hit compounds with preferred physicochemical properties should be 
prioritized over those with higher activity but inferior physicochemical properties.115 The review also 
emphasized the need to favor compounds with properties that support penetration into the various 




4.2.3 ADME properties 
Absorption 
a. Solubility 
The passage of drugs through the human body begins with the administration of the drug. This can be 
accomplished via several different routes based on the drug target, the therapeutic dose required, 
and the formulation of the drug. These routes offer different advantages as well as drawbacks. Oral 
administration is the most common route of delivery as it carries the fewest complications for 
patients, although it presents an array of difficulties for development scientists.115 The drug first enters 
the mouth where it can be partly solubilized, before moving into the esophagus from where it can 
make its way into the stomach. This is the first significant obstacle to drug absorption.351 The stomach 
forms part of the gastrointestinal tract (GIT), which also includes the small and large intestines. The 
pH of the GIT is extremely important in determining the dissolution rate of compounds, and fluctuates 
between acidic and neutral conditions, as shown in Figure 4.2 below. 
 
Figure 4.2. pH of the GIT 
 
This process of solubilization involves chemical breakdown by the various constituents of the GIT, as 
well as physical breakdown of the compound by GIT movements.352 Solubility can be defined as the 
maximum concentration that a compound reaches in a solvent when at equilibrium with its solid 
state.353 However, this value constantly fluctuates based on various external conditions. The solubility 
should therefore be determined under various conditions, such as the differing pH levels found in vivo. 
This is particularly important when considering TB, as the pH levels in the different microenvironments 
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of TB pathology are diverse, with the macrophage varying from a pH of 4.5 to 6.4 depending on 
activation status.18,164 This certainly contributes to the lack of efficacy seen in these 
microenvironments as the compound could simply precipitate out of solution when placed in a pH 
environment in which it is not soluble.      
Solubility may be defined as either kinetic or thermodynamic.353 Kinetic solubility implies that 
equilibrium is not reached between the dissolved and solid compound, while in thermodynamic 
solubility, equilibrium is reached between the dissolved and solid material.354 The dissolution rate is 
less influential in the measurement of kinetic solubility due to the compound being dissolved in DMSO. 
This may cause a slight disagreement between the thermodynamic and kinetic measurements of 
compound solubility as thermodynamic solubility involves the use of no prior dissolution step. 
The determination of kinetic and thermodynamic solubility answers two related but distinctive ideas. 
Kinetic solubility determines whether a compound will precipitate, while thermodynamic solubility 
predicts how well a compound dissolves.355 Kinetic solubility is the preferred choice for drug discovery 
because of its high throughput and cost-effectiveness.355 As mentioned, the GIT is a labyrinth 
consisting of varying pH environments, constituents, and rates of transition, which makes predicting 
how a drug will respond to the changing conditions extremely difficult.  
Nevertheless, assumptions can be made about how a drug will behave based on knowledge obtained 
from examination of drug behavior in artificial environments such as pH buffers and solutions. Bio-
relevant buffers that closely resemble properties of the conditions of the GIT are able to simulate what 
may happen to a drug during its passage through the digestive system.356 Some key examples include 
fasted state simulated intestinal fluid (FaSSIF) buffer and fed state simulated intestinal fluid (FeSSIF) 
buffer. These bio-relevant buffers contain a mixture of lecithins (phospholipids) and bile salts (sodium 
taurocholate) and are designed to replicate the GIT fluids as accurately as possible.357  
In combination, the assays that are used to predict the solubility within these compartments, 
providing that they are used in the correct sequence, should allow one to predict how effectively the 
drug will make its way to the target site. 
 
b. Lipophilicity 
Lipophilicity is a measure of how a compound will partition into an aqueous or organic (lipophilic) 
environment.358 Essentially, this demonstrates how effectively a compound is able to move from an 
aqueous solution through a membranous barrier. The lipophilicity of a compound is primarily assessed 
using values for the apparent partition co-efficient, which shows the tendency of a compound to 
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partition into either a hydrophilic phase (aqueous buffer) or a lipophilic phase (octanol).359 This 
predicts whether the compound will cross membranes, as the properties of octanol are thought to be 
similar to those of lipid bilayer membranes, making it a good solvent for the representation of passive 
diffusion across biological membranes.358  
Lipophilicity data may aid in predicting the penetration and efficacy of a drug in various pH 
environments, which is particularly relevant for TB, since low lipophilicity limits absorption and 
decreases oral bioavailability (BA).360 The basic principle of absorption dictates a definite order of 
actions that must occur for a compound to be absorbed into the systemic circulation. Following oral 
administration, the compound should first disintegrate, then dissolve, and finally diffuse across the 
surface of the intestinal epithelial membrane, before passing into the systemic circulation.358  
 
c. Permeability 
Permeability, another property related to absorption, is a measure of how well a drug can cross 
cellular membranes and is a rate limited process.361 However, permeability is focused on the specific 
transport mechanisms a compound uses to penetrate the human microenvironments. This is one of 
the most difficult properties to assess accurately in vitro as the cell membrane contains numerous 
transporters that allow a molecule to pass from one side of the membrane to the other.362 Passive 
diffusion occurs when molecules move by Brownian motion through the various layers of the cell 
membrane.363 Passage through membranes can also occur by means of numerous other transporters 
and transport systems, such as active transport and para-cellular transport.364  
Permeability may be determined using artificial membranes, mammalian tissue, as well as by means 
of in silico tests. Artificial membrane assays include the parallel artificial membrane permeability assay 
(PAMPA), which measures the ability of drugs to cross an artificial chemical membrane on a filter plate. 
It is limited in its applications as it is only able to measure passive cellular diffusion of small molecular-
weight molecules (<800 Da) accurately.365 The majority of permeability assessments carried out to 
date generally use Madin-Darby canine kidney (MDCK) and human colon adenocarcinoma cells (Caco-
2).358 MDCK cells are derived from dog kidneys and this makes it difficult to predict many of the 
mechanisms that occur in the human intestine, and the method focuses instead on generalized 
transporters that are shared by both cell types.366 Conversely, the Caco-2 cell permeability assay is 
derived from human carcinoma cells, making predictions surrounding issues such as transport systems 
far more predictive of the human transport system than other assays.364,367,368 Shortcomings of both 
the MDCK and Caco-2 assays include the complicated culturing procedures, high costs both in terms 
of maintenance and culturing, low turnaround times, and low sample throughput.369 However, it is 
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important to determine permeability: if the compound possesses poor permeability properties, it will 
be unable to enter the cell and the BA will be low. 
The lipophilicity of a compound will undoubtedly have an influence on the permeability of that 
compound. Lipophilicity has an ideal range for which the permeability is consistently high, while values 
above and below this range are associated with poorly permeable compounds. As illustrated in Figure 
4.3, an ideal compound will display a moderate experimental LogD value (between 1 and 3) as 
compounds in this range generally show favorable solubility and permeability, resulting in increased 
intestinal absorption and moderate metabolic activity.361 Problems with compounds that have a LogD 
value greater than 3 include poor predicted aqueous solubility and subsequently poor predicted BA, 
while compounds with a LogD value below 1 are predominantly concerned with poor lipid bilayer 
permeability.360  
The partition coefficient (LogP) and distribution coefficient (LogD), differ in their respective 
measurement of the ionized concentration of the molecule. LogP, refers to the partitioning of 
unionized concentration of molecules into the aqueous and organic phases, whilst LogD refers to the 
distribution of all compound species (both ionized and neutral), making LogD values slightly more 
difficult to interpret.358 Therefore, we need to be cognizant of the fact that lipophilicity is influenced 
by the pH at which the compound is tested and that general rules such as the one above do not always 
apply.370 Compound ionization at particular pH values influences the partitioning of the drug into 
either the aqueous phase (if the drug is ionized) or into the organic octanol phase (if the drug is in the 
neutral form). Acidity or basicity, as measured by the pKa, are thus extremely important when 
discussing LogD values.  
Lipinksi’s Rule of Five aimed to provide a set of guidelines for the discovery of compounds with better 
predicted absorption and BA.371 According to the Rule of Five, compounds that have MW <500 g/mol, 
will have greater predicted solubility and permeability leading to increased absorption and BA both in 
vitro and in vivo.354,371 Notably, the Rule of Five does not cover compounds which are substrates for 
transporters making it difficult to use as a definite rule for all compounds.  
  




Figure 4.3. General rule for lipophilicity (LogD) values and their relationship to solubility and 
permeability (adapted from Kerns and Di, 2008)  
 
The properties of permeability, lipophilicity, and solubility are inextricably linked in a balancing act 
that ultimately determines how the compound is absorbed. For example, increasing the lipophilic 
properties by adding more hydrophobic functional groups will increase permeability while decreasing 
solubility.358 These properties must be optimized early in the drug discovery stage as the important in 
vivo BA of the compound is also influenced by the interaction of these properties which ultimately 
dictate compound absorption. 
 
Distribution 
Once absorbed, a compound can be distributed throughout the body, a very important factor in the 
context of TB, a disease that can affect multiple sites. The parameter associated with distribution is 
known as the volume of distribution (Vd). This is a theoretical value and is referred to as a 
proportionality constant between the amount of compound present in the body and the 
concentration of compound in the body fluid where the measurement is recorded.372 Distribution of 
the drug within the body is dependent on numerous factors, including binding to various components 
such as blood, tissues, and plasma proteins. This is due to the fact that only the unbound fraction is 




a. Protein binding 
There are specific plasma protein binding interactions that occur in the human body, with human 
serum albumin (HSA) being the main drug carrier.374 HSA is the most abundant protein in plasma, 
controlling the fluid distribution between body compartments.374 Plasma proteins have an important 
influence on the pharmacokinetics and pharmacodynamics of drugs.  
The apparent Vd is an estimate of the extent to which drugs are distributed throughout the body. 
Drugs that are highly bound to plasma proteins are usually not well distributed and have low Vd values, 
while drugs that have larger free fractions are available for distribution to various tissues, which is 
known as the ‘free drug theory’.372  
It is not only distribution that is affected by plasma protein binding. Vital processes such as metabolism 
and elimination are affected by the binding of plasma proteins. The glomerular filtration rate and 
hepatic uptake rate are both directly affected by plasma protein binding. This is highlighted by drugs 
such as propranolol, which relies on the plasma proteins to which it is bound for delivery to the 
liver.375,376 This is known as flow-dependent hepatic elimination.  
In addition, non-specific microsomal binding is an important factor. The use of microsomal fractions 
and other liver-related cells to determine the rate of drug metabolism is commonplace in the drug 
discovery field. However, as in other areas of the body, free or unbound drug is thought to be the only 
fraction that is available for interaction with metabolizing enzymes in the liver. The use of liver 
microsomal proteins to determine the clearance and metabolism of compounds requires the 
additional calculation of the free fraction of compound available to the body after binding to the 
microsomal proteins.377,378 Inclusion of microsomal protein binding data can have a significant impact 
on the overall clearance value calculated using liver fractions, with some drugs exhibiting a 
discrepancy of several degrees of magnitude in the clearance ratio.378 These more accurate predictions 
will aid drug discovery scientists to model the clearance of drugs in vivo more effectively.  
Commonly used protein binding assays include equilibrium dialysis, ultrafiltration, and 
ultracentrifugation. The rapid equilibrium dialysis (RED) method makes use of an equilibrium dialysis 
membrane with a low molecular-weight cut-off, so proteins or protein-bound molecules cannot 
cross.379 The spiked biological material is added to the one side of the insert and buffer is added to the 
other side, after which samples are harvested from both sides to measure how much free drug has 
managed to cross the membrane. The advantages of this procedure include the high accuracy of the 
results and the intermediate throughput of samples. The disadvantages include the laborious nature 
of the assay making it difficult to fully automate, as well as the fact that leakage from the RED inserts 
has been reported at high shaking speeds.379  
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The ultrafiltration method relies on a brief incubation of the compound in plasma, followed by the 
filtration of the mixture through a low molecular-weight cut-off filter. The advantages of this method 
include the fact that it offers higher throughput and therefore more samples can be analyzed at one 
time. One of the major disadvantages for the use of this method is that it is commonplace to see non-
specific binding of proteins to the membrane, which makes results less consistent.380  
The ultracentrifugation method involves the spiking of compound to plasma and the use of ultra-high-
speed centrifugation (>40 000 rpm).381 The ultracentrifugation method separates the protein-bound 
compound from the unbound protein component based on differing molecular weights. The 
advantages of this method include the fact that the method is straightforward and avoids the 
membrane interference of the RED and ultrafiltration methods. Disadvantages include the amount of 
time needed for sample preparation, which cannot be easily mechanized.  
 
Metabolism 
Drug metabolism refers to a biochemical transformation into more polar forms so that compounds 
are more water-soluble and can thus be excreted in urine and bile.358 This occurs by two types of 
reactions known as phase I and phase II metabolism. Phase I reactions cause a change to the molecular 
structure of the compound (e.g., by oxidation or dealkylation reactions), while phase II involves the 
addition of polar groups to the molecule by conjugation reactions.382 The drug may also be 
metabolized before reaching the systemic circulation, which can be a major source of compound 
breakdown. This is known as first-pass metabolism. The liver is the main organ responsible for drug 
metabolism and contains high concentrations of drug-metabolizing enzymes. The dominant enzymes 
involved in the metabolism of drugs are the cytochrome P450 enzymes, uridine 5'-diphospho (UDP)-
glucuronosyltransferases, and esterases.382 Together, these three enzyme groups account for 
approximately 95% of all drug metabolism.383  
Drug metabolism involves the following process: the drug binds to the enzyme, it is chemically 
modified by the enzyme, and finally the drug metabolites dissociate from the enzyme. Assessing this 
process in vitro is accomplished using a metabolic stability assay. The assay is used to identify 
compounds that may be metabolically labile. To do in vitro screens, it is important to have the 
biological material that contains the specific enzymes, such as cytochrome P450 and esterases. The 
preparation of liver materials is extremely important and involves the isolation of liver fractions from 
a specific donor (e.g., mouse, rat, dog, or human). A repeated centrifugation process is followed by 
collection of the cell pellet produced at the end of the process known as liver fractionation. The 
process produces fractions containing metabolizing enzymes in varying concentrations. Among the 
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various in vitro metabolic stability approaches, the use of liver microsomes has gained a reputation 
for being an extremely useful indicator of drug metabolism. A measure of the disappearance of the 
parent drug can be analyzed over a set time period or, alternatively, the prominent metabolites that 
form from the parent compound can be identified and measured, both of which allow the assessment 
of how significantly the parent compound has been metabolized.384 The predicted t1/2 (amount of time 
taken for the compound to reach half of its original starting concentration), predicted Clint (the rate at 
which a specific organ metabolizes the compound excluding all other factors), and hepatic extraction 
ratio, are factors that can be determined using the various fractions of the liver in biological assays. 
Increased metabolic stability has far-reaching secondary effects, including decreased drug-drug 
interactions, fewer potential side-effects, and greater drug effectiveness. 
Blood is also composed of numerous enzymes that influence the metabolism of drugs in the body, 
with the most important enzymes present being the esterases. Ester hydrolysis by esterases occurs 
primarily through the influence of cholinesterases (including acetyl cholinesterases, pseudo-choline 
esterases, and various other esterases), or alternatively by the esterases located in the liver. These 
hydrolysis reactions can have a definite effect on the duration of action of certain drugs.385 Esters, 
lactones, lactams, carbamates, sulphamides, and peptide mimetics are vulnerable to plasma 
hydrolysis.  
The stability of a compound in plasma is important as compounds need to be in their active form in 
the plasma to offer a beneficial effect when they reach the target sites. If the compound is unstable, 
it will likely show poor in vivo efficacy, as less of the drug will be available to accomplish its intended 
task unless the drug produces active metabolites. Assessing how compounds are affected by enzymes 
present in the plasma is usually accomplished using an in vitro plasma stability assay. This assay is 
commonly completed at a later-stage during ADME studies and is usually reserved for esters, amides, 
and lactones that are susceptible to plasma esterase activity. One problematic aspect of plasma 
stability assays is that metabolism is organism-specific and may even vary between batches of plasma 
from the same species.386  
Those aspects of metabolism involving the generation of metabolites and their identification were 
considered here but could not be examined in this study because of time constraints. 
 
Elimination 
Once metabolized, it is necessary for the drug to be cleared from the body to prevent the build-up of 
drug levels and of potentially toxic metabolites. The efficiency of this process is dependent on blood 
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flow through the organs of clearance, the efficiency of the organ of clearance, and various other 
factors including plasma protein binding.387 The major organs of clearance include the liver and the 
kidneys, with the liver being the major source of drug clearance simply because of its high metabolizing 
enzyme expression and extensive blood perfusion. In conjunction with the metabolic role of the liver, 
drugs can also be cleared by biliary elimination. The products of this type of hepatic clearance are 
either stored in the gall bladder or excreted in the feces. The primary role of the kidney is to produce 
urine (to allow filtrate elimination), whilst simultaneously regulating water loss. This task is 
accomplished through the presence of the complex structures of the kidney, which filter out 
compound and concentrate it in the urine. 
 
4.2.4 Allometric scaling and in vitro/in vivo correlations 
Human PK parameters predicted using in vitro assays have been evaluated and are utilized in many 
drug discovery programs today. Initial dose prediction studies were performed using allometry based 
primarily on the work of Kleiber.388 This work focused on the theory that many of the physiological 
properties within different species were closely correlated to body mass and could be scaled up to 
higher species using mathematical ratios. However, this approach does not factor in the complexities 
associated with particular drug-like properties such as free drug and drug clearance. In an attempt to 
address this, McGinnity and colleagues validated an approach to human dose predictions that takes 
into account factors contributing to human PK such as clearance, Vd, protein binding, and various 
other parameters.389  
The approach is centered around the concept of efficacy being achieved if free drug concentrations 
are above the level of efficacy required at the target site.390 Importantly, this concept has recently 
been improved upon by Page and colleagues who realized that, although the McGinnity method relied 
predominantly on in vitro-derived data, in vivo data and estimated values were required to 
supplement certain parameters.390 It was shown that their novel approach had stronger correlation to 
the in vivo efficacy for a number of drugs, providing a sufficiently robust method for compound ranking 
and further progression decisions.390 In the current study, this method will be used for deciding 




4.3 Results and discussion 
4.3.1 Compound activity, cytotoxicity, and ADME properties 
Compounds (Figure 4.4) were tested (work completed by Ronnett Seldon, IDM, UCT) against H37Rv-
Mtb in 7H9 oleic acid-albumin-dextrose-catalase (OADC) medium at varying concentrations. Activity 
was measured according to a change in Alamar blue fluorescence (denoted as % inhibition) and the 
concentration at which 90% inhibition occurred (MIC90) was determined as shown in Figure 4.5. The 
artemisinin derivatives, Coco-296 and Coco-298, could not be tested using the Alamar blue 
fluorescence method because of the interference of artemisinin-based compounds with the end-point 
involving the Alamar blue reaction. This necessitated the counting of colony forming units (CFU) to 
determine the minimum bactericidal concentration for these compounds (performed by the Wiid 
group, Stellenbosch University). The activity of the compounds ranged from sub-micromolar to 89 µM 
for some of the less active compounds (Table 4.1). 
 






Figure 4.5. Representative graph of PHX 1 activity against Mtb H37Rv in 7H9 OADC medium 
 
Active compounds were then tested against both Vero and Chinese hamster ovarian (CHO) cell lines 
to determine cytotoxicity levels for each compound.  









The compounds included in this study possess molecular weights (MW) in the range 400-600 g/mol 
with the exception of DPINH which has a MW of 303.31 g/mol. When compared with commonly used 
first and second-line anti-TB compounds, most of the compounds displayed similar molecular weights 










PHX 1 0.194 168 219 
DPINH 0.366 130 126 
RMB 041 1.61 80 94 
RMB 043 4.16 84 116 
RMB 073 1.88 34 49 
Coco-296 89 100 120 




Figure 4.6. Molecular weight (g/mol) of known anti-TB compounds and experimental compounds from 
this study (g/mol) 
4.3.2 Solubility 
Kinetic solubility of the compounds was measured at pH 2, 6.5, and 7.4. Low, moderate, and high 
solubilities are defined as 5-49 µM, 50-150 µM, and >150 µM, respectively, with a threshold value of 
10 µM used in this study to determine whether compounds may experience problems further in the 
ADME screening cascade, particularly at pH 7.4.391,392 Overall, the compounds displayed moderate to 
high solubility over the three pH levels tested (Table 4.2). 
Table 4.2. Kinetic solubilities (µM) at three pH levels 
Compounds 
Kinetic solubility (µM) 
pH 2 pH 6.5 pH 7.4 
PHX 1 125 26 49 
DPINH >150 >150 130 
RMB 041 >150 100 97 
RMB 043 >150 120 47 
RMB 073 >150 90 87 
Coco-296 76.8 60 83 
Coco-298 74 58 93 
 
The change in pH did not seem to affect the solubility profiles of Coco-296, -298, or DPINH, all of which 
showed very similar solubility at all pH levels tested (Table 4.2). The Coco-compounds showed 























the pH range tested (Figure 4.7). PHX 1, RMB 041, RMB 043, and RMB 073 showed distinctive 
differences in solubilities over the various pH levels. As discussed, ionized molecules tend to be more 
soluble in aqueous media than neutral molecules because of the enhanced polarity of ionized 
molecules.393  
In the context of TB, solubility at a pH of 4.5-6 (macrophage pH) is important, and this was generally 
moderate to high (in this study at a pH of 6.5) (>50 µM) for all compounds except PHX 1. This comes 
with the caveat that various other intracellular environmental peculiarities to the macrophage were 
not measured and therefore a direct comparison cannot be drawn. However, it is likely that the 
compounds will be soluble in their passage through the GIT, with PHX 1 potentially experiencing 
problems with solubility during passage through areas of a higher pH.    
 

































Figure 4.7. Solubilities of compounds with associated pH values 
 
4.3.3 Lipophilicity and permeability 
The lipophilicity of the compounds was assessed according to the ratio of partitioning into the octanol 
phase from buffer at pH 7.4 according to the methods presented in Chapter 3. Most of the compounds 
had LogD7.4 values in the ideal space between 1 and 3 (Figure 4.8 and Table 4.3). The Coco compounds 
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did not have LogD values between 1 and 3, which may indicate a decreased ability to permeate cellular 
membranes.  
 
Table 4.3. Lipophilicity (LogD7.4) of compounds 
Compounds Lipophilicity (LogD) 
PHX 1 1.32 
DPINH 1.5 
RMB 041 1.48 
RMB 043 1.84 


























Figure 4.8. LogD7.4 values of compounds 
 
This was confirmed by the PAMPA results (Table 4.4 and Figure 4.9) obtained for the same set of 
compounds using the methods presented in Chapter 3. The majority of compounds displayed 
permeability (LogPapp) values of less than -5. Moreover, with the exception of the Coco compounds, 
all of the compounds were in the high permeability range (>-5). Higher permeability in this case, is 
certainly associated with compounds that are soluble at pH 7.4. This explains the low LogD values 




Table 4.4. Permeability (LogPe) of compounds 
Compounds Permeability (LogPe) 
PHX 1 -4.2 
DPINH -4.2 
RMB 041 -4.2 
RMB 043 -4.5 



























































Figure 4.9. Permeability of compounds (LogPe) 
 
The properties of solubility and permeability are often compared with the biopharmaceutical 
classification system (BCS) in order to predict how well the drug will be absorbed in vivo.394 Solubility 
classification is based on the highest dose used in clinical treatment. This dose is tested over a 
recommended pH range of 1-7.5 (for this study, pH 2 to 7.4 was used). A drug is considered highly 
soluble when the highest dose is able to dissolve in 250 mL or less of aqueous media, based on the 
FDA’s fasting volunteer dosing which is usually administered in clinical trials with a glass of water.394 
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In this regard, the majority of the compounds tested in this study were indeed moderately to highly 
soluble, placing them in class I or III (Figure 4.10).  
The permeability assessment of the compounds is traditionally based on in vivo human intestinal 
permeability but there is precedence for using in vitro surrogate values.394,395 Moreover, the 
permeability of the majority of compounds in this study was high, placing these compounds in the 
class I or class II classes.    
 
 
Figure 4.10. Biopharmaceutical classification system (BCS) used to predict in vivo absorption and 
bioavailability of a compound (Amidon et al., 1995) 
 
In summary, the moderate to high solubility and high permeability of the compounds would rank them 
as class I for PHX 1, DPINH, and the RMB compounds. The low solubility and low permeability would 
place the Coco compounds in class IV.395 Compounds in class I usually have high in vivo BA. This is 
primarily due to their absorption being favorable. In comparison with other anti-TB compounds, the 
compounds displayed similar characteristics to the compounds levofloxacin (LVX) and ofloxacin (OFLX) 







Table 4.5. BCS of currently used TB drugs 








4.3.4 Metabolic stability 
The metabolic stabilities of the compounds were assessed in human, mouse, rat, and dog liver 
microsomal fractions according to the methods presented in Chapter 3. The assay took place over 1 h 
and thus extrapolation was reliable to 2.5 times the assay limit (>150 minutes). The compounds were 
relatively stable, with DPINH displaying the lowest stability (Table 4.6). This inversely correlates with 
the predicted Clint (mL/min/kg) as DPINH has the highest predicted clearance of the compounds. The 
inclusion of species in addition to the mouse species used in vivo allows for the allometric scaling of 
the data to predict a human dose.       
 
Table 4.6. Metabolic stability in mouse, rat, human, and dog microsomal fractions presented as t1/2 
and Clint 
Compound 
Microsomal t1/2 (min) Predicted Clint (mL/min/kg) 
Mouse Rat Human Dog Mouse Rat Human Dog 
PHX 1 >150 >150 >150 142.40 12.59 14.68 17.30 19.20 
DPINH 15.86 17.98 13 21.10 121.40 178.40 297.22 220.4 
RMB 041 >150 >150 >150 >150 10.42 15.65 15.90 13.90 
RMB 043 >150 >150 >150 >150 16.43 16.91 20.50 18.78 
RMB 073 >150 >150 >150 >150 14.86 11.25 14.81 12.83 
Coco-296 95.10 102.70 119.80 84.30 20.92 30.38 56.97 44.89 





4.3.5 Plasma protein and microsomal protein binding 
Plasma protein binding and microsomal protein binding were assessed using an ultracentrifuge 
technique. Low, medium, and high binding are defined by free fractions of <0.5, 0.5-0.05, and >0.05, 
respectively.351,400 Overall, the plasma protein and microsomal protein binding for the compounds was 
medium to low (Table 4.7). The binding of compounds to plasma proteins and microsomal proteins is 
important in the correction of plasma PK concentrations and in vitro clearance values (Table 4.8).  
 
Table 4.7. Plasma protein and microsomal protein binding presented as fraction unbound (Fu) for 
human, rat, and mouse  
Compound 
Plasma protein binding Microsomal protein binding 
Human Mouse Rat Human Mouse Rat 
PHX 1 0.19 0.11 0.29 0.32 0.21 0.22 
DPINH 0.13 0.10 0.13 0.09 0.08 0.09 
RMB 041 0.10 0.26 0.21 0.16 0.12 0.10 
RMB 043 0.23 0.21 0.18 0.24 0.10 0.12 
RMB 073 0.16 0.09 0.16 0.18 0.15 0.15 
Coco-296 0.12 0.15 0.14 0.18 0.09 0.12 
Coco-298 0.22 0.13 0.12 0.13 0.12 0.18 
 
 
The Obach group published data on a number of compounds which had been adjusted according to 
microsomal protein binding and plasma protein binding using Equation 4.1. This review argues378 for 
the use of both unbound microsomal and unbound plasma concentrations to predict the clearance in 
plasma in vivo. This is because drug sequestered in microsomes and plasma proteins is unavailable for 
interaction with the microsomal enzymes and plasma enzymes respectively. This also allows for a 
better predictions to be drawn from in vitro and in vivo situations as the inclusion of both unbound 
fractions leads to a lower level of error in predicting the in vivo human clearance from microsomal 















Where Clplasma is the corrected clearance in human plasma; Q is hepatic blood flow; CLint is calculated 
from microsomal fractions; fuplasma is the fraction unbound in plasma; fumic is the fraction unbound in 
microsomal fractions 
 




PHX 1 5.51 
DPINH 18.75 
RMB 041 9.51 
RMB 043 17.18 





4.3.6 Plasma stability and blood plasma partitioning ratio 
Compound stability in plasma was determined for all compounds in fresh human plasma. Human 
plasma contains several hydrolase enzymes which may cause compound degradation. Compound 













PHX 1 >150 
DPINH >150 
RMB 041 >150 
RMB 043 >150 




However, these compounds were not subject to significant degradation with most compounds 
achieving a stability value greater than 150 min (Table 4.9). This indicates that compounds are 
predicted to be stable in the plasma of humans. Coco 296 displayed the greatest degradation with a 
predicted t1/2 in plasma of less than 150 min. This did not cause significant concern, with the 
compound predicted to persist for longer than 2 h in the plasma.  
 
Related to the plasma stability is the determination of BPP ratio (Table 4.10). Calculations to determine 
the PK parameters of a specific compound are usually calculated using plasma samples. If the 
compound preferentially binds or interacts with the red blood cell (RBC) component, the data 
obtained from the PK analysis would be misleading. In the case of BPP ratios greater than 1 (indicative 
of association of the drug with an erythrocytic component), the plasma clearance would overestimate 










Table 4.10. BPP in human and mouse 
Compound 
Blood-to-plasma partitioning ratio 
(BPP) 
Human Mouse 
PHX 1 0.58 0.45 
DPINH 0.95 0.78 
RMB 041 0.87 0.72 
RMB 043 0.56 0.49 
RMB 073 2.10 1.20 
Coco-296 0.85 0.63 
Coco-298 0.75 0.59 
 
In this study, BPP ratios were smaller than 1 for many of the compounds, meaning that a significant 
portion of the drug was associated with the plasma portion of the blood over the time period tested 
(4 h). However, RMB 073 associated significantly more with the RBC component than the plasma, 
indicating that the plasma concentrations used in further PK studies may overestimate blood 
clearance (Table 4.10).   
 
4.3.7 In vitro dose prediction 
In vitro compound data were used to predict an effective human in vivo dose using PK Tool (Certara, 
NJ, USA). PK Tool makes use of two phases of data analysis. The first phase uses a variety of in vitro 
data points which in this study were determined in the mouse, human, rat, and dog species. More 
specifically these data included bound microsomal and plasma clearance values, blood/plasma 
partitioning values, and finally in vitro efficacy and cytotoxicity values. These values were then used 
to calculate a predicted unbound blood clearance rate and unbound microsomal clearance rate (as 
presented in Appendix A) using a number of equations.  
The second phase makes use of allometric scaling from a number of species ranging in size from 
rodents to primates, increasing in metabolic rate and mass respectively, with scaling based on 
Kleiber’s law.388 Data is scaled to predict human dose clearance values using different species body 
weights. In this study, the scaled data is used to generate a simulated PK curve using a one-
compartment model. The predicted human dose is then calculated using an equation which 
determines the dose required to maintain the plasma drug concentration above the specified efficacy 
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value for the duration of the simulated period. Representative data presented below in Figure 4.11 
show the concentration versus time graph for the predicted in vivo dose and how this corresponds to 
the blue in vitro efficacy and red cytotoxicity levels. The simulations are predictive for a single oral 
dose over the period of 24 h in this study. Calculations are described further in Appendix A.  
 
 
Figure 4.11. Representative predicted human concentration versus time curve for PHX 1, with the 
cytotoxicity shown in red and in vitro efficacy shown in blue  
 
The model also provides a predicted efficacious human dose value for each compound as presented 
in Table 4.11. The values were calculated from a complete in vitro data set encompassing human, rat, 
and mouse data, and in part, data from dogs.  
 
Table 4.11. Human dose values predicted from in vitro data by PK Tool for a single oral dose over a 24 




PHX 1 23.36 
DPINH 159.18 
RMB 041 64.48 
RMB 043 283.22 






PHX 1 and RMB 041 were the two compounds that provided the lowest effective dose at 23.36 and 
64.48 mg/kg respectively, with the dose for a 70-kg human being 1.64 and 4.51 g, respectively, per 24 
h. This dose is quite different to those of current first-line anti-TB drugs, with RIF and INH dosed at 10 
mg/kg and 5 mg/kg, respectively.7 The Coco compounds displayed the highest predicted dose due to 
the high in vitro MIC value and relatively high clearance rate in microsomal fractions. Whilst DPINH 
displayed significantly higher clearance values in all species, the compound had a comparably low MIC 
value, requiring a lower dose of compound to maintain the simulated plasma concentration above the 
MIC for the dosing period. It is important to highlight that these concentrations are simulated in the 
plasma, offering a distal measure to target site concentrations, as discussed. However, potential 
cytotoxicities and dosing problems for further animal testing, such as unreasonable dosing volumes 
or concentrations can be recognized early in the drug development pipeline using this method. The 
above predictions are completed using in vitro data, utilizing PK parameter predictions and will be 
compared to predictions using experimentally determined murine in vivo parameters in Chapter 6.  
 
4.3.8 Compound progression to murine PK model 
The compound properties were utilized in a manner which provided an indication of how the 
compounds might fare in an in vivo situation. The choice of compound progression was multifactorial 
in this study. Firstly, a higher selectivity against Mtb was desirable for initial compound selection. PHX 
1 and DPINH displayed the highest selectivity indices based on their low in vitro Mtb MIC90 values and 
high in vitro cytotoxicity values. Coco 296 and Coco 298 displayed the lowest selectivity indices in this 
study, with neither compound meeting the selectivity index of 10 or higher required by the UCT AEC 
to progress into murine experiments. 
The Coco compounds, which were hypothesized to form an integral part of the ROS-generating 
regimen (discussed in Chapter 1) were included in the in vitro ADME experiments to determine 
whether any information pertaining to compound structure could be learned and applied to future 
studies. Although the Coco compounds displayed relatively low activity against H37Rv, the compounds 
offered the potential to synergize with other compounds. Therefore, the Coco compounds were not 
tested in the murine models used in this study, but were included in the in vitro synergy and 
intracellular macrophage models to test the viability of the synergistic ROS-generating regimen within 
intracellular bacilli (as presented in Chapter 9).  
The second selection criterion applied in this study was the selection of in vitro ADME properties which 
may promote compound permeation at the target site. These properties included higher LogPapp or 
LogD, as a measure of how well the compound might permeate the membranes on its path towards 
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the lung. Additionally the compound needed to pass through the GIT, requiring that the compound be 
in a soluble form at all the associated pH values. The compound would then proceed through the liver, 
a process which was measured by the microsomal stability assay and then find its way into the 
circulation. In the anti-TB example, the compound would then be required to leave the plasma and 
traverse through a number of cellular and tissue barriers, towards the lung and other areas of Mtb 
dissemination. This process of leaving the plasma was measured in this study by the plasma stability, 
BPP ratio, and plasma protein binding assays.  
A decision based solely on one property would lead to the exclusion of a compound which may possess 
favorable activity. Therefore, in this study an approach based on potentially flagging properties which 
may lead to problems further down the pipeline was implemented to avoid late-stage failures. The 
compounds possessed moderate to high solubility values with the only potential problem observed 
with the solubility of PHX 1 at pH 6.5, with all compounds above the threshold value of 10 µM. The 
first tier of the screening cascade also included LogD and LogPapp measurements with the majority of 
the compounds displaying favorable results, with the notable exception of the Coco compounds. The 
Coco compounds displayed low LogD and low LogPapp values, making it difficult to motivate for the 
progression of the compounds to in vivo testing.  
The tier 2 assays provided data on the protein binding and microsomal stability of the compounds. 
The majority of the compounds showed relatively low to moderate binding and low clearance values 
indicating that the compounds would not be subject to metabolism by the liver. DPINH was the 
exception to this, displaying relatively high clearance values compared to the other compounds in this 
study for all species. DPINH also displayed moderate plasma binding and moderate microsomal 
protein binding. This is likely to lead to a shorter half-life for DPINH in vivo, possibly leading to a 
decrease in compound exposure in the plasma and target sites. However, we could not assume that 
the in vitro data would translate directly into the in vivo situation. Given the high in vitro selectivity 
index and favorable LogD, LogPapp, and high solubility displayed by DPINH, it was decided to test the 
compound in the murine in vivo PK model.  
The tier 3 assays in this study were used to predict how the compounds would perform within the 
plasma. High compound stability in plasma was observed for all of the compounds with Coco 296 
displaying the lowest stability. The BPP of most of the compounds indicated that the compounds 
associated to a larger extent with the plasma component of murine and human whole-blood. RMB 
073 was the exception to this, pointing to a stronger association with the RBC component of whole-
blood. This provided an indication that the values observed for RMB 073 in murine whole-blood were 
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predicted to be lower than those in the plasma, but this was not flagged as a reason for eliminating 
the compound from the murine whole-blood PK model.        
After completing the first two approaches, it was decided that a third in vivo dose prediction would 
be used for associating multiple properties with one another. The data generated from this model 
supported the choice of the five compounds, namely, PHX 1, DPINH, RMB 041, RMB 043, and RMB 
073, which were chosen for further investigation in a murine PK model. It must be noted that the 
predictive strength of the dose prediction was low due to absence of comparable in vivo data at this 
point and therefore the actual values obtained in this manner must be used a guide to facilitate 
compound selection rather than potential dosing strategies. Using all three of the approaches above, 
PHX 1, RMB 041, RMB 043, RMB 073, and DPINH were selected for further testing in an in vivo murine 
PK model.    
 
4.4 Conclusion 
From the ADME and in vitro testing of the compounds, PHX 1, DPINH, RMB 041, RMB 043, and RMB 
073 showed the most favorable drug-like properties and were chosen for testing in a murine 
pharmacokinetic model. PHX 1 and RMB 041 showed the most promising in vitro properties with both 
compounds achieving relatively low in vitro clearance rates in all species. RMB 041 displayed higher 
relative solubility (at all of the tested pH values) and higher lipophilicity than PHX 1 which may result 
in RMB 041 traversing the GIT and making its way to the target site more efficiently than PHX 1. 
However, the higher free fractions in both plasma and microsomal fractions of PHX 1 for all species 
(with the exception of murine plasma) may result in more unbound drug in the human body when 
compared with RMB 041. The higher free fraction and low clearance rate of PHX 1 consequently 
resulted in the lowest predicted human in vivo dose followed closely by RMB 041. This was followed 








The aims of the work described in this chapter included the development and partial validation of LC-
MS/MS methods for the quantification of anti-TB compound levels in murine blood. All seven 
compounds were included in the method development and partial validation process to ensure that 
any data produced using these methods for murine whole-blood analysis was reliable and consistent.  
 
5.2 Introduction 
5.2.1 LC-MS/MS within the drug discovery pipeline 
Drug discovery is the process of generating chemical matter, evaluating the chemical properties of 
each compound, and finally, deciding on the most promising chemical entities to promote in producing 
an efficacious and safe drug for human usage.115,401 This process, termed the discovery and 
development pipeline,34,115 is extremely competitive amongst academic research groups and industry 
players alike, with each trying to increase the rate at which compounds progress from hit to lead 
status.93,402,403 The introduction of LC-MS/MS has allowed for the rapid assessment of compound 
properties within this environment.404,405 There are a number of MS systems that can be interfaced 
with high-performance liquid chromatography (HPLC) including the single-quadrupole HPLC-MS,404,406 
the triple quadrupole MS/MS system which can be used for both bioanalysis and metabolite 
identification,407–409 the time-of-flight (TOF) instrument which can also be used to investigate spectra 
with higher mass resolution,192,410 and the ion-trap mass spectrometer404,411 which can be used for 
structural elucidation of compounds.   
LC-MS/MS has become integral to many drug discovery efforts as it offers increased sensitivity and 
specificity compared to other methods that rely on chromophores, fluorescence, or compound 
labeling.412,413 Importantly, advances in LC-MS technologies have allowed for the integration of this 
methodology into a variety of laboratory settings.414 From routine clinical laboratories focusing on 
drug-level monitoring through to proteomic research groups monitoring disease-related protein-level 
changes, MS has changed the way in which scientists are able to effectively measure various changes 
in their experimental systems. The limitations of the technique include its expense, labour-intensive 
sample preparation, and training requirements.404,412 As MS technologies and sample preparation 
techniques improve, the accuracy of sample analysis and the variety of samples that can be analyzed 
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will surely increase accordingly, shedding light on previously restricted clinical and biological 
phenomena.415      
  
5.2.2 Method development and validation 
Before any samples can be analyzed, LC-MS/MS method development needs to take place. A suitable 
LC-MS/MS method makes the processing of critical data for the analysis of various pharmaceutical 
components possible.416 The method needs to fulfil the intended task of producing high-quality and 
consistent data. The use of reverse-phase chromatography predominates amongst chromatographers 
accounting for 60-70% of LC methods.417 In summary, a polar mobile phase and a non-polar stationary 
phase are used to separate non-polar compounds. However, samples are often analyzed in various 
matrices including plasma, blood, urine, and tissues, along with other divergent matrices.418 This 
makes the development of a bioanalytical method slightly more challenging. To deal with these 
complexities, bioanalysis is divided into three general phases: sample collection, sample preparation, 
and sample separation and detection.419 In order to address each of these, it is important to consider 
the following:  
(i) Does the method measure the correct/intended analyte? 
(ii) What is the degree of variability for each measurement? 
(iii) Is the method sensitive enough to cover the appropriate concentration range for the 
study? 
(iv) How do the processes of sample collection and storage affect the bioanalytical 
measurement of the samples?   
To adequately address these queries, method validation was conducted in this study. This is a process 
that ensures reproducible data are generated with the LC-MS/MS method.420 Method validation may 
be effected in several ways. Full validation is performed for a newly developed method and is a 
requirement for analysis of clinical samples.343 Alternatively, partial method validation can be carried 
out for bioanalytical methods that have already been validated or which do not need to fully meet the 
United States Food and Drug Administration (FDA) and European Medicine Agency (EMA) guidelines 
for bioanalytical method validation. This is commonly used in early pre-clinical sample analysis.343,421 
Finally, cross validation is used where two or more bioanalytical methods or techniques are used to 
analyze the same set of samples.343,421,422   
80 
 
In full/partial validation of a method, certain parameters are to be included: (i) linearity, (ii) accuracy, 




To determine murine sample concentrations, experimental samples as well as duplicate or triplicate 
standard curves comprising at least five concentration points are analyzed concurrently via LC-MS/MS. 
Compound concentrations can then be extrapolated from the standard curves. The standard curve 
may be analyzed using either linear or quadratic regression and weighting of the 
concentration/response curve may be applied to obtain greater linearity.  
The variation in back-calculated standard curve sample values must not exceed 15% for the standards, 
excluding the LLOQ which cannot exceed 20%.343 Quality control (QC) samples are also required at 
high, medium, and low concentrations to demonstrate the accuracy and precision of samples with 
known concentrations using the standard curve. These QC samples must be spiked at 80% of the upper 
limit of quantitation (ULOQ), at the mid-point of the standard curve, and also at three times the LLOQ 
concentration.343 Importantly, 75% of the standard samples and 67% of the QC samples have to be 
used in order to validate the curve. For full validations, fresh samples must be prepared on three 
different days. 
(ii) Accuracy 
Determination of accuracy in method validation is vital and occurs throughout the process. The closer 
a calculated value is to the true value, the greater the accuracy will be.423 This is applied to the standard 
curve and QC samples which should not exceed 15% of the true value. 
(iii) Precision  
It is important to distinguish accuracy from precision as the terms are often incorrectly interchanged. 
Precision is the degree of variation between replicates423 and is reflected in method validation as the 
percentage coefficient of variation (%CV). This again should not exceed 15% for all standard and QC 
samples.343 
(iv) Selectivity             
The selectivity of the method is defined as the ability of the LC-MS/MS method to accurately and 
precisely distinguish the desired analyte from both endogenous components and other compounds 
present in the matrix.343,421 This is measured in this study using a low concentration of compound 
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spiked into the respective matrices in order to determine whether any endogenous matrix 
components suppress the ionization of the compound of interest. 
(v) Sensitivity  
Method sensitivity, a parameter related to selectivity, refers to the ability of the method to accurately 
determine the amount of compound within a sample at low concentration. This is reflected as a 
measure of the LLOQ, which should be five times the analyte response of a blank extracted sample.343 
(vi) Stability 
It is essential to assess compound stability to determine whether any loss of compound sensitivity is 
obtained during experiment-specific storage, extraction, or analysis conditions. Stability parameters 
that are evaluated in this study include freeze-thaw stability of whole-blood samples, the stability of 
whole-blood samples on ice for the duration of the extraction procedure, the stability of the 
compounds in both oral and intravenous formulations, and the assessment of autosampler stability 
which provides a measure of stability on instrument during total analysis time. The FDA recommends 
that the sample degradation, measured in comparison to a freshly prepared and extracted sample, 
should not exceed 15%.343  
(vii) Carryover 
Carryover is referred to as the influence of a previously injected sample on the analysis of a 
subsequent injection and can be caused by a number of factors.424,425 Carryover is usually assessed by 
injecting a blank extracted sample directly after the highest standard included in the study, which 
should provide a peak area of less than 20% of the LLOQ.343 If significant carryover is detected, 
increased washing of the autosampler needle, stronger wash solvents or more washes between 
samples can overcome this issue.424 
(viii) Matrix effects (ME) and extraction efficiency 
ME is a phenomenon that occurs when the apparent concentration of an analyte of interest is either 
suppressed or enhanced by the addition of the analyte to a particular matrix.426–428 This is due to salts, 
phospholipids, and other endogenous substances often present in different matrices, competing with 
the analyte during the process of ionization. ME are measured by comparing an extracted matrix 
sample to a sample prepared in solvent, and the difference between the two analyte responses should 
not be greater than 15%.343,419 Erratic ME can cause loss of linearity, accuracy, and precision within a 
particular study.426,429 This problem is often solved by employing more extensive sample preparation 
techniques, changing the column/mobile phase, or changing the ion source.426,427 Similarly, extraction 
efficiency is determined by comparing a sample extracted from a particular matrix to one spiked 
directly into a solvent. The ratio between the two responses need not be 1, although the ratio should 
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remain consistent over the concentration range of sample analysis.343 With all of these parameters 
analyzed, more confidence can be placed in the results obtained from clinical or pre-clinical samples 
obtained from various human trials or animal models, respectively.419  
 
5.3 Results and discussion 
5.3.1 Compound infusion 
The development of the LC-MS/MS methods was started with the infusion of freshly prepared stock 
solutions (500 ng/mL) of each compound, prepared in 1:1 (v:v) ACN and LC-MS/MS-grade water 
containing 0.1% formic acid (FA), or 5 mM ammonium acetate in ACN, or 5 mM ammonium acetate in 
H2O. Compounds were infused in positive electrospray ionization (ESI) mode at a rate of 10 µL/min. 





Figure 5.1. Product ion scans of (A) RMB 041, (B) RMB 043, (C) RMB 073, (D) PHX 1, (E) DPINH, (F) Coco 








An AB Sciex 4000Q-Trap® instrument was set to multiple reaction monitoring (MRM)430 mode with 
monitoring of both the corresponding precursor and product ions from each compound (Table 5.1). A 
single MRM transition was monitored for all of the compounds as this allowed for the quantitative 
analysis of murine samples. Carbamazepine was used as the IS for all analytes in the PK studies. This 
analyte displayed sufficient baseline separation from the different compounds of interest in this study 
and precision between replicates for each analyte batch submitted for LC-MS/MS analysis. Following 
successful infusion, an LC-MS/MS method was developed for each compound. Multiple columns were 
tested in combination with several mobile phases. The final columns and mobile phase combinations 
are presented in Table 5.2. 
 
Table 5.1. MRM transitions for each compound  














RMB 041 505.2→418.0 150 81 10 43 10 
      
RMB 043 504.4→477.2 150 86 10 55 18 
      
RMB 073 521.4→416.0 150 91 10 39 10 
      
PHX 1 395.2→351.2 150 66 10 49 22 
      
DPINH 304.2→78.0 150 76 10 59 12 
      
Coco 298 557.2→163.2 150 82 10 29 20 
      
Coco 296 489.2→223.2 150 91 10 49 16 
      
Carbamazepine 
(IS) 
237.1→194.1 150 71 10 29 4 








Table 5.2. LC-MS/MS column and mobile phase conditions  
Analyte Column Mobile phase Run time 
RMB 041 Gemini NX C18 
2.6 µm, 50 x 2.1 
mm 
0.1% FA in ACN/0.1% FA in H2O 6 min 
RMB 043 Gemini NX C18 
2.6 µm, 50 x 2.1 
mm 
0.1% FA in ACN/0.1% FA in H2O 6 min 
RMB 073 Gemini NX C18 
2.6 µm, 50 x 2.1 
mm 
0.1% FA in ACN/0.1% FA in H2O 6 min 
PHX 1 Gemini NX C18 
2.6 µm, 50 x 2.1 
mm 
0.1% FA in ACN/0.1% FA in H2O 6 min 
DPINH Luna PFP               
3 µm, 50 x 4.6 
mm 
0.1% FA in ACN/0.1% FA in H2O 8 min 
Coco 298 Gemini NX C18 
2.6 µm, 50 x 2.1 
mm 
5 mM ammonium acetate in ACN/ 
5 mM ammonium acetate in H2O 
6 min 
Coco 296 Gemini NX C18 
2.6 µm, 50 x 2.1 
mm 
5 mM ammonium acetate in ACN/ 
5 mM ammonium acetate in H2O 
6 min 
 
5.3.2 Extraction method for murine whole-blood samples 
Sensitivity obtained using ACN protein precipitation was sufficient to analyze murine PK samples 
(lowest standard for all compounds 0.98 ng/mL). Protein precipitation using 150 µL ACN (containing 
IS, carbamazepine) was used to extract 20 µL of murine whole-blood in this study.  
 
5.3.3 LC-MS/MS method development 
The HPLC gradients used for each compound are presented in Figures 5.2-5.8 with representative 
chromatograms presented in Appendix B. All compounds eluted within the gradient or slightly 
thereafter, with column and mobile phase conditions providing consistent retention times (RT). The 
compounds eluted away from the solvent front, where co-elution with more hydrophilic molecules is 
likely. The compounds also eluted away from the end of the HPLC gradient where compounds such as 




Figure 5.2. Final HPLC gradient used for RMB 041a 
aWhere solvent A (blue) is H2O (0.1% FA) and solvent B (red) is ACN (0.1% FA); elution of RMB 041 
(green triangle, RT: 3.48 min) and IS (orange triangle, RT: 2.34 min) 
 
 
Figure 5.3. Final gradient used for RMB 043a 
aWhere solvent A (blue) is H2O (0.1% FA) and solvent B (red) is ACN (0.1% FA); elution of RMB 043 






Figure 5.4. Final HPLC gradient used for RMB 073 
aWhere solvent A (blue) is H2O (0.1% FA) and solvent B (red) is ACN (0.1% FA); elution of RMB 073 
(green triangle, RT: 3.21 min) and IS (orange triangle, RT: 2.49 min) 
 
 
Figure 5.5. Final HPLC gradient used for PHX 1a 
aWhere solvent A (blue) is H2O (0.1% FA) and solvent B (red) is ACN (0.1% FA); elution of PHX 1 (green 





Figure 5.6. Final HPLC gradient used for DPINHa 
aWhere solvent A (blue) is H2O (0.1% FA) and solvent B (red) is ACN (0.1% FA); elution of DPINH (green 
triangle, RT: 2.32 min) and IS (orange triangle, RT: 2.80 min) 
 
 
Figure 5.7. Final HPLC gradient used for Coco 298a 
aWhere solvent A (blue) 5 mM ammonium acetate in H2O and solvent B (red) is 5 mM ammonium 






Figure 5.8. Final HPLC gradient used for Coco 296a 
aWhere solvent A (blue) 5 mM ammonium acetate in H2O and solvent B (red) is 5 mM ammonium 
acetate in ACN; elution of Coco 296 (green triangle, RT: 2.51 min) and IS (orange triangle, RT: 2.32 
min) 
 
5.3.4 Partial method validation 
The LC-MS/MS methods were partially validated.343,421 Partial method validation consisted of a 
number of tests that were completed for each analyte to determine whether the compounds were 
stable in each possible experimental situation involved with sample collection, storage, and 
processing. These tests included (i) mouse whole-blood stability (ice and -80°C), (ii) autosampler 
stability, (iii) PO and IV formulation stability, (iv) ME, and (v) recovery.   
In this study the stability values are reported as percentage stability values which reflected the stability 
of the compound in relation to a fresh sample prepared just before analysis.432 Compound stability 
was assessed at both a high and low concentration for murine whole-blood (freeze-thaw and on ice) 
and samples assessed for on-instrument stability. Only high concentrations for the oral and IV 
formulation stability samples were tested as these compounds were dosed at a single high 
concentration.  
The stabilities of these samples were within a 20% range of the freshly prepared sample of the same 
concentration (Table 5.3) and extracted using ACN containing IS. The compound DPINH consistently 
displayed the lowest sample stability across the various tests and was outside of the 15% limit for 
most of the stability tests. However, the other compounds were all within the validation cut-off of 
15%, indicating good compound stability. Care was taken when assessing DPINH murine whole-blood 
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samples, with the implementation of measures such as minimizing the number of freeze-thaw cycles, 
working on ice during extraction, and preparation of the IV and oral formulations as close to the time 
of dosing as possible. These samples were not injected for a period of longer than 48 h. 
 
Table 5.3. Stability testinga 
Compound 
Murine whole-












Concentration Highb Lowb Highb Lowb Highb Lowb Highb Highb 
RMB 041 91.2 89.2 98.7 99.2 94.1 92.1 98.0 90.3 
RMB 043 109.0 102.4 92.5 91.3 99.1 99.8 89.0 93.1 
RMB 073 92.3 87.6 97.3 89.5 102.0 105.3 89.3 98.8 
PHX 1 89.0 88.4 85.0 86.0 91.7 92.2 84.9 93.5 
DPINH 82.2 89.2 81.2 82.7 80.6 80.1 82.7 89.9 
avalues presented as percentages compared to that obtained from a freshly prepared sample; bHigh, 
4000 ng/mL; low, 10 ng/mL 
 
The ME for each compound were assessed according to methods outlined in various publications.426,433 
This assessment involved the preparation of a sample that was spiked into a pre-extracted matrix (A), 
which was compared to a sample spiked directly into injection solvent (B). ME were determined using 
an equation developed by Matuszewski et al., 2003.426 A value of less than 100% indicates ion 
suppression and a value of greater than 100% is indicative of ion enhancement.  The majority of 
compounds exhibited ME that deviated by less than 15% from the mean peak area of the solvent 
samples, indicating insignificant ME for these compounds. DPINH displayed the greatest ME in mouse 
whole-blood at the high and low concentration. The ME for DPINH did not result in a significant 
decrease in ion suppression. This was monitored by assessing the lowest standard of each calibration 
curve. A general trend in higher ME was observed at lower concentrations of compound, an effect 
that has been noted previously.432 The ME for many of the compounds were within the acceptable 









𝑿 𝟏𝟎𝟎  
Where A is the pre-extracted matrix peak area response, B is the peak area response of a sample 
spiked directly into injection solvent, and ME is expressed as a percentage. 
 
Table 5.4. ME assessment in murine blooda 
Analyte 
Mean ratio of 
peak areas in 
murine blood (A) 
Mean ratio of peak 
areas in solvent (B) 
%ME a 
Standard deviation 
of murine blood 
values 
%CVb 
Concentration Highc Lowc High Low High Low High Low High Low 
RMB 041 5.62 0.26 5.83 0.29 96.39 89.66 0.291 0.0045 5.18 1.73 
RMB 043 4.21 0.17 4.32 0.19 97.45 89.47 0.402 0.0073 9.56 4.29 
RMB 073 4.01 0.11 4.44 0.13 90.31 84.61 0.390 0.0024 9.72 2.20 
PHX 1 3.39 0.13 3.59 0.15 94.42 86.67 0.203 0.0018 5.98 1.38 
DPINH 3.21 0.12 3.62 0.15 88.67 80.00 0.490 0.0089 15.26 7.42 
aMatrix effect%; aPercent coefficient of variation; bhigh, 4000 ng/mL; low, 10 ng/mL 
 
The percentage recovery from murine whole-blood using ACN was calculated according to Equation 
5.2. This assessment involved the preparation of a sample that was spiked into a pre-extracted matrix 
(A) and comparing it to a sample that was spiked into a specific matrix and then subsequently 
extracted (C). The recovery percentage for the compounds (Table 5.5) was between 83.33% and 
96.75%. More importantly, the majority of compounds had percentage recoveries that were similar 
at both the high and low concentrations tested. This indicated that the extraction recovery was more 
likely to be consistent over the entire calibration curve range. The exception to this was RMB 073, with 
a high percentage recovery at the high concentration and a lower percentage recovery at the lower 
concentration. The potential association of RMB 073 with the RBC component of murine whole-blood 
may explain the irregularities seen at the high and low concentrations. Standard and quality control 
samples were monitored closely to assess whether this differential compound recovery resulted in 
loss of percentage nominal accuracy (% NOM) or precision (%CV) across the different concentrations 
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of the calibration curve but both %NOM and %CV were within the 15% deviation allowed for murine 
calibration and QC samples in Chapter 6.      




 𝑿 𝟏𝟎𝟎 
Where A is the pre-extracted matrix peak area response and C is the peak area response of a sample 
spiked into a matrix sample and then extracted. 
 
Table 5.5. Recovery from murine whole-blood using ACN 
Analyte 
Mean ratio of 
peak areas in 
murine blood 
Mean ratio of 








Concentrations Highb Lowb High Low High Low High Low High Low 
RMB 041 5.42 0.27 5.83 0.29 92.97 93.10 0.112 0.006 2.07 2.22 
RMB 043 4.18 0.18 4.32 0.19 96.75 94.74 0.148 0.008 3.54 4.44 
RMB 073 4.29 0.10 4.44 0.12 96.62 83.33 0.326 0.003 7.59 3.00 
PHX 1 3.14 0.14 3.59 0.15 87.47 93.33 0.229 0.005 7.29 3.57 
DPINH 3.33 0.13 3.62 0.15 91.99 86.67 0.447 0.003 13.42 2.31 
aPercentage coefficient of variation; bhigh, 4000 ng/mL; low, 10 ng/mL 
 
Before using the LC-MS/MS assays to analyze murine whole-blood PK samples, the assays were 
assessed for their accuracy, precision, sensitivity, and selectivity, as discussed. In summary, the assays 
performed well during murine PK sample analysis with standard and QC samples achieving a %NOM 
between 85.2% and 113.3% with CV’s below 13.9% for all compounds indicating good accuracy and 
precision. Sensitivity of the assays was determined by assessing the %NOM and %CV of the lowest 
concentration sample on the calibration curve. The LLOQ for calibration curve samples was 
determined to be 0.98 ng/mL for all five compounds. The correlation coefficients for all curves were 
greater than or equal to 0.99. Each assay was selective for the particular compound of interest 
extracted from murine whole-blood (representative chromatograms are presented in Appendix B).  
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The assays for each compound were successfully validated, which provided confidence in the 
procedure (Figure 5.9) and the results obtained from sample collection through to sample processing 
and LC-MS/MS analysis for each compound.       
 
Figure 5.9. LC-MS/MS method development and validation workflow 
 
5.4 Conclusion 
LC-MS/MS methods were developed for seven compounds, with the completion of assay validation 
for the five compounds to be assessed in a murine whole-blood PK model. Mouse whole-blood 
stability on ice and at -80°C was assessed with good compound stability reported for all compounds. 
The compounds were also assessed in oral and IV formulations and for on-instrument stability, with 
all compounds displaying high stability when compared to freshly prepared samples. DPINH was 
reported to have the lowest stability in the majority of the stability tests, indicating that care needed 
be taken when assessing this compound during murine blood PK analysis. ME were assessed for all 
five compounds with DPINH displaying the greatest ME. Recovery percentages for each assay were 
calculated with RMB 073 displaying the largest disparity between recovery from high and low 
concentration samples. These effects were monitored during murine blood PK sample analysis. The 






























The aims of this chapter were to measure the whole-blood concentrations of each novel compound 
selected for murine pharmacokinetic analyses. Data generated in this chapter were used in comparing 
the novel anti-TB compounds to literature data available for known anti-TB drugs. Finally, we aimed 
to use both the in vivo data generated from this chapter to produce human dose predictions for 
selected novel compounds to drive compound progression and inform possible animal and human 
dosing for future studies.   
 
6.2 Ethics statement 
All study procedures were conducted with prior approval from the UCT Animal Ethics Committee 
(013/032). The experiments were conducted in accordance with the National Code for animal use in 
South Africa and mice were housed according to the details described in chapter 3.434 
 
6.3 Introduction 
6.3.1 Animal models within TB drug discovery 
Animal models are an invaluable tool for drug discovery with numerous models enabling the 
determination of effective doses, toxicity, and general PK and PD responses.435 The selection of an in 
vivo animal model is based on a number of considerations including cost, logistics, and scientific 
reasoning.436 
Because of the complex nature of TB disease, a number of animal models have been used to capture 
a specific aspect of the disease, including clinical features, pathological changes, bacterial 
dissemination, bacterial loads, and immunological features.91,97,434,437–440 Various murine models have 
been favored for TB drug discovery, with approximately 60% of animal studies in TB involving the 
mouse441 because of their low cost, moderate compound requirements, availability of historical data, 
and genetically defined strains.14,436 Extensive testing of the murine model has taken place in both 
acute and chronic conditions, partially validating the model.14,442 The main arguments against the use 
of the murine model point to the disparities in the pathology of Mtb in humans and in mice.97 The 
granulomas generated in the traditionally used mouse efficacy models consist of lymphocyte and 
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macrophage aggregates rather than the well-defined granuloma structures found in humans following 
Mtb infection.443–446 Importantly, the progression of TB disease within the C57BL/6 and BALB/c murine 
models is also significantly different from that in humans, with a distinct lack of the caseating 
granuloma phenotype and the absence of Langhans giant cells and class epithelioid cells, which are 
key phenotypic characteristics in human TB disease progression.14,447 More clinically relevant data may 
be gained from the C3HeB/FeJ murine model, which somewhat recapitulates cavitation within a 
mouse but still lacks certain human TB disease characteristics.97,448–450  
Following treatment success in mice, compounds are often tested in higher species before making 
their way into human treatment regimens. This is essential as no single animal model completely 
captures the complexity of disease progression and therefore cannot consistently recapitulate 
treatment in humans.441,450 Progression through successive animal models should therefore reveal 
more detail about how a compound will behave in an infected human patient and so careful selection 
of each model should be made. In this study, the uninfected murine model was initially adopted to 
translate our in vitro efficacy/toxicity and ADME data into an in vivo model. Importantly, the results 
obtained within this model might change once the animals are infected with Mtb. However, the 
infected murine models are far costlier and have specialized biosafety level requirements. Therefore 
it is essential that early pre-clinical studies such as this are conducted in order to bridge the in vitro/in 
vivo divide and avoid costly failures further down the discovery pipeline. 
 
6.4 Results and discussion 
6.4.1 Summary of formulation, dosing procedure, and murine whole-blood assay    
As mentioned in chapter 3, mice were administered compound via oral (PO) or intravenous (IV) dosing. 
The PO formulation involved the dissolution of compounds in 100% hydroxypropyl methylcellulose 
(HPMC). The drug was subsequently administered by oral gavage at a dose of 20 mg/kg (n = 3) with a 
total formulation volume of approximately 200 µL (dosed per bodyweight). Blood samples, 
approximately 20 µL, were collected via tail bleeding at 0.5, 1, 3, 5, 8, 10, 24, and 48 h after dosing.  
The IV doses (5 mg/kg) were formulated in a 1:3:6 v/v solution of dimethylacetamide (DMA), 
polyethylene glycol (PEG), and polypropylene glycol (PPG) and injected into the murine penile vein (n 
= 3) with total volume per drug administration approximately 80 μL (dosed per bodyweight). Blood 
samples were collected via tail bleeding (approximately 20 µL) at 0.083, 0.5, 1, 3, 5, 8, 10, 24, and 48 
h post dose. The murine blood samples were collected from three mice per dosing group (IV and oral) 
for a total of six mice (n = 6) over a 48 h period. 
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Briefly, compounds were extracted from the samples via precipitation with ACN containing 1 µg/mL 
carbamazepine as the IS. Samples were vortexed (1 min) and centrifuged at 5590 g for 5 min, before 
the supernatants were removed from each sample and submitted for LC-MS/MS analysis. Blank 
murine whole-blood samples were spiked with serially diluted concentrations of each compound to 
generate calibration (0.98 – 4000 ng/mL) and quality control (2-3200 ng/mL) samples. These samples 
were extracted using the same method as described above. Calibration curves were constructed using 
data from the LC-MS/MS analyese and were used to quantitatively determine murine whole-blood 
concentrations in this study.  
 
6.4.2 LC-MS/MS assay performance summary 
The assays performed well during murine PK sample analysis with standard and QC samples achieving 
a %NOM between 85.2% and 113.4% with CV’s below 13.9% for all samples indicating good precision. 
The lower limit of quantitation for calibration curve samples was 0.98 ng/mL for all five compounds, 
and the correlation coefficients for all curves were greater than or equal to 0.99. Carryover was also 
assessed in each experiment using an extract from a blank sample injected after the highest standard 
(representative chromatograms presented in Appendix B). 
 
6.4.3 Murine whole-blood PK concentrations and PK parameters    
Beyond the selection of active anti-TB agents, dose optimization of drugs relies upon the predictive 
nature of an in vivo system.126,451 The resultant PK data (Table 6.1) obtained from the murine 
experiments allow for the selection of compounds for inclusion in further studies whilst also 
determining a predicted human dose. The drug concentrations in Figures 6.1-6.10 were used to 
calculate the PK parameters as presented in Table 6.1 using a non-compartmental analysis approach. 
This method involves the use of the trapezoidal rule, where the area under the murine whole-blood 
concentration-time graph is divided into sequential trapezoids which are summed to determine the 
AUC, which is then used to determine the elimination half-life (t1/2), apparent volume of distribution 
(Vd), clearance, and percentage BA (%BA). The maximum concentration achieved (Cmax), , and the time 
at which the Cmax is reached (Tmax) are also presented.452,453 
The IV formulation total concentration versus time graphs are displayed in Figure 6.1-6.5 with 
compound concentrations compared to their respective in vitro MIC concentrations. These 
comparisons are discussed later in this chapter. Standard deviations were used to generate error bars 
for each sampling time-point (n = 3). 
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Figure 6.1. Total concentrations for PHX 1 following intravenous dosing (IV) in an uninfected murine 
model 






























Figure 6.2. Total concentrations for RMB 041 following intravenous dosing (IV) in an uninfected murine 
model 
































































Figure 6.4. Total concentrations for RMB 073 following intravenous dosing (IV) in an uninfected murine 
model 






























Figure 6.5. Total concentrations for DPINH following intravenous dosing (IV) in an uninfected murine 
model 
 
Differential profiles for each compound were displayed in the IV formulation total concentration 
versus time graphs, with the Cmax for each compound occurring directly after compound injection. The 
IV formulation PK profiles display values which are above the lower limit of quantification (LLOQ) for 
48 h for RMB 041, RMB 043, and RMB 073. However, PHX 1 and DPINH concentrations could only be 
quantitated up until 24 h and 5 h, respectively, with samples below the LLOQ beyond these respective 
time-points.   
The PO formulation PK profiles (Figure 6.6-6.10) display values which are above the LLOQ at 48 h for 
PHX 1, RMB 041, RMB 043, and RMB 073. However, DPINH concentrations could only be quantitated 
up until 10 h, with samples below the LLOQ beyond this respective time-point. Again, the MIC90 values 
for each compound were included and these are discussed later in this chapter. 
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Figure 6.6. PHX 1 total concentration (oral administration) in an uninfected murine PK model 



























































Figure 6.8. RMB 043 total concentration (oral administration) in an uninfected murine PK model 






















































Figure 6.10. DPINH total concentration (oral administration) in an uninfected murine PK model 
 
Drug candidates need to be effective against Mtb bacilli that are present in vastly different host 
conditions, are both replicating and non-replicating, and reside in discrete compartments created by 
the lesion pathology in humans infected with TB.14,17,454 This requires particular chemical properties 
that are manifest in key PK indices derived from various in vivo models.14 Compounds possessing high 
Vd that are able to make their way into the lesion and penetrate into the caseum should be 
prioritized.14,24 Similarly, compounds with extended half-lives and sustained anti-TB activity are sought 
after as these could be key to killing persistent bacterial populations whilst suppressing the 
development of resistance.2  
The calculated murine elimination half-life (mean ± SD), Vd, total clearance, AUC, Cmax, Tmax, and %BA 











Table 6.1. Pharmacokinetic parameters from murine experiments with standard deviations shown for 
each value (n = 3)a 
Compound t1/2 (h) 
Tmax 
(h) 







IV (n = 3) 
PHX 1 2.5 ± 0.4 - - 11.1 ± 0.1 58 ± 4 2133.3 ± 143.0 - 
DPINH 0.6 ± 0.3 - - 3.3 ± 0.2 91.9 ± 2.3 500.9 ± 320.1 - 
RMB041 62.3 ± 6.7 - - 1.2 ± 0.03 23.1 ± 0.3 29250.4 ± 309.0 - 
RMB043 8.6 ± 0.4 - - 4.6 ± 1.6 70.5 ± 4.2 10068.4 ± 127.8 - 
RMB073 15.3 ± 3.2 - - 3.9 ± 0.5 34.5 ± 1.3 15940.0 ± 400.0 - 
Oral (n = 3) 
PHX 1 3.7 ± 0.7 0.5 4.2 ± 0.5 - - 1275.4 ± 120.0 14.9 ± 0.2 
DPINH 1.4 ± 0.2 0.5 2.0 ± 0.4 - - 134.9 ± 25.3 26.9 ± 0.4 
RMB041 23.3 ± 2.5 0.5 5.4 ± 0.4 - - 25012.2 ± 1081.0 21.4 ± 1.0 
RMB043 6.2 ± 0.8 0.5 5.6 ± 1.4 - - 8915.7 ± 1017.0 22.1 ± 2.2 
RMB073 11.6 ± 1.3 0.5 2.0 ± 0.1 - - 3771.0 ± 298.0 5.9 ± 1.3 
a t½ half-life; Tmax time to maximum concentration; Cmax maximum concentration; Vd apparent volume 
of distribution; (Vd), Cltot calculated total clearance; AUC area under the curve.  
 
The RMB compounds (041, 043, and 073) present relatively long half-lives when compared with those 
of other drugs such as RIF (7.19 h ± 0.42),455,456 INH (1.7 h ± 0.17),457,458 PZA (1.05 h ± 0.14)458, BDQ 
(53.00 h ± 6.00),459,460 CLZ (87.46 h),461 and MXF (1.3 h).462 Similarly, PHX 1 possesses a relatively high 
Vd of 11.1 L/Kg when compared to drugs such as LZD (0.63 L/kg),463 and gatifloxacin (GTX, 2.00 L/kg ± 
0.3)464. Many of these values were adapted from TB infected murine models and therefore 
comparisons must be undertaken with caution. 
DPINH displays slightly less favorable PK properties in this model with a relatively short oral half-life, 
a low Cmax, and a relatively low exposure, somewhat skewing the %BA which was comparatively high 
in this study. Intriguingly, the compound disappears from circulation extremely quickly following IV 
and oral dosing, and closely resembles the PK curves obtained for INH in other studies.465,466 This could 
point to a possible prodrug effect, in which the main compound produces a more active metabolite. 
Clearly, more effort is required to positively identify either a novel mechanism of action (to avoid INH 
resistance) or a novel metabolite by metabolite identification (MetID) studies. The work is being 
pursued, but is beyond the scope of this study.  
In the context of the in vitro ADME results obtained in Chapter 4, the compounds PHX 1, RMB 041, 
043, and 073 all had relatively low clearance rates in the murine microsomal stability assay. Combined 
with the moderate to high solubility and high permeability, this resulted in relatively high exposures 
and half-lives for each of these compounds, with a resultant moderate BA for the compound set.  
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It must also be noted that many of the PK properties for the known TB drugs are derived from infected 
TB murine models, potentially negating a direct comparison between these results and the results 
obtained in this study using uninfected animals. However, as a pre-clinical screen, the uninfected 
murine model still offers great value in translating in vitro-determined ADME properties into an in vivo 
model in a biosafety level (BSL) II environment. Early identification of compounds that possess a high 
Vd or t1/2 is essential to developing a targeted drug regimen that is potentially able to penetrate into 
the complex granuloma environment.15,14 It is also extremely valuable to gain an appreciation of how 
the drug is able to accumulate in tissues and organs; this will be addressed in Chapters 8 and 9. It is 
important to understand what influence these properties will have on anti-TB efficacy. 
 
6.4.4 PK/PD drivers for anti-TB efficacy 
As discussed in Chapter 1, three main drivers of PK/PD relationships exist for anti-TB agents: (i) 
AUC/MIC, (ii) Cmax/MIC, and (iii) %T>MIC. The AUC/MIC and the resultant %T>MIC might offer a more 
assured level of drug exposure and potential efficacy, particularly in diseases where the target site is 
not associated with the plasma. These PK/PD indices involve the use of multiple points for calculation 
of each value rather than a single Cmax point; thus, there could be significant differences in Cmax values 
between murine replicate samples but less variation in exposure parameters.130,467 The PK/PD 
properties determined in an uninfected murine PK model are presented in Table 6.2. These values are 
compared with PK/PD values from literature calculated using an infected murine model of TB 
presented in Table 6.3. 
 
Table 6.2. PK/PD properties in an uninfected murine modela 
Compound Cmax/MIC AUC/MIC %T>MIC 
RMB 041 3.35 258.92 33.33 
RMB 043 1.33 15.03 4.20 
RMB 073 1.06 79.03 4.20 
PHX 1 21.59 109.53 20.80 
DPINH 8.31 6.10 8.33 
aCmax/MIC maximum concentration achieved in murine PK analyses divided by the in vitro MIC; 
AUC/MIC area under the curve obtained during murine PK analysis divided by the in vitro MIC; %T>MIC 






Table 6.3. PK/PD properties of known drugs in an infected murine model of TBa  
Compound Cmax/MIC AUC/MIC %T>MIC 
RIF 100 1500 100 
INH 660 1300 80 
EMB 11 33 35 
PZA 25 35 25 
CLZ 1 20 0 
MXF 17 88 100 
Mefloquine (MQ) 0.5 8 0 
PA-824 20 166 58 
BDQ 10 100 80 
aAdapted from Dartois and Barry III, 2013 
The PK properties of the different compounds differed significantly in the murine model (Table 6.2 
and 6.3). As noted, the mice used in this study are not infected with Mtb. These MIC values are derived 
from broth-cultured Mtb and therefore must be interpreted with care. The practice of using MIC 
values to determine drug susceptibility has also recently received scrutiny.468,469 Nevertheless, the 
compounds RMB 041 and PHX 1 were superior to the other novel compounds included in this study, 
specifically with regards to Cmax/MIC and %T>MIC for PHX 1, and AUC/MIC and %T>MIC for RMB 041. 
When compared with data from an infected murine study (Table 6.3) the compounds showed 
AUC/MIC and Cmax/MIC values similar to those of MXF, PA-824, and BDQ. However, the compounds in 
this study had significantly lower %T>MIC values.     
 
6.4.5 PK and PD correction using in vitro plasma protein binding 
Whilst these PK properties and comparisons with known drugs seem promising for some of the 
compounds, the free fraction available in vivo remains an important factor when considering drug 
PK/PD interactions. The in vitro murine protein plasma binding experiments carried out in the ADME 
studies (Chapter 4) were used to adjust the total drug concentrations according to the fraction 
unbound (Fu) concentrations. Importantly, these Fu concentrations more closely predict the 
concentration of drug that is pharmacologically active in vivo.470–472 With this in mind, the drug 
concentrations in plasma were adjusted using the respective protein binding values in Table 6.4 below. 
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Figure 6.11. PHX 1 total and fraction unbound concentrations (oral administration) in an uninfected 
murine PK model 
 
Compound Murine Plasma 
protein binding (Fu) 
PHX 1 0.11 
DPINH 0.10 
RMB 041 0.26 
RMB 043 0.21 
RMB 073 0.09 
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Figure 6.12. RMB 041 total and fraction unbound concentrations (oral administration) in an uninfected 
murine PK model 
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Figure 6.13. RMB 043 total and fraction unbound concentrations (oral administration) in an uninfected 
murine PK model 
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Figure 6.14. RMB 073 total and fraction unbound concentrations (oral administration) in an uninfected 
murine PK model 
 
































Figure 6.15. DPINH total and fraction unbound concentrations (oral administration) in an uninfected 
murine PK model 
The unbound concentrations from this study were used to calculate the PK/PD parameters for the 
compounds included in the uninfected murine PK model (Table 6.5), whilst the PK/PD properties 
derived from the Mtb-infected model were also corrected for protein binding (Table 6.6), allowing for 





Table 6.5. PK/PD properties corrected for protein binding in an uninfected murine modela      
Compound fCmax/MIC fAUC/MIC %fT>MIC  
RMB 041 0.88 67.32 0  
RMB 043 0.28 3.16 0  
RMB 073 0.09 7.11 0  
PHX 1 2.38 12.05 4.20  
DPINH 0.83 0.61 0  
aCmax/MIC maximum concentration achieved in murine PK analyses divided by the in vitro MIC; 
AUC/MIC area under the curve value obtained during murine PK analysis divided by the in vitro MIC; 
%T>MIC the percentage of time concentration of drug remains above the in vitro MIC value; and 
where the (f) associated with the various parameters denotes the parameter adjusted for plasma 




Table 6.6. PK/PD properties corrected for protein binding of known drugs in an infected murine model 
of TBa  
Compound fCmax/MIC fAUC/MIC %fT>MIC 
RIF 20 300 100 
INH 400 800 60 
EMB  8 25 25 
PZA 15 21 19 
CLZ 0.02 <1 0 
MXF 10 53 80 
MQ 0.1 1.6 0 
PA-824 2 16 21 
BDQ 0.1 1 0 
aAdapted from Dartois and Barry III, 2013 
 
The PK/PD parameters, when corrected for protein binding and compared to a total MIC, were 
significantly influenced by the moderate to high protein binding calculated in vitro. Following 
correction for protein binding (Table 6.5), the compounds resembled PA-824, BDQ, CLZ, and 
mefloquine (MQ, Table 6.6) in terms of free (f-)Cmax/MIC and fAUC/MIC but still did not compare to 
the superior %fT>MIC values for the known compounds. Whilst the majority of the novel compounds 
in this study displayed a zero value for the %fT>MIC parameter, which might appear to be of concern, 
109 
 
several drugs which have shown clinical efficacy such as BDQ473–475 and CLZ476–478 both display a free 
drug concentration of zero for the duration of the experiment. This is probably due to the 
disconnect93,454 often observed when comparing the diseased patient to a diseased mouse, where 
protein binding479,480 along with several other factors including basic experimental duration481 may 
vary significantly. Therefore, the fAUC of PHX 1 and RMB 041 and the %fT>MIC for PHX 1 present 
favorable results in this uninfected murine model, potentially driving the efficacy of these two 
compounds. Importantly, these results will need to be confirmed using an Mtb-infected murine model, 
where an in vivo MIC and PK parameters will allow for more informed conclusions to be drawn. In 
addition, whilst the plasma concentrations used to generate the PK parameters in these studies 
provide insights into how the compounds might behave in an in vivo model, human pulmonary TB is 
found in locations distant from the plasma. Subsequent analyses in murine lung fluids and organ 
tissues would allow for target site concentration PK/PD values to be determined.      
 
6.4.6 Human dose prediction  
Finally, human dose predictions for the compounds that possessed the most favorable murine whole-
blood PK and in vitro ADME properties, namely PHX 1 and RMB 041 are presented. In a process similar 
to that described in Chapter 4, allometric scaling coupled with the use of both in vitro and murine in 
vivo PK data was used to calculate the predicted human dose (further methodology provided in 
Appendix A).  
The data included for the human dose prediction included in vivo values derived from the murine PK 
experiments, namely CL, Vd (steady state), absorption rate constant (ka), and BA (as a fraction). In 
summary, PK Tool predicted the clearance of the compound using both Clint and blood and microsomal 
clearance from both in vitro and in vivo sources, making use of physiological parameters derived from 
various publications to supplement the model. This predicted clearance value is subsequently 
corrected for protein binding and along with other parameters is used to generate an allometrically-
scaled predicted dose that is required to sustain drug exposure above an experimentally determined 
efficacy line (e.g. an in vitro MIC level). 
There are certainly limitations to the model including the inability of certain enzymes and transporters 
to be effectively scaled, leading to possible under- or overestimations of clearance.482 The combination 
of in vitro and in vivo data relies heavily on the ability of both datasets to effectively predict conditions 
within the human in vivo environment, with lower weight species providing greater variation in 
predicting certain parameters such as clearance.482 In this regard, the predictive strength algorithm, 
which determines the number of relevant in vivo datasets from different species used, provided a 
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moderate to low predictive readout for this study based on the inclusion of only murine in vivo data. 
The doses predicted for PHX 1 and RMB 041, respectively, were 10.2 mg/kg and 11.4 mg/kg, for once 
daily dosing. This equates to a dose for a 70 kg individual of 714 mg per day for PHX 1 and 798 mg per 
day dose for RMB 041. This is comparable to the daily dose of RIF recommended by the WHO of 600 
mg per day and lower than a number of second line treatments.7 This is a significant improvement on 
the dose calculated for the same compounds using only in vitro data, which were 23.36 mg/kg and 
64.48 mg/kg for PHX 1 and RMB 041, respectively, with a low level of predictive strength.  
Overall, the inclusion of in vivo PK data significantly enhanced the predictive strength of the human 
dose predictions, and highlighted the need to conduct both in vitro and in vivo experiments in parallel 
in order to achieve the most predictive testing cascade possible. Although caution should be used 
when considering predicted doses derived from data using an uninfected murine model, the results 
point to the potentially low efficacious human doses required for both RMB 041 and PHX 1.  
 
6.5 Conclusion 
The LC-MS methods developed in chapter 6 were used to analyze the five compounds selected for PK 
testing based on their ADME and in vitro efficacy properties. The compounds that showed the most 
favorable PK properties were RMB 041 and PHX 1. When the PK parameters of the compounds were 
compared to their respective in vitro MIC values, the PK/PD parameters for PHX 1 and RMB 041 were 
comparable with some of the clinically efficacious anti-TB drugs. Following correction for plasma 
protein binding PHX 1 and RMB were notably comparable with BDQ, MQ, and CLZ. PHX 1 and RMB 
041 displayed predicted human dose levels that were lower than many clinically used second line 
treatments. The results of more in-depth analyses described in subsequent chapters will reveal 





7. Murine organ accumulation study of novel compounds 
 
7.1 Aim 
The aim of this chapter was to investigate the concentration of drug in various murine organs after 
oral administration. We assessed drug concentration in organs that could play a major role in the 
processing and accumulation of drug in the human body, focusing on organs that are commonly 
affected by pulmonary and disseminated TB. The compounds PHX 1 and RMB 041 were chosen for 
analysis in these experiments, as PHX 1 displayed the largest volume of distribution compared to the 
other compounds in this study, indicating potential accumulation within various organs. RMB 041 
displayed the longest half-life of the compounds in this study, again indicating that the compound may 
permeate into organs because of its long exposure in the circulatory system.     
 
7.2 Ethics statement 
All animal studies in this chapter were performed in the UCT Satellite Animal Unit and were carried 
out with prior approval from the UCT AEC (approval number 017/013) in accordance with the National 
Code for animal use in research, education, diagnosis, and testing of drugs and related substances in 




7.3.1 Organ drug concentrations in drug discovery 
Drug dosing and treatment duration are often determined via therapeutic drug monitoring and plasma 
concentrations. Plasma concentrations are often compared to in vitro drug efficacy data to predict 
drug efficacy in vivo. Whilst plasma concentrations are important, they do not take into account the 
complexities that the drug faces in crossing tissue barriers. The target of the antibacterial agent is 
often not the plasma but rather a specific organ or multiple organs, as is the case for TB treatment. 
Therefore, it can be argued that better predictions for a compound’s efficacy would be obtained by 
determining specific drug concentrations at the target organ.483 In order to avoid under- or over-
estimating the drug levels that are present within the organ of interest, studies assessing drug 




Amphotericin B (AmB) has been studied via a wide variety of techniques because of its efficacy against 
fungal infections, including Aspergillus fumigatus. Studies showed that, following short dosing periods 
of 3 to 6 h, the AmB plasma concentration was 5.2-fold lower than that in the lung tissue. Interestingly, 
this effect was enhanced in infected lung tissue, resulting in greater drug accumulation.484,485 
Moreover, the same trend was observed after treatment with a novel nitroimidazole compound 
administered to Mtb-infected mice, with the infected lung tissue producing a stronger [14C] signal than 
that obtained from plasma after 2 h.486 Using the same principle of radiometric quantification, the 
first-line TB drugs PZA, RIF, and INH were also investigated. Liu et al., 2010 found that this trend was 
consistent with that observed in larger primate species (baboons), this time using only uninfected 
animals.487  
The pharmaceutical industry faces challenges in the form of rising costs and a lack of efficiency in the 
protracted drug development pipeline.488,489 The development of more predictive and clinically 
relevant preclinical models has been identified as a way to address the rise in drug candidate failures. 
It is hoped that these new models will generate reliable data that better predict drug efficacy and 
safety in humans.490,491 Ensuring that compound concentrations are monitored as free fractions in 
organ(s) in which the disease prevails will allow better prediction of efficacy, rather than relying on 
proxies of target site concentration such as plasma concentrations.127    
 
7.3.2 Methodology used to determine organ concentrations 
In order to determine in vivo organ concentrations, two types of methods exist: invasive (organ 
harvesting and microdialysis), and non-invasive (positron emission tomography (PET) and magnetic 
resonance spectroscopy (MRS)).492 Non-invasive methods such as PET and fluorescence molecular 
tomography (FMT) scanning allow for the semi-quantitative determination of organ concentrations 
and have been used extensively to determine drug concentrations in sensitive tissues and in the blood-
brain barrier (BBB).493,494 However, there are limitations to these methods, including the difficulty in 
determining unbound tissue concentrations, the troublesome radiometric labelling of compounds, 
and the limited sensitivity of the technique.495  
Invasive methods such as microdialysis and organ homogenization combined with LC-MS/MS have 
allowed the accurate determination of unbound concentrations.492,496 These unbound concentrations 
were deemed more relevant to this study, and we therefore adopted an organ homogenate approach 
to determine organ concentrations here. The methodology used in this study includes LC-MS/MS 
quantification of drug concentrations from standard curves prepared using blank organ homogenate 
which has demonstrated reliability in other studies.497–499 
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The limitations of this approach included the use of different animals to determine concentrations 
over the time course used in this study, as this may lead to inter-individual variation in drug 
concentrations. This was considered, and concentrations were adjusted according to organ weight 
and density. Efforts were made to reduce the number of mice used per experiment considering the 
ethical implication of these experiments. Two mice with similar weights were selected at each time-
point, although this does not ensure that the organ weights would be the same. The results obtained 
did not differ significantly amongst replicates and therefore did not affect the conclusions drawn from 
this study. The second limitation we considered was the effect of the different tissues on LC-MS/MS 
signal. The ME, stability in homogenate, and recovery from each organ were measured to address 
these concerns. No statistically significant differences were observed. 
This method is not able to distinguish between the unbound fraction in the intercellular compartment 
and interstitial fluid, as the homogenization process disrupts cellular compartment integrity.500 This 
might have been addressed using a technique such as MALDI-MSI, however the quantitation of 
unbound drug concentration is arguably less accurate in determining quantitative drug 
concentrations, offering semi-quantitative low-resolution images.501 Newer techniques, such as liquid 
extraction surface analysis mass spectrometry imaging (LESA-MSI), are effective tissue profiling and 
imaging techniques that allow for quantitative drug concentrations in tissue samples, thus offering an 
alternative to LC-MS/MS-based techniques.502 
The final limitation is that of residual blood contamination in the organs, and this was addressed by 
flushing organs with saline. Residual blood could influence drug concentration in the organs by 
disrupting the osmotic balance within the tissue, causing loss of drug from tissue samples. Samples 
were flushed multiple times with an osmotically balanced saline solution, and although this does not 
prevent all drug loss, it does ensure that the majority of the blood is cleared from each organ.   
        
7.3.3 Repositioning organ concentration determination in the drug discovery pipeline 
Drug discovery and development is a multifactorial process that incorporates numerous parameters 
when assessing novel compounds. Recently, scientists have attempted to bridge the gap between 
experimentally determined PK and PD parameters and use this knowledge to better understand how 
a drug might fare in human clinical trials. This can be achieved by looking more closely at unbound 
drug concentrations obtained at the target site. The importance of determining unbound 
concentration has been described by Morgan et al. as “one of the three pillars of survival” for 
progressing a compound down the drug discovery pipeline, along with sufficient binding to the target 
and target modulation.503   
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7.4 Method development 
The development of the extraction method used to determine drug concentration in each organ 
involved a streamlined workflow (Figure 7.1). This allowed for the determination of the organ 
concentrations whilst ensuring that the extraction and LC-MS/MS methods were optimized. The 
process involved developing and optimizing an LC-MS/MS method, ensuring that the extraction 
procedure yielded the best possible MS data and, finally, ensuring completion of a partial method 
validation, taking into account drug stability during the various conditions the samples might face 
during analysis. Optimized LC-MS/MS methods as described in chapter 5, were used to quantitatively 
determine murine organ concentrations (Figure 7.1).  
 
Figure 7.1. Murine organ analysis workflow 
The assay development process involved testing a number of extraction methods in order to 
determine which method was able to produce the highest, most reproducible signal with the lowest 
background (highest signal-to-noise ratio). The extraction methods tested included protein 
precipitation using ACN and MEOH and testing a liquid-liquid extraction method (LLE) at pH values 
from 3-10. The method chosen was a LLE using ethyl acetate and a Britton Robinson buffer (0.1 M) 
prepared at pH 4 for PHX 1 and pH 10 for RMB 041. The methods used to partially validate the LC-
MS/MS and extraction methods were similar to those reported in Chapter 3 for murine whole-blood, 
with the inclusion of a LLE method and using the various organ matrices.     
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Partial method validation was included in this study to assess how the assay would perform when 
analyzing murine organ samples. This included assessing the extraction efficiency, ME of the 
compounds, and the stability of compounds in organ homogenates at -80°C for 48 h as well as on ice 
for 2 h (n =3 for all samples).  
 
7.4.1 Percentage recoveries of PHX 1 and RMB 041 from murine organ homogenates 
Percentage recoveries using LLE for PHX 1 and RMB 041 were assessed in each tissue type using similar 
methodologies reported for the determination of murine blood recovery (presented in Chapter 3 and 
Chapter 5). In summary, this experiment involved the preparation of samples that were spiked into a 
pre-extracted matrix (extracted using LLE), which was compared to samples that were spiked into 
mouse blank organ homogenate and subsequently extracted. This experiment was completed in 
triplicate at low (10 ng/mL) and high (4000 ng/mL) compound concentrations. All percentage 























Figure 7.2. Percentage recovery of high compound concentrations of PHX 1 and RMB 041 from murine 
























Figure 7.3. Percentage recovery of low compound concentration PHX 1 and RMB 041 from murine 
organs using LLE (n = 3 for each organ; data presented as means ± SD) 
 
The percentage recoveries assessed at both a low and high concentration for PHX 1 and RMB 041, 
displayed values of above 80% for all organ samples. RMB 041 displayed the lowest percentage 
recovery from murine liver homogenate with values of 83.2 ± 0.9% and 87.4 ± 0.3% from the high and 
low concentration samples, respectively. The PHX 1 recovery from both high and low concentration 
samples was above 90% for all organ samples. This provided evidence that the LLE extraction method 
used for each compound was reliable and that the analysis of each organ sample in this study would 
provide consistent results. 
 
7.4.2 Percentage stability of PHX 1 and RMB 041 in murine organ homogenates 
The percentage stabilities of PHX 1 and RMB 041 in murine organs were assessed according the similar 
methodologies as those used in murine blood, reported in Chapter 3. In summary, these conditions (-
80°C over 48 h and on ice for 2 h) replicated the extraction procedure on bench which was completed 
on ice, and the freeze-thaw cycles of samples post-animal sample collection. The percentage stability 
represents compound loss due to instability. This was determined by comparing freshly spiked 
samples at the respective low (15 ng/mL) and high (4000 ng/mL) concentrations to the stability 
samples exposed to either -80°C for 48 h or kept on ice for 2 h. The samples were then extracted using 
the LLE methods described in Chapter 3 and submitted for LC-MS/MS analysis. LC-MS/MS peak areas 
for the stability samples were divided by the peak areas of the freshly prepared samples and multiplied 
by 100 to obtain percentages. Percentages greater than 85% were obtained for both compounds 
stored at -80°C and on ice (Figure 7.4 and Figure 7.5, respectively).    
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Figure 7.4. PHX 1 and RMB 041 stability in murine organs stored at -80°C (data presented as combined 






















Figure 7.5. PHX 1 and RMB 041 stability in murine organs stored on ice for 2 h (presented as combined 
data for low and high concentrations; n = 3 for each organ; data presented as means ± SD) 
 
Both of the compounds displayed percentage stabilities of greater than 85% indicating that neither 
experimental condition would result in the degradation of PHX 1 or RMB 041. Therefore PHX 1 and 
RMB 041 could be stored at -80°C for up to 48 h and extracted on ice for up to 2 h without experiencing 




7.4.3 Matrix effect (ME) assessment in murine organ homogenates for PHX 1 and RMB 041 
ME were assessed in each organ to ensure that no signal enhancement or suppression occurred as a 
result of organ ME (Figure 7.6). In summary, ME were assessed by spiking compounds in triplicate at 
low (10 ng/mL) and high (4000 ng/mL) concentrations into pre-extracted mouse organ samples 
(extracted using LLE), which was compared to samples spiked at the same concentrations directly into 
injection solvent (mixture of 1:1 ACN:H2O (v:v, containing 0.1% FA)). Organ samples were extracted 
using a LLE method and submitted for LC-MS/MS anlaysis. The difference in LC-MS/MS response 
between the samples is then assumed to be due to interference by the matrix (murine organ 
homogenates). ME were calculated by dividing the normalized peak area response of the analyte 
spiked into injection solvent by the normalized peak area response of the analyte spiked into the pre-
extracted matrix and multiplying by 100 to obtain a percentage. Data was combined for high and low 
concentrations in Figure 7.6. Mild signal enhancement or suppression was observed in each organ 
with all ME ratios falling within 0.2 units either side of one.  



























Figure 7.6. ME for PHX 1 and RMB 041 at high and low concentrations (presented as combined data) 
in each tissue type (n = 6 for each organ; data presented as means ± SD) 
 
PHX 1 and RMB 041 displayed the highest ME 1 for in the murine spleen homogenate. However, the 
ME for both PHX 1 and RMB 041 were within the acceptable deviation 0.2 units for all organ 
homogenates, indicative of the fact that neither compound would be exposed to significant ion 




7.4.4 Summary of LC-MS/MS assay and protocol for murine organ PK experiments 
Compounds were prepared in theoretical fixed volumes for the average weight of each mouse. Mice 
(n = 6) were dosed at 10 mg/kg, and three mice were dosed with vehicle control (100% HPMC) in order 
to obtain blank organs for calibration curves. Mice (M) were then anesthetized at 1 h, 8 h and 24 h 
post dosing (n = 2 per time-point). Euthanasia via exsanguination was performed on M1 and M2 in 
order to confirm murine death. The organs were flushed with saline and dissected out of each mouse 
before being flash frozen. This was repeated for M3, M4, M5, and M6 at the corresponding time-
points. To obtain blank matrix for calibration curves in order to determine concentrations of drug in 
the organs, the process was repeated in the other three mice that received only vehicle control. 
Organs were weighed, homogenized and subsequently extracted using a LLE method. Organ samples 
(30 µL) were extracted using ethyl acetate and 0.1 M Britton Robinson buffers prepared at a pH of 4 
and 10 for PHX 1 and RMB 041, respectively. The samples were vortexed (1 min) and centrifuged at 
10621 g (5 min). The sample supernatant was removed, dried down under nitrogen and reconstituted 
in injection solvent (1:1 H2O: ACN) before being submitted for LC-MS/MS analysis. Standard (3.9 - 4000 
ng/mL) and quality control (10 – 3200 ng/mL) samples were spiked into corresponding organ samples 
to generate standard curves which were used to quantitatively determine the concentration of each 
analyte in the respective murine organ samples. LC-MS/MS analyses were performed using the same 
methods used for murine PK concentrations as presented in Chapter 5.  
 
7.5 Results and discussion 
7.5.1 LC-MS/MS assay performance 
A quadratic regression equation, plotting peak area ratio against concentration was fitted to the 
calibration curves. The curves were also weighted by 1/concentration (1/x). The %NOM for all 
calibration and QC samples was between 84.2 ± 4.1 and 117.7 ± 4.1% in this study, with %CV of the 
same calibration and QC samples between 89.2 ± 6.1 and 114.9 ± 3.1%, with representative 
chromatograms presented in Appendix C. This indicated that the murine organ calibration curve 
values were well within the acceptable 20% deviation used in this study for both calibration curve and 
QC values and that the murine organ assay performed well in the analysis of murine organ samples. 
 
7.5.2 Correcting murine organ concentrations for organ density 
Different tissue types have varying densities, which were corrected for using experimentally 
determined values in Table 7.1. Concentrations were then divided by the specific weight of the tissue 
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to yield a value per mg of tissue. The area under the concentration/mg versus time graph provided an 
exposure value for each organ.   
 
Table 7.1. Specific organ densities and correction factors used 
Tissue type Density 
(g/mL) 
Correction 
factor used Blood 0.99 1.0 
Liver 0.97 1.0 
Lung 0.87 0.9 
Heart 0.93 0.9 
Kidney 0.98 1.0 
Spleen 0.91 0.9 
Brain 0.86 0.9 
 
7.5.3 Murine organ concentrations of PHX 1 and RMB 041 
Murine organ concentrations were determined as described above, for PHX 1 and RMB 041 in this 
study with the results presented in subsequent figures, by correcting quantitatively determined organ 
concentrations for their specific organ density and organ weight with data presented as 
concentrations in nmol/mg of tissue (Figure 7.7). 







































Figure 7.7. Total PHX 1 concentrations in murine organs (oral dose, 10 mg/kg) (n = 2 per time-point; 
data presented as means ± SD) 
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Organ concentrations obtained for PHX 1 indicate drug accumulation within the lung (Cmax 22.4 ± 2.35 
nmol/mg) and heart (18.83 ± 3.16 nmol/mg) tissue. Significantly lower concentrations were reported 
in the murine kidney, spleen, brain, and liver for PHX 1. Concentrations were significantly different at 
the 1 and 8 h time-points with concentrations in the heart and lungs decreasing to similar 
concentrations seen in the other organs at the 24 h time point.  
Organ AUC was assessed by determining the area under the concentration time curve to provide 
values of exposure for each organ in the murine model over the 24 h testing period which is displayed 









Figure 7.8. PHX 1 exposure in each organ (AUC) (n = 2 per time-point; data presented as means ± SD) 
 
Exposure in these organs was also higher with AUC values of 9669 ± 120.2 min.nmol/mg and 12450 ± 
45.2 min.nmol/mg for lung and heart tissue, respectively. These results are consistent with findings 
from murine experiments using the structurally similar riminophenazine antibiotic CLZ.504 Long-term 
drug exposure over a period of 8 weeks resulted in accumulation of CLZ into the spleen, lungs, and 
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other organs, thus leading to the formation of crystal-like drug inclusions (CLDIs). However, the results 
of this study are difficult to compare with ours considering important study design differences: the 
present study focused on a 24 h period of standardized dosing to investigate detectable drug 
accumulation, while the study by Baik et al. included intensive dosing over 3-8 weeks and a follow-up 
washout period.504  
Nevertheless, the trends observed with regard to accumulation of the compounds within murine 
organs are similar. The greatest exposure was observed in the lung, heart, and spleen 1 h after dosing, 
followed by a significant decrease in all drug levels. Moreover, the brain and kidneys showed no 
significant drug accumulation at any stage (Figure 7.7 and Figure 7.8). Baik et al. postulated that 
accumulation of drug in the spleen following cessation of drug administration may be due to 
immunomodulated accumulation of CLZ in macrophages,505 a characteristic also observed after PHX 1 
administration in this study. This is unsurprising, as the structures of PHX 1 and CLZ are similar in that 
they both possess a phenoxazine core. Both compounds are lipophilic and weakly basic.506 As such, 
these drugs, with their lysosomal trapping capacity, tend to accumulate in acidic organelle 
compartments via pH-dependent ion trapping mechanisms, potentially explaining accumulation in 
specific organ compartments.507   
RMB 041 concentrations were assessed using the same methodology described above for PHX 1. This 
resulted in the concentration time curve produced below (Figure 7.9). 
















































RMB 041 accumulated to significantly lower levels than PHX 1 in all organs, with the greatest 
concentrations observed in the lungs, spleen, and heart. Relatively low levels of RMB 041 were seen 
in the murine liver, kidney and brain. It must be noted that RMB 041, although achieving lower 
maximum concentrations in all organs, displayed similar concentrations to PHX 1 after 24 h, 
particularly in the lungs. Compounds that maintain high concentrations in tissues for a prolonged time-
period have a greater chance of clearing an infectious agent such as Mtb. This is supported by RMB 
041’s long half-life observed both in vitro and in vivo in Chapter 4 and Chapter 6, respectively. 
Alternative explanations for the extended half life of RMB 041 accompanied by minimal drug 
accumulation in the murine organs, includes the accumulation of compound into adipose tissues508 
and organs, which were not assessed in this study such as the intestines.     
Murine exposures for RMB 041 in each organ were assessed using the area under the concentration 




Figure 7.10. Total drug exposure (AUC) in organs after oral administration of RMB 041 (n = 2 per time-




These results showed that the greatest exposure of RMB 041 in murine organs over 24 h was observed 
in the lungs, spleen, and heart (Figure 7.10). However, these exposures were significantly lower than 
those obtained for PHX 1. 
Comparative studies for the compounds in this study are scarce, as only the plasma concentrations of 
DQ, a quinolone derivative, have been assessed.509 A study involving the quinolone antibiotics LVX, 
ciprofloxacin (CIP), and ampicillin, administered at a significantly higher dose (120 mg/kg) in a 
Streptococcus pneumoniae-infected mouse model, showed large maximal lung concentrations of 5.95, 
1.10, and 1.71 µg/g, respectively.510 This is supported by evidence of the uptake of fluoroquinolones 
into human-derived macrophage cells.20,511,512 The fluoroquinolones, however, differ significantly in 
their ability to permeate into cells and tissues, and even small changes in the structure of the 
compound could lead to differences in accumulation, as observed for RMB 041.  
Administration of higher or multiple doses of either of these compounds may lead to increased 
concentrations in the lungs and, with very little brain or liver exposure, the risk of toxicity is low. A 
concern arising from this study was the relatively high exposure of PHX 1 in cardiac tissue. As it is 
unknown whether these compounds may cause human ether à-go-go-related gene (hERG) inhibition, 
which could interfere with electrical conductivity in the heart and result in arrhythmic conditions such 
as drug-induced QT prolongation, confirmation of compound-related hERG toxicity is advisable before 
increasing the dose.513 
       
7.5.4 Free drug concentrations 
It is essential to properly understand how much free drug is available to treat a specific microbe at 
the target site where the disease persists. In this study, drug concentrations were adjusted according 
to the protein binding experiments conducted for each tissue type (Table 7.2). Organ binding values 
reported were corrected using a modified plasma protein binding ultracentrifugation method 
(presented in Chapter 3) for each organ over 4 h with tissue concentrations of 0.4 mg/mL of each 















Blood 0.88 0.82 
Liver 0.99 0.91 
Lung 0.97 0.93 
Heart 0.98 0.97 
Brain 0.98 0.98 
Kidney 0.97 0.97 
Spleen 0.94 0.92 
 
Although PHX 1 seemed to accumulate significantly within the lungs and heart, the high degree of 
binding provided a predicted free fraction of compound (Figure 7.11), which was below the bound 
MIC90 level in these tissues (0.194 µM). The total concentration of RMB 041 was also significantly 
below the bound MIC90 level of 1.61 µM.  
In order to adjust the MIC90 value for binding to Mtb and various media components a binding 
experiment specific to the Mtb screening assay would have to be carried out. Investigating compound 
binding to OADC 7H9 media and Mtb in the BSL III environment was not possible in this study as the 
ultracentrifuge required to complete this assay was not present within the BSL III.  
Nevertheless, assuming the binding to media components is similar to that in the plasma protein 
binding assay (similar pH and contains albumin fraction),375 with fraction unbound values of 0.19 and 
0.1 for PHX 1 and RMB 041, respectively, the values for PHX 1 would be above the estimated free 
MIC90 value of 0.037 µM for approximately 8 hours for the heart, lung, and blood concentrations. RMB 
041 was still below the 0.124 µM estimated free MIC90 value for all organ concentrations. This free 
MIC90 value used may be significantly different once corrected for binding to OADC 7H9 media and 
Mtb and must be interpreted with caution. The Mtb MIC90 value for each tissue type assessed in this 
study may also be very different in the in vivo situation.     
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Figure 7.11. Free concentration of PHX 1 (µM) following correction according to tissue binding  
 
The practice of comparing tissue concentrations determined in healthy animals to MIC values 
determined in different experiments has been criticized by Mouton and colleagues, who have stated 
that such data sets are not comparable, and that disease state could significantly alter the values 
obtained in these experiments.516  
In order to better utilize these data, the compounds assessed could be compared to other drugs 
known to accumulate significantly in healthy animal tissues. For example, BDQ, a clinically successful 
drug, administered at 25 mg/kg accumulates to significant levels within healthy murine lung tissue 
(Cmax, 24 µM) but is also highly protein bound, leaving 0.18 µM free drug available, a value that is 
slightly higher than that for PHX 1 and significantly higher than that for RMB 041.517  
The progression of these compounds would allow for testing in an Mtb-infected murine model, 
providing the chance to measure MIC values and drug concentrations in infected mice. This would 
provide a clearer understanding of whether in vivo efficacy and accumulation are influenced by the 
introduction of Mtb infection. Administration of multiple or higher doses could also be assessed over 
a longer time-period to evaluate drug accumulation in a more clinically relevant situation, as no drug 
is ever administered once-off and measured for 24 h in clinical practice.  
 
7.6 Conclusion 
The murine organ analysis provided an insightful glimpse into the exposure of each murine organ to 
the compounds PHX 1 and RMB 041, the two compounds that yielded the most promising results in 
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murine blood PK experiments. PHX 1 showed significant accumulation in the heart and lung tissues, 
whilst RMB 041 accumulated in these tissues to a significantly lesser extent, although neither 
compound produced free fractions greater than their respective MIC90 values. However, PHX 1 
displayed free lung concentrations above a free MIC90 value corrected for plasma protein binding for 
approximately 8 h. Progression into an infected murine model coupled with multiple-dosing would 




8. Murine pharmacokinetic study of novel compound accumulation in 
epithelial lining fluids and associated cells   
 
8.1 Aim 
Drug concentrations in the epithelial lining fluid (ELF) were determined in a murine bronchoalveolar 
lavage (BAL) model. This was carried out to determine whether PHX 1, the lead compound that 
showed effective penetration into lungs, was able to penetrate into the lung fluid in which infected 
alveolar macrophages (AMs) reside. 
 
8.2 Ethics statement 
All animal studies in this chapter were performed in the UCT Satellite Animal Unit and were carried 
out with prior approval from the UCT AEC (approval number 017/013) in accordance with the National 
Code for animal use in research, education, diagnosis, and testing of drugs and related substances in 




8.3.1 The blood-alveolar barrier 
The blood-alveolar barrier (Figure 8.1) is made up of two membranes: the capillary wall and alveolar 
wall leading to the lung. These membranes are separated by an interstitial fluid-filled space which 
carries oxygen and nutrients to the surrounding cells.518 Antibiotics are required to cross through the 
capillary wall and the interstitial fluid, and finally make their way through the epithelial membrane 
where they can interact with AMs. The fenestrated capillary bed allows passive diffusion of molecules 
larger than 1000 Da, but the epithelial cells are far less permissive, forming tight junctions to stop 
penetration into the ELF of the lung.519 Drugs are therefore required to interact with the epithelial 




Figure 8.1. Blood-alveolar barrier comprising the capillary space, interstitial space, and epithelial lining 
(adapted from Cunha, 1991)  
 
8.3.2 Importance of drug concentrations in the ELF 
Pulmonary AMs and the ELF have been identified as important sites of clinical infection for numerous 
pulmonary infectious diseases, including TB. Over the past few decades a number of in vitro and 
clinical studies have highlighted the need for target site concentrations to be determined using ELF 
concentrations as criterion for progression, as is the case in many other infectious diseases.520–523 This 
is primarily due to the fact that Mtb, unlike other infectious agents, is not contained within tractable 
locales, thus making it difficult to both study and treat. ELF has recently been highlighted as an 
important site to measure drug concentrations due to its proximity to the site of infection and also 
due to its role as a reservoir for bacteria.524,525  
Torrelles and colleagues discuss the path of a bacillus from inhalation to infection in the context of 
interaction points (IPs, Figure 8.2). These IPs between the bacillus and host immune sites form vital 
checkpoints in disease progression. They include but are not limited to: (i) the nasal cavity and sinuses, 
(ii) the trachea and main stem bronchi, which separate into the bronchioles (iii), and finally terminate 
in the alveoli (iv). The ELF forms part of the alveolar complex and is sometimes referred to as alveolar 
lining fluid. It is composed of a lipid monolayer which serves as a surfactant, reducing tension during 




Figure 8.2. Movement of Mtb and interaction points with host defenses (adapted from Torrelles et al., 2017)  
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The ELF is regarded as an extremely important environment in the context of host-immune cell 
responses, and houses a number of immune cells including AMs, although other cell types are also 
recruited to this area, such as lymphocytes, neutrophils, and dendritic cells, forming the stage for Mtb-
phagocyte interactions.525,526 The involvement of isolated ELF in disease control is still debated with 
some research pointing to better disease outcomes after ELF-pathogen interaction.527 This is thought 
to be due to a significant decrease in critical virulence factors, surface mannose-capped 
lipoarabinomannan (ManLAM), and trehalose dimycolate (TDM), ultimately affecting how these 
bacterial cells are able to interact with host cells and affecting the progression of infection and 
bacterial persistence.528 In addition, ELF has been shown to interfere with the mycobacterial cell wall 
via ELF hydrolases secreted by resident alveolar cells.529,530 As the site of infection, the ELF provides an 
important environment that is accessible by various techniques. The study of this environment in the 
context of drug discovery offers us a much more predictive and contextualized proxy for drug efficacy 
than plasma.       
 
8.3.3 Measuring ELF concentrations 
Antibiotic concentrations in ELF have been measured using a number of different methods and lung 
fluids including sputum, respiratory tract secretions, bronchial mucosa, ELF, and BAL fluid.531,532 
Traditional methods to measure drug concentrations in lung tissues were developed using tissue 
samples obtained during surgery.516,533 Tissue samples are often homogenized and, whilst they provide 
a good average concentration of overall drug penetration into organs, the information regarding 
specific compartmental penetration is lost due to the processing of organ samples, sometimes leading 
to poor target-site drug concentration predictions.516 Drug concentrations in sputum samples and 
bronchial secretions are considered poor predictors of drug penetration because of the diluting effect 
of saliva in these samples, thus leading to under- or over-estimation of drug concentrations.521,531,534  
Drug concentrations in ELF and macrophages seem to provide the best predictive values of target-site 
concentrations because of their proximity to the initial target site of mycobacterial infection, although 
obtaining these samples is often difficult and uncomfortable for patients.519 Knowledge of drug 
concentrations in intrapulmonary fluid has been promoted for use in drug design and dosing 
determinations, as ELF provides a representative environment of lung biology, particularly for lower 
respiratory tract infections.534,535 
The BAL procedure, which has been performed clinically for nearly two decades, is favorable because 
of its non-technical nature, which has been improved by the use of bronchoscopic microsampling 
probes (BMS).536 Clinical BAL procedures vary in a number of aspects, including the dwell time of the 
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PBS solution between lavages, the number of lavages performed, the aspiration pressure applied, and 
the volume of fluid injected into the lungs, all of which can have an effect on the drug concentrations 
measured.537,538 
Therefore, care must be taken in assessing the literature to find the most consistent methodologies 
used during the procedure as no standardized methods are used.521,539 Our assessment lead to the use 
of a 10 s dwell time between aspirations and a total of four lavages with 100 µL PBS each, discarding 
the initial lavage fluid sample. This study, as in the previous organ study, would have held greater 
statistical power by increasing the number of mice per time-point. However, the mice used in this 
study were again of similar body weight, providing us with data from which statistically significant 
conclusions could be drawn because of the low inter-individual variation. However, in order to use 
these concentrations to inform dosages in clinical trials, the experiment should be repeated using a 
greater number of animals.     
BAL fluid consists of a number of components including the introduced PBS, ELF, AMs, and other cell 
debris, and it is therefore essential for the ‘apparent’ ELF volume to be determined.540,541 The low 
molecular weight, non-polar urea molecule has been used to correct for volume in several studies 
because of its ability to cross the blood-alveolar barrier freely and maintain equilibrium in both ELF 
and plasma compartments.542 This estimated ELF volume is a potential limitation, possibly leading to 
an over-/under-estimation of drug levels.537 However, without performing potentially risky and costly 
direct sampling in the lung,543 we cannot obtain ELF without diluting with PBS via the BAL procedure. 
BAL offers several advantages as the washing of the lung allows for a more global fluid analysis, 
encompassing a greater area of the lung microenvironment. The procedure presents a moderate level 
of difficulty with the surgical exposure of the trachea in mice being the most technically challenging 
aspect of the procedure.   
Urea concentration is measured in both the plasma and BAL fluids, and this ratio is used to determine 
the approximate ELF volume in the sample.542 Different assay kits are available to measure urea 
concentrations and this has introduced some variability in the calculation of drug concentrations in 
ELF. The method chosen in this study makes use of a modified enzymatic assay kit (QuantiChrom urea 
assay kit DIUR-500, BioAssay Systems) to determine ELF volume within the BAL samples.544  
Cell lysis and blood contamination have also been suggested as possible limitations in this method, 
and that the initial aspirate should be discarded because of contamination with AMs, which would 
increase the concentration of drugs that are subject to lysosomal trapping or accumulation within 
macrophages.532,534 This was addressed in our study using a trypan blue staining method coupled to 
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automated cell counting. High cell numbers were recorded in the first aspirate, which then decreased 
in subsequent aspirates. Blood contamination was not seen in any of the murine BAL samples.   
These methods have been used for both human and murine subjects and have shown that drugs such 
as azithromycin accumulate to significantly higher levels in lung fluids and cells, with many of the 
studies indicating high intracellular accumulation, often associated with intracellular efficacy.545,546    
      
8.3.4 Summary of LC-MS/MS assay and murine ELF PK protocol 
Compound was prepared in theoretical fixed volumes for the average weight of each mouse. Mice (n 
= 6) were dosed at 10 mg/kg, and three mice were dosed with vehicle control (100% HPMC) in order 
to obtain blank organs for calibration curves. A blood sample (15 µL) was taken 10 min before the BAL 
procedure from M1 and M2 via tail tip bleeding, followed by the immediate vortexing (1 minute) and 
centrifugation (5 min, 10621 g) of samples to obtain plasma. This was carried out to allow the 
comparison of murine plasma concentrations of PHX 1 to the concentrations in murine ELF and lung 
cells. Mice were then anesthetized at 1 h, 8 h, and 24 h post dosing (n = 2 per time-point). After 
confirming that mice were anesthetized, the trachea was exposed and wash fluid containing PBS was 
introduced in four separate volumes (100 µL) into the lungs of M1 and M2 via the lavage tube, 
aspirated inside of the lung and was then removed using the same syringe. The last three washes per 
animal were collected on ice and the total volumes collected were recorded. This process was 
repeated for M3, M4, M5, and M6 at the corresponding time-points. In order to obtain blank ELF fluid, 
the process was also repeated for mice (n = 3) which were dosed with vehicle control.  
BAL samples were processed by initially spinning down the aspirate to pellet any cells, followed by 
removal of the aspirate supernatant. The determination of ELF volumes was completed using a 
colormetric assay kit (Quantichrom urea assay kit DIUR-500, Bioassay systems) and analyzed using a 
BioRad iMark™ Microplate Absorbance Reader (CA, USA) as described in Chapter 3.    
Cellular, plasma, and lung fluid samples were processed by the addition of 150 µL of ACN containing 
IS carbamazepine (1 µg/mL) to 20 µL of each respective sample, followed by vortexing (1 minute) and 
centrifugation (5 min, 10621 g). Supernatants were then removed and dried down under nitrogen and 
reconstituted for LC-MS/MS analysis using injection solvent. Standards (3.9 – 4000 ng/mL) and QC 
samples (6- 3200 ng/mL) were prepared in each matrix (pooled blank murine matrices) in triplicate 
and were extracted using the same ACN protein precipitation method as above. LC-MS/MS analysis 
was performed using the same methods used for murine PK concentrations. Calibration curves were 
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constructed in each matrix (n = 3) and used to quantitatively determine the concentration of PHX 1 in 
each murine matrix. 
 
8.4 Results and discussion 
8.4.1 ELF volume determination 
The BAL procedure results in the dilution of ELF and other cellular constituents in each sample. In this 
study, a colorimetric assay (Figure 8.3) using the following reaction principle was carried out: urea is 
hydrolyzed by urease to form ammonium carbonate, followed by a secondary reaction in which 2-
ketoglutarate reacts with ammonium in the presence of glutamate dehydrogenase (GLDH) and the 
coenzyme NADH, producing L-glutamate.547 In this reaction, for each mole of urea hydrolyzed, two 
moles of NADH are oxidized to NAD+. The rate of decrease of the NADH concentration is directly 





Figure 8.3. Colorimetric urea assay (decreasing concentration from left to right) 
 
To test the linearity of the curve, urea standard samples were prepared (in triplicate) by spiking known 
concentrations of urea into PBS buffer (Figure 8.4). The method (described in Chapter 3) enabled 
accurate measurement of urea in the samples from 0.39-100 µg/mL using absorbance readings from 
an iMark™ Microplate Absorbance Reader (BioRad). ELF and plasma samples were compared to a 
constructed calibration curve which was used to quantitatively determine urea concentrations in 






Figure 8.4. Representative standard curve for urea spiked in PBS buffer (n = 3 for each data point; 
presented as means ± SD) 
 
Following urea concentration determination in plasma and ELF, the volume of ELF within the sample 
could be estimated (Equation 3.10) using urea concentrations determined in both plasma and urea 
samples. ELF volumes ranged from 260 to 281 µL, which comprised 80 ± 7.1% of the total volume of 
BAL fluid collected.  
Samples were then centrifuged to obtain cell pellets. Intracellular drug concentrations were 
determined to quantify drug concentrations within immune cells, particularly AMs, which make up 
most of the cellular volume in the ELF.519,532 Cells were counted for each BAL sample using a trypan 
blue/automated cell counting method as described in Chapter 3. Most of the fluid obtained from the 
first lavage consisted of a mixture of tissue, cells, and lung fluids from the proximal airways, making 
the accurate determination of lung fluid and cellular concentrations extremely difficult. Therefore, the 
initial lavage sample was discarded for each murine sampling period, with subsequent washes for a 
particular mouse being pooled to give a single sample per time-point per mouse (n = 6 total samples 
over 24 h).  
  
8.4.2 Determination of ELF fluid, intracellular, and plasma drug concentration  
Following ELF volume determination, quantitative drug concentrations were determined for plasma, 
AMs, and BAL samples (representative chromatograms presented in Appendix D). Calibration curve 
samples (3.9 - 4000 ng/mL) as well as QC samples (6 - 3200 ng/mL) were spiked in triplicate into blank 
murine macrophage cell lysate, BAL fluid, and plasma. The curves were analyzed via quadratic linear 
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regression and weighted (1/concentration) with curves displaying R2 values of 0.9956, 0.9990, and 
0.9989 for cell lysate (AMs), BAL fluid, and plasma, respectively, for PHX 1. The CVs for all standards 
and QCs were below 15%.  
 
BAL fluid concentrations were adjusted using estimated ELF concentrations (Equation 3.11), which 
allowed for comparison with plasma drug concentrations. ELF concentrations can be significantly 
influenced by AM lysis during BAL processing, leading to the over-estimation of ELF concentration. The 
cellular component was therefore centrifuged, and the BAL fluid supernatant removed, allowing for 
the separate analysis of the two components. Therefore, in total, three components were assessed 
including the plasma, AM, and ELF concentrations.  
 
8.4.3 Drug concentration interpretation 
Plasma concentrations in patient samples are commonly used proxies for predicting drug 
concentrations at the site of infection.548 There have been various efforts to try to integrate 
pharmacological properties with their ability to penetrate into the ELF and plasma.548,549 However, as 
has previously been shown, intracellular infectious agents such as Mtb are present in areas of the 
human body that are more difficult to reach, thus making plasma a poor proxy in most cases.15,16 
Compound concentrations were quantitatively determined (as presented in Chpater 3) in the AM, ELF, 
and plasma and compared to the PHX 1 Mtb MIC90 value (Figure 8.5).  









































PHX 1 plasma concentrations in this study were greater than the Mtb  MIC90 value for this compound 
for approximately 7 h, achieving a maximum concentration (Cmax) of 200 ± 75 ng/mL (Figure 8.5). Drug 
exposure in plasma was calculated using the area-under-the-curve (AUC), providing a value of 57269 
ng/mL/min. The level of PHX 1 in the ELF was significantly higher, with a time above MIC90 of 8 h and 
a Cmax of 452 ± 22 ng/mL. Although the time above MIC90 is very similar to that in plasma, the higher 
Cmax achieved in ELF causes the AUC to be significantly higher at 98231 ng/mL/min, or nearly two-fold 
greater than the level achieved in plasma.  
In order to correct for possible cell lysis during sample processing which may lead to the over-
estimation of ELF drug concentration, an equation was developed by Kiem and Schentag.519 The result 
is referred to as the original ELF concentration and is calculated using Equation 8.1 below. The original 
ELF concentrations in this study were still significantly above the MIC for approximately 7.5 h with Cmax 
415 ± 20 ng/mL.    
 
Equation 8.1. Original ELF concentration 
OCELF= mCELF × (1 + Vcell/VELF) - Ccell × Vcell/VELF 
 
where mCELF is the measured ELF concentration, Vcell is the volume of lysed cells, VELF is the volume of 
ELF analyzed, and Ccell is the intracellular drug concentration measured 
 
This disparity between ELF and plasma is further highlighted by the lung fluid cell concentrations. The 
predominant cell type within ELF is AMs (83%),532 in which the compound PHX 1 accumulates to 
significant levels (presented in Chapter 9). The concentrations of compound measured in the cell pellet 
were significantly higher than that in plasma and ELF, achieving a Cmax of 895 ± 23 ng/mL with a 
calculated AUC of 248490 ng/mL/min, approximately four-fold higher than in plasma samples, and 
two-fold higher than in ELF.  
When discussing these disparate compound concentrations within the context of a therapeutic 
window, the importance of determining target-site concentrations becomes clearer. If plasma 
concentrations were used in this study to predict drug efficacy, we would conclude that drug 
concentrations are maintained above the MIC for a maximum of 7 h. However, if drug concentration 
was measured in lung cells, the time during which drug concentrations are above the MIC90 would be 
closer to 17 h. The potential toxicity of compounds is also highlighted here. If we were to double the 
dose of the compound administered, and we assumed a corresponding increase in ELF and AM drug 
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concentrations, these microenvironments would be exposed to concentrations two- and four-fold 
higher, respectively, possibly pushing the compound into the toxic range.  
This problem is not as evident in the dosing of RIF primarily because of the lower concentrations 
observed in ELF and AM when compared to that in plasma (Figure 8.6).550 The cited study highlights 
the fact that the majority of patients are not receiving an adequate dose of RIF. The significantly lower 
ELF and AM concentrations could therefore be increased by increasing the dose of RIF administered 
(currently 600 mg). This lack of rifamyicn penetration into the ELF and subsequent cavity caseum was 
further explored in a comparative study between RIF and the suggested replacement drug, 
rifapentine,551,552 in an Mtb-infected New Zealand White rabbit model.553 Using MALDI-MSI and 
quantitiative LC-MS/MS, the authors highlighted the lower rifapentine penetration into the cavitary 
caseum as a possible explaination for the lack of rifapentine efficacy seen in phase two clinical trials 
in patients with larger cavitary lesions.553 This study further highlighted the need to measure drug 
concentrations in a number of different locations pertinent to Mtb infection.       
 
Figure 8.6. RIF exposure in plasma, ELF, and AM (Goutelle et al., 2009) 
 
In another study, INH concentrations were also analyzed in three different cellular environments, 
revealing that mean drug exposure in ELF was higher than that in plasma. However, due to variability 
in reported drug concentrations, no statistically significant conclusions could be drawn.554 Similar 
results were reported for MXF, PZA, and LNZ, with greater drug concentrations in ELF than that in 
plasma.555–557 It must also be noted that neither the mice used in this study nor the patients in the 
above MXF, PZA or LNZ studies were infected with Mtb, a factor which could significantly influence 
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the different drug concentrations achieved within each compartment.537 A number of different ELF 
studies have been conducted looking at the ELF concentrations observed for known anti-TB 
compounds. One of the main predictors for penetration into the target site, is the ratio between the 
ELF concentration and the plasma concentration, which is usually presented as a Log ratio, with a 
higher log ratio indicative of higher concentrations in the ELF compared to the plasma.534,558 This log 
ratio for PHX 1 (0.65) in this study was higher than CIP521,559,560(-0.2), and similar to INH561(1), 
LZD556,562,563(0.7), and RIF564,565(0.7), whilst ethionamide566(2.8), MXF567(1.5), and PZA555(3.2) showed 
significantly higher ratios, indicative of their superior intrapulmonary penetration. 
However, recent literature points to several flaws associated with determining an ELF/plasma 
concentration using single-point values such as the Cmax.548,549,558 The systemic hysteresis associated 
with both ELF and plasma concentrations requires a more stable PK parameter to be determined such 
as an AUC measurement. In this study the ELFAUC/plasmaAUC for PHX 1 provided a value of 1.72, which 
still indicates moderate to high penetration and subsequent exposure in the ELF.  
All of the known anti-TB drugs described above have shown clinical efficacy and comparing the log 
ratio of ELF/plasma concentrations to the data obtained in this study for PHX 1 proved useful as results 
could be compared. Comparing the ELF exposures to plasma exposures could be an effective screening 
tool in progressing a compound further in the candidate selection process.558 However, caution should 
be maintained using drug concentrations measured in uninfected models to infer potential anti-
tubercular activity in vivo. The final jump into clinical trials should only follow testing in infected in vivo 
models as disease state could influence the concentrations determined in this study.516  
 
8.5 Conclusion 
The assessment of PHX 1 concentrations within the ELF and AM environments afforded a more 
focused analysis of the target site within a murine model. PHX 1 levels within the ELF and AM were 
significantly higher than those measured in plasma, thus indicating potential compound permeation 
within these environments where Mtb has been identified. Whilst these results were encouraging, 
caution had to be maintained in over-interpreting these results, as the use of healthy mice and small 
sample size per time-point imposed limitations on this study. Nevertheless, the results motivated for 





9. Converging on the target site: development and implementation of 
a novel assay to measure intracellular drug exposure and correlate 
intracellular efficacy in Mtb-infected THP-1 cells 
9.1 Aim 
This chapter presents work used to determine whether the selected compounds were able to 
accumulate within the macrophage. Perturbations to the macrophage environment were included to 
test whether any changes were observed in compound-specific patterns of accumulation. The model 
was also able to distinguish whether the intracellular accumulation of compound translated to 
intracellular efficacy, potentially allowing for a PK/PD analysis at the target site of infection. This was 
extended to include combinations of compounds that showed potential 2-D synergy, allowing for the 
ultimate determination of potentially efficacious regimens at the target site.   
 
9.2 Introduction 
9.2.1 Problem identification – addressing the target site in anti-TB drug discovery  
Dartois et al., 2014 eloquently outlined the need to understand how individual compounds distribute 
into the different host cell environments.15 It is generally acknowledged that, in order to predict how 
a drug will respond in the human body, the PK/PD relationship in various tissues and cells must be 
understood fully.38,75 Given the propensity for Mtb to infect different microenvironments of the body, 
it is essential that efforts are focused on producing drugs that are active in all environments. Antibiotic 
efficacy is tempered by persistent bacteria, drug metabolism, permeation, and efflux mechanisms, all 
of which are accessible to study by drug discovery scientists given the enormous variety of 
technologies available today, but which have remained poorly investigated. 
 
9.2.2 Understanding the importance of the unit of infection in the context of drug discovery 
Humans as a species are able to manage Mtb infection with reasonable efficacy with only 5-10% of 
infections translating into clinical TB disease.80 However, considering the prevalence of the pathogen, 
this still equates to over one and a half million deaths per year.568 The success of Mtb as an infectious 
agent is accounted for by its ability to persist within the human host. The term describing one of the 
most identifying features of Mtb, the ability of the pathogen to infect the macrophage,83 was recently 
summarized by VanderVen and colleagues as the “minimal unit of infection.” This description 
encompasses both the innate immune response towards Mtb and the bacterial pathogenicity of Mtb.  
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Our understanding of the early Mtb infection of macrophages comes primarily from phagocyte 
populations found in mouse models.82,95,96 It has been shown by these studies that the bacillus is able 
to infect several cell types.82 This includes at least five distinct populations of cells, including alveolar 
macrophages, interstitial macrophages, dendritic cells, monocytes, and neutrophils.68,82,569,570 
Importantly, it is the classically activated macrophages and neutrophils that have been shown to offer 
the optimal intracellular environment in vivo to allow persistence of bacterial populations.68,82,571,572 In 
the human body, it is thought that the macrophage is where the majority of the Mtb lifecycle is spent, 
preventing full maturation of the phagolysosome and other metabolic events to allow proliferation 
within this environment.101,162,573–575 Support for these results is presented in several studies that 
highlight and reinforce the importance of understanding the role of each cell type recruited to the site 
of infection.576–578 The dynamics of immune cell recruitment to the site of infection and eventual 
formation of a granuloma are very complex, and this complexity is further exacerbated in vivo.183,579 
Relating cell recruitment to disease progression in response to drug treatment is even more 
troublesome.580 It is, however, important for drug discovery efforts to focus on the unique intracellular 
environments in which Mtb is able to reside, as novel drugs that target specific intracellular bacilli may 
hold the key to shortening treatment.93,581–583  
 
9.2.3 Selection of the THP-1 cell line provides a biologically similar alternative to patient-derived cells 
whilst allowing for perturbations to experimental conditions    
THP-1, a surrogate cell-line that is commonly used in lieu of primary macrophages,584,585 was 
historically derived from the peripheral blood of a patient with an acute case of monocyte 
leukemia.586,587 This has become an extremely valuable cell-line that retains many of the structural and 
functional properties of macrophage cells.586 This allows for the study of disease phenotypes and 
perturbations to this system, whilst limiting the amount of variation introduced by the use of patient-
derived monocytes or macrophages.588  
It is important to outline the disadvantages of using this cell-line. Many articles simply overlook the 
fact that THP-1 cells are not macrophages, using this term interchangeably with ‘monocytes’.589 
Monocyte-derived macrophages (MDMs) have been shown to produce different responses in reaction 
to various activation stimuli when compared to THP-1 cells.588,590–592 Despite this drawback, studies 
such show that the diminished genetic variation in THP-1 cells leads to similar treatment responses 
following infection and drug treatment.590 The THP-1 cell line was chosen here because many 
perturbations to the experimental system would be introduced requiring a large quantity of cells. 
Unfortunately, MDMs do not readily replicate and require repeated patient donation.593 THP-1 cells 
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are easily differentiated and can be stored in their non-differentiated state in liquid nitrogen. Human-
derived THP-1 cells offer more phenotypically relevant features than J774 or RAW 264.7 macrophages, 
offering a less variable genetic background when compared to human MDMs; this was the primary 
reason for selecting this this cell-line for the studies described below.594 
 
9.3 Method development and optimization of the Mtb-infected THP-1 cell assay 
9.3.1 Development of the uninfected macrophage model to allow assay optimization outside of the 
BSL III environment  
Culturing of THP-1 cells reveals key concepts for optimization 
The macrophage experiments in this chapter were carried out using THP-1 cells in 24-well plate-
format. Initial cell culture conditions were optimized before compounds could be added to the 
experimental conditions. Factors to be taken into account in order to obtain results that were 
reproducible included: (i) the duration of THP-1 cell viability, (ii) the volume of medium required to 
sustain cells, and (iii) ensuring that the cells matured to a THP-1 phenotype and adhered to the surface 
of the plate (based on PMA concentrations). 
 
THP-1 cell viability relies on a number of factors, including serum concentration for optimum growth 
The duration of THP-1 cell viability can be determined using multiple techniques including the use of 
plate readers, flow cytometers, and coulter counters. Viability in this experiment was determined via 
trypan blue staining and an automated coulter counter (as described in Chapter 3). According to 
literature, macrophages grow and are viable for 4-14 days depending on numerous factors including 
cell type, serum concentration, and cell density.589,595 Serum concentration was assessed during THP-
1 culture but similar results were obtained when supplementing with 10%, 20%, and 30% FBS (Figure 
9.1). In this study, using a serum concentration of 10%, cells displayed an average viability of above 


























Figure 9.1. Serum (FBS) concentration versus THP-1 cell viability 
 
PMA addition enabled the rapid differentiation of the THP-1 cell line 
In order to differentiate monocytes into macrophage-like cells, the use of increasing concentrations 
of PMA was tested.596–598 Consideration needs to be given to the conditions under which the 
monocytes mature, and caution must be taken in interpreting data when publications fail to do this.599 
The use of PMA pushes the THP-1 cell line to a phenotype that displays slightly reduced proliferative 
rate, increased phagocytosis and adherence to surfaces, and higher CD14 expression than 
undifferentiated cells, essentially forcing the cells into a macrophage-like state.588,594,600 With this in 
mind, several cell culture conditions were tested using varying concentrations of PMA (0.1 µM, 1 µM, 
and 10 µM). THP-1 cells were seeded at a density of 5 x 105 cells/well and differentiated for 24 h in 
RPMI medium supplemented with different concentrations of PMA. Cultures containing 0.1 µM PMA 
showed the highest number of adherent cells, which were also phenotypically more mature (larger 
cell size and had more distinctive nuclei present). This was in contrast with the 10-µM PMA culture, 
which resulted in far fewer cells adhering to the surface of the plate. 
  
Summary of the THP-1 cell culture conditions in this study 
Optimized culture conditions (0.1 µM PMA in 500 µL RPMI supplemented with 10% FBS) were used to 
seed 5 x 105 cells/well (Figure 9.2). THP-1 cells were continuously cultured for 8 days, using RPMI 





Figure 9.2. Final THP-1 cell culture conditions. Left, cells cultured for 24 h; Right, cells cultured for 8 
days (scale bar 100 μm) 
 
This allowed the viability of THP-1 cells in 24-well plates to be maintained with the monocytes 
(displayed in the left panel of Figure 9.2) maturing into macrophage-like THP-1 cells which remained 
viable for 8 days in this study (displayed in the right panel of Figure 9.2). This was deemed a sufficient 
period of time to monitor compound accumulation and the potentially associated intracellular efficacy 
and was similar or longer in duration in comparison to other studies.154,601,602 
 
EDTA provided the most effective method for successfully detaching THP-1 cells 
In order to assess drug concentrations, cell viability, and cell number the THP-1 cells needed to be 
detached from the surface to which they had adhered. In the literature, three main methods for cell 
detachment were described, including the commercially available Acutase™ (Thermofisher, USA), 
trypsin, and varying concentrations of EDTA.603–605 From these options, the efficacy of cell detachment 
(visual inspection) and time taken to process each sample were assessed. Briefly, the methods of THP-
1 cell detachment were assessed by seeding 5 x 105 cells/well in a 24-well plate and continuously 
culturing the cells for 7 days, where-after 200 µL of each of the detachment solutions was added, 
including Acutase™, trypsin (5 mM), and EDTA (5 mM). Cells were incubated for 5 min with each 
detachment solution followed by cell counting using the trypan blue exclusion test. Cells were also 
viewed under the ZOE™ Fluorescent Cell Imager (BioRad, CA, USA) to monitor for cell detachment by 




Figure 9.3. THP-1 cells grown for 7 days prior to detachment using 5 mM EDTA solution 
 
Figure 9.4. Single well after detaching with 5 mM EDTA solution (5 min incubation) 
 
The use of a solution of 5 mM EDTA was selected as the best method as the results were reproducible 
following a 5 min incubation with EDTA. The EDTA solution did not appear to be cytotoxic to the cells 
during the time taken to record cell numbers using the automated coulter counter. The EDTA also 
removed the majority of THP-1 cells from the 24-well plate as indicated by Figure 9.3 and Figure 9.4.    
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LVX chosen as the drug to investigate initial THP-1 perturbations  
Following the optimization of THP-1 cell culture conditions and THP-1 detachment, anti-TB 
compounds were introduced to the assay. Drug concentrations for cellular experiments were based 
on a number of different aspects. MIC concentrations, clinical relevance, and cellular cytotoxicity are 
the factors that were considered in this study. Initially, the assay was developed using the clinically 
used second-line fluoroquinolone LVX. LVX was chosen because of its known ability to permeate into 
macrophages606 and the fact that its use in macrophage assays had been reliably established in various 
publications.35,512    
 
ACN (0.1% Triton X) and Chloroform were identified as the most effective extraction methods 
The next optimization step involved compound recovery from THP-1 cells. Initial efforts were focused 
on the choice of extraction solvent (Figure 9.5). This was assessed by seeding 5 x 105 cells/well in a 24-
well plate. LVX (1 µg/mL) was added into the RPMI media and subsequently added to the THP-1 cells 
in a volume of 500 µL. THP-1 cells were detached using 100 µL of each extraction solvent (in triplicate) 
after removal of the RPMI medium. Samples were vortexed (1 minute) and centrifuged (5 min, 10621 
g). Supernatants were then removed and dried down under nitrogen and reconstituted in injection 
solvent (1:1 H2O:ACN) before being submitted for LC-MS/MS analysis. LVX ws monitored using a 
362.40 → 318.10 m/z transition. The solvent that achieved maximum compound extraction was ACN 


















































Figure 9.5. Methods of extraction from THP-1 cells following the addition of 5 µg/mL LVX (n = 3 per 




The use of ACN (0.1% Triton X) and chloroform:methanol solutions produced a greater average peak 
area, measured in counts per second (CPS), than H2O and ACN. The ACN (0.1% Triton X) and 
chloroform:methanol extraction methods produced LVX results which were more consistent, as 
indicated by the lower standard deviation for each method compared to ACN and H2O. Therefore, ACN 
(0.1%Triton X) was chosen as the extraction method to be used for compound extraction from THP-1 
cells.  
 
Demonstration of the stability of LVX in THP-1 cell culture conditions 
It was important to demonstrate that LVX was stable in all media conditions associated with THP-1 
cell culture, as compound instability would have resulted in significantly lower drug concentrations in 
the LC-MS/MS analyses, making THP-1 assay development difficult. In order to test the stability of LVX 
in THP-1 cell culture conditions, 5 x 105 cells/well were seeded in a 24-well plate. LVX (1 µg/mL) was 
added into the RPMI media and subsequently added to the THP-1 cells in a volume of 500 µL per well. 
Medium was removed from the 24-well plate at 0, 15, 30, 60, and 180 min post-drug addition (n = 3 
per time-point). This sample containing cells was referred to as the cell culture sample.  
LVX stability was also assessed in different media conditions including RPMI media containing no cells 
(new media), RPMI media which had been used for cell culture but which had not received LVX 
treatment (old media), and cell lysate produced by the addition of ACN (0.1% Triton X) prior to the 
addition of LVX (cell extract). LVX was extracted at each time-point using ACN (0.1% Triton X) 
containing deuterated IS (LVX-D8, 1 µg/mL). LVX-D8 was obtained from Toronto Research Chemicals 
(Toronto, Canada). Samples were vortexed (1 minute) and centrifuged (5 min, 10621 g). Supernatants 
were then removed and dried down under nitrogen and reconstituted in injection solvent (1:1 H2O: 
ACN) before being submitted for LC-MS/MS analysis. LC-M/MS transitions for LVX and LVX-D8 were 
monitored at 362.4→318.1 and 370.4 →326.1, respectively. Compound stability was assessed by 
dividing the LC-MS/MS peak area obtained for LVX (CPS) by the LC-MS/MS peak area of LVX-D8 (CPS). 
LVX in cell culture, cell extract, old media, and new medium displayed percentage stabilities of 101.2 
± 0.03%, 91.2 ± 0.07%, 102.5 ± 0.02%, and 100.3 ± 0.05%, respectively (Figure 9.6).     
 






Figure 9.6. LVX (1 µg/mL) stability in experimental media (means ± SD; n = 3 per time-point) 
 
Levofloxacin displayed stability for 180 min of greater than 90% in all of the media conditions tested 
in this study and could therefore be used to develop the THP-1 assay.  
 
The utilization of ELF values as a proxy for in vivo target site drug concentrations correlated well with 
in vitro- determined levels of drug to be added   
Some studies have simply ignored the need to include clinically relevant drug concentrations in their 
assays, instead focusing entirely on in vitro data. However, this evades the ultimate goal of the in vitro 
assay, which is to provide clinically relevant data to help with dosing predictions further down the 
drug discovery pipeline.607 The workflow for choosing a compound dose in this study was determined 
as follows for each compound: initial in vitro compound screens to determine general activity against 
H37Rv were conducted, followed immediately by macrophage and Vero cell-line cytotoxicity 
assessments.  
This was completed to ascertain whether selectivity against Mtb was present and, more importantly, 
whether any compound toxicity was observed. If any ELF or plasma values were available in the 
literature then these were used as relevant estimates for proximal macrophage values. However, for 
novel compounds, concentrations in ELF were often not available and, therefore, surrogate values 
from mouse ELF or plasma concentrations were used instead of clinical data. Use of drug 
concentration values that were as closely representative as possible of those at the target site was 
desirable; therefore, epithelial lining fluid (ELF) concentrations stated in the literature were used as 
our proximal value for dosing concentrations. Although this may be an over-estimation of actual target 
site values, these were the most clinically relevant values available. In the literature, clinically 
measured LVX ELF values were found to be 12.29 ± 7.41 µg/ml (mean ± SD).532,608–612 However, the 
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Mtb MIC90 value for intracellular efficacy experimentally determined in this study was 0.25 
µg/mL.These values presented a significant disparity, forcing the use of a final concentration 
somewhere between the reported ELF and MIC90 values of 5 µg/mL.  
 
Optimized extraction method accounts for the majority of drug in preliminary LVX experiment 
Using this concentration of LVX (5 µg/mL), we were able to quantitatively account for the majority of 
the drug added in the experiment (experiment layout presented in chapter 3). Briefly, THP-1 cells were 
seeded at 5 x 105 cells/well in a 24-well plate. LVX (5 µg/mL) was added into the RPMI media and 
subsequently added to the THP-1 cells in a volume of 500 µL per well. Medium was removed from the 
24-well plate at 0, 1, 2, 24, and 48 h post-drug addition (n = 3 per time-point). EDTA was used to detach 
cells and allowed for cell counting by trypan blue exclusion using a TC-20 automated cell counter. LVX 
was extracted at each time-point using ACN (0.1% Triton X) containing deuterated IS (LVX-D8, 1 
µg/mL). Blank cell lysates (lysed using ACN (0.1% Triton X)) were spiked with serially diluted compound 
concentrations and extracted using the same procedure above to generate calibration and quality 
control samples. Extracellular concentrations were determined by spiking serially diluted 
concentrations of LVX into media removed from the untreated cells to generate calibration and quality 
control samples, which were then extracted using the same procedure as above. Samples were then 
vortexed (1 minute) and centrifuged (5 min, 10621 g). Supernatants were removed and dried down 
under nitrogen and reconstituted in injection solvent (1:1 H2O:ACN) before being submitted for LC-
MS/MS analysis. LC-M/MS transitions for LVX and LVX-D8 were monitored at 362.4→318.1 and 370.4 
→326.1, respectively Calibration curves were constructed for for each matrix and used to 
quantitatively determine intracellular and extracellular LVX drug concentrations (Figure 9.7).     

































Figure 9.7. LVX intracellular and extracellular concentrations in an uninfected THP- 1 cell experiment 
(n = 3; data presented as means ± SD) 
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The equilibrium value (concentration at an assumed steady state) at 2h obtained in these experiments 
was also similar to that obtained by Rey-Jurado et al., 2013 (1 µg/mL), reinforcing the validity of this 
approach.613 The decrease in the wash samples corresponded to an increase in sample concentration. 
There was, however, an average difference of 4.2% of drug that was left unaccounted for and could 
possibly be explained by non-specific binding, ME, or extraction efficiency in this experiment. Possible 
drug metabolism cannot be ruled out as the cause of the compound disappearance by cellular 
metabolism.602,614 
 
Uninfected THP-1 cells display differential drug uptake prompting for confirmation of this effect in the 
Mtb-infected THP-1 model   
Following the successful LVX experiment in THP-1 cells, a preliminary experiment for several first- and 
second-line TB drugs, as well as novel compounds was completed using the same experimental 
procedure as described for LVX above. Briefly, THP-1 intracellular accumulation (Table 9.1) was 
monitored at a standardized concentration of 5 μg/mL, in 5 x 105 cells/well over a period of 48 h as 
outlined above (n = 3 per time-point). Quantitative estimations of intracellular drug concentrations 
were measured using LC-MS/MS Transitions for BDQ, MXF, RIF, LNZ, LVX were monitored at 555.21 → 
57.80, 402.19 → 384.00, 823.91 → 791.20, 337.86 → 296.30, and 362.4 → 318.10 m/z, respectively. 
Deuterated IS was used for each of the known compounds with transitions monitored for BDQ-D6, 
MXF-D4, RIF-D3, LNZ-D3, and LVX-D8 at 561.10 →64.10, 406.30 → 388.20, 826.50 → 794.40, 340.90 
→ 297.30, and 370.40 → 326.10 m/z, respectively. Carbamazepine was used as the IS for RMB 041, 
PHX 1, DPINH, and Coco 296 and LC-MS/MS transitions are reported for each novel compound in 
Chapter 5. The goal of this experiment was to determine if any discernible patterns of drug 
accumulation could be observed after 48 h. In addition, cell viability and cell number were determined 
using the trypan blue exclusion method and TC-20 automated coulter counter (BioRad) as outlined in 
Chapter 3. The compounds showed diverse abilities to enter the THP-1 cell environment (Table 9.1 

















































Figure 9.8. Drug accumulation (intracellular concentrations) in uninfected THP-1 cell experiment 
following the addition of 5 µg/mL of each compound 
 
The cell number and viability did not seem to be affected by the addition of drug for the period of 48 
h, with cell numbers maintained at values of greater than 4 x 105 cells/well for all of the samples. Cell 
viability remained consistent over the course of the experiment with viability measured at greater 














Table 9.1. Intracellular accumulation and viability in THP-1 cells treated with 5 µg/mL of each 







LVX 860 ± 56.56 95 ± 4.20 
BDQ 4410 ± 190.91 93 ± 4.90 
MXF 3374 ± 48.79 87 ± 2.70 
LZD 770 ± 14.14 92 ± 3.13 
RIF 3050 ± 62.93 89 ± 2.46 
PHX 1 4750 ± 127.27 92 ± 5.89 
DPINH 1280 ± 113.13 91 ± 6.20 
RMB 041 
Coco 296 
953.5 ± 28.27 
613.5 ± 19.26 
97 ± 2.53 
98 ± 1.21 
 
The compounds showed diverse abilities to enter the THP-1 cell environment as has been reported in 
literature for the known anti-TB drugs.15,16,615,616 Whilst these different patterns of accumulation 
seemed to hold some promise in explaining the activity of various compounds, care had to be taken 
in doing so as no intracellular activity data had been generated up until this point. Nevertheless, high 
compound accumulation was observed for a number of the compounds included in this study which 
displayed low levels of cytotoxicity for the duration of the 48 h experiment.  
 
Patterns of drug accumulation identified in uninfected THP-1 cells showed strong correlations to the 
Dartois model of in vivo granuloma accumulation 
The work of Dartois (2016), provided significant insight into potential patterns of drug accumulation 
(Figure 9.9) within the cells involved with granuloma formation, including macrophages, indicating 
that compound accumulation may not simply be a straight forward pattern of distribution.35,172 The 
four distinct patterns of drug penetration identified in this model were: (i) prompt and homogeneous 
distribution with the absence of accumulation appearing over time (INH/LZD), which may explain the 
predominant killing of extracellular bacteria by INH, (ii) prompt and heterogeneous distribution with 
a high degree of accumulation in the cellular rim rather than the caseum (fluoroquinolones), (iii) 
slower distribution with gradual accumulation of drug over time (RIF) explaining the intracellular killing 
of Mtb, and (iv) prompt distribution with significant accumulation in the cellular layers and poor 












Figure 9.9. Patterns of accumulation in the various layers of the granuloma (adapted from Dartois 
2016) 
 
Whilst the THP-1 cells do not come close to recapitulating the intricacies within the granuloma 
environment, the data in Figure 9.8 certainly showed some of these patterns displayed in Figure 9.9. 
The wide range of drugs tested in this study makes it possible to relate our data from the uninfected 







homogeneous distribution followed by a lack of accumulation was associated with the compound LZD 
in the Dartois model. LZD in this study, rapidly reached an equilibrium level (within 15 min) and then 
failed to accumulate further for the rest of the experiment. This observation is supported by the work 
done by Lemaire et al., 2009 and others, which showed similar concentrations and patterns to the 
work in this study, with LZD displaying lower intracellular concentrations than the majority of other 
tested compounds.617,618  
The second pattern identified by the Dartois model was rapid and heterogeneous distribution of 
compound with accumulation in the cellular portion of the granuloma. The fluoroquinolones have 
long been known as a class of drug that has been shown to accumulate within a variety of cells 
including THP-1 cells.606,619,620 The uptake of the fluoroquinolones in this study (MXF and LVX) displayed 
this pattern of accumulation, with MXF accumulating to a slightly higher degree than LVX. This was 
confirmed by the work of Michot et al., 2005, in which the group compared several fluoroquinolones’ 
varying degrees of accumulation at steady state.512 This steady state was also reached at 
approximately the same time in our study (30 min). Mechanisms of compound uptake for 
fluoroquinolones are thought to be driven by factors including amino acid transporters activated by 
PMA,621 transport by protein kinase C or mitogen activated protein kinase,622 and simple diffusion.20 
Fluoroquinolones like MXF have shown intracellular activity and might be considered as controls for 
future experiments as moderate to high accumulating references.   
RIF was the third drug assessed. In the Dartois model, the rifamycins accumulated exceedingly slowly 
over time but reached significant levels in the cellular regions of the granuloma. The RIF concentration 
reached within THP-1 cells in this study was high, as displayed by the Dartois model.172 Finally, the 
rapid accumulating compound BDQ was assessed. BDQ, a novel diarylquinolone derivative, has shown 
pronounced accumulation within the cellular rim of granulomas and in THP-1 cells.517 BDQ clearly 
showed the same degree of accumulation in this study with equilibrium levels greater than 4 µg/mL 
being reached after less than 30 min. This compound could certainly be used as a control for 
compounds that accumulate to high levels. 
 
Accumulation of novel compounds showed promising similarities to accumulation patterns of clinically 
used drugs  
The novel compounds DPINH, Coco-296, RMB 041, and PHX 1 were tested in this assay. Notably, the 
compounds displayed varying degrees of accumulation. PHX 1 showed relatively high levels of 
accumulation compared to the other novel compounds in this assay, which was unsurprising 
considering the previously discussed similarity between CLZ and PHX, with CLZ shown to accumulate 
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to high levels within the Dartois model.172 The accumulation levels measured for PHX 1 were similar 
to those of BDQ in this study.  
Comparatively lower accumulation was observed for DPINH. This could be because of the 
aforementioned potential of the compound to undergo metabolism to INH, a compound with 
relatively poor cellular accumulation properties.35,623 RMB 041 and Coco 296 accumulated to relatively 
low levels within uninfected THP-1 cells, achieving levels similar to those of LZD and LVX. These 
differential levels of accumulation which could, to some degree, explain clinical accumulation of these 
compounds was encouraging and allowed us to move forward with the implementation of further 
perturbations to the model.    
 
Flow cytometry and fluorescence microscopy analyses complement compound levels observed during 
LC-MS/MS analyses 
To further explore the novel compounds that displayed relatively high levels of accumulation, we 
wanted to determine whether the accumulation in THP-1 cells was influenced by the perturbation of 
pathogen inclusion, whilst simultaneously complimenting the LC-MS/MS accumulation levels using 
flow cytometry and fluorescence microscopy.  
Initial LC-MS/MS quantitation was performed on PHX series compounds and compared to CLZ. Briefly, 
THP-1 cells were seeded at 5 x 105 cells/well and infected for 30 minutes at an MOI of 5 using GFP-
labeled Msm, as used in other studies.601,602 THP-1 cells were treated with 1 µg/mL of each PHX 
compound (PHX 1, 2, 6, 8, 10, 14, 15) and their accumulation was compared at the 2 h time-point 
(Figure 9.10) to that of the control CLZ, a structurally similar compound known to possess anti-Mtb 
activity,624,625 as well as inherent fluorescence.505,626 Medium was removed from the 24-well plate at 2 
h post-drug addition followed by the addition of EDTA to detach cells and allow for cell counting via 
trypan blue exclusion using a TC-20 automated cell counter (as presented in Chapter 3). Each 
compound was extracted at the 2 h time-point using ACN (0.1% Triton X) containing carbamazepine 
IS (1 µg/mL). Blank cell lysates containing Msm (lysed using ACN (0.1% Triton X)) were spiked with 
serially diluted compound concentrations to generate calibration (3.9 – 1000 ng/mL) and quality 
control (6 – 800 ng/mL) samples, which were then extracted using the same procedure as above. 
Samples were then vortexed (1 minute) and centrifuged (5 min, 10621 g). Supernatants were removed 
and dried down under nitrogen and reconstituted in injection solvent (1:1 H2O:ACN) before being 
submitted for LC-MS/MS analysis. LC-MS transitions for PHX 1, PHX 2, PHX 6, PHX 8, PHX 10, PHX 14, 
PHX 15, and CLZ were monitored at 395.2 → 351.2, 428.93 → 370.4, 395.48 → 351.40, 395.48 → 
351.60, 396.46 →352.40, 408.52 → 350.20, 424.52 → 351.90, and 474.40 → 431. 30, respectively. 
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Calibration curves were subsequently constructed and used to quantitatively determine intracellular 
drug concentrations (Figure 9.10).    
  
 
Figure 9.10. Intracellular THP-1 accumulation (after 2 h) of PHX series and CLZ (1 µg/mL) in THP-1 cells 
infected with Msm (data presented as means ± SD) 
 
PHX compounds showed different equilibrium levels of accumulation with PHX 1, 6, and 8 achieving 
levels greater than 700 ng/mL, and CLZ, PHX 2, 10, 14, and 15 all achieving levels lower than 600 
ng/mL. PHX 1, 6, and 8 showed significantly greater accumulation than the reference compound (p > 
0.05, Student’s t test). PHX 6 showed high accumulation at 840 ng/mL, whilst PHX 2 showed limited 
accumulation at 250 ng/mL.  
The phenoxazine compounds also offered the unique opportunity to study their permeation by label-
free fluorescence, considering their ability to auto-fluoresce due to their phenoxazine core 
structure.627–630 This experiment was used to compliment the accumulation observed in LC-MS/MS 
analyses via visual inspection, whilst simultaneously preparing for THP-1 cell infection moving forward 
into the BSL III environment (Figure 9.12 and Figure 9.13). To avoid bias, the samples were double-
blinded during analysis via fluorescence microscopy. In summary, THP-1 cells were seeded in a 24-well 
plate containing a single pre-treated (poly-L-lysine) cover slip at 5 x 105 cells/well. After PMA 
maturation for 24 h, the cells were infected with a log-phase culture of GFP-expressing Msm at a 
multiplicity of infection (MOI) of 5. The infection was allowed to continue for 30 minutes after which 
the wells were washed with fresh RPMI medium. RPMI medium containing 1 µg/mL drug was added 
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to each well. The experiment was allowed to progress for an additional 2 h before the wells were again 
washed with RPMI medium. The cover slips were carefully removed from each well and adhered to a 
microscope slide containing a single drop of paraformaldehyde. Microscope slides were then 
examined using an Axio Scope A1 microscope and images were captured using a Zeiss 1 MP 
monochrome camera (Carl Zeiss, Germany). Samples were exposed to the same exposure settings for 
respective channels for image acquisition. Green fluorescence from the GFP bacteria (panel A of Figure 
9.11) was detected using a 488 nm excitation filter and a 510 nm emission filter set. Red fluorescence 
from the compounds was detected using a 587 nm excitation laser filter and 610 nm long-pass 
emission filter (panel B of Figure 9.11). Bright-field imaging was used to detect the position of the 





Figure 9.11. Fluorescence microscopy images showing treated (1 µg/mL PHX 1) THP-1 cells infected 
with Msm (top), and untreated infected cells (bottom), scale bar 300 µM 
 
Upon visual inspection of both untreated and PHX 1-treated cell populations, the red fluorescence of 
PHX 1 in Msm-infected cells was discernible. This did not lead to a qualitative decrease in green 
fluorescence, with similar levels GFP-expressing Msm detected in both untreated and treated cells. 
The time of drug interaction or the lack of activity of PHX 1 against Msm may explain this lack of 
efficacy seen in these images.    
 
PHX 1 Treated Cells 
Untreated Cells 




Figure 9.12. PHX 2 accumulation in THP-1 cells (scale bar 100 µM) 
 
Figure 9.13. PHX 1 accumulation in THP-1 cells (scale bar 100 µM) 
 
Analysis of compound accumulation using fluorescence microscopy was able to discern between 
compounds that accumulated to a lesser extent such as PHX 2 and CLZ and those that accumulated to 
a higher degree such as PHX 1, 6, and 8. This was qualitatively determined by visual inspection, with 
all of the compounds displaying fluorescence intensity greater than untreated cells. These 
experiments provided complimentary analyses of the high levels of compound accumulation seen for 
PHX 1 during LC-MS/MS analyses. However, better controls to determine whether each compound 
provides the same level of fluorescence at the same intracellular concentration would be required to 
validate this approach.   
In addition, flow cytometry (Figure 9.14) was used to isolate Msm-infected THP-1 cell populations 
whilst simultaneously monitoring PHX 1 accumulation in the APC channel (red fluorescence, 650 nm 
excitation and 660 nm emission wavelengths). In brief, THP-1 cells were seeded at a concentration of 
5 x 105 cells/well, in triplicate. After PMA maturation for 24 h, the cells were infected with a log-phase 
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culture of GFP-expressing Msm at a MOI of 5. The infection was allowed to continue for 30 minutes 
after which the wells were washed with fresh RPMI medium. RPMI medium containing 1 µg/mL of 
drug was added to each well. The experiment was allowed to progress for an additional 2 h before the 
wells were again washed with RPMI medium. Cells were detached using 200 µL of EDTA (5 mM). 
Samples were left unfixed as fixation agents may have caused cell lysis and loss of drug. Sorting was 
completed using the FACS Jazz™ cell sorter instrument for 10 000 events per samples (BD, NJ, USA). 
Gating was initially based on forward and side scatter (size of macrophage) to differentiate debris and 
undifferentiated cells, followed by further gating based on the live/dead stain SYTOX® (used according 
to manufacturer’s instruction). Samples were analyzed and further sorted based on green 
fluorescence (GFP-infected cells), providing both uninfected and infected populations of cells. Results 
were analyzed using the FlowJo software package.  
  
     
 




The PHX 1 LC-MS/MS results were further complemented using flow cytometry with the clear 
accumulation of PHX 1 over time in the red APC channel seen in Figure 9.14 (movement from right to 
left of both cell populations). This supported the accumulation that was seen in the fluorescence 
microscopy experiments using untreated and PHX 1 treated Msm-infected cells. The accumulation 
over time was recorded in both the flow cytometry and LC-MS/MS analyses with a steady state being 
achieved for both at the 2 h mark. Unfortunately, these analyses were not carried out for Mtb infection 
studies in the BSL III environment due to the lack of fluorescence microscopy and flow cytometry 
equipment at the time in the BSL III laboratory. These analyses offer the opportunity to complement 
the LC-MS/MS analyses and should therefore be pursued in future work.    
 
9.3.2 H37Rv-infected macrophage model 
Development of the infected THP model for pre-clinical drug discovery: focusing on the unit of 
infection 
Mtb is a facultative intracellular organism that is able to infect and grow in the macrophage 
environment.80,206,631 As such, the sterilization of the intracellular environment should be the goal of 
novel drug discovery programs.15,75,623,632 The infected THP-1 model is not unique and has been 
incorporated using Msm, Pseudomonas aeruginosa, and various other organisms including 
Mtb.59,584,595,633,634 However, very few studies have been conducted using H37Rv as the infectious agent 
whilst examining compound accumulation and intracellular efficacy within the same experimental 
system.  
The infected macrophage assay was developed based on the uninfected assay used in this study, as 
well as several relevant publications.15,35,511,601,602,635–639 However, notable additions to the uninfected 
protocol needed to occur when moving the assay into the BSL III environment. These changes were: 
(i) the infection protocol, where H37Rv would be the organism used, (ii) the extraction of samples, 
which would need to both extract the compound from the matrix but also ensure that the samples 
would be sterilized for removal from the BSL III area, and (iii) the inclusion of a step to measure drug 
efficacy. 
 
Optimization of Mtb MOI was vital to extending the lifespan of THP-1 cells, which ensured extended 
experimental timespans 
The macrophage-like cells were maintained in the same manner as in the uninfected assay and a 24-
well culture format was conserved. A log-phase culture of H37Rv was used to infect THP-1 cells (5 x 
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105 cells/well) at an MOI of 5. The viability and cell number of infected THP-1 cells was assessed using 
a trypan blue exclusion method (as described in Chapter 3) over a period of 7 days, which showed a 
cell viability percentage of 80.3 ± 0.5% over this time period. The MOI used in literature varies 
significantly based on the desired disease state the experiment aims to replicate and this has been 
reviewed extensively.206,635,640  
The starting bacterial load can have an enormous impact on the results of the experiments as starting 
too high (MOI ≥ 10) results in THP-1 cell death within a few days or hours,206,641,642 and large CFU 
readings at the end of the experiment independent of drug concentration, whilst a starting 
concentration with far fewer bacterial cells (MOI ≤ 1) simply allows the THP-1 cells to eliminate the 
bacteria without drug treatment, leading to higher efficacy readings.86,206,640,643 In the literature, an 
MOI of between 5 and 10 was generally used and in this study, we adopted an MOI of 5 to allow for 
drug efficacy and accumulation to be monitored.206,595,640,641,644   
 
Chloroform/methanol extraction procedure allowed for simultaneous sample sterilization and 
compound extraction 
Considering the need to sterilize samples, the extraction method needed to be changed from ACN, to 
a method involving the addition of chloroform. A LLE procedure was used, with a 3:1 
methanol:chloroform (v:v) ratio. This proved an effective sterilizing technique and was also shown to 
extract sufficient compound in order for quantitation to occur.  
 
The THP-1 cell cytotoxicity assay revealed no cytotoxic effects  
Relating the concentrations achieved within macrophages to clinically relevant concentrations is 
important as without meaningful in vitro concentrations achieved within the THP-1 model, we cannot 
hope to translate these into clinically relevant findings. It has been suggested that clinically achievable 
concentrations in plasma and ELF should be included as the dosing concentration of drug to translate 
in vitro to in vivo efficacy.20 For the known TB drugs where clinical experiments using ELF 
measurements have been obtained, retrospective analyses are slightly easier.  
The approach used in this study focused primarily on using a standardized 20X MIC comparison 
amongst compounds in order to incorporate the assay into our screening cascade. This translated into 
concentrations similar to those achieved in the plasma and ELF for a number of the compounds. RIF 
has been shown to achieve maximum concentrations of approximately 2 µg/mL in the ELF of patients, 
a dose that is similar to the one used in this study.519,645 In other studies, concentrations for MXF 
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plasma at the 24-h timepoint following a once-off 400 mg oral dose in healthy volunteers compared 
to our study at 5 µg/mL, however, the Cmax achieved in ELF was approximately 10 µg/mL,557,567,646 
almost double the concentration used in this in vitro model. The plasma Cmax achieved for MXF is 
approximately 4 µg/mL, a value that more closely resembled the value used within this study.647–649 
BDQ, following treatment with a dose of 100 mg, provided plasma concentrations of approximately 
0.8 µg/mL, very similar to the 0.6 µg/mL used in this study.650,651 No clinical trials measuring ELF 
concentrations could be found in the literature. The PHX 1 concentration used during this study was 
very similar to both the maximum concentrations observed in ELF (0.6 µg/mL) and plasma (1.913 
µg/mL) obtained in murine experiments. The similarities of the starting doses of all the compounds to 
their in vivo concentrations provides a solid grounding for more clinically relevant conclusions to be 
drawn from these experiments as the model is better able to mimic the concentrations these 
macrophage-like cells would be exposed to in vivo.   
Therefore, trends in accumulation were monitored using drug concentrations approximately 20X the 
compound Mtb MIC90 which were shown above to be similar to a number of physiologically relevant 
concentrations for compounds included in this study. This assumption might not hold for certain 
compounds and provided the potential for under-/over-estimation of target site concentrations. 
These assumptions were necessary as a starting point for assay implementation and could be adjusted 
following the publication of new information, such as a more clinically relevant ELF concentrations.       
Compounds were tested at 20X MIC for each compound in the infected-THP-1 model, which for some 
compounds was a relatively high concentration. The cytotoxicity of these drugs was subsequently 
tested in THP-1 cells (5 x 105 cells/well) via an MTT assay (as described in Chapter 3) for a period of 7 
days (Figure 9.15). The concentrations of compound the THP-1 cells were exposed to range from 0.01 
µM to 50 µM, with each compound concentration tested in triplicate. Drugs displayed cytotoxicity IC50 
values ranging from 10 µM to greater than 50 µM (Figure 9.15).  
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Figure 9.15. THP-1 cytotoxicity for compounds (n = 3; data presented as means ± SD)  
 
The IC50 value for each compound was significantly higher than the 20X MIC value for the majority of 
the compounds included in this study, with the exception of Coco 296. Whilst Coco 296 displayed a 
relatively high IC50 value in comparison to the other compounds in this study, the compound also 
displayed a relatively high MIC90 value. Using a 20X MIC value would have resulted in an excessively 
high concentration of compound (in excess of 1000 µM) being used in the assay which would have 
resulted in the toxic levels being reached in the THP-1 cells and in the loss of clinical relevance for this 
particular compound. Therefore, a value of 40 µM (cytotoxicity value in THP-1 cells for which greater 
than 80% survival was observed) was used for this particular compound in further testing and in the 
absence of murine plasma or ELF values. This offered the only deviation from the set 20X MIC value 
used within this study. For the compounds used in this study, this cytotoxicity result provided a clear 
indication that THP-1 cells would not be negatively affected by the drug concentrations used in this 
study. 
 
Summary of the Mtb-infected THP-1 cell assay 
During these Mtb-infected experiments, THP-1 cells (5 x 105 cells/well, addition of PMA for 24 h) were 
grown and adhered to 24-well plates according to the methods in Chapter 3, in triplicate for each time-
point (24, 48, 72, and 96 h post dosing). Following infection for 3 h with Mtb::mCherry, wells were 
washed (three times) with RPMI medium to remove dead THP-1 cells and extracellular Mtb. Drug was 
then added to each well at 20X MIC in 500 µL of RPMI medium. In addition, three wells in each plate 
165 
 
were left without drug treatment (following Mtb infection) and served as untreated controls, whilst 
an additional three wells of THP-1 cells were left uninfected and were used as uninfected controls.  
Thereafter, at time-points of 24, 48, 72, and 96 h post dosing, cells were washed (three times with 300 
µL RPMI medium). This was followed by the addition of 200 µL EDTA (5 mM), after which 10 min was 
allowed for the cells to detach. Trypan blue-stained cells were counted using the automated cell 
counter as described in Chapter 3. An aliquot of 5 µL of the remaining supernatant was added to 90 
µL RPMI medium and 10 µL of this solution was streaked onto hygromycin-containing 7H10 plates and 
placed at 37°C for counting 21 days following plating, in triplicate for each time-point. The remaining 
supernatant (150 µL) was added directly to an Eppendorf tube containing chloroform:methanol (3:1, 
v:v) and IS (1 µg/mL).  
After the collection of samples at the remaining time-points, the samples were surface-
decontaminated and stored at -80°C overnight. Samples were removed from the BSL III laboratory and 
processed, according to the methods outlined in Chapter 3). Briefly, the samples were thawed, 
vortexed (1 min), and centrifuged (5 min, 10621 g). Supernatants were transferred into a 96-well 
analysis plate, and dried down under a gentle stream of NO2 gas to concentrate. The samples were 
then reconstituted in a mixture of 1:1 H2O:ACN (v:v, containing 0.1% FA) before analysis via LC-MS/MS. 
Samples were analyzed using quantitative LC-MS/MS assays as described in Chapter 5 for the novel 
compounds and several clinically-used assays (Division of Clinical Pharmacology, UCT) were modified 
for use in this study. MXF, BDQ, and RIF were analyzed using the LC-MS/MS transitions 
402.191→384.00, 555,210→57.8, and 823.918→791.2 m/z, respectively. Deuterated IS was used for 
each known anti-TB drug and the transitions for MXF-D4, BDQ-D6, and RIF-D3 were monitored at 
406.3→388.2, 561.1→64.1, and 826.5→794.4 m/z, respectively. The novel compound transitions 
were followed according to data presented in Chapter 5. Chromatographic separation was performed 
using an Agilent 1200 Rapid Resolution HPLC system consisting of a binary pump, degasser, and auto-
sampler (Agilent, Little Falls, Wilmington, USA) coupled to an AB Sciex 4000 QTrap, hybrid triple 
quadrupole linear ion trap mass spectrometer (AB Sciex, JHB, South Africa).  
Blank infected cell lysates (lysed using chloroform:methanol) were spiked and extracted using the 
same procedure above to generate compound specific standard and quality control samples. These 
were then used to construct calibration curves which were subsequently used to quantitate the 
amount of analyte in each respective sample. Extracellular concentrations were determined by spiking 
serially diluted concentrations of compound into media removed from untreated THP-1 cells to 
generate calibration and quality control samples, which were then extracted using the same 
procedure as above and used to quantitate the amount of compound in each extracellular sample.  
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9.4 Results and discussion 
LC-MS/MS assay performance 
The LC-MS/MS assay performed well in the analysis of infected THP-1 cell samples with the %NOM for 
all calibration and QC samples between 89.5 ± 7.4 and 110.4 ± 2.2% in this study, with %CV of the 
same calibration and QC samples between 87.2 ± 3.1 and 108.7 ± 5.7%, with representative 
chromatograms presented in Appendix E. This indicated that the murine organ calibration curve values 
were well within the acceptable 20% deviation used in this study for both calibration curve and QC 
values and that the THP-1 LC-MS/MS assay performed well in the analysis of infected THP-1 cell 
samples. 
 
Distinctive accumulation ratios were reported in Mtb-infected THP-1 cells over a 96 h period 
An intracellular accumulation ratio, defined as the intracellular compound concentration divided by 
the extracellular concentration, was used in this study to allow comparison between compounds 
added at different concentrations (representative chromatography presented in Appendix E). This 
required the measurement of both intracellular and extracellular concentrations of drug as shown in 
a number of publications.20,36,615,616,636,637,652–654 Intracellular sample concentrations were determined 
as previously discussed in Chapter 3, whilst extracellular sample concentrations were determined by 
analyzing the media from each untreated well, which was obtained before washing of the cells 
occurred (Figure 9.16).  







































Figure 9.16. Intracellular THP-1 accumulation ratios for all compounds included in this study (n=3; data 
presented as means ± SD) 
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Due to the 2-D nature of the experiment, the monolayer of cells is exposed to a consistent 
concentration of drug in the medium, which eventually leads to an equilibrium level being reached. 
For many of the drugs, this point occurred approximately 24-48 h after drug administration. However, 
PHX 1 and BDQ, seemed to continue to accumulate as indicated by the upward trend of the 
intracellular ratio lines even at the final time-point and could possibly have achieved higher levels of 
intracellular accumulation if a longer experimental time-course had been implemented. The 
accumulation ratios in this study were significantly different. RMB 041 showed the lowest levels of 
intracellular accumulation at 0.25, PHX 1 displayed accumulation levels of around 2.5 to 3 similar to 
RIF, whilst MXF and BDQ showed the greatest accumulation in the infected THP-1 cells (5.45 and 55, 
respectively, Figure 9.16). The known drugs RIF,20,636 MXF,616,636,655 and BDQ35,61 have been shown to 
achieve similar intracellular accumulation ratios, although in uninfected THP-1 cells, as those 
presented in this study.  
 
Calculated lipophilicity showed moderate correlation with intracellular accumulation in infected THP-
1 cells  
Intracellular accumulation in relation to the physicochemical properties of the compounds was 
assessed to better explain the different patterns of compound accumulation seen in this study. The 
cLogP of each the compounds was compared to its respective intracellular accumulation ratio in 


























Figure 9.17. Compound intracellular accumulation ratio (I/E) compared with cLogP  
 
Sarathy et al., 2016 reported a strong correlation between caseum binding and compound lipophilicity 
(cLogP).19 In this study, there was a correlation between compounds at the extremes of the cLogP 
scale and compound accumulation in infected-THP-1 cells, as BDQ and RMB 041 with their respective 
high and low cLogP displayed corresponding high and low levels of intracellular accumulation. The 
same effect was seen for PHX 1 and MXF. MXF with its slightly higher cLogP value displayed slightly 
more intracellular accumulation than PHX 1. However, RIF was an outlier in this dataset, as it displayed 
a lower intracellular accumulation ratio than the majority of the compounds despite its relatively high 
cLogP value. This lack of correlation stems mainly from the low intracellular RIF concentrations in this 
study, possibly a by-product of the delayed uptake of RIF, which may not have been captured by this 
experiment.  
The trend of comparing compound accumulation to physicochemical properties was continued using 
the ADME values obtained in this study. PHX 1 displayed slightly better permeability and lipophilicity 
compared to RMB 041, possibly explaining the difference in compound uptake into THP-1 cells. 
However, RMB 041 displayed significantly better solubility at macrophage-relevant pH values 
compared to PHX 1, possibly leading to less PHX 1 making its way into macrophages.164 One of the 
limitations of the THP-1 assay is that it is unable to discern compound simply bound to the outside of 
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THP-1 cells and that entering the cell. Therefore the protein binding of these compounds may also 
play a role in explaining the differences in observed compound accumulation.    
 
Relating compound efficacy to intracellular accumulation offers perspectives into intracellular PK/PD 
relationships at the target site 
Moderate to high compound accumulation does not necessarily translate into similar levels of 
intracellular efficacy.656 This is due to the aforementioned complexities that are increased by cellular 
involvement such as drug binding, metabolism, sequestration into organelles, and pH changes. 
Compound efficacy was determined in this study, following drug addition and subsequent washing as 
described in Chapter 3 using EDTA (5 mM) by detaching the infected THP-1 cells. An aliquot of 5 µL of 
the supernatant was added to 90 µL RPMI medium and 10 µL of this solution was streaked onto 
hygromycin-containing 7H10 plates and placed at 37°C for counting 21 days following plating. 
Compound efficacy was determined at 24, 48, 72 and 96 h by CFU plating (n = 3 per time point) and is 
shown in Figure 9.18. 
 













*** All treatments statistically
signif icant (p< 0.001) compared















Figure 9.18. Efficacy (determined by CFU count) for each compound/combination included in this 




The most notable example of an intracellular disconnect between efficacy and accumulation is 
reported for MXF, a drug that shows relatively high accumulation within cells but comparatively poor 
intracellular activity.182,602,623 This is again demonstrated in this particular study with MXF displaying 
moderate efficacy relative to the accumulation with approximately 0.5 log10CFU/mL difference from 
the starting log10CFU/mL in the 96 h assay (Figure 9.18), similar to the efficacy of PHX 1 which showed 
a 0.8 log10CFU/mL decrease. This is in contrast to BDQ which showed significant accumulation in 
infected THP-1 cells and subsequently a log10CFU/mL difference of 1.52. Although RIF did not show 
the same degree of accumulation, the compound still achieved an efficacy of approximately 1.54 
log10CFU/mL, decrease highlighting the need to capture both efficacy and accumulation 
measurements in the same experiments. The difference in THP-1 cell efficacy between the RIF and 
MXF was not surprising given various other reports on the compounds.15,39,168                  
This PK/PD relationship was further scrutinized according to the various time-points at which samples 
were taken. Various methods for determining an intracellular PD response have been used, including 
determining the decrease in log10CFU/mL,20,657 determining the efficacy rate over a certain time 
period,615 and using various models to predict a PD value that indicates efficacy.39,168 In this study, a 
single drug concentration was used as opposed to a series of different concentrations and therefore, 
modeling the drug efficacy in response to drug concentration becomes difficult. A more reliable 
approach was adopted by determining the efficacy resulting from the intracellular drug concentration 
reached and subsequently elicited a decrease in log10CFU/mL. The kill rate from the point the 
compounds had reached equilibrium (48 h) was also calculated (Table 9.2) to determine the rate at 
which the log10CFU/mL occurred per hour.  







Kill rate (48-96 h) 
∆log10CFU/mL 
per h 
Untreated + 1.70 NA -0.012 
RMB 041 - 0.11 0.25 0.002 
BDQ - 1.52 55.00 0.023 
PHX 1 - 0.82 3.00 0.012 
MXF - 0.50 5.45 0.006 
RIF - 1.54 3.00 0.022 
  NA, not assessed 
 
The greatest ∆log10CFU/mL efficacy for single compounds was achieved by RIF, with BDQ displaying 
similar efficacy. Importantly, PHX 1 displayed better efficacy than MXF, whilst RMB 041 seemed to 
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display very little activity in this model, maintaining bacterial numbers throughout the 96 h 
experiment.  
 
Promising synergistic interactions identified between novel PHX 1 and Coco 296 derivatives  
The novel compounds PHX 1 and Coco 296 have been hypothesized to promote the production of ROS 
through the potentially-synergistic process of redox-cycling. With this in mind, a basic two-
dimensional synergy assay was performed to determine whether any discernible synergism occurred 
between the compounds. PHX 1 was serially diluted in RPMI medium along the x-axis (column 3-11), 
with synergistic concentrations ranging from 25 - 0.19 µM, whilst Coco 296 was serially diluted across 
the y-axis (rows B - H), with synergistic concentrations ranging from 100 – 0.15 µM (Figure 9.19).  
 
 
Figure 9.19. 2-D synergy assay for the PHX 1/Coco 296 combination against drug-sensitive H37Rv, 
where the MIC90 is denoted by the red dotted line for PHX 1  
 
Synergy was reported for this combination, with a fractional inhibitory concentration index (FICI) for 
PHX 1/Coco 296 calculated at less than 0.5 using the Equation 3.12 (presented in chapter 3).346 This 
FICI value was indicative of synergy using the PHX 1/Coco 296 combination.346 Minimum values 
required to produce 2-D synergy were also noted for each compound including PHX 1 (153.10 ng/mL) 




Favorable synergistic interaction confirmed and delineated using the infected THP-1 model 
Following the observed synergistic interaction between PHX 1 and Coco 296 in the 2-D synergy 
experiments, we wanted to confirm whether this effect was conserved in infected THP-1 cells. To 
compare these results to the single dose efficacy and combinations already obtained using single 
drugs, each compound was dosed at 20X MIC90 of PHX 1 and at 40 µM for Coco 296, as discussed. The 
2-D synergy assays informed the required synergy level of each compound necessary to obtain in vitro 
synergy. The combination of PHX 1 and Coco 296 was investigated in the infected THP-1 cell model for 
intracellular accumulation using quantitative LC-MS/MS (Figure 9.20), as described in Chapter 3, at 
time-points of 24, 48, 72, and 96 h (n = 3 for each time-point). In this experiment intracellular drug 
concentrations are reported in ng/mL to allow comparisons to be made with the minimum levels 
required for 2-D synergy (Figure 9.19).        
 






































Figure 9.20. Intracellular synergy experiment for PHX 1/Coco 296 in H37Rv-infected THP-1 cells (n= 3; 
data presented as means ± SD)  
 
In the PHX 1/Coco 296 combination, both compounds reached their respective intracellular synergy 
levels after approximately 48 h (Figure 9.20), and maintained these levels until the 96 h time-point. 
Caution should certainly be maintained when assessing these concentrations as 20X MIC of PHX 1 and 
40 µM of Coco 296 was used in this experiment, concentrations that may not be clinically achievable 
for both compounds, particularly not for Coco 296. This experiment also relied on the assumption that 
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the 2-D synergy level would be similar in both extracellular and intracellular bacteria, which may not 
be the case for either compound.  
It was important to determine whether each drug used in the PHX 1/Coco 296 combination reaching 
these intracellular 2-D levels resulted in an increase in efficacy when compared to PHX 1 dosed alone. 
In the same experiment, CFU counts (Figure 9.21) were determined at time-points of 24, 48, 72, and 
96 h (in triplicate) by plating lysate on hygromycin-containing 7H10 plates. These plates were placed 
at 37°C for counting 21 days following plating.  
 
























Figure 9.21. Intracellular efficacy for PHX 1 and PHX 1/Coco 296 in H37Rv-infected THP-1 cells (n= 3; 
data presented as means ± SD)  
 
The PHX 1 and PHX 1/Coco 296 combination showed similar CFU counts up until the 48 h time point. 
Thereafter, the PHX 1/Coco 296 combination showed significantly more efficacy at the remaining 72 
and 96 h time-points. This is possibly due to the 2-D synergy levels being reached by each compound 
at the 48 h time-point, translating into an increase in efficacy at the same time-point, indicative of 
potential synergy when compared to the efficacy of PHX 1 dosed alone. 
The efficacy results obtained for the drug combinations were also compared to the known anti-TB 
drugs included in this study along with the novel compound RMB 041 (Figure 9.22). 
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*** All treatments statistically
signif icant (p< 0.001) compared
to untreated control at 48 h
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Figure 9.22. Complete set of intracellular efficacy results obtained during this study 
 
RIF displayed the greatest efficacy at the 48 h time-point with the PHX 1/Coco 296 combination 
displaying significantly better efficacy at the 96 h time-point than all of the known anti-TB compounds 
included in this study. All of the compounds displayed significantly better efficacy than the untreated 
control in these experiments.     
Compound efficacy is displayed as ∆log10CFU/mL efficacy and kill rate from 48 to 96 h, whilst the 
accumulation ratio is shown for comparison (Table 9.3).    







Kill rate(48-96 h) 
∆log10CFU/mL per 
h 
Untreated + 1.70 NA -0.012 
RMB 041 - 0.11 0.25 0.002 
BDQ - 1.52 55.00 0.023 
PHX 1 - 0.82 3.00 0.012 
MXF - 0.50 5.45 0.006 
RIF - 1.54 3.00 0.022 
PHX 1/Coco 296 - 1.90 3.00/0.08 0.036 
 NA, not assessed 
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As discussed, the PHX 1/Coco 296 combination was more efficacious than the known anti-TB drugs 
included in this study. This is supported by the higher kill rate from 48 to 96 h, which was superior to 
both RIF and BDQ. The decreases in Log10CFU/mL for all of the compounds included in this study are 
considerably better compared to the untreated control, indicating that the intracellular control 
displayed by these compounds is not due to experimental processing.       
 
Future perspectives for the promising PHX 1/Coco 296 combination  
Given the intracellular efficacy of the combination of PHX 1/Coco 296, it would certainly be interesting 
to compare the efficacy of this combination at clinically relevant doses in primary macrophages to 
other clinically used combinations of the compounds tested in this study. It would also be important 
to confirm whether the compound accumulation and efficacy changed if the model was to be adapted 
to a three-dimensional structure.168,658,659 Experiments at different dosages would allow for a more 
detailed understanding of compound efficacy. This would confirm whether the efficacy shown by PHX 
1/Coco 296 presented in this study could possibly be replicated in vivo. The translation of the in vitro 
data presented in this study to in vivo efficacy in an animal model would validate the results obtained 
using this model, potentially motivating for its utilization in future drug discovery endeavors.  
 
Novel target site model indicates the need for a paradigm shift in anti-TB drug discovery  
Current PK/PD approaches (Figure 9.23) make use of plasma concentrations as proxies for target site 
concentrations, however evidence has been presented in this thesis that a more efficient approach to 
developing drugs that are efficacious at the target site might be obtained by focusing early drug 
discovery efforts on the target site. In this regard, a proposed paradigm involving certain adjustments 
to the current pipeline might yield better results. In this proposed pipeline, initial selective activity 
would still be determined by screening against Mtb. Following confirmed activity and low cytotoxicity, 
compounds would be assessed using intracellular efficacy/accumulation assays in a variety of immune 
cell environments. Following success in these assays, compound dosing for in vivo efficacy assays 
would be determined using target site concentrations obtained from ELF/organ PK experiments. 
Alternative approaches include the use of murine blood PK or in vitro ADME assays, for inclusion in in 
silico models to predict dosing concentrations required to achieve successful sterilization of the 
multiple sites of TB pathology. Finally, a murine in vivo efficacy model would be used to confirm the 





Figure 9.23. Current and proposed PK/PD pipeline for anti-TB drug discovery 
 
9.5 Conclusion 
This chapter highlighted the need to better understand how compound efficacy and intracellular 
accumulation are related. Using proxies such as plasma concentrations for diseases such as TB simply 
does not account for the array of intricacies associated with the different microenvironments, of which 
this model is able to simulate a few. The development of this model was described from inception to 
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application. The model makes it possible to test both the efficacy and accumulation of combinations 
of compounds in the same experimental system. This allows for the translation of potential in vitro 
synergy to be confirmed in an intracellular setting and delineated in one model. Further in vitro and 
in vivo testing will allow for the confirmation of the predictive strength of this model. From this study, 




10. Conclusions and future perspectives 
 
10.1 Summary of research findings 
As outlined in Chapter 2, this thesis presented two major ideas: (i) that a drug development pipeline 
that prioritized compounds based on “lesion-penetrating” ability could be developed, and (ii) 
drugs/drug combinations could be developed to incorporate particular mechanisms of action that best 
suited those different environments. These ideas were further delineated to incorporate several aims: 
i) to investigate whether the compounds selected displayed initial selective activity against Mtb, ii) to 
determine whether the compounds possessed the appropriate physicochemical properties to 
penetrate into the microenvironments in which Mtb is able to survive, iii) to evaulate whether these 
physicochemical properties were able to sufficiently explain the accumulation of the compounds in a 
number of murine microenvironments, including murine blood, various organs, ELF, and associated 
cell types within the lungs, iv) to investigate whether once at the unit of infection, the compounds 
were able to penetrate into an infected macrophage environment and maintain the efficacy displayed 
in standard Mtb culture screens, and v) to identify combinations of novel compounds that could 
potentiate ROS production and facilitate Mtb control and eradication in extracellular and intracellular 
settings.  
These aims were fulfilled through the use of a number of techniques, including LC-MS/MS, HPLC, flow 
cytometry, fluorescence microscopy, various in vitro cell culture techniques, and several in vivo animal 
experiments. Although this study provided answers to a number of research questions, several novel 
research questions, such as the identification of possible active metabolites, emerged. This is not 
unexpected in a drug discovery setting and will subsequently be addressed in future studies. 
In Chapter 4, a group of compounds hypothesized to produce ROS and showing selective activity 
against H37Rv in vitro were tested in an array of ADME assays. Five of these compounds possessed 
promising in vitro physicochemical properties and were predicted to penetrate the various 
microenvironments of an in vivo system. Subsequent predicted human doses provided further 
motivation for the inclusion of the chosen compounds in a murine PK model. 
The subsequent chapters (Chapter 5 and 6) aimed to determine, using the successfully partially 
validated LC-MS/MS methods, whether IVIVC could be drawn for the chosen group of five compounds 
in an in vivo PK murine model. The compounds displayed markedly different profiles with many of the 
in vitro properties able to predict the behavior of the compounds in vivo. PHX 1 and RMB 041 displayed 
the highest apparent volume of distribution and longest half-life, respectively, indicating the potential 
of these compounds to permeate into the various microenvironments associate with TB pathology. 
179 
 
These assumptions of permeation are based on the compounds’ promising properties and need to be 
assessed further. 
In Chapter 7, the potential of these compounds to permeate and accumulate within the various organs 
and tissues associated with compound distribution was assessed in a 24 h murine organ PK study. 
Notably, PHX 1 accumulated to high levels within the heart and lungs of the mouse, whilst RMB 041 
showed comparatively low levels of permeation into these tissues. Although PHX 1 displayed high 
levels of permeation within the lung tissue, it could not be assumed that the compound would be able 
to penetrate into the lung fluids and cells of the mouse.  
Therefore, in Chapter 8, a model of BAL fluid drug concentration determination was implemented to 
calculate the concentrations of PHX 1 in murine ELF, plasma, and alveolar cells. PHX 1 exposure within 
the ELF and alveolar cells was significantly higher than that in plasma, highlighting the potential of the 
compound to penetrate the deeper recesses of the lungs but also indicating the need to assess 
concentrations closer to the target site of pulmonary TB as opposed to using plasma as a surrogate 
measure. Nevertheless, accumulation within ELF and intracellular environment does not always 
translate into intracellular efficacy. 
In Chapter 9, intracellular efficacy was assessed using a newly developed Mtb-infected THP-1 cell 
model. This model required optimization and testing at various stages of the model’s development to 
ensure that a predictive and useful model reproducing several intracellular features was produced. 
This model allowed for the determination and comparison of a number of known and novel anti-TB 
compounds with regard to their intracellular accumulation ratios and intracellular efficacy. This 
supported the ability of PHX 1 to accumulate in an intracellular environment to levels similar to those 
of RIF, whilst RMB 041 again showed significantly lower intracellular accumulation. One of the main 
aims of the study was to identify a ROS-inducing combination of compounds that could maintain 
efficacy in both intracellular and extracellular environments. Two-dimensional synergy between PHX 
1 and a novel artemisinin derivative was identified and confirmed in the Mtb-infected THP-1 model. 
The efficacy was superior to that of other single drug combinations included in this study and could 
be explained by the respective compounds accumulating to levels greater than those required for 
synergy. The current study therefore highlights the ability of the employed screening cascade to 
identify novel compounds and compound combinations that could potentially result in greater efficacy 
than that of known TB compounds. Further testing in patient-derived macrophages and Mtb-infected 
in vivo murine models will allow us to determine the validity of this approach in translating these 




10.2 Limitations and problems     
The main limitations in the current study should be acknowledged to inform future work. These 
limitations are outlined here.  
 
10.2.1 ADME assays 
The predictive strength of the ADME assays used in this study is often debated. In particular, the 
PAMPA assay is often replaced by assays such as the Caco-2 assay, which allows the measurement of 
both passive and active uptake as opposed to PAMPA assay which measures only the passive 
permeability of each compound. The Caco-2 assay will be conducted in future work and compared to 
the PAMPA assay to determine whether any differences can be determined.  
 
10.2.2 Sample size for murine studies (whole-blood PK, organ PK, and ELF) 
As mentioned, the sample size for these studies was relatively small, particularly in the organ and ELF 
studies (n = 2 per time-point). The predictive strength of the experiment might have been increased 
by the inclusion of more animals at each time-point (as calculated using a power calculation). The 
results obtained did not differ significantly amongst replicates and therefore did not affect the 
conclusions drawn from this study.  
 
10.2.3 Complex nature of TB 
As discussed, Mtb is able to infect a number of different immune cells often leading to the formation 
of a 3-D granuloma structure. This 3-D interaction of immune cells is not represented in the 2-D cell 
model used in this study, possibly leading to a lack of representative disease phenotypical features.  
The model does not make use of patient-derived cells, instead using the far less variable THP-1 cell 
line. This lack of biological variation may again lead to a lack of representative phenotypical 
information in this model. However, as discussed, the THP-1 cell line displays sufficient macrophage-
like properties whilst eliminating some of the ‘biological noise’, which makes determining any 
experimental signal far easier than when using patient-derived cells. These results do necessitate 
confirmation in patient-derived cells to determine whether similar patterns of accumulation and 




10.2.4 Drug concentrations used within THP-1 cells 
The standardized 20X MIC concentration adopted in this study may lead to skewed levels of 
accumulation and efficacy. As mentioned in the text, many of the levels used were similar to those 
measured in ELF and plasma, as well as those used in other THP-1 studies. However, use of a range of 
concentrations in this model would allow us to confirm whether the drugs are simply overcoming 
transport mechanisms and forcing their way into the macrophage or are genuinely able to permeate 
and accumulate within the macrophage.  
 
10.2.5 Cell count 
Cell viability was monitored by counting trypan blue-stained cells on the automated cell counter. 
These counts were verified via microscopy. While the THP-1 and infected THP-1 cells showed minimal 
decrease in terms of their viability and cell number over the course of each experiment, greater insight 
into drug concentrations per cell may have been gained by using a flow cytometry approach. This was 
not possible in this particular study as at the time there was no flow cytometer in the BSL III facility. 
This will be incorporated into future work.   
 
10.2.6 Comparison with combinations in the THP-1 model 
Use of the THP-1 cell line also facilitated the use of combinations of compounds within the model. In 
this study, the novel Coco 296 was used in combination with PHX 1. Although the PHX 1/Coco 296 
combination was shown to produce superior efficacy compared to the other compounds tested in this 
study, there were no comparison made with standard combinations of TB drugs such as RIF/INH or 
novel combinations such as BDQ/RIF, which could have informed the clinical relevance of this study 
further. This will be conducted in further studies. 
 
10.2.7 Testing of Coco 296 
In the screening cascade used in this study, Coco 296 was effectively eliminated due to the relatively 
poor activity and poor in vitro ADME properties displayed by the compound. As such, no plasma or 
ELF values were measured in order to determine whether biologically appropriate in vivo levels were 
applied to the in vitro THP-1 assay. The prerequisite for testing compounds in a murine model requires 
a selectivity index of greater than 10 (UCT AEC), and therefore no murine work could be carried out 
on these compounds without adequate reasons. The confirmation of both extracellular and 
intracellular synergy should provide sufficient evidence to carry out in vivo murine testing for Coco 
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296, allowing for the confirmation of whether the in vitro levels of Coco 296 used in this study are 
biologically plausible based on ELF values.          
  
10.3 Summary of contributions to the field 
This work provides evidence of a novel set of compounds with selective activity against Mtb, some of 
which have shown promising in vitro and in vivo properties. The compounds have been tested in a 
drug discovery pipeline that included several in vitro ADME assays, a murine whole-blood PK model, 
murine organ and ELF testing, and finally a novel Mtb-infected THP-1 cell assay. This allowed for the 
identification of the potentially efficacious PHX 1 and PHX 1/Coco 296 combination which should, 
considering these results, be progressed for further testing. The study also reaffirms the need for 
better proxies of drug concentrations, such as ELF and intracellular concentrations, at the site of 
pulmonary TB. This is vital for the design of better drug regimens and the implementation of these 
regimens in a clinical setting. 
 
10.4 Suggestions for future research 
The drug development pipeline used in this study offers some insightful results and certainly motivates 
for the inclusion of the PHX 1/ Coco 296 combination in further in vitro and in vivo tests. These tests 
include but are not limited to: i) investigating intracellular accumulation and efficacy in primary 
macrophages, ii) investigating the long term toxicity of PHX 1 and Coco 296 in in vitro and in vivo 
models, iii) assessing the efficacy of these novel agents in combination with known anti-TB 
compounds, and iv) testing combinations or single compounds within an Mtb-infected murine model. 
These results will inform whether the compound and/or compound combination should be tested in 
further in vivo models and show potential clinical relevance. The study also provides a proposed 
testing paradigm for the use in future anti-TB drug discovery endeavors, with a shift away from plasma 
concentrations as a proxy for target site concentrations.       
The work described here has yielded a number of promising conclusions. However, as with any 
research-based work, the studies have also generated several more questions that were deemed 
beyond the scope of this research. As discussed, the compound DPINH displayed significant 
breakdown whilst maintaining in vitro efficacy, indicating the possible production of active 
metabolites. Therefore, metabolite identification should be carried out for all these novel compounds 
to ensure that active and toxic metabolites are identified and quantitated in future studies.  
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The Mtb-infected THP-1 cell model was used to assess only a single drug concentration for each 
compound. This posed the question of whether the effect of each compound was concentration-
dependent and warrants further studies at different concentrations. This would also allow for the 
modeling of the data obtained to possibly formulate an in vitro pharmacometric model of target site 
PK/PD, similar to the work of Pienaar et al., 2017.39  
The pharmacometric modeling of target site PK/PD could potentially involve the use of different 
datasets including data derived from infected murine in vivo models and would certainly warrant 
further attention. The integration of these datasets is particularly relevant and would potentially help 
to reduce the burden of TB by increasing the transition from the bench to the clinic of much needed 
novel anti-TB agents. Given the promising data displayed thus far by some of the novel chemical 






1. Dheda, K. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of 
multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir. Med. 
5, 291–360 (2017). 
2. Hoagland, D. T., Liu, J., Lee, R. B. & Lee, R. E. New agents for the treatment of drug-resistant 
Mycobacterium tuberculosis. Adv. Drug Deliv. Rev. 102, 55–72 (2016). 
3. Kyu, H. H. et al. The global burden of tuberculosis: results from the Global Burden of Disease 
Study 2015. Lancet Infect. Dis. 18, 261–284 (2016). 
4. Wallis, R. S. et al. Tuberculosis—advances in development of new drugs, treatment regimens, 
host-directed therapies, and biomarkers. Lancet Infect. Dis. 16, e34–e46 (2016). 
5. Schito, M., Hanna, D. & Zumla, A. Tuberculosis eradication versus control. Int. J. Infect. Dis. 56, 
10–13 (2017). 
6. WHO End TB strategy. WHO End TB Strategy Who (2015). 
7. WHO. World Health Organisation Global Tuberculosis Report 2016 (2016). 
8. Naidoo, P. et al. The South African Tuberculosis Care Cascade: Estimated Losses and 
Methodological Challenges. J. Infect. Dis. 216, S702–S713 (2017). 
9. Hermans, S., Boulle, A., Caldwell, J., Pienaar, D. & Wood, R. Temporal trends in TB notification 
rates during ART scale-up in Cape Town: An ecological analysis. J. Int. AIDS Soc. 18, (2015). 
10. Russell, D. G., Barry, C. E. & Flynn, J. L. NIH Public Access. Russell J. Bertrand Russell Arch. 328, 
852–856 (2010). 
11. Barry, C. E. et al. The spectrum of latent tuberculosis: rethinking the goals of prophylaxis. Nat 
Rev Microbiol 7, 845–855 (2009). 
12. Dheda, K. et al. Drug penetration gradients associated with acquired drug resistance in 
tuberculosis patients. Am. J. Respir. Crit. Care Med. (2018). 
13. Knudson, S. E., Kumar, K., Awasthi, D., Ojima, I. & Slayden, R. A. In vitro-in vivo activity 
relationship of substituted benzimidazole cell division inhibitors with activity against 
Mycobacterium tuberculosis. Tuberculosis 94, 271–276 (2014). 
14. Dartois, V. & Barry, C. E. A Medicinal Chemists’ Guide to Lead Optimization for Tuberculosis. 
Bioorg. Med. Chem. Lett. 23, 4741–4750 (2013). 
15. Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. 
Nat. Rev. Microbiol. 12, 159–167 (2014). 
16. Kjellsson, M. C. et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents 
in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56, 446–57 (2012). 
17. Dartois, V. & Barry, C. E. Clinical pharmacology and lesion penetrating properties of second- 
and third-line antituberculous agents used in the management of multidrug-resistant (MDR) 
and extensively-drug resistant (XDR) tuberculosis. Curr. Clin. Pharmacol. 5, 96–114 (2010). 
18. Lenaerts, A., Barry, C. E. & Dartois, V. Heterogeneity in tuberculosis pathology, 
microenvironments and therapeutic responses. Immunol. Rev. 264, 288–307 (2015). 




20. Carryn, S., Van Bambeke, F., Mingeot-Leclercq, M. P. & Tulkens, P. M. Comparative intracellular 
(THP-1 macrophage) and extracellular activities of β-lactams, azithromycin, gentamicin, and 
fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. 
Antimicrob. Agents Chemother. 46, 2095–2103 (2002). 
21. Lin, P. L. et al. Sterilization of granulomas is common in active and latent tuberculosis despite 
within-host variability in bacterial killing. Nat. Med. 20, 75 (2013). 
22. Cadena, A. M., Fortune, S. M. & Flynn, J. L. Heterogeneity in tuberculosis. Nat. Rev. Immunol. 
17, 691-702 (2017). 
23. Martin, C. J. et al. Digitally Barcoding Mycobacterium tuberculosis Reveals In Vivo Infection 
Dynamics in the Macaque Model of Tuberculosis. MBio 8, 12–17 (2017). 
24. Sarathy, J. P. et al. Extreme drug tolerance of Mycobacterium tuberculosis in caseum. 
Antimicrob. Agents Chemother. 62, AAC.02266-17 (2017). 
25. Liu, Y. et al. Immune activation of the host cell induces drug tolerance in Mycobacterium 
tuberculosis both in vitro and in vivo. J. Exp. Med. 213, 809–825 (2016). 
26. Bansal-Mutalik, R. & Nikaido, H. Mycobacterial outer membrane is a lipid bilayer and the inner 
membrane is unusually rich in diacyl phosphatidylinositol dimannosides. Proc. Natl. Acad. Sci. 
111, 4958 LP-4963 (2014). 
27. Grant, S. S. et al. Identification of Novel Inhibitors of Nonreplicating Mycobacterium 
tuberculosis Using a Carbon Starvation Model. ACS Chem. Biol. 8, 2224–2234 (2013). 
28. Zhang, Y. J. et al. Tryptophan biosynthesis protects mycobacteria from CD4 T cell-mediated 
killing. Cell 155, 1296–1308 (2013). 
29. Van Boogaard, J. Den, Kibiki, G. S., Kisanga, E. R., Boeree, M. J. & Aarnoutse, R. E. New drugs 
against tuberculosis: Problems, progress, and evaluation of agents in clinical development. 
Antimicrob. Agents Chemother. 53, 849–862 (2009). 
30. Reynolds, J. & Heysell, S. K. Understanding pharmacokinetics to improve tuberculosis 
treatment outcome. Expert Opin. Drug Metab. Toxicol. 10, 813–823 (2014). 
31. Awasthi, D. & Freundlich, J. S. Antimycobacterial Metabolism : Illuminating Mycobacterium 
tuberculosis Biology and Drug Discovery. Trends Microbiol. xx, 1–12 (2017). 
32. Warrier, T. et al. N-methylation of a bactericidal compound as a resistance mechanism in 
Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. 113, E4523 LP-E4530 (2016). 
33. Sarathy, J. P., Dartois, V. & Lee, E. J. D. The Role of Transport Mechanisms in Mycobacterium 
Tuberculosis Drug Resistance and Tolerance. Pharmaceuticals 5, 1210–1235 (2012). 
34. Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery 
for tuberculosis. Nature 469, 483–490 (2011). 
35. Prideaux, B. et al. The association between sterilizing activity and drug distribution into 
tuberculosis lesions. Nat. Med. 21, 1223 (2015). 
36. Prideaux, B. et al. High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in 
Tuberculosis-Infected Rabbit Lungs and Granulomatous Lesions. Anal. Chem. 83, 2112–2118 
(2011). 
37. Lenaerts, A., Barry, C. E. & Dartois, V. Heterogeneity in tuberculosis pathology, 
microenvironments and therapeutic responses. Immunol. Rev. 264, 288–307 (2015). 
186 
 
38. Zimmerman, M. et al. Ethambutol partitioning in tuberculous pulmonary lesions explains its 
clinical efficacy. Antimicrob. Agents Chemother. AAC.00924-17 (2017). 
39. Pienaar, E. et al. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in 
tuberculosis granulomas using a multi-scale systems pharmacology approach. PLOS 
Computational Biology 13, (2017). 
40. Mitchison, D. & Davies, G. The chemotherapy of tuberculosis: past, present and future. Int. J. 
Tuberc. Lung Dis. 16, 724–732 (2012). 
41. Sarathy, J., Dartois, V., Dick, T. & Gengenbacher, M. Reduced drug uptake in phenotypically 
resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents 
Chemother. 57, 1648–1653 (2013). 
42. Xie, Z., Siddiqi, N. & Rubin, E. J. Differential Antibiotic Susceptibilities of Starved Mycobacterium 
tuberculosis Isolates. Antimicrob. Agents Chemother. 49, 4778–4780 (2005). 
43. Mandal, S., Zhou, Y., Shibata, A. & Destache, C. J. Confocal fluorescence microscopy: An ultra-
sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells. AIP 
Adv. 5, 84803 (2015). 
44. Lammertink, B. H. A. et al. Dynamic Fluorescence Microscopy of Cellular Uptake of Intercalating 
Model Drugs by Ultrasound-Activated Microbubbles. Mol. Imaging Biol. 19, 683–693 (2017). 
45. Manning, A. J. et al. A high content microscopy assay to determine drug activity against 
intracellular Mycobacterium tuberculosis. Methods 127, 3–11 (2017). 
46. Scarabelli, S. et al. Evaluating Cellular Drug Uptake with Fluorescent Sensor Proteins. ACS 
Sensors 2, 1191–1197 (2017). 
47. Stone, M. R. L., Butler, M. S., Phetsang, W., Cooper, M. A. & Blaskovich, M. A. T. Fluorescent 
Antibiotics: New Research Tools to Fight Antibiotic Resistance. Trends Biotechnol. 36, 523–536 
(2018). 
48. Baron, V. O. et al. in Gillespie S. (eds) Antibiotic Resistance Protocols. Methods in Molecular 
Biology, vol 1736. Humana Press, New York, NY (ed. Gillespie, S. H.) 41–50 (Springer New York, 
2018). 
49. Yokoyama, M., Nishimura, T., Yamada, K., Ohno, Y. & Sakurai, Y. Proposal of estimation method 
for drug concentration in blood by Raman spectroscopy of tear fluids. in The 6th 2013 
Biomedical Engineering International Conference 1–4 (2013). 
50. Chuchuen, O. et al. Quantitative Analysis of Microbicide Concentrations in Fluids, Gels and 
Tissues Using Confocal Raman Spectroscopy. PLoS One 8, e85124 (2014). 
51. Ilinski, P. et al. The Direct Mapping of the Uptake of Platinum Anticancer Agents in Individual 
Human Ovarian Adenocarcinoma Cells Using a Hard X-ray Microprobe. Cancer Res. 63, 1776 
LP-1779 (2003). 
52. Sakurai, H. et al. Direct visualization and quantification of the anticancer agent, cis-
diamminedichloro-platinum(II), in human lung cancer cells using in-air microparticle-induced 
X-ray emission analysis. Cancer Sci. 99, 901–904 (2008). 
53. Rajendran, R. et al. Nuclear Microscopy: A Novel Technique for Quantitative Imaging of 
Gadolinium Distribution within Tissue Sections. Microsc. Microanal. 15, 338–344 (2009). 




55. Solon, E. G. Autoradiography techniques and quantification of drug distribution. Cell Tissue Res. 
360, 87–107 (2015). 
56. Mammatas, L. H. et al. Molecular imaging of targeted therapies with positron emission 
tomography: the visualization of personalized cancer care. Cell. Oncol. (Dordr). 38, 49–64 
(2015). 
57. Matthews, P. M., Rabiner, E. A., Passchier, J. & Gunn, R. N. Positron emission tomography 
molecular imaging for drug development. Br. J. Clin. Pharmacol. 73, 175–186 (2012). 
58. Ankrah, A. O. et al. PET/CT imaging of Mycobacterium tuberculosis infection. Clin. Transl. 
Imaging 4, 131–144 (2016). 
59. Bhat, J., Narayan, A., Venkatraman, J. & Chatterji, M. LC-MS based assay to measure 
intracellular compound levels in Mycobacterium smegmatis: Linking compound levels to 
cellular potency. J. Microbiol. Methods 94, 152–158 (2013). 
60. Gordon, L. J. et al. Direct Measurement of Intracellular Compound Concentration by RapidFire 
Mass Spectrometry Offers Insights into Cell Permeability. J. Biomol. Screen. 21, 156–164 (2015). 
61. Chen, C. et al. Verapamil targets membrane energetics in Mycobacterium tuberculosis. 
Antimicrob. Agents Chemother. 62, AAC.02107-17 (2018). 
62. Prideaux, B., Lenaerts, A. & Dartois, V. Imaging and spatially resolved quantification of drug 
distribution in tissues by mass spectrometry. Curr. Opin. Chem. Biol. 44, 93–100 (2018). 
63. Prentice, B. M., Chumbley, C. W. & Caprioli, R. M. Absolute Quantification of Rifampicin by 
MALDI Imaging Mass Spectrometry Using Multiple TOF/TOF Events in a Single Laser Shot. J. 
Am. Soc. Mass Spectrom. 28, 136–144 (2017). 
64. Fisher, G. L. et al. A New Method and Mass Spectrometer Design for TOF-SIMS Parallel Imaging 
MS/MS. Anal. Chem. 88, 6433–6440 (2016). 
65. Gumbo, T., Lenaerts, A. J., Hanna, D., Romero, K. & Nuermberger, E. Nonclinical Models for 
Antituberculosis Drug Development: A Landscape Analysis. J. Infect. Dis. 211, S83–S95 (2015). 
66. Schump, M. D., Fox, D. M., Bertozzi, C. R. & Riley, L. W. Subcellular partitioning and 
intramacrophage selectivity of antimicrobial compounds against Mycobacterium tuberculosis. 
Antimicrob. Agents Chemother. 61, 1–12 (2017). 
67. O’Garra, A. et al. The Immune Response in Tuberculosis. Annu. Rev. Immunol. 31, 475–527 
(2013). 
68. Eum, S.-Y. et al. Neutrophils Are the Predominant Infected Phagocytic Cells in the Airways of 
Patients With Active Pulmonary TB. Chest 137, 122–128 (2010). 
69. Lowe, D. M., Redford, P. S., Wilkinson, R. J., O’Garra, A. & Martineau, A. R. Neutrophils in 
tuberculosis: friend or foe? Trends Immunol. 33, 14–25 (2012). 
70. Kaplan, G. et al. Mycobacterium tuberculosis Growth at the Cavity Surface: a 
Microenvironment with Failed Immunity . Infect. Immun. 71, 7099–7108 (2003). 
71. Hernández-Pando, R. et al. Persistence of DNA from Mycobacterium tuberculosis in 
superficially normal lung tissue during latent infection. Lancet 356, 2133–2138 (2000). 
72. Barrios-Payán, J. et al. Extrapulmonary Locations of Mycobacterium tuberculosis DNA During 
Latent Infection. J. Infect. Dis. 206, 1194–1205 (2012). 
73. Reece, S. T. et al. Mycobacterium tuberculosis-Infected Hematopoietic Stem and Progenitor 
188 
 
Cells Unable to Express Inducible Nitric Oxide Synthase Propagate Tuberculosis in Mice. J. 
Infect. Dis. 217, jiy041-jiy041 (2018). 
74. Beigier-Bompadre, M. et al. Mycobacterium tuberculosis infection modulates adipose tissue 
biology. PLoS Pathog. 13, e1006676 (2017). 
75. Evangelopoulos, D., Fonseca, J. D. da & Waddell, S. J. Understanding anti-tuberculosis drug 
efficacy: Rethinking bacterial populations and how we model them. Int. J. Infect. Dis. 32, 76–
80 (2015). 
76. Cohen, J. Approval of Novel TB Drug Celebrated-With Restraint. Science 339, 130–130 (2013). 
77. Saito, K. et al. Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium 
tuberculosis results in differentially detectable populations. Proc. Natl. Acad. Sci. 114, E4832 
LP-E4840 (2017). 
78. Wakamoto, Y. et al. Dynamic Persistence of Antibiotic-Stressed Mycobacteria. Science 339, 91–
95 (2013). 
79. Horsburgh, C. R., Barry, C. E. & Lange, C. Treatment of Tuberculosis. N. Engl. J. Med. 373, 2149–
2160 (2015). 
80. Vanderven, B. C., Huang, L., Rohde, K. H. & Russell, D. G. The minimal unit of infection: M. 
tuberculosis in the macrophage. Microbiol. Spectr. 4, 1–26 (2017). 
81. Ehrt, S. & Rhee, K. Y. Mycobacterium Tuberculosis Metabolism and Host Interaction: Mysteries 
and Paradoxes. Curr. Top. Microbiol. Immunol. 374, 163–188 (2013). 
82. Srivastava, S., Ernst, J. D. & Desvignes, L. Beyond macrophages: The diversity of mononuclear 
cells in tuberculosis. Immunol. Rev. 262, 179–192 (2014). 
83. Rohde, K., Yates, R. M., Purdy, G. E. & Russell, D. G. Mycobacterium tuberculosis and the 
environment within the phagosome. Immunol. Rev. 219, 37–54 (2007). 
84. Russell, D. G. The evolutionary pressures that have molded Mycobacterium tuberculosis into 
an infectious adjuvant. Curr. Opin. Microbiol. 16, 78–84 (2013). 
85. Fortune, S. M. & Rubin, E. J. The Complex Relationship between Mycobacteria and 
Macrophages: It’s Not All Bliss. Cell Host Microbe 2, 5–6 (2007). 
86. Raffetseder, J. et al. Replication rates of mycobacterium tuberculosis in human macrophages 
do not correlate with mycobacterial antibiotic susceptibility. PLoS One 9, 1–10 (2014). 
87. Christophe, T. et al. High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase 
as a Target for Intracellular Antimycobacterial Inhibitors. PLoS Pathog. 5, e1000645 (2009). 
88. Brodin, P. & Christophe, T. High-content screening in infectious diseases. Curr. Opin. Chem. 
Biol. 15, 534–539 (2011). 
89. Stanley, S. A. et al. Identification of Host-Targeted Small Molecules That Restrict Intracellular 
Mycobacterium tuberculosis Growth. PLoS Pathog. 10, e1003946 (2014). 
90. VanderVen, B. C. et al. Novel Inhibitors of Cholesterol Degradation in Mycobacterium 
tuberculosis Reveal How the Bacterium’s Metabolism Is Constrained by the Intracellular 
Environment. PLoS Pathog. 11, 1–20 (2015). 
91. Dalton, J. P. et al. Screening of anti-mycobacterial compounds in a naturally infected zebrafish 
larvae model. J. Antimicrob. Chemother. 72, 421–427 (2017). 
189 
 
92. Guirado, E. & Schlesinger, L. S. Modeling the Mycobacterium tuberculosis Granuloma – the 
Critical Battlefield in Host Immunity and Disease. Front. Immunol. 4, 98 (2013). 
93. Yuan, T. & Sampson, N. S. Hit Generation in TB Drug Discovery: From Genome to Granuloma. 
Chem. Rev. 118, 1887–1916 (2018). 
94. Huang, L. & Russell, D. G. Protective immunity against tuberculosis: what does it look like and 
how do we find it? Curr. Opin. Immunol. 48, 44–50 (2017). 
95. Leemans, J. C. et al. Macrophages play a dual role during pulmonary tuberculosis in mice. J. 
Infect. Dis. 191, 65–74 (2005). 
96. Leemans, J. C. et al. Depletion of Alveolar Macrophages Exerts Protective Effects in Pulmonary 
Tuberculosis in Mice. J. Immunol. 166, 4604–4611 (2001). 
97. Kramnik, I. & Beamer, G. Mouse models of human TB pathology: roles in the analysis of necrosis 
and the development of host-directed therapies. Semin. Immunopathol. 38, 221–237 (2016). 
98. Nuermberger, E., Sizemore, C., Romero, K. & Hanna, D. Towards an evidence-based non-clinical 
roadmap for evaluating the efficacy of new TB drug regimens: Proceedings of a Critical Path to 
TB Drug Regimens (CPTR)-National Institute of Allergy and Infectious Disease (NIAID) in vivo 
Pharmacology Workshop for Tu. Antimicrob. Agents Chemother. 60, 1177–1182 (2016). 
99. Fejer, G. et al. Nontransformed, GM-CSF–dependent macrophage lines are a unique model to 
study tissue macrophage functions. Proc. Natl. Acad. Sci. U. S. A. 110, E2191–E2198 (2013). 
100. Ginhoux, F., Schultze, J. L., Murray, P. J., Ochando, J. & Biswas, S. K. New insights into the 
multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 
17, 34 (2015). 
101. Flynn, J. L., Chan, J. & Lin, P. L. Macrophages and control of granulomatous inflammation in 
tuberculosis. Mucosal Immunol. 4, 271–278 (2011). 
102. O’Neill, L. A. J., Kishton, R. J. & Rathmell, J. A guide to immunometabolism for immunologists. 
Nature Reviews Immunology 16, 553–565 (2016). 
103. Eisenreich, W., Heesemann, J., Rudel, T. & Goebel, W. Metabolic Adaptations of Intracellullar 
Bacterial Pathogens and their Mammalian Host Cells during Infection (‘Pathometabolism’). 
Microbiol. Spectr. 3, (2015). 
104. Fange, D., Nilsson, K., Tenson, T. & Ehrenberg, M. Drug efflux pump deficiency and drug target 
resistance masking in growing bacteria. Proc. Natl. Acad. Sci. 106, 8215 LP-8220 (2009). 
105. Bhamidi, S. et al. Detailed Structural and Quantitative Analysis Reveals the Spatial Organization 
of the Cell Walls of in Vivo Grown Mycobacterium leprae and in Vitro Grown Mycobacterium 
tuberculosis. J. Biol. Chem. 286, 23168–23177 (2011). 
106. Niederweis, M., Danilchanka, O., Huff, J., Hoffmann, C. & Engelhardt, H. Mycobacterial outer 
membranes: in search of proteins. Trends Microbiol. 18, 109–116 (2010). 
107. Louw, G. E. et al. A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance . Antimicrob. 
Agents Chemother. 53, 3181–3189 (2009). 
108. te Brake, L. H. M. et al. The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise 
as a Target in Drug Development: Unraveling the Black Box. Annu. Rev. Pharmacol. Toxicol. 58, 
010617-052438 (2018). 
109. Balganesh, M. et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in 
190 
 
antituberculosis activity of potential drug candidates. Antimicrob. Agents Chemother. 56, 
2643–2651 (2012). 
110. Dinesh, N., Sharma, S. & Balganesh, M. Involvement of Efflux Pumps in the Resistance to 
Peptidoglycan Synthesis Inhibitors in Mycobacterium tuberculosis. Antimicrob. Agents 
Chemother. 57, 1941–1943 (2013). 
111. Adams, K. N., Szumowski, J. D. & Ramakrishnan, L. Verapamil, and Its Metabolite Norverapamil, 
Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-
tubercular Drugs. J. Infect. Dis. 210, 456–466 (2014). 
112. Adams, K. N. et al. Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-
Induced Efflux Mechanism. Cell 145, 39–53 (2011). 
113. Liu, J. et al. Mutations in efflux pump Rv1258c (Tap) cause resistance to pyrazinamide and other 
drugs in M. tuberculosis. bioRxiv 249102 (2018). 
114. Rodriguez-Rivera, F. P., Zhou, X., Theriot, J. A. & Bertozzi, C. R. Visualization of mycobacterial 
membrane dynamics in live cells. J. Am. Chem. Soc. 139, 3488–3495 (2017). 
115. Mdluli, K., Kaneko, T. & Upton, A. The Tuberculosis Drug Discovery and Development Pipeline 
and Emerging Drug Targets. Cold Spring Harb. Perspect. Med. 5, a021154–a021154 (2015). 
116. Galagan, J. E. et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 
499, 178–183 (2013). 
117. Boshoff, H. I. M. & Barry 3rd, C. E. Tuberculosis — metabolism and respiration in the absence 
of growth. Nat. Rev. Microbiol. 3, 70 (2005). 
118. Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 
Nat. Med. 19, 1157–1160 (2013). 
119. Wei, J. et al. Identification of a Mycobacterium tuberculosis Gene That Enhances Mycobacterial 
Survival in Macrophages. J. Bacteriol. 182, 377–384 (2000). 
120. P.M. Shah, W. Junghanns, W. S. Dose-response relationship of bactericidal activity in E. coli, K. 
pneumoniae and Staphylococcus aureus. Dtsch med Wochenschr 101, 325–328 (1976). 
121. Sloan, D. J. et al. Genetic determinants of the pharmacokinetic variability of rifampin in 
Malawian adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 61, 1–9 (2017). 
122. Wright, D. F. B., Winter, H. R. & Duffull, S. B. Understanding the time course of pharmacological 
effect: a PKPD approach. Br. J. Clin. Pharmacol. 71, 815–823 (2011). 
123. Upton, R. N. & Mould, D. R. Basic Concepts in Population Modeling, Simulation, and Model-
Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods. CPT 
Pharmacometrics Syst. Pharmacol. 3, e88 (2014). 
124. Pasipanodya, J. & Gumbo, T. An Oracle: Antituberculosis Pharmacokinetics-
Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future. 
Antimicrob. Agents Chemother. 55, 24 LP-34 (2011). 
125. Gumbo, T., Angulo-Barturen, I. & Ferrer-Bazaga, S. Pharmacokinetic-Pharmacodynamic and 
Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for 
Industry and Academia. J. Infect. Dis. 211, S96–S106 (2015). 
126. Lyons, M. A. & Lenaerts, A. J. Computational pharmacokinetics/pharmacodynamics of rifampin 
in a mouse tuberculosis infection model. J. Pharmacokinet. Pharmacodyn. 42, 375–389 (2015). 
191 
 
127. ML, R., Zou, L., RM, S. & KE, D. Importance of Drug Pharmacokinetics at the Site of Action. Clin. 
Transl. Sci. 10, 133–142 (2017). 
128. Craig, W. A. Interrelationship between pharmacokinetics and pharmacodynamics in 
determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 
22, 89–96 (1995). 
129. Craig, W. A. State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: 
Rationale for Antibacterial Dosing of Mice and Men. Clin. Infect. Dis. 26, 1–10 (1998). 
130. Vaddady, P. K., Lee, R. E. & Meibohm, B. In vitro pharmacokinetic/pharmacodynamic models 
in anti-infective drug development: focus on TB. Future Med. Chem. 2, 1355–1369 (2010). 
131. Pasipanodya, J. G., Srivastava, S. & Gumbo, T. Meta-analysis of clinical studies supports the 
pharmacokinetic variability hypothesis for acquired drug resistance and failure of 
antituberculosis therapy. Clinical Infectious Diseases 55, 169–177 (2012). 
132. Pasipanodya, J. G., Srivastava, S. & Gumbo, T. Acquired drug resistance because of 
pharmacokinetic variability in a young child with tuberculosis. Pediatric Infectious Disease 
Journal 33, 1205 (2014). 
133. Pasipanodya, J. G., Nuermberger, E., Romero, K., Hanna, D. & Gumbo, T. Systematic analysis of 
hollow fiber model of tuberculosis experiments. Clin. Infect. Dis. 61, S10–S17 (2015). 
134. Pasipanodya, J. G. et al. Serum drug concentrations predictive of pulmonary tuberculosis 
outcomes. J. Infect. Dis. 208, 1464–1473 (2013). 
135. Gumbo, T. et al. Selection of a moxifloxacin dose that suppresses drug resistance in 
Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and 
mathematical modeling. J Infect Dis 190, 1642–1651 (2004). 
136. Dheda K, Lenders L, G. T. New insights into the pathogenesis of drug-resistant TB and 
implications for clinical management. keystone Symp. Tuberc. co-morbidities 
immunopathogenesis; 2016; Keystone Resort, Keystone, Color. USA; 2016. (2016). 
137. Diacon, A. H. et al. Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary 
Tuberculosis Evidenced by Positive Sputum Smears . Antimicrob. Agents Chemother. 51, 2994–
2996 (2007). 
138. Gu, H. F. et al. Nicotinate-curcumin impedes foam cell formation from THP-1 cells through 
restoring autophagy flux. PLoS One 11, 1–15 (2016). 
139. Vinegoni, C. et al. Advances in measuring single-cell pharmacology in vivo. Drug Discov. Today 
20, 1087–1092 (2015). 
140. Bekker, A. et al. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in 
Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob. 
Agents Chemother. 60, 2171—2179 (2016). 
141. Denti, P. et al. Pharmacokinetics of rifampicin in African children-Evaluation of the new WHO 
dosing guidelines. in 10th International workshop on clinical pharmacology of tuberculosis 
drugs (2017). 
142. Thee, S. et al. Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in Children Younger 
than Two Years of Age with Tuberculosis: Evidence for Implementation of Revised World Health 
Organization Recommendations. Antimicrob. Agents Chemother. 55, 5560–5567 (2011). 
143. Seddon, J. A. & Schaaf, H. S. Drug-resistant tuberculosis and advances in the treatment of 
192 
 
childhood tuberculosis. Pneumonia 8, 20 (2016). 
144. Nijland, H. M. J. et al. Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients 
with Tuberculosis. Clin. Infect. Dis. 45, 1001–1007 (2007). 
145. Cokol, M., Kuru, N., Bicak, E., Larkins-Ford, J. & Aldridge, B. B. Efficient measurement and 
factorization of high-order drug interactions in Mycobacterium tuberculosis. Sci. Adv. 3, 
e1701881 (2017). 
146. Blanc, L., Lenaerts, A., Dartois, V. & Prideaux, B. Visualization of Mycobacterial Biomarkers and 
Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging. Anal. Chem. 90, 6275–6282 
(2018). 
147. Dawson, R. et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-
824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, 
open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul. 
Lancet 385, 1738–1747 (2017). 
148. Warner, D. F. & Mizrahi, V. Shortening Treatment for Tuberculosis — Back to Basics. N. Engl. J. 
Med. 371, 1642–1643 (2014). 
149. Kislitsyna, N. A. & Kotova, N. I. Rifampicin and isoniazid concentration in the blood and resected 
lungs in tuberculosis with combined use of the preparations. Probl Tuberk 8, 63–65 
150. Canetti, G., Parrot, R., Porven, G. & Le Lirzin, M. Rifomycin levels in the lung and tuberculous 
lesions in man. Acta Tuberc Pneumol Belg. 60, 315–322 (in French) (1969). 
151. Sauermann, R. et al. Antibiotic abscess penetration: Fosfomycin levels measured in pus and 
simulated concentration-time profiles. Antimicrob. Agents Chemother. 49, 4448–4454 (2005). 
152. Wagner, C., Sauermann, R. & Joukhadar, C. Principles of Antibiotic Penetration into Abscess 
Fluid. Pharmacology 78, 1–10 (2006). 
153. Scaglione, F. & Paraboni, L. Influence of pharmacokinetics/pharmacodynamics of antibacterials 
in their dosing regimen selection. Expert Rev. Anti. Infect. Ther. 4, 479–490 (2006). 
154. Stanley, S. A. et al. Identification of Host-Targeted Small Molecules That Restrict Intracellular 
Mycobacterium tuberculosis Growth. PLoS Pathog. 10, (2014). 
155. Queval, C. J. et al. A Microscopic Phenotypic Assay for the Quantification of Intracellular 
Mycobacteria Adapted for High-throughput/High-content Screening. J. Vis. Exp.83, 1–16 
(2014). doi:10.3791/51114 
156. de Carvalho, L. P. S. et al. Metabolomics of Mycobacterium tuberculosis Reveals 
Compartmentalized Co-Catabolism of Carbon Substrates. Chem. Biol. 17, 1122–1131 (2010). 
157. Chakraborty, P., Kulkarni, S., Rajan, R. & Sainis, K. Drug Resistant Clinical Isolates of 
Mycobacterium tuberculosis from Different Genotypes Exhibit Differential Host Responses in 
THP-1 Cells. PLoS One 8, 1–9 (2013). 
158. Halouska, S., Fenton, R. J., Barletta, R. G. & Powers, R. Predicting the in vivo Mechanism of 
Action for Drug Leads using NMR Metabolomics. ACS Chem. Biol. 7, 166–171 (2012). 
159. Halouska, S. et al. Metabolomics Analysis Identifies D-Alanine-D-alanine Ligase as the Primary 
Lethal Target of D-cycloserine in Mycobacteria. J. Proteome Res. 13, 1065–1076 (2014). 
160. Prosser, G. A. & de Carvalho, L. P. S. Metabolomics Reveal d-Alanine:d-Alanine Ligase As the 




161. Deborah‐Ann, J. & D., S. K. The efficacy of certain anti‐tuberculosis drugs is affected by binding 
to α‐1‐acid glycoprotein. Biomed. Chromatogr. 20, 551–560 (2006). 
162. Ehrt, S. & Schnappinger, D. Mycobacterial survival strategies in the phagosome: Defense 
against host stresses. Cell. Microbiol. 11, 1170–1178 (2009). 
163. MacMicking, J. D., Taylor, G. A. & McKinney, J. D. Immune control of tuberculosis by IFN-
gamma-inducible LRG-47. Science 302, 654–659 (2003). 
164. Vandal, O. H., Nathan, C. F. & Ehrt, S. Acid resistance in Mycobacterium tuberculosis. Journal 
of Bacteriology 191, 4714–4721 (2009). 
165. Zhang, Y. & Mitchison, D. The curious characteristics of pyrazinamide: A review. International 
Journal of Tuberculosis and Lung Disease 7, 6–21 (2003). 
166. Mitchison, D. A. & Coates, A. R. M. Predictive In Vitro Models of the Sterilizing Activity of Anti-
Tuberculosis Drugs. Curr. Pharm. Des. 10, 3285–3295 (2004). 
167. Mitchison, D. A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 
66, 219–225 (1985). 
168. Schaaf, K. et al. A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium 
Tuberculosis. Assay Drug Dev. Technol. 14, 345–354 (2016). 
169. Gillespie, S. H. et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. 
N. Engl. J. Med. 371, 1577–1587 (2014). 
170. Wayne, L. G. & Sohaskey, C. D. Nonreplicating persistence of mycobacterium tuberculosis. 
Annu. Rev. Microbiol. 55, 139–163 (2001). 
171. Gengenbacher, M., Rao, S. P. S., Pethe, K. & Dick, T. Nutrient-starved, non-replicating 
Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for 
maintenance of ATP homeostasis and viability. Microbiology 156, 81–87 (2010). 
172. Dartois, V. Drug penetration into tuberculosis lesions. in Crick TB Symposium, London School of 
Public Health and Tropical Medicine, 24 March (2016). 
173. Bielecka, M. K., Tezera, L. B., Zmijan, R. & Drobniewski, F. Culture Platform Integrated with 
Microfluidics To Address Antimicrobial Resistance in Tuberculosis. 8, (2017). 
174. Tezera, L. B. et al. Dissection of the host-pathogen interaction in human tuberculosis using a 
bioengineered 3-dimensional model. Elife 6, e21283 (2017). 
175. Breslin, S. & O’Driscoll, L. Three-dimensional cell culture: the missing link in drug discovery. 
Drug Discov. Today 18, 240–249 (2013). 
176. Devarasetty, M., Mazzocchi, A. R. & Skardal, A. Applications of Bioengineered 3D Tissue and 
Tumor Organoids in Drug Development and Precision Medicine: Current and Future. BioDrugs 
32, 53–68 (2018). 
177. Workman, V. L., Tezera, L. B., Elkington, P. T. & Jayasinghe, S. N. Controlled Generation of 
Microspheres Incorporating Extracellular Matrix Fibrils for Three-Dimensional Cell Culture. 
Adv. Funct. Mater. 24, 2648–2657 (2014). 
178. Kapoor, N. et al. Human Granuloma In Vitro Model, for TB Dormancy and Resuscitation. PLoS 
One 8, (2013). 
194 
 
179. Braian, C., Svensson, M., Brighenti, S., Lerm, M. & Parasa, V. R. A 3D Human Lung Tissue Model 
for Functional Studies on Mycobacterium tuberculosis Infection. J. Vis. Exp. 104, 1–9 (2015). 
180. Parasa, V. R. et al. Inhibition of tissue matrix metalloproteinases interferes with 
Mycobacterium tuberculosis-induced granuloma formation and reduces bacterial load in a 
human lung tissue model. Front. Microbiol. 8, (2017). 
181. Parasa, V. R. et al. Modeling Mycobacterium tuberculosis early granuloma formation in 
experimental human lung tissue. Dis. Model. Mech. 7, 281–288 (2014). 
182. Silva-Miranda, M. et al. High-content screening technology combined with a human granuloma 
model as a new approach to evaluate the activities of drugs against Mycobacterium 
tuberculosis. Antimicrob. Agents Chemother. 59, 693–697 (2015). 
183. Marakalala, M. J. et al. Inflammatory signaling in human Tuberculosis granulomas is spatially 
organized. Nat. Med. 22, 531–538 (2016). 
184. Al Shammari, B. et al. The Extracellular Matrix Regulates Granuloma Necrosis in Tuberculosis. 
J. Infect. Dis. 212, 463–473 (2015). 
185. Babcock, G. T. & Wikström, M. Oxygen activation and the conservation of energy in cell 
respiration. Nature 356, 301–309 (1992). 
186. Loi, V. Van, Rossius, M. & Antelmann, H. Redox regulation by reversible protein S-thiolation in 
bacteria   . Frontiers in Microbiology   6, 187 (2015). 
187. Ezraty, B. et al. Fe-S Cluster Biosynthesis Controls Uptake of Aminoglycosides in a ROS-Less 
Death Pathway. Science 340, 1583 LP-1587 (2013). 
188. Dickinson, B. C. & Chang, C. J. Chemistry and biology of reactive oxygen species in signaling or 
stress responses. Nat. Chem. Biol. 7, 504–511 (2011). 
189. Winterbourn, C. C. Reconciling the chemistry and biology of reactive oxygen species. Nat. 
Chem. Biol. 4, 278 (2008). 
190. Imlay, J. A. Cellular Defenses against Superoxide and Hydrogen Peroxide. Annu. Rev. Biochem. 
77, 755–776 (2008). 
191. Dharmaraja, A. T. Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance 
in Cancer and Bacteria. J. Med. Chem. 60, 3221–3240 (2017). 
192. Finkel, T. et al. Oxidants, oxidative stress and the biology of ageing. Nature 408, 239–247 
(2000). 
193. Imlay, J. A. Oxidative Stress. EcoSal Plus 3, (2009). 
194. Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by 
targeting GAPDH. Science 350, 1391–1396 (2015). 
195. Covarrubias, A., Byles, V. & Horng, T. ROS sets the stage for macrophage differentiation. Cell 
Res. 23, 984 (2013). 
196. Sena, L. A. & Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. 
Cell 48, 158–167 (2012). 
197. Redza-Dutordoir, M. & Averill-Bates, D. A. Activation of apoptosis signalling pathways by 
reactive oxygen species. Biochim. Biophys. Acta - Mol. Cell Res. 1863, 2977–2992 (2016). 
198. Keyer, K. & Imlay, J. A. Superoxide accelerates DNA damage by elevating free-iron levels. Proc. 
195 
 
Natl. Acad. Sci. U. S. A. 93, 13635–13640 (1996). 
199. Rosner, J. L. & Storz, G. Effects of peroxides on susceptibilities of Escherichia coli and 
Mycobacterium smegmatis to isoniazid. Antimicrob. Agents Chemother. 38, 1829–1833 (1994). 
200. Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A. & Collins, J. J. A Common Mechanism 
of Cellular Death Induced by Bactericidal Antibiotics. Cell 130, 797–810 (2007). 
201. Liu, Z. et al. Role of ROS and Nutritional Antioxidants in Human Diseases. Front. Physiol. 9, 477 
(2018). 
202. Santos, A. L., Sinha, S. & Lindner, A. B. The Good, the Bad, and the Ugly of ROS: New Insights 
on Aging and Aging-Related Diseases from Eukaryotic and Prokaryotic Model Organisms. Oxid. 
Med. Cell. Longev. 2018, 1941285 (2018). 
203. Wayne, L. G. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic 
and microaerophilic conditions. Am. Rev. Respir. Dis. 114, 807–811 (1976). 
204. Wayne, L. G. & Hayes, L. G. An in vitro model for sequential study of shiftdown of 
Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 
64, 2062–2069 (1996). 
205. Corper, H. J. & Cohn, M. L. The viability and virulence of old cultures of tubercle bacilli. Tubercle 
32, 232–237 (1951). 
206. Mahamed, D. et al. Intracellular growth of Mycobacterium tuberculosis after macrophage cell 
death leads to serial killing of host cells. Elife 6, (2017). 
207. Voskuil, M. I., Bartek, I. L., Visconti, K. & Schoolnik, G. K. The Response of Mycobacterium 
Tuberculosis to Reactive Oxygen and Nitrogen Species. Front. Microbiol. 2, 105 (2011). 
208. Mishra, B. B. et al. Nitric oxide prevents a pathogen-permissive granulocytic inflammation 
during tuberculosis. Nat. Microbiol. 2, 17072 (2017). 
209. Castaneda, O. A., Lee, S.-C., Ho, C.-T. & Huang, T.-C. Macrophages in oxidative stress and 
models to evaluate the antioxidant function of dietary natural compounds. J. Food Drug Anal. 
25, 111–118 (2017). 
210. Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K. & Schmidt, H. H. H. W. 
Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. 
Antioxid. Redox Signal. 23, 406–427 (2015). 
211. Segal, A. W. Absence of both cytochrome b-245 subunits from neutrophils in X-linked chronic 
granulomatous disease. Nature 326, 88–91 (1987). 
212. Opitz, N., Drummond, G. R., Selemidis, S., Meurer, S. & Schmidt, H. H. H. W. The ‘A’s and ‘O’s 
of NADPH oxidase regulation: A commentary on ‘Subcellular localization and function of 
alternatively spliced Noxo1 isoforms’. Free Radic. Biol. Med. 42, 175–179 (2007). 
213. Carnesecchi, S. et al. A Key Role for NOX4 in Epithelial Cell Death During Development of Lung 
Fibrosis. Antioxid. Redox Signal. 15, 607–619 (2011). 
214. van der Vliet, A. NADPH oxidases in lung biology and pathology,host defence enzymes, and 
more. Free Radic. Biol. Med. 44, 938–955 (2008). 
215. Tyagi, P., Dharmaraja, A. T., Bhaskar, A., Chakrapani, H. & Singh, A. Mycobacterium tuberculosis 
has diminished capacity to counteract redox stress induced by elevated levels of endogenous 
superoxide. Free Radic. Biol. Med. 84, 344–354 (2015). 
196 
 
216. Si, M. et al. Overexpression of Mycothiol Disulfide Reductase Enhances Corynebacterium 
glutamicum Robustness by Modulating Cellular Redox Homeostasis and Antioxidant Proteins 
under Oxidative Stress. Sci. Rep. 6, 29491 (2016). 
217. Postma, N. S., Mommers, E. C., Eling, W. M. C. & Zuidema, J. Oxidative stress in malaria; 
implications for prevention and therapy. Pharm World Sci 18, 121–129 (1996). 
218. Jackett, P. S., Aber, V. R. & Lowrie, D. B. Virulence and resistance to superoxide, low pH and 
hydrogen peroxide among strains of Mycobacterium tuberculosis. J. Gen. Microbiol. 104, 37–
45 (1978). 
219. Shiloh, M. U. et al. Phenotype of mice and macrophages deficient in both phagocyte oxidase 
and inducible nitric oxide synthase. Immunity 10, 29–38 (1999). 
220. Cooper, A. M., Segal, B. H., Frank, A. A., Holland, S. M. & Orme, I. M. Transient loss of resistance 
to pulmonary tuberculosis in p47(phox-/-) mice. Infect. Immun. 68, 1231–1234 (2000). 
221. Nathan, C. Inducible nitric oxide synthase in the tuberculous human lung. American Journal of 
Respiratory and Critical Care Medicine 166, 130–131 (2002). 
222. Yang, C.-S., Yuk, J.-M. & Jo, E.-K. The role of nitric oxide in mycobacterial infections. Immune 
Netw 9, 46–52 (2009). 
223. Mohan, V. P. et al. Effects of tumor necrosis factor alpha on host immune response in chronic 
persistent tuberculosis: Possible role for limiting pathology. Infect. Immun. 69, 1847–1855 
(2001). 
224. Gardam, M. A. et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of 
action and clinical management. Lancet Infect. Dis. 3, 148–155 (2003). 
225. Voskuil, M. I. et al. Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium 
tuberculosis Dormancy Program. J. Exp. Med. 198, 705–713 (2003). 
226. Firmani, M. A. & Riley, L. W. Reactive nitrogen intermediates have a bacteriostatic effect on 
Mycobacterium tuberculosis in vitro. J. Clin. Microbiol. 40, 3162–3166 (2002). 
227. Shiloh, M. U. & Nathan, C. F. Reactive nitrogen intermediates and the pathogenesis of 
Salmonella and Mycobacteria. Current Opinion in Microbiology 3, 35–42 (2000). 
228. Garbe, T. R., Hibler, N. S. & Deretic, V. Response of Mycobacterium tuberculosis to reactive 
oxygen and nitrogen intermediates. Mol. Med. 2, 134–142 (1996). 
229. Van Acker, H. & Coenye, T. The Role of Reactive Oxygen Species in Antibiotic-Mediated Killing 
of Bacteria. Trends Microbiol. 25, 456–466 (2017). 
230. Keren, I., Wu, Y., Inocencio, J., Mulcahy, L. R. & Lewis, K. Killing by Bactericidal Antibiotics Does 
Not Depend on Reactive Oxygen Species. Science 339, 1213 LP-1216 (2013). 
231. Liu, Y. & Imlay, J. A. Cell death from antibiotics without the involvement of reactive oxygen 
species. Science 339, 1210–1213 (2013). 
232. Kalyanaraman, B. et al. Measuring reactive oxygen and nitrogen species with fluorescent 
probes: challenges and limitations. Free Radic. Biol. Med. 52, 1–6 (2012). 
233. Dwyer, D. J. et al. Antibiotics induce redox-related physiological alterations as part of their 
lethality. Proc. Natl. Acad. Sci. U. S. A. 111, E2100–E2109 (2014). 
234. Dwyer, D. J., Collins, J. J. & Walker, G. C. Unraveling the Physiological Complexities of Antibiotic 
Lethality. Annu. Rev. Pharmacol. Toxicol. 55, 313–332 (2015). 
197 
 
235. Belenky, P. et al. Bactericidal antibiotics induce toxic metabolic perturbations that lead to 
cellular damage. Cell Rep. 13, 968–980 (2015). 
236. Zhao, X. & Drlica, K. Reactive oxygen species and the bacterial response to lethal stress. Curr. 
Opin. Microbiol. 21, 1–6 (2014). 
237. Zhao, X., Hong, Y. & Drlica, K. Moving forward with reactive oxygen species involvement in 
antimicrobial lethality. J. Antimicrob. Chemother. 70, 639–642 (2015). 
238. Wu, Y., Vulić, M., Keren, I. & Lewis, K. Role of oxidative stress in persister tolerance. Antimicrob. 
Agents Chemother. 56, 4922–4926 (2012). 
239. Storz, G. & Altuvia, S. B. T.-M. in E. in Oxygen Radicals in Biological Systems Part D 234, 217–
223 (Academic Press, 1994). 
240. Yoon, S. J., Park, J. E., Yang, J.-H. & Park, J.-W. OxyR regulon controls lipid peroxidation-
mediated oxidative stress in Escherichia coli. J. Biochem. Mol. Biol. 35, 297–301 (2002). 
241. Wei, Q. et al. Global regulation of gene expression by OxyR in an important human 
opportunistic pathogen. Nucleic Acids Res. 40, 4320–4333 (2012). 
242. Fischer, H. M. Genetic regulation of nitrogen fixation in rhizobia. Microbiol. Rev. 58, 352–386 
(1994). 
243. Farhana, A., Saini, V., Kumar, A., Lancaster, J. R. & Steyn, A. J. C. Environmental Heme-Based 
Sensor Proteins: Implications for Understanding Bacterial Pathogenesis. Antioxid. Redox Signal. 
17, 1232–1245 (2012). 
244. Taabazuing, C. Y., Hangasky, J. A. & Knapp, M. J. Oxygen Sensing Strategies in Mammals and 
Bacteria. J. Inorg. Biochem. 133, 63–72 (2014). 
245. Sheplock, R., Recinos, D. A., Mackow, N., Dietrich, L. E. P. & Chander, M. Species-specific 
residues calibrate SoxR sensitivity to redox-active molecules. Mol. Microbiol. 87, 368–381 
(2013). 
246. Semchyshyn, H., Bagnyukova, T. & Lushchak, V. Involvement of soxRS regulon in response of 
Escherichia coli to oxidative stress induced by hydrogen peroxide. Biochemistry 70, 1238–44 
(2005). 
247. Crack, J. C., Le Brun, N. E., Thomson, A. J., Green, J. & Jervis, A. J. in Globins and Other Nitric 
Oxide-Reactive Proteins, Part B (ed. Poole, R. K. B. T.-M. in E.) 437, 191–209 (Academic Press, 
2008). 
248. Myers, K. S. et al. Genome-scale Analysis of Escherichia coli FNR Reveals Complex Features of 
Transcription Factor Binding. PLoS Genet. 9, e1003565 (2013). 
249. Morales, E. H. et al. Probing the ArcA regulon under aerobic/ROS conditions in Salmonella 
enterica serovar Typhimurium. BMC Genomics 14, 626 (2013). 
250. Evans, M. R. et al. Analysis of the ArcA regulon in anaerobically grown Salmonella enterica sv. 
Typhimurium. BMC Microbiol. 11, 58 (2011). 
251. Sivaramakrishnan, S. & De Montellano, P. R. O. The DosS-DosT/DosR Mycobacterial Sensor 
System. Biosensors 3, 259–282 (2013). 
252. Mehra, S. et al. The DosR Regulon Modulates Adaptive Immunity and Is Essential for 
Mycobacterium tuberculosis Persistence. Am. J. Respir. Crit. Care Med. 191, 1185–1196 (2015). 
253. Hudock, T. A. et al. Hypoxia Sensing and Persistence Genes Are Expressed during the 
198 
 
Intragranulomatous Survival of Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Biol. 56, 
637–647 (2017). 
254. Mishra, S. & Imlay, J. Why do bacteria use so many enzymes to scavenge hydrogen peroxide? 
Arch. Biochem. Biophys. 525, 145–160 (2012). 
255. Seaver, L. C. & Imlay, J. A. Alkyl Hydroperoxide Reductase Is the Primary Scavenger of 
Endogenous Hydrogen Peroxide in Escherichia coli. J. Bacteriol. 183, 7173–7181 (2001). 
256. Cambier, C. J., Falkow, S. & Ramakrishnan, L. Host Evasion and Exploitation Schemes of 
Mycobacterium tuberculosis. Cell 159, 1497–1509 (2014). 
257. Kaufmann, S. H. E. & Dorhoi, A. Inflammation in tuberculosis: interactions, imbalances and 
interventions. Curr. Opin. Immunol. 25, 441–449 (2013). 
258. Carlioz, A. & Touati, D. Isolation of superoxide dismutase mutants in Escherichia coli: is 
superoxide dismutase necessary for aerobic life? EMBO J. 5, 623–630 (1986). 
259. Loewen, P. C. Isolation of catalase-deficient Escherichia coli mutants and genetic mapping of 
katE, a locus that affects catalase activity. J. Bacteriol. 157, 622–626 (1984). 
260. Saini, V. et al. Ergothioneine Maintains Redox and Bioenergetic Homeostasis Essential for Drug 
Susceptibility and Virulence of Mycobacterium tuberculosis. Cell Rep. 14, 572–585 (2016). 
261. Lamprecht, D. A. et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against 
itself. Nat. Commun. 7, (2016). 
262. Richard-Greenblatt, M. et al. Regulation of ergothioneine biosynthesis and its effect on 
Mycobacterium tuberculosis growth and infectivity. J. Biol. Chem. 290, 23064–23076 (2015). 
263. Singh, A. et al. Mycobacterium tuberculosis WhiB3 responds to O(2) and nitric oxide via its 
[4Fe-4S] cluster and is essential for nutrient starvation survival. Proc. Natl. Acad. Sci. U. S. A. 
104, 11562–11567 (2007). 
264. Trivedi, A., Singh, N., Bhat, S. A., Gupta, P. & Kumar, A. in Advances in Microbial Physiology (ed. 
Poole, R. K. B. T.-A. in M. P.) 60, 263–324 (Academic Press, 2012). 
265. Brynildsen, M. P., Winkler, J. A., Spina, C. S., MacDonald, I. C. & Collins, J. J. Potentiating 
antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat. 
Biotechnol. 31, 160–165 (2013). 
266. Siddens, L. K., Krueger, S. K., Henderson, M. C. & Williams, D. E. Mammalian Flavin-Containing 
Monooxygenase (FMO) as a Source of Hydrogen Peroxide. Biochem. Pharmacol. 89, 141–147 
(2014). 
267. Vilchèze, C. et al. Enhanced respiration prevents drug tolerance and drug resistance in 
Mycobacterium tuberculosis. 114, 4495–4500 (2017). 
268. Raj, L. et al. Selective killing of cancer cells with a small molecule targeting stress response to 
ROS. Nature 475, 231–234 (2011). 
269. Fang, F. C. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. 
Nat. Rev. Microbiol. 2, 820 (2004). 
270. Korshunov, S. S. & Imlay, J. A. A potential role for periplasmic superoxide dismutase in blocking 
the penetration of external superoxide into the cytosol of Gram-negative bacteria. Mol. 
Microbiol. 43, 95–106 (2002). 
271. Imlay, J. A. How oxygen damages microbes: Oxygen tolerance and obligate anaerobiosis. 
199 
 
Advances in Microbial Physiology 46, 111–153 (2002). 
272. Sellamuthu, S., Singh, M., Kumar, A. & Singh, S. K. Type-II NADH Dehydrogenase (NDH-2): a 
promising therapeutic target for antitubercular and antibacterial drug discovery. Expert Opin. 
Ther. Targets 21, 559–570 (2017). 
273. Yano, T. et al. Reduction of clofazimine by mycobacterial type 2 NADH: Quinone 
Oxidoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species. 
J. Biol. Chem. 286, 10276–10287 (2011). 
274. Wolucka, B. A. Biosynthesis of D-arabinose in mycobacteria - A novel bacterial pathway with 
implications for antimycobacterial therapy. FEBS Journal 275, 2691–2711 (2008). 
275. Piton, J., Foo, C. S.-Y. & Cole, S. T. Structural studies of Mycobacterium tuberculosis DprE1 
interacting with its inhibitors. Drug Discov. Today 22, 526–533 (2017). 
276. Haynes, R. K. et al. Reactions of Antimalarial Peroxides with Each of Leucomethylene Blue and 
Dihydroflavins: Flavin Reductase and the Cofactor Model Exemplified. ChemMedChem 6, 279–
291 (2010). 
277. Haynes, R. . et al. Interactions between Artemisinins and other Antimalarial Drugs in Relation 
to the Cofactor Model—A Unifying Proposal for Drug Action. ChemMedChem 7, 2204–2226 
(2012). 
278. Haynes, R. K., Cheu, K.-W., N’Da, D., Coghi, P. & Monti, D. Considerations on the mechanism of 
action of artemisinin antimalarials: part 1--the ‘carbon radical’ and ‘heme’ hypotheses. 
Infectious disorders drug targets 13, (2013). 
279. Haynes, R. K. et al. Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: 
Relationship with flavoenzyme function and antimalarial mechanism of action. ChemMedChem 
5, 1282–1299 (2010). 
280. Buchholz, K. et al. Interactions of methylene blue with human disulfide reductases and their 
orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52, 183–191 (2008). 
281. WHO. Global Tuberculosis Report 2017 (2017). 
282. Mitchison, D. A. & Davies, G. R. Assessment of the Efficacy of New Anti-Tuberculosis Drugs. 
Open Infect. Dis. J. 2, 59–76 (2008). 
283. Hollstein, U. Actinomycin. Chemistry and mechanism of action. Chem. Rev. 74, 625–652 (1974). 
284. Okafor, C. O. Synthesis, properties and uses of angular phenoxazines. Dye. Pigment. 7, 103–
131 (1986). 
285. Katz, E. & Weissbach, H. Biosynthesis of the Actinomycin Chromophore; Enzymatic Conversion 
of 4-Methyl-3-hydroxyanthranilic Acid to Actinocin. J. Biol. Chem. 237, 3–6 (1962). 
286. Viveiros, M. & Amaral, L. Enhancement of antibiotic activity against poly-drug resistant 
Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 17, 225–228 (2001). 
287. Iwata, A., Yamaguchi, T., Sato, K., Izumi, R. & Tomoda, A. Antiviral activity of 2-amino-4,4α-
dihydro-4α-7-dimethyl-3H-phenoxazine-3-one on poliovirus. Tohoku J. Exp. Med. 200, 161–
165 (2003). 
288. Abe, A., Yamane, M. & Tomoda, A. Prevention of growth of human lung carcinoma cells and 
induction of apoptosis by a novel phenoxazinone, 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-
phenoxazine-3-one. Anticancer. Drugs 12, (2001). 
200 
 
289. Shimamoto, T., Tomoda, A., Ishida, R. & Ohyashiki, K. Antitumor effects of a novel phenoxazine 
derivative on human leukemia cell lines in vitro and in vivo. Clin. Cancer Res. 7, 704–708 (2001). 
290. Bolognese, A. et al. Antitumor Agents. 1. Synthesis, Biological Evaluation, and Molecular 
Modeling of 5H-Pyrido[3,2-a]phenoxazin-5-one, a Compound with Potent Antiproliferative 
Activity. J. Med. Chem. 45, 5205–5216 (2002). 
291. Shimizu, S. et al. Phenoxazine compounds produced by the reactions with bovine hemoglobin 
show antimicrobial activity against non-tuberculosis mycobacteria. Tohoku J. Exp. Med. 203, 
47–52 (2004). 
292. Foley, J. W., Song, X., Demidova, T. N., Jilal, F. & Hamblin, M. R. Synthesis and properties of 
benzo[a]phenoxazinium chalcogen analogues as novel broad-spectrum antimicrobial 
photosensitizers. J. Med. Chem. 49, 5291–5299 (2006). 
293. Frade, V. H. J., Sousa, M. J., Moura, J. C. V. P. & Gonçalves, M. S. T. Synthesis of naphtho[2,3-
a]phenoxazinium chlorides: Structure–activity relationships of these heterocycles and 
benzo[a]phenoxazinium chlorides as new antimicrobials. Bioorg. Med. Chem. 16, 3274–3282 
(2008). 
294. Crossley, M. L., Turner, R. J., Hofmann, C. M., Dreisbach, P. F. & Parker, R. P. Chemotherapeutic 
Dyes. II. 5-Arylamino-9-dialkylaminobenzo[a]phenoxazines. J. Am. Chem. Soc. 74, 578–584 
(1952). 
295. Crossley, M. L., Hofmann, C. M. & Dreisbach, P. F. Chemotherapeutic Dyes. III. 5-
Heterocyclicamino-9-dialkylaminobenzo[a]phenoxazines. J. Am. Chem. Soc. 74, 584–586 
(1952). 
296. Goldstein, H. & Ludwig-Semelitch, Z. No Title. Helv. Chima Acta 2, 655 (1919). 
297. Girard, A. Novel derivatives phenoxazine and processes for their preparation. United States 
Pat. Off. (1962). 
298. Rahavendran, S. V. & Karnes, H. T. Application of Rhodamine 800 for Reversed Phase Liquid 
Chromatographic Detection Using Visible Diode Laser-Induced Fluorescence. Anal. Chem. 68, 
3763–3768 (1996). 
299. Jose, J. & Burgess, K. Benzophenoxazine-based fluorescent dyes for labeling biomolecules. 
Tetrahedron 62, 11021–11037 (2006). 
300. Stužka, V., Šimánek, V. & Stránský, Z. Infra-red spectroscopy of benzo(α)phenoxazines. 
Spectrochim. Acta Part A Mol. Spectrosc. 23, 2175–2183 (1967). 
301. William Lown, J. Anthracycline and anthraquinone anticancer agents: Current status and recent 
developments. Pharmacol. Ther. 60, 185–214 (1993). 
302. Alberti, A. et al. Antitumor Agents 4. Characterization of Free Radicals Produced during 
Reduction of the Antitumor Drug 5H-Pyridophenoxazin-5-one:  An EPR Study. Biochemistry 42, 
11924–11931 (2003). 
303. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G. & Monks, T. J. Role of Quinones in 
Toxicology. Chem. Res. Toxicol. 13, 135–160 (2000). 
304. Motohashi, N., Mitscher, A. . & Meyer, R. ChemInform Abstract: Potential Antitumor 
Phenoxazines. ChemInform 22, (2010). 




306. Kristiansen, J. E. et al. Phenothiazines as a solution for multidrug resistant tuberculosis: From 
the origin to present. Int Microbiol 18, 1–12 (2015). 
307. Boshoff, H. I. M. et al. The transcriptional responses of Mycobacterium tuberculosis to 
inhibitors of metabolism. Novel insights into drug mechanisms of action. J. Biol. Chem. 279, 
40174–40184 (2004). 
308. Grzegorzewicz, A. E. et al. Assembling of the Mycobacterium tuberculosis cell wall core. J. Biol. 
Chem. 291, 18867–18879 (2016). 
309. Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs Jr., W. R. & Sacchettini, J. C. Modification 
of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science. 279, 98–
102 (1998). 
310. World Health Organization, W. H. & Global Tuberculosis Programme. WHO treatment 
guidelines for drug-resistant tuberculosis : 2016 update. Who 56 (2016). 
311. Chien, J. Y. et al. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. 
Clin. Microbiol. Infect. 21, 59–68 (2015). 
312. Menzies, D. et al. Standardized Treatment of Active Tuberculosis in Patients with Previous 
Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis. 
PLOS Med. 6, e1000150 (2009). 
313. Haas, W. H. et al. Molecular analysis of katG gene mutations in strains of Mycobacterium 
tuberculosis complex from Africa. Antimicrob. Agents Chemother. 41, 1601–1603 (1997). 
314. Scior, T., Meneses Morales, I., Garcés Eisele, S. J., Domeyer, D. & Laufer, S. Antitubercular 
isoniazid and drug resistance of Mycobacterium tuberculosis - A review. Arch. Pharm. 
(Weinheim). 335, 511–525 (2003). 
315. Jenkins, H. E., Zignol, M. & Cohen, T. Quantifying the burden and trends of isoniazid resistant 
tuberculosis, 1994-2009. PLoS One 6, (2011). 
316. Hu, Y.-Q. et al. Isoniazid derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 133, 
255–267 (2017). 
317. Biradha, K., Sarkar, M. & Rajput, L. Crystal engineering of coordination polymers using 4,4’-
bipyridine as a bond between transition metal atoms. Chem. Commun. (Camb).0, 4169–4179 
(2006). 
318. van Agtmael, M. A., Eggelte, T. A. & van Boxtel, C. J. Artemisinin drugs in the treatment of 
malaria: from medicinal herb to registered medication. Trends Pharmacol. Sci. 20, 199–205 
(1999). 
319. Zheng, H. et al. Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence. 
Nat. Chem. Biol. 13, 218 (2016). 
320. Zhou, F.-W. et al. Design, synthesis, and biological evaluation of dihydroartemisinin–
fluoroquinolone conjugates as a novel type of potential antitubercular agents. Bioorg. Med. 
Chem. Lett. 24, 1912–1917 (2014). 
321. Morake, M. et al. Preliminary Evaluation of Artemisinin–Cholesterol Conjugates as Potential 
Drugs for the Treatment of Intractable Forms of Malaria and Tuberculosis. ChemMedChem 13, 
67–77 (2018). 
322. Miller, M. J. et al. Design, Synthesis and Study of a Mycobactin-artemisinin Conjugate that has 




323. Hatcher, H. C., Singh, R. N., Torti, F. M. & Torti, S. V. Synthetic and natural iron chelators: 
therapeutic potential and clinical use. Future Med. Chem. 1, 1643–1670 (2009). 
324. Choi, W. H. Novel Pharmacological Activity of Artesunate and Artemisinin: Their Potential as 
Anti-Tubercular Agents. J. Clin. Med. 6, 30 (2017). 
325. Fang, Z., Sampson, S. L., Warren, R. M., Gey Van Pittius, N. C. & Newton-Foot, M. Iron 
acquisition strategies in mycobacteria. Tuberculosis 95, 123–130 (2015). 
326. Ratledge, C. Iron, mycobacteria and tuberculosis. in Tuberculosis 84, 110–130 (2004). 
327. Banerjee, S., Farhana, A., Ehtesham, N. Z. & Hasnain, S. E. Iron acquisition, assimilation and 
regulation in mycobacteria. Infection, Genetics and Evolution 11, 825–838 (2011). 
328. Addla, D. et al. Rational design, synthesis and antitubercular evaluation of novel 2-
(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids. Bioorg. Med. Chem. Lett. 24, 233–236 
(2014). 
329. Menendez, C. et al. Chemical synthesis and biological evaluation of triazole derivatives as 
inhibitors of InhA and antituberculosis agents. Eur. J. Med. Chem. 52, 275–283 (2012). 
330. Keri, R. S., Patil, S. A., Budagumpi, S. & Nagaraja, B. M. Triazole: A Promising Antitubercular 
Agent. Chem. Biol. Drug Des. 86, 410–423 (2015). 
331. Taylor, M. A. & Bartram, D. J. The history of decoquinate in the control of coccidial infections 
in ruminants. J. Vet. Pharmacol. Ther. 35, 417–427 (2012). 
332. Andriole, V. T. The quinolones: past, present, and future. Clin. Infect. Dis. 41 Suppl 2, S113-9 
(2005). 
333. Aubry, A., Pan, X. S., Fisher, L. M., Jarlier, V. & Cambau, E. Mycobacterium tuberculosis DNA 
Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity. 
Antimicrob. Agents Chemother. 48, 1281–1288 (2004). 
334. Onodera, Y., Tanaka, M. & Sato, K. Inhibitory activity of quinolones against DNA gyrase of 
Mycobacterium tuberculosis. J Antimicrob Chemother 47, 447–450 (2001). 
335. Gay, J. D., DeYoung, D. R. & Roberts, G. D. In vitro activities of norfloxacin and ciprofloxacin 
against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. 
kansasii. Antimicrob. Agents Chemother. 26, 94–96 (1984). 
336. Beteck, R. M. et al. Straightforward conversion of decoquinate into inexpensive tractable new 
derivatives with significant antimalarial activities. Bioorganic Med. Chem. Lett. 26, 3006–3009 
(2016). 
337. Crosby, N. in Determination Of Veterinary Residues In Food, 1st ed. ISBN: 9781845698171 
(Cambridge: Woodhead Publishing Ltd, 1997). 
338. Mosmann, T. Rapid Colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assay. J. Immunol. Methods 65, 55–63 (1983). 
339. Sieuwerts, A. M., Klijn, J. G. M., Peters, H. A. & Foekens, J. A. The MTT Tetrazolium Salt Assay 
Scrutinized: How to Use this Assay Reliably to Measure Metabolic Activity of Cell Cultures in 
vitro for the Assessment of Growth Characteristics, IC50-Values and Cell Survival. Clin. Chem. 
Lab. Med. 33, 813–824 (1995). 
340. Ammerman, N. C., Beier-Sexton, M. & Azad, A. F. Growth and Maintenance of Vero Cell Lines. 
203 
 
Curr. Protoc. Microbiol., Appendix-4E (2008). 
341. Ioerger, T. R. et al. Variation among genome sequences of H37Rv strains of Mycobacterium 
tuberculosis from multiple laboratories. J. Bacteriol. 192, 3645–3653 (2010). 
342. Takaki, K., Ramakrishnan, L. & Basu, S. A zebrafish model for ocular tuberculosis. PLoS One 13, 
e0194982 (2018). 
343. FDA. Guidance for Industry Bioanalytical Method Validation Guidance for Industry Bioanalytical 
Method Validation. Bioanalytical method validation (2018). 
344. Strober, W. Trypan Blue Exclusion Test of Cell Viability. Curr. Protoc. Immunol. Appendix 3, 
(2001). 
345. Chen, P., Gearhart, J., Protopopova, M., Einck, L. & Nacy, C. A. Synergistic interactions of SQ109, 
a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother. 
58, 332–337 (2006). 
346. Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. 
Antimicrob. Chemother. 52, 1–1 (2003). 
347. Hodgson, J. ADMET—turning chemicals into drugs. Nat. Biotechnol. 19, 722 (2001). 
348. Zhang, D., Luo, G., Ding, X. & Lu, C. Preclinical experimental models of drug metabolism and 
disposition in drug discovery and development. Acta Pharm. Sin. B 2, 549–561 (2012). 
349. Yu, H. & Adedoyin, A. ADME–Tox in drug discovery: integration of experimental and 
computational technologies. Drug Discov. Today 8, 852–861 (2003). 
350. Vrbanac, J. & Slauter, R. in A Comprehensive Guide to Toxicology in Preclinical Drug 
Development 3–30 (Academic Press, 2013). 
351. Kerns, E. H., Di, L. & Carter, G. T. In vitro solubility assays in drug discovery. Curr. Drug Metab. 
9, 879–85 (Academic Press, 2008). 
352. Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and Methods 56–85. 
(Academic Press, 2008). 
353. Alsenz, J. & Kansy, M. High throughput solubility measurement in drug discovery and 
development. Adv. Drug Deliv. Rev. 59, 546–567 (2007). 
354. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. 
Pharmacol. Toxicol. Methods 44, 235–249 (2000). 
355. Elder, D. & Holm, R. Aqueous solubility: Simple predictive methods (in silico, in vitro and bio-
relevant approaches). International Journal of Pharmaceutics 453, 3–11 (2013). 
356. Dressman, J. B., Vertzoni, M., Goumas, K. & Reppas, C. Estimating drug solubility in the 
gastrointestinal tract. Advanced Drug Delivery Reviews 59, 591–602 (2007). 
357. Clarysse, S., Brouwers, J., Tack, J., Annaert, P. & Augustijns, P. Intestinal drug solubility 
estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal 
fluids. Eur. J. Pharm. Sci. 43, 260–269 (2011). 
358. Di, L. & Kerns, E. H. in Drug-like properties : concepts, structure design and methods from ADME 
to toxicity optimization 39–50 (Academic Press, 2016). 
359. Kerns, E. H., Di, L., Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and 
Methods 260–270 (Academic Press, 2008). 
204 
 
360. Kerns, E. H., Di, L., Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and 
Methods 43–47 (Academic Press, 2008). 
361. Kerns, E. H., Di, L., Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and 
Methods 86–99 (Academic Press, 2008). 
362. Sugano, K. et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat. 
Rev. Drug Discov. 9, 597 (2010). 
363. Brodin, B., Steffansen, B. & Nielsen, C. U. Passive diffusion of drug substances: the concepts of 
flux and permeability. Molecular Biopharmaceutics (Pharmaceutical Press, 2010). 
364. Artursson, P., Neuhoff, S., Matsson, P. & Tavelin, S. Passive Permeability and Active Transport 
Models for the Prediction of Oral Absorption. Compr. Med. Chem. II. 259–278 (2007). 
365. Di, L. & Kerns, E. H. Profiling drug-like properties in discovery research. Current Opinion in 
Chemical Biology 7, 402–408 (Academic Press, 2003). 
366. Balimane, P. & Chong, S. A critique of cell culture models for intestinal permeability. Drug 
Discov. Today 10, 335–343 (2005). 
367. Hubatsch, I., Ragnarsson, E. G. E. & Artursson, P. Determination of drug permeability and 
prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2, 2111–2119 (2007). 
368. Nagahara, N., Tavelin, S. & Artursson, P. Contribution of the paracellular route to the pH-
dependent epithelial permeability to cationic drugs. J. Pharm. Sci. 93, 2972–2984 (2004). 
369. Kerns, E. H., Di, L., Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and 
Methods 287–298 (Academic Press, 2008). 
370. Arnott, J. A. & Planey, S. L. The influence of lipophilicity in drug discovery and design. Expert 
Opin. Drug Discov. 7, 863–875 (2012). 
371. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P. J. Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development setting. 
Adv. Drug Deliv. Rev. 23, 3–25 (1997). 
372. Smith, D. A., Beaumont, K., Maurer, T. S. & Di, L. Volume of Distribution in Drug Design. J. Med. 
Chem. 58, 5691–5698 (2015). 
373. Dasgupta, A. in Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, 
Physiological Conditions, and Pharmacogenomics 71–100 (Elsevier Press Inc, 2016). 
374. Fanali, G. et al. Human serum albumin: From bench to bedside. Mol. Aspects Med. 33, 209–290 
(2012). 
375. Schmidt, S., Gonzalez, D. & Derendorf, H. Significance of Protein Binding in Pharmacokinetics 
and Pharmacodynamics. J. Pharm. Sci. 99, 1107–1122 (2010). 
376. Heuberger, J., Schmidt, S. & Derendorf, H. When is Protein Binding Important? J. Pharm. Sci. 
102, 3458–3467 (2013). 
377. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal 
intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding 
to microsomes. Drug Metab. Dispos. 27, 1350–1359 (1999). 
378. Obach, R. S. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic 
clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and 
propranolol. Drug Metab. Dispos. 25, 1359–1369 (1997). 
205 
 
379. Waters, N. J., Jones, R., Williams, G. & Sohal, B. Validation of a Rapid Equilibrium Dialysis 
Approach for the Measurement of Plasma Protein Binding. J. Pharm. Sci. 97, 4586–4595 (2008). 
380. Lee, K. J. et al. Modulation of nonspecific binding in ultrafiltration protein binding studies. 
Pharm. Res. 20, 1015–1021 (2003). 
381. Srikanth, C. H., Chaira, T., Sampathi, S., V. B., S. & Bambal, R. B. Correlation of in vitro and in 
vivo plasma protein binding using ultracentrifugation and UPLC-tandem mass spectrometry. 
Analyst 138, 6106 (2013). 
382. Kerns, E. H., Di, L., Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and 
Methods 137–II (Academic Press, 2008). 
383. Fowler, S. & Zhang, H. In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 
Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug 
Interactions. AAPS J. 10, 410–424 (2008). 
384. Kerns, E. H., Di, L., Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and 
Methods 329–347 (Academic Press, 2008). 
385. Meyer, M. R., Schütz, A. & Maurer, H. H. Contribution of human esterases to the metabolism 
of selected drugs of abuse. Toxicol. Lett. 232, 159–166 (2015). 
386. Di, L. & Kerns, E. H. Biological assay challenges from compound solubility: strategies for 
bioassay optimization. Drug Discovery Today 11, 446–451 (2006). 
387. Beaumont, K. & Smith, D. a. Does human pharmacokinetic prediction add significant value to 
compound selection in drug discovery research? Curr. Opin. Drug Discov. Devel. 12, 61–71 
(2009). 
388. Kleiber, M. Body size and metabolism. Hilgardia 6(11), 315–353 (1932). 
389. McGinnity, D. F., Collington, J., Austin, R. P. & Riley, R. J. Evaluation of human pharmacokinetics, 
therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8, 463–
479 (2007). 
390. Page, K. M. Validation of Early Human Dose Prediction: A Key Metric for Compound Progression 
in Drug Discovery. Mol. Pharm. 13, 609–620 (2016). 
391. Hill, A. P. & Young, R. J. Getting physical in drug discovery: a contemporary perspective on 
solubility and hydrophobicity. Drug Discov. Today 15, 648–655 (2010). 
392. Lawrence, N. University of Cape Town, H3D Standard Operating Procedure- Kinetic solubility. 
5, (2015). 
393. Li, A. P. Preclinical in vitro screening assays for drug-like properties. Drug Discov. Today 
Technol. 2, 179–185 (2005). 
394. Cardot, J.-M., Garcia Arieta, A., Paixao, P., Tasevska, I. & Davit, B. Implementing the 
Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, 
Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches. AAPS 
J. 18, 1039–1046 (2016). 
395. Amidon, G. L., Lennernäs, H., Shah, V. P. & Crison, J. R. A Theoretical Basis for a 
Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and 
in Vivo Bioavailability. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 12, 413–420 (1995). 
396. Becker, C. et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: 
206 
 
Ethambutol Dihydrochloride. J. Pharm. Sci. 97, 1350–1360 (2008). 
397. Becker, C. et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: 
Isoniazid. J. Pharm. Sci. 96, 522–531 (2007). 
398. WHO. Biopharmaceutics Classification System ( BCS ) -based biowaiver applications : anti-
tuberculosis medicines. WHO Prequalification Med. Program. 96, (2009). 
399. Becker, C. et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: 
Pyrazinamide. J. Pharm. Sci. 97, 3709–3720 (2008). 
400. Monash Institute of Pharmaceutical Sciences, Parkville, V. 3052 & Australia. Centre for Drug 
Candidate Optimisation (CDCO) Standard Operating Procedure. 
401. Zuniga, E. S., Early, J. & Parish, T. The future for early-stage tuberculosis drug discovery. Future 
Microbiol. 10, 217–229 (2015). 
402. Vjecha, M. J., Tiberi, S. & Zumla, A. Accelerating the development of therapeutic strategies for 
drug-resistant tuberculosis. Nat. Rev. Drug Discov. 17, 607–608 (2018). 
403. Mikušová, K. & Ekins, S. Learning from the past for TB drug discovery in the future. Drug Discov. 
Today 22, 534–545 (2017). 
404. Korfmacher, W. A. Foundation review: Principles and applications of LC-MS in new drug 
discovery. Drug Discov. Today 10, 1357–1367 (2005). 
405. Holčapek, M., Jirásko, R. & Lísa, M. Recent developments in liquid chromatography–mass 
spectrometry and related techniques. J. Chromatogr. A 1259, 3–15 (2012). 
406. Espada, A., Molina-Martin, M., Dage, J. & Kuo, M.-S. Application of LC/MS and related 
techniques to high-throughput drug discovery. Drug Discov. Today 13, 417–423 (2008). 
407. Ackermann, B. L. & Murphy, M. J. B. and A. T. Recent Advances in use of LC/MS/MS for 
Quantitative High-Throughput Bioanalytical Support of Drug Discovery. Current Topics in 
Medicinal Chemistry 2, 53–66 (2002). 
408. Xu, X., Lan, J. & Korfmacher, W. A. Rapid LC/MS/MS Method Development for Drug Discovery. 
Anal. Chem. 77, 389 A-394 A (2005). 
409. Watt, A. P., Mortishire-Smith, R. J., Gerhard, U. & Thomas, S. R. Metabolite identification in 
drug discovery. Curr. Opin. Drug Discov. Devel. 6, 57–65 (2003). 
410. Chen, G., Pramanik, B. N., Liu, Y. & Mirza, U. A. Applications of LC/MS in structure identifications 
of small molecules and proteins in drug discovery. J. mass Spectrom. 42, 279–287 (2007). 
411. March, R. E. Quadrupole ion traps. Mass Spectrom. Rev. 28, 961–989 (2009). 
412. Adaway, J. E. & Keevil, B. G. Therapeutic drug monitoring and LC–MS/MS. J. Chromatogr. B 
883–884, 33–49 (2012). 
413. Iwamoto, N. & Shimada, T. Recent advances in mass spectrometry-based approaches for 
proteomics and biologics: Great contribution for developing therapeutic antibodies. 
Pharmacol. Ther. 185, 147–154 (2018). 
414. Abdel-Rehim, M. & Jagerdeo, E. in J Cazes: Encyclopedia of Chromatography 634–644 (CRC 
Press, 2010). 
415. van den Ouweland, J. M. W. & Kema, I. P. The role of liquid chromatography–tandem mass 
spectrometry in the clinical laboratory. J. Chromatogr. B 883–884, 18–32 (2012). 
207 
 
416. Reid, G. L. et al. REVERSED-PHASE LIQUID CHROMATOGRAPHIC METHOD DEVELOPMENT IN AN 
ANALYTICAL QUALITY BY DESIGN FRAMEWORK. J. Liq. Chromatogr. Relat. Technol. 36, 2612–
2638 (2013). 
417. Agilent Technologies. The LC Handbook. (2015). 
418. Schug, K. A. The Role of Selectivity in Liquid Chromatography Method Development. Innovators 
in Chromatography (2015). Accessed 18 June 2018 
419. Moein, M. M., El Beqqali, A. & Abdel-Rehim, M. Bioanalytical method development and 
validation: Critical concepts and strategies. J. Chromatogr. B 1043, 3–11 (2017). 
420. Peters, F. T., Drummer, O. H. & Musshoff, F. Validation of new methods. Forensic Sci. Int. 165, 
216–224 (2007). 
421. European Medicines Agency, London. Guideline on bioanalytical method validation (2011) 
Committee for Medicinal Products for Human use. (2015). 
422. Blume, H. et al. Workshop/conference report on EMA draft guideline on validation of 
bioanalytical methods. Eur. J. Pharm. Sci. 42, 300–305 (2011). 
423. Stevenson, L. et al. 2013 White Paper on recent issues in bioanalysis:‘hybrid’–the best of LBA 
and LCMS. Bioanalysis 5, 2903–2918 (2013). 
424. Hughes, N. C., Wong, E. Y. K., Fan, J. & Bajaj, N. Determination of carryover and contamination 
for mass spectrometry-based chromatographic assays. AAPS J. 9, E353–E360 (2007). 
425. Whitmire, M., Ammerman, J. & Lisio, P. de. LC-MS/MS Bioanalysis Method Development, 
Validation, and Sample Analysis: Points to Consider When Conducting Nonclinical and Clinical 
Studies in Accordance with Current Regulatory Guidances. J. Anal. Bioanal. Tech. 1, (2011). 
426. Matuszewski, B. K., Constanzer, M. L. & Chavez-Eng, C. M. Strategies for the assessment of 
matrix effect in quantitative bioanalytical methods based on HPLC− MS/MS. Anal. Chem. 75, 
3019–3030 (2003). 
427. Annesley, T. M. Ion suppression in mass spectrometry. Clin. Chem. 49, 1041–1044 (2003). 
428. George, R. et al. Enhancement and Suppression of Ionization in Drug Analysis Using HPLC-
MS/MS in Support of Therapeutic Drug Monitoring: A Review of Current Knowledge of Its 
Minimization and Assessment. Ther. Drug Monit. 40, 1–8 (2018). 
429. Matuszewski, B. K. Standard line slopes as a measure of a relative matrix effect in quantitative 
HPLC–MS bioanalysis. J. Chromatogr. B 830, 293–300 (2006). 
430. Roepstorff, P. & Fohlman, J. Letter to the editors. Biomed. Mass Spectrom. 11, 601 (1984). 
431. Van Eeckhaut, A., Lanckmans, K., Sarre, S., Smolders, I. & Michotte, Y. Validation of 
bioanalytical LC–MS/MS assays: evaluation of matrix effects. J. Chromatogr. B 877, 2198–2207 
(2009). 
432. Caban, M., Migowska, N., Stepnowski, P., Kwiatkowski, M. & Kumirska, J. Matrix effects and 
recovery calculations in analyses of pharmaceuticals based on the determination of β-blockers 
and β-agonists in environmental samples. J. Chromatogr. A 1258, 117–127 (2012). 
433. Marchi, I., Rudaz, S. & Veuthey, J.-L. Sample preparation development and matrix effects 
evaluation for multianalyte determination in urine. J. Pharm. Biomed. Anal. 49, 459–467 
(2009). 
434. Clark, S., Hall, Y. & Williams, A. Animal models of tuberculosis: guinea pigs. Cold Spring Harb. 
208 
 
Perspect. Med. 5, a018572 (2014). 
435. Freires, I. A., Sardi, J. de C. O., de Castro, R. D. & Rosalen, P. L. Alternative animal and non-
animal models for drug discovery and development: bonus or burden? Pharm. Res. 34, 681–
686 (2017). 
436. Cooper, A. M. Mouse Model of Tuberculosis. Cold Spring Harb. Perspect. Med. 5, a018556 
(2015). 
437. Waters, W. et al. Tuberculosis immunity: opportunities from studies with cattle. Clin. Dev. 
Immunol. 2011, (2010). 
438. Myllymäki, H., Niskanen, M., Oksanen, K. E. & Rämet, M. Animal models in tuberculosis 
research–where is the beef? Expert Opin. Drug Discov. 10, 871–883 (2015). 
439. Peng, X., Knouse, J. A. & Hernon, K. M. Rabbit models for studying human infectious diseases. 
Comp. Med. 65, 499–507 (2015). 
440. Phuah, J. et al. The Effects of B cell Depletion on early Mycobacterium tuberculosis infection in 
Cynomolgus Macaques. Infect. Immun.84, 1301-1311 (2016). 
441. Zhan, L., Tang, J., Sun, M. & Qin, C. Animal Models for Tuberculosis in Translational and 
Precision Medicine. Frontiers in Microbiology. 8, 717 (2017). 
442. Barry, C. E. The Death of the ‘Three Ms’. ACS Infect. Dis. 1, 578–579 (2016). 
443. Kramnik, I. & Beamer, G. Mouse models of human TB pathology: roles in the analysis of necrosis 
and the development of host-directed therapies. Semin. Immunopathol. 38, 221–237 (2016). 
444. Basaraba, R. J. & Hunter, R. L. Pathology of Tuberculosis: How the Pathology of Human 
Tuberculosis Informs and Directs Animal Models. Microbiol. Spectr. 5, (2017). 
445. Fonseca, K. L., Rodrigues, P. N. S., Olsson, I. A. S. & Saraiva, M. Experimental study of 
tuberculosis: From animal models to complex cell systems and organoids. PLOS Pathog. 13, 
e1006421 (2017). 
446. Orme, I. & Gonzalez‐Juarrero, M. Animal models of M. tuberculosis infection. Curr. Protoc. 
Microbiol. 7, 10A–5 (2017). 
447. Ordonez, A. A. et al. Mouse model of pulmonary cavitary tuberculosis and expression of matrix 
metalloproteinase-9. Dis. Model. Mech 9, 779 LP-788 (2016). 
448. Lanoix, J. P., Lenaerts, A. J. & Nuermberger, E. L. Heterogeneous disease progression and 
treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 8, 603–610. 
(2015). 
449. Lanoix, J.-P., Betoudji, F. & Nuermberger, E. Sterilizing activity of pyrazinamide in combination 
with first-line drugs in a C3HeB/FeJ mouse model of tuberculosis. Antimicrob. Agents 
Chemother. 60, AAC-02637 (2015). 
450. Cadena, A. M., Fortune, S. M. & Flynn, J. L. Heterogeneity in tuberculosis. Nat. Rev. Immunol. 
17, 691 (2017). 
451. Williams, K. et al. Sterilizing activities of novel combinations lacking first- and second-line drugs 
in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56, 3114–3120 (2012). 
452. Gabrielsson, J. & Weiner, D. in Computational Toxicology: Volume I (eds. Reisfeld, B. & Mayeno, 
A. N.) 377–389 (Humana Press, 2012). 
209 
 
453. Gabrielsson, J. & Weiner, D. Pharmacokinetic and pharmacodynamic data analysis: concepts 
and applications. 2, (CRC Press, 2001). 
454. Barry, C. E. The Death of the ‘Three Ms’. ACS Infectious Diseases 1, 578–579 (2016). 
455. Lyons, M. a, Reisfeld, B., Yang, R. S. & Lenaerts,  a J. A physiologically based pharmacokinetic 
model of rifampin in mice. Antimicrob Agents Chemother 57, 1763–1771 (2013). 
456. Ji, B. et al. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of 
tuberculosis in mice. Am. J. Respir. Crit. Care Med. 148, 1541–1546 (1993). 
457. Jayaram, R. et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model 
of tuberculosis. Antimicrob. Agents Chemother. 48, 2951–2957 (2004). 
458. Grosset, J. & Ji, B. in Experimental Chemotherapy of Mycobacterial Diseases BT (eds. 
Gangadharam, P. R. J. & Jenkins, P. A.) 51–97 (Springer US, 1998). 
459. Rouan, M. C. et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl 
metabolite in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56, 1444–1451 
(2012). 
460. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium 
tuberculosis. Science 307, 223–227 (2005). 
461. Swanson, R. V. et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse 
model of tuberculosis. Antimicrob. Agents Chemother. 59, 3042–3051 (2015). 
462. Siefert, H. M., Kohlsdorfer, C., Steinke, W. & Witt, A. Pharmacokinetics of the 8-
methoxyquinolone, moxifloxacin: tissue distribution in male rats. J. Antimicrob. Chemother.  
43, 61–67 (1999). 
463. Slatter, J. G. et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of 
linezolid in mouse, rat and dog. Xenobiotica 32, 907–924 (2002). 
464. Johnson, J. L. et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin 
and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10, 605–612 (2006). 
465. Almeida, D. et al. Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide 
Combination in a Mouse Model of Tuberculosis . Antimicrob. Agents Chemother. 53, 4178–
4184 (2009). 
466. Grosset, J., Truffot-Pernot, C., Lacroix, C. & Ji, B. Antagonism between isoniazid and the 
combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents 
Chemother. 36, 548–551 (1992). 
467. Nielsen, E. I., Cars, O. & Friberg, L. E. Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of 
Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose 
Optimization. Antimicrob. Agents Chemother. 55, 4619–4630 (2011). 
468. Dick, T. & Dartois, V. TB drug susceptibility is more than MIC. Nat. Microbiol. 3, 971–972 (2018). 
469. Hicks, N. D. et al. Clinically prevalent mutations in Mycobacterium tuberculosis alter propionate 
metabolism and mediate multidrug tolerance. Nat. Microbiol. 3, 1032–1042 (2018). 
470. Gonzalez, D., Schmidt, S. & Derendorf, H. Importance of Relating Efficacy Measures to Unbound 
Drug Concentrations for Anti-Infective Agents. Clin. Microbiol. Rev. 26, 274–288 (2013). 
471. Beer, J., Wagner, C. C. & Zeitlinger, M. Protein Binding of Antimicrobials: Methods for 
Quantification and for Investigation of its Impact on Bacterial Killing. AAPS J. 11, 1 (2009). 
210 
 
472. Zeitlinger, M. A. et al. Protein Binding: Do We Ever Learn? Antimicrob. Agents Chemother. 55, 
3067–3074 (2011). 
473. Diacon, A. H. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. 
N. Engl. J. Med. 371, 723–732 (2014). 
474. Pym, A. S. et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant 
tuberculosis. Eur. Respir. J. ERJ-00724 (2015). 
475. Borisov, S. E. et al. Effectiveness and safety of bedaquiline-containing regimens in the 
treatment of MDR-and XDR-TB: a multicentre study. Eur. Respir. J. 49, 1700387 (2017). 
476. Tang, S. et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, 
multicenter, randomized controlled study in China. Clin. Infect. Dis. 60, 1361–1367 (2015). 
477. Dalcolmo, M. et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: 
a nationwide report from Brazil. Eur. Respir. J. 49, 1602445 (2017). 
478. Padayatchi, N. et al. Clofazimine in the treatment of extensively drug-resistant tuberculosis 
with HIV coinfection in South Africa: a retrospective cohort study. J. Antimicrob. Chemother. 
69, 3103–3107 (2014). 
479. Ramakrishnan, K. et al. Serum zinc and albumin levels in pulmonary tuberculosis patients with 
and without HIV. Japanese J. Infect. Dis. 61, 202–204 (2008). 
480. Svensson, E. M., Dosne, A. & Karlsson, M. O. Population Pharmacokinetics of Bedaquiline and 
Metabolite M2 in Patients With Drug‐Resistant Tuberculosis: The Effect of Time‐Varying 
Weight and Albumin. CPT Pharmacometrics Syst. Pharmacol. 5, 682–691 (2016). 
481. Ammerman, N. C. et al. Impact of Clofazimine Dosing on Treatment-Shortening of the First-
Line Regimen in a Mouse Model of Tuberculosis. Antimicrob. Agents Chemother.62, 00636 
(2018). 
482. Hosea, N. A. et al. Prediction of human pharmacokinetics from preclinical information: 
comparative accuracy of quantitative prediction approaches. J. Clin. Pharmacol. 49, 513–533 
(2009). 
483. Müller, M., Dela Peña, A. & Derendorf, H. Issues in Pharmacokinetics and Pharmacodynamics 
of Anti-Infective Agents: Distribution in Tissue. Antimicrobial Agents and Chemotherapy 48, 
1441–1453 (2004). 
484. Smith, P. J. et al. Effects of dosing regimen on accumulation, retention and prophylactic efficacy 
of liposomal amphotericin B. J. Antimicrob. Chemother. 59, 941–951 (2007). 
485. Watanabe, A. et al. Comparison between concentrations of amphotericin B in infected lung 
lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B 
(AmBisome). Int. J. Infect. Dis. 14, (2010). 
486. Sonopo, M. S. et al. Carbon-14 radiolabeling and in vivo biodistribution of a potential anti-TB 
compound. J. Label. Compd. Radiopharm. 58, 23–29 (2015). 
487. Liu, L. et al. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, 
rifampicin and pyrazinamide in baboons. J. Med. Chem. 53, 2882–2891 (2010). 
488. Paul, S. M. et al. How to improve RD productivity: The pharmaceutical industry’s grand 
challenge. Nature Reviews Drug Discovery 9, 203–214 (2010). 
489. Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in 
211 
 
pharmaceutical R&D efficiency. Nature Reviews Drug Discovery 11, 191–200 (2012). 
490. Bowes, J. et al. Reducing safety-related drug attrition: The use of in vitro pharmacological 
profiling. Nature Reviews Drug Discovery 11, 909–922 (2012). 
491. Caponigro, G. & Sellers, W. R. Advances in the preclinical testing of cancer therapeutic 
hypotheses. Nature Reviews Drug Discovery 10, 179–187 (2011). 
492. Langer, O. & Müller, M. Methods to assess tissue-specific distribution and metabolism of drugs. 
Curr. Drug Metab. 5, 463–481 (2004). 
493. Vasquez, K. O., Casavant, C. & Peterson, J. D. Quantitative Whole Body Biodistribution of 
Fluorescent-Labeled Agents by Non-Invasive Tomographic Imaging. PLoS One 6, e20594 (2011). 
494. Yang, Z. et al. Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric 
nanoparticles. Nanotechnology 20, (2009). 
495. Lin, J. H. Tissue distribution and pharmacodynamics: a complicated relationship. Curr. Drug 
Metab. 7, 39–65 (2006). 
496. Elmquist, W. F. & Sawchuk, R. J. Use of microdialysis in drug delivery studies. Advanced Drug 
Delivery Reviews 45, 123–124 (2000). 
497. Mariappan, T. T., Mandlekar, S. & Marathe, P. Insight into tissue unbound concentration: utility 
in drug discovery and development. Curr Drug Metab 14, 324–340 (2013). 
498. Takai, N., Tanaka, Y. & Saji, H. Quantification of Small Molecule Drugs in Biological Tissue 
Sections by Imaging Mass Spectrometry Using Surrogate Tissue-Based Calibration Standards. 
Mass Spectrom. 3, A0025–A0025 (2014). 
499. Tamvakopoulos, C. S. et al. Determination of brain and plasma drug concentrations by liquid 
chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 14, 1729–1735 
(2000). 
500. Fridén, M. et al. Development of a high-throughput brain slice method for studying drug 
distribution in the central nervous system. Drug Metab. Dispos. 37, 1226–1233 (2009). 
501. Reyzer, M. L., Hsieh, Y., Ng, K., Korfmacher, W. A. & Caprioli, R. M. Direct analysis of drug 
candidates in tissue by matrix‐assisted laser desorption/ionization mass spectrometry. J. Mass 
Spectrom. 38, 1081–1092 (2003). 
502. Swales, J. G. et al. Spatial Quantitation of Drugs in tissues using Liquid Extraction Surface 
Analysis Mass Spectrometry Imaging. Sci. Rep. 6, 1–9 (2016). 
503. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and 
pharmacological principles toward improving Phase II survival. Drug Discovery Today 17, 419–
424 (2012). 
504. Baik, J., Stringer, K. A., Mane, G. & Rosania, G. R. Multiscale Distribution and Bioaccumulation 
Analysis of Clofazimine Reveals a Massive Immune System-Mediated Xenobiotic Sequestration 
Response. Antimicrob. Agents Chemother. 57, 1218–1230 (2013). 
505. Baik, J. & Rosania, G. R. Macrophages Sequester Clofazimine in an Intracellular Liquid Crystal-
Like Supramolecular Organization. PLoS One 7, e47494 (2012). 
506. Wan, H. et al. High-throughput screening of pKa values of pharmaceuticals by pressure-assisted 




507. De Duve, C. et al. Lysosomotropic agents. Biochem. Pharmacol. 23, (1974). 
508. Hartmann, G. et al. Disposition into Adipose Tissue Determines Accumulation and Elimination 
Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice. Drug Metab. 
Dispos. 44, 428–434 (2016). 
509. Li, Q. et al. Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and 
Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites. Malar. Res. Treat. 
2017, 7508291 (2017). 
510. Ishida, Y., Kurosaka, Y., Murakami, Y., Otani, T. & Yamaguchi, K. Therapeutic effect of oral 
levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by 
penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory 
concentrations of the quinolones are similar. Chemotherapy 45, 183–191 (1999). 
511. Vallet, C. M. et al. Cellular accumulation of fluoroquinolones is not predictive of their 
intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a 
pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. Int. J. 
Antimicrob. Agents 38, 249–256 (2018). 
512. Michot, J.-M., Seral, C., Van Bambeke, F., Mingeot-Leclercq, M.-P. & Tulkens, P. M. Influence 
of Efflux Transporters on the Accumulation and Efflux of Four Quinolones (Ciprofloxacin, 
Levofloxacin, Garenoxacin, and Moxifloxacin) in J774 Macrophages. Antimicrob. Agents 
Chemother. 49, 2429–2437 (2005). 
513. Raschi, E., Ceccarini, L., De Ponti, F. & Recanatini, M. hERG-related drug toxicity and models for 
predicting hERG liability and QT prolongation. Expert Opin. Drug Metab. Toxicol. 5, 1005–1021 
(2009). 
514. Kalvass, J. C., Olson, E. R., Cassidy, M. P., Selley, D. E. & Pollack, G. M. Pharmacokinetics and 
pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of 
unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J. Pharmacol. 
Exp. Ther. 323, 346–355 (2007). 
515. Nakai, D., Kumamoto, K., Sakikawa, C., Kosaka, T. & Tokui, T. Evaluation of the protein binding 
ratio of drugs by a micro-scale ultracentrifugation method. J. Pharm. Sci. 93, 847–854 (2004). 
516. Mouton, J. W. et al. Tissue concentrations: Do we ever learn? J. Antimicrob. Chemother. 61, 
235–237 (2008). 
517. Irwin, S. M. et al. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by 
Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. ACS 
Infect. Dis. 2, 251–267 (2016). 
518. Matthes, S. A., Hadley, R., Roman, J. & White, E. S. in Comparative Biology of the Normal Lung 
387–402 (2015). 
519. Kiem, S. & Schentag, J. J. Interpretation of antibiotic concentration ratios measured in epithelial 
lining fluid. Antimicrobial Agents and Chemotherapy 52, 24–36 (2008). 
520. Honeybourne, D. Antibiotic penetration in the respiratory tract and implications for the 
selection of antimicrobial therapy. Curr. Opin. Pulm. Med. 3, 170–174 (1997). 
521. Baldwin, D. R., Honeybourne, D. & Wise, R. Pulmonary disposition of antimicrobial agents: in 
vivo observations and clinical relevance. Antimicrob. Agents Chemother. 36, 1176 (1992). 
522. Fish, D. N. Bronchoscopic sampling of drug concentrations: penetration to tissue is the issue. 
Am. J. Respir. Crit. Care Med. 168, 1263–1265 (2003). 
213 
 
523. Drusano, G. L. Infection Site Concentrations: Their Therapeutic Importance and the Macrolide 
and Macrolide‐Like Class of Antibiotics. Pharmacother. J. Hum. Pharmacol. Drug Ther. 25, 
(2005). 
524. Torrelles, J. B., Scordo, J. M., Sidiki, S., Moliva, J. I. & Arcos, J. The human lung mucosa 
determines Mycobacterium tuberculosis infection outcome in the alveolar epithelium. J. 
Immunol. 198, 57.6 LP-57.6 (2017). 
525. Torrelles, J. B. & Schlesinger, L. S. Integrating Lung Physiology, Immunology, and Tuberculosis. 
Trends Microbiol. 25, 688–697 (2017). 
526. Schorey, J. S. & Schlesinger, L. S. Innate Immune Responses to Tuberculosis. Microbiol. Spectr. 
4, 3–31 (2016). 
527. Arcos, J. et al. Mycobacterium tuberculosis Cell Wall released Fragments by the Action of the 
Human Lung Mucosa modulate Macrophages to Control Infection in a IL-10 Dependent 
Manner. Mucosal Immunol. 10, 1248–1258 (2017). 
528. Arcos, J. et al. Human Lung Hydrolases Delineate Mycobacterium tuberculosis–Macrophage 
Interactions and the Capacity To Control Infection. J. Immunol. 187, 372–381 (2011). 
529. Nicod, L. P. Lung defences: An overview. Eur. Respir. Rev. 14, 45–50 (2005). 
530. Mason, R. J. Biology of alveolar type II cells. Respirology 11 Suppl, S12-5 (2006). 
531. Dhanani, J. et al. Antimicrobial chemotherapy and lung microdialysis: a review. Int. J. 
Antimicrob. Agents 36, 491–500 (2010). 
532. Rodvold, K. A., Gotfried, M. H., Still, J. G., Clark, K. & Fernandes, P. Comparison of plasma, 
epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in 
healthy adult subjects. Antimicrob. Agents Chemother. 56, 5076–81 (2012). 
533. Liu, P., Müller, M. & Derendorf, H. Rational dosing of antibiotics: The use of plasma 
concentrations versus tissue concentrations. in International Journal of Antimicrobial Agents 
19, 285–290 (2002). 
534. Rodvold, K. A., George, J. M. & Yoo, L. Penetration of Anti-Infective Agents into Pulmonary 
Epithelial Lining Fluid. Clin. Pharmacokinet. 50, 637–664 (2011). 
535. Ambrose, P. G. et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not 
just for mice anymore. Clin. Infect. Dis. 44, 79–86 (2007). 
536. Hasegawa, N. et al. Concentrations of clarithromycin and active metabolite in the epithelial 
lining fluid of patients with Mycobacterium avium complex pulmonary disease. Pulm. 
Pharmacol. Ther. 22, 190–193 (2009). 
537. Kiem, S. & Schentag, J. J. Interpretation of epithelial lining fluid concentrations of antibiotics 
against methicillin resistant Staphylococcus aureus. Infect. Chemother. 46, 219–225 (2014). 
538. Mimoz, O. & Dahyot-Fizelier, C. Mini-broncho-alveolar lavage: a simple and promising method 
for assessment of antibiotic concentration in epithelial lining fluid. Intensive Care Med. 33, 
1495–1497. (2007). 
539. Baldwin, D. R., Honeybourne, D. & Wise, R. Pulmonary disposition of antimicrobial agents: 
methodological considerations. Antimicrob. Agents Chemother. 36, 1171–1175 (1992). 
540. Gerding, D. N., Hughes, C. E., Bamberger, D. M., Foxworth, J. & Larson, T. A. Extravascular 
antimicrobial distribution and the respective blood concentrations in humans. Antibiot. Lab. 
214 
 
Med. 4, 835–899 (1991). 
541. Bamberger, D. M., Foxworth, J. W., Bridwell, D. L., Shain, C. S. & Gerding, D. N. Extravascular 
antimicrobial distribution and the respective blood and urine concentrations in humans. 
Antibiot. Lab. Med. 5th ed. Philadelphia Lippincott Williams Wilkins 719–814 (2005). 
542. Rennard, S. I. et al. Estimation of volume of epithelial lining fluid recovered by lavage using 
urea as marker of dilution. J. Appl. Physiol. 60, 532–538 (1986). 
543. Beamer, S., Jaroszewski, D. E., Viggiano, R. W. & Smith, M. L. Chapter 2 - Optimal Processing of 
Diagnostic Lung Specimens. Practical Pulmonary Pathology: A Diagnostic Approach (Elsevier 
Inc., 2018). 
544. Berkhout, J. et al. Pharmacokinetics and Penetration of Ceftazidime and Avibactam into 
Epithelial Lining Fluid in Thigh- and Lung-Infected Mice. Antimicrob. Agents Chemother. 59, 
2299–2304 (2015). 
545. Lucchi, M. et al. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar 
macrophages and lung tissue following a single oral dose of extended or immediate release 
formulations of azithromycin. J. Antimicrob. Chemother. 61, 884–891 (2008). 
546. Rodvold, K. A., Danziger, L. H. & Gotfried, M. H. Steady-state plasma and bronchopulmonary 
concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. 
Agents Chemother. 47, 2450–2457 (2003). 
547. Jung, D., Biggs, H., Erikson, J. & Ledyard, P. U. New colorimetric reaction for end-point, 
continuous-flow, and kinetic measurement of urea. Clin. Chem. 21, 1136–1140 (1975). 
548. Aulin, L. B. S. et al. Validation of a Model Predicting Anti-infective Lung Penetration in the 
Epithelial Lining Fluid of Humans. Pharm. Res. 35, 26 (2018). 
549. Välitalo, P. A. J. et al. Structure-based prediction of anti-infective drug concentrations in the 
human lung epithelial lining fluid. Pharm. Res. 33, 856–867 (2016). 
550. Goutelle, S. et al. Population modeling and Monte Carlo simulation study of the 
pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. 
Agents Chemother. 53, 2974–81 (2009). 
551. Dorman, S. E. et al. Substitution of rifapentine for rifampin during intensive phase treatment 
of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206, 
1030–1040 (2012). 
552. Dorman, S. E. et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, 
dose-ranging trial. Am. J. Respir. Crit. Care Med. 191, 333–343 (2015). 
553. Rifat, D. et al. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis 
and correlation with clinical trial data. Sci. Transl. Med. 10, eaai7786 (2018). 
554. Lalande, L. et al. Population modeling and simulation study of the pharmacokinetics and 
antituberculosis pharmacodynamics of isoniazid in lungs. Antimicrob. Agents Chemother. 59, 
5181–5189 (2015). 
555. Conte, J. E., Golden, J. A., Duncan, S., McKenna, E. & Zurlinden, E. Intrapulmonary 
concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43, 1329–1333 (1999). 
556. Conte, J. E., Golden, J. A., Kipps, J. & Zurlinden, E. Intrapulmonary pharmacokinetics of linezolid. 
Antimicrob. Agents Chemother. 46, 1475–1480 (2002). 
215 
 
557. Soman, A., Honeybourne, D., Andrews, J., Jevons, G. & Wise, R. Concentrations of moxifloxacin 
in serum and pulmonary compartments following a single 400 mg oral dose in patients 
undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44, 835–838 (1999). 
558. Rodvold, K. A., Hope, W. W. & Boyd, S. E. Considerations for effect site pharmacokinetics to 
estimate drug exposure: concentrations of antibiotics in the lung. Curr. Opin. Pharmacol. 36, 
114–123 (2017). 
559. Schuler, P. et al. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, 
epithelial lining fluid, and polymorphonuclear leucocytes. Eur. Respir. J. 10, 1130–1136 (1997). 
560. Gotfried, M. H., Danziger, L. H. & Rodvold, K. A. Steady-state plasma and intrapulmonary 
concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119, 1114–
1122 (2001). 
561. Conte, J. E. et al. Effects of gender, AIDS, and acetylator status on intrapulmonary 
concentrations of isoniazid. Antimicrob. Agents Chemother. 46, 2358–2364 (2002). 
562. Honeybourne, D., Tobin, C., Jevons, G., Andrews, J. & Wise, R. Intrapulmonary penetration of 
linezolid. J. Antimicrob. Chemother. 51, 1431–1434 (2003). 
563. Boselli, E. et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered 
to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33, 1529–1533 
(2005). 
564. Ziglam, H. M., Baldwin, D. R., Daniels, I., Andrews, J. M. & Finch, R. G. Rifampicin concentrations 
in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 
600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 
50, 1011–1015 (2002). 
565. Conte, J. E., Golden, J. A., Kipps, J. E., Lin, E. T. & Zurlinden, E. Effect of sex and AIDS status on 
the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin. Pharmacokinet. 43, 395–
404 (2004). 
566. Conte, J. E. et al. Effects of AIDS and gender on steady-state plasma and intrapulmonary 
ethionamide concentrations. Antimicrob. Agents Chemother. 44, 1337–1341 (2000). 
567. Capitano, B. et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, 
and azithromycin in older adults. Chest 125, 965–973 (2004). 
568. World Health Organization Regional Office for South-East Asia. Bending the curve - ending TB: 
Annual report 2017. 1–76 (2017). 
569. Orme, I. M. & Basaraba, R. J. The formation of the granuloma in tuberculosis infection. in 
Seminars in immunology 26, 601–609 (Elsevier, 2014). 
570. Russell, D. G., Cardona, P.-J., Kim, M.-J., Allain, S. & Altare, F. Foamy macrophages and the 
progression of the human tuberculosis granuloma. Nat. Immunol. 10, 943 (2009). 
571. Warner, D. F. & Mizrahi, V. The survival kit of Mycobacterium tuberculosis. Nat. Med. 13, 282 
(2007). 
572. Repasy, T. et al. Bacillary replication and macrophage necrosis are determinants of neutrophil 
recruitment in tuberculosis. Microbes Infect. 17, 564–574 (2015). 
573. Russell, D. G. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. 
Immunol. Rev. 240, 252–268 (2011). 
216 
 
574. Tan, S. & Russell, D. G. Trans‐species communication in the M ycobacterium tuberculosis‐
infected macrophage. Immunol. Rev. 264, 233–248 (2015). 
575. Ehrt, S., Schnappinger, D. & Rhee, K. Y. Metabolic principles of persistence and pathogenicity 
in Mycobacterium tuberculosis. Nat. Rev. Microbiol. 16, 496–507 (2018). 
576. Mattila, J. T. et al. Microenvironments in Tuberculous Granulomas Are Delineated by Distinct 
Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and Arginase 
Isoforms. J. Immunol. 191, 773–784 (2013). 
577. Marino, S. et al. Macrophage polarization drives granuloma outcome during Mycobacterium 
tuberculosis infection. Infect. Immun. 83, 324–338 (2015). 
578. Dorhoi, A. et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice 
by modulating lung phagocyte dynamics. Eur. J. Immunol. 44, 2380–2393 (2014). 
579. Minton, K. Granuloma macrophage differentiation. Nat. Rev. Immunol. 16, 1 (2016). 
580. Huang, L., Nazarova, E. V, Tan, S., Liu, Y. & Russell, D. G. Growth of Mycobacterium tuberculosis 
in vivo segregates with host macrophage metabolism and ontogeny. J. Exp. Med. 215, 1135–
1152 (2018). 
581. Machado, D., Girardini, M., Viveiros, M. & Pieroni, M. Challenging the ‘drug-likeness’ dogma 
for new drug discovery in tuberculosis. Front. Microbiol. 9, 1367 (2018). 
582. Young, D. B., Perkins, M. D., Duncan, K. & Barry, C. E. Confronting the scientific obstacles to 
global control of tuberculosis. J. Clin. Invest. 118, 1255–1265 (2008). 
583. Aljayyoussi, G. et al. Pharmacokinetic-Pharmacodynamic modelling of intracellular 
Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. 
Sci. Rep. 7, 502 (2017). 
584. Fontán, P., Aris, V., Ghanny, S., Soteropoulos, P. & Smith, I. Global transcriptional profile of 
Mycobacterium tuberculosis during THP-1 human macrophage infection. Infect. Immun. 76, 
717–725 (2008). 
585. Chanput, W., Mes, J. J. & Wichers, H. J. THP-1 cell line: an in vitro cell model for immune 
modulation approach. Int. Immunopharmacol. 23, 37–45 (2014). 
586. Tsuchiya, S. et al. Establishment and characterization of a human acute monocytic leukemia 
cell line  (THP-1). Int. J. cancer 26, 171–176 (1980). 
587. Tsuchiya, S. et al. Induction of maturation in cultured human monocytic leukemia cells by a 
phorbol diester. Cancer Res. 42, 1530–1536 (1982). 
588. Tedesco, S. et al. Convenience versus Biological Significance: Are PMA-Differentiated THP-1 
Cells a Reliable Substitute for Blood-Derived Macrophages When Studying in Vitro 
Polarization? Frontiers in Pharmacology.9, 71 (2018). 
589. Theus, S. A., Cave, M. D. & Eisenach, K. D. Activated THP-1 Cells: an Attractive Model for the 
Assessment of Intracellular Growth Rates of Mycobacterium tuberculosis Isolates . Infect. 
Immun. 72, 1169–1173 (2004). 
590. Bosshart, H. & Heinzelmann, M. THP-1 cells as a model for human monocytes. Ann. Transl. 
Med. 4, 438–438 (2016). 
591. Shiratori, H. et al. THP-1 and human peripheral blood mononuclear cell-derived macrophages 
differ in their capacity to polarize in vitro. Mol. Immunol. 88, 58–68 (2017). 
217 
 
592. Tedesco, S. et al. Phenotypic activation and pharmacological outcomes of spontaneously 
differentiated human monocyte-derived macrophages. Immunobiology 220, 545–554 (2015). 
593. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental 
guidelines. Immunity 41, 14–20 (2014). 
594. Qin, Z. The use of THP-1 cells as a model for mimicking the function and regulation of 
monocytes and macrophages in the vasculature. Atherosclerosis 221, 2–11 (2018). 
595. Riendeau, C. J. & Kornfeld, H. THP-1 cell apoptosis in response to Mycobacterial infection. 
Infect. Immun. 71, 254–259 (2003). 
596. Daigneault, M., Preston, J. A., Marriott, H. M., Whyte, M. K. B. & Dockrell, D. H. The 
identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and 
monocyte-derived macrophages. PLoS One 5, e8668 (2010). 
597. Park, E. K. et al. Optimized THP-1 differentiation is required for the detection of responses to 
weak stimuli. Inflamm. Res. 56, 45–50 (2007). 
598. Traore, K. et al. Signal transduction of phorbol 12-myristate 13-acetate (PMA)-induced growth 
inhibition of human monocytic leukemia THP-1 cells is reactive oxygen dependent. Leuk. Res. 
29, 863–879 (2005). 
599. Aldo, P. B., Craveiro, V., Guller, S. & Mor, G. Effect of culture conditions on the phenotype of 
THP-1 monocyte cell line. Am. J. Reprod. Immunol. 70, 80–86 (2013). 
600. Sumiya, Y. et al. Macrophage activation mechanisms in human monocytic cell line-derived 
macrophages. Anticancer Res. 35, 4447–4451 (2015). 
601. Bhat, J., Narayan, A., Venkatraman, J. & Chatterji, M. LC–MS based assay to measure 
intracellular compound levels in Mycobacterium smegmatis: Linking compound levels to 
cellular potency. J. Microbiol. Methods 94, 152–158 (2013). 
602. Sorrentino, F. et al. Development of an intracellular screen for new compounds able to inhibit 
Mycobacterium tuberculosis growth in human macrophages. Antimicrob. Agents Chemother. 
60, 640–645 (2016). 
603. Bajpai, R., Lesperance, J., Kim, M. & Terskikh, A. V. Efficient propagation of single cells accutase‐
dissociated human embryonic stem cells. Mol. Reprod. Dev. Inc. Gamete Res. 75, 818–827 
(2008). 
604. Fong, D., Duceppe, N. & Hoemann, C. D. Mesenchymal stem cell detachment with trace trypsin 
is superior to EDTA for in vitro chemotaxis and adhesion assays. Biochem. Biophys. Res. 
Commun. 484, 656–661 (2017). 
605. Zhang, B. et al. Different methods of detaching adherent cells significantly affect the detection 
of TRAIL receptors. Tumori J. 2012, 800–803 (2015). 
606. Cartier, M. B., Scorneaux, B., Zenebergh, A., Desnottes, J. F. & Talkers, P. M. Cellular uptake, 
localization and activity of fluoroquinolones in uninfected and infected macrophages. J. 
Antimicrob. Chemother. 26, 27–39 (1990). 
607. Polli, J. E. In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In 
Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms. AAPS 
J. 10, 289–299 (2008). 
608. Andrews, J. M. et al. Concentrations of levofloxacin (HR 355) in the respiratory tract following 
a single oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 
218 
 
40, 573–577 (1997). 
609. Hutschala, D. et al. In Vivo Measurement of Levofloxacin Penetration into Lung Tissue after 
Cardiac Surgery . Antimicrob. Agents Chemother. 49, 5107–5111 (2005). 
610. Conte, J. E., Golden, J. A., McIver, M., Little, E. & Zurlinden, E. Intrapulmonary 
pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic 
obstructive pulmonary disease. Int. J. Antimicrob. Agents 30, 422–427 (2007). 
611. Zhang, J. et al. Permeability and Concentration of Levofloxacin in Epithelial Lining Fluid in 
Patients With Lower Respiratory Tract Infections. J. Clin. Pharmacol. 50, 922–928 (2010). 
612. Kuti, J. L. & Nicolau, D. P. Presence of infection influences the epithelial lining fluid penetration 
of oral levofloxacin in adult patients. Int. J. Antimicrob. Agents 45, 512–518 (2018). 
613. Rey-Jurado, E., Tudó, G., Soy, D. & González-Martín, J. Activity and interactions of levofloxacin, 
linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium 
tuberculosis isolates in a human macrophage model. Int. J. Antimicrob. Agents 42, 524–530 
(2013). 
614. Olsson, B. et al. in Controlled pulmonary drug delivery 21–50 (Springer, 2011). 
615. Lemaire, S., Van Bambeke, F. & Tulkens, P. M. Cellular accumulation and pharmacodynamic 
evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against 
Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 
macrophages. Antimicrob. Agents Chemother. 53, 3734–3743 (2009). 
616. Paillard, D., Grellet, J., Dubois, V., Saux, M.-C. & Quentin, C. Discrepancy between Uptake and 
Intracellular Activity of Moxifloxacin in a Staphylococcus aureus-Human THP-1 Monocytic Cell 
Model. Antimicrob. Agents Chemother. 46, 288–293 (2002). 
617. Lemaire, S., Van Bambeke, F., Appelbaum, P. C. & Tulkens, P. M. Cellular pharmacokinetics and 
intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and 
endothelial (HUVEC) cell lines. J. Antimicrob. Chemother. 64, 1035–1043 (2009). 
618. Pascual, Á., Ballesta, S., García, I. & Perea, E. J. Uptake and Intracellular Activity of Linezolid in 
Human Phagocytes and Nonphagocytic Cells. Antimicrob. Agents Chemother. 46, 4013–4015 
(2002). 
619. Easmon, C. S. & Crane, J. P. Uptake of ciprofloxacin by macrophages. J. Clin. Pathol. 38, 442–
444 (1985). 
620. Garcia, I., Pascual, A., Ballesta, S., Joyanes, P. & Perea, E. J. Intracellular penetration and activity 
of gemifloxacin in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 44, 
3193–3195 (2000). 
621. Walters, J. D., Zhang, F. & Nakkula, R. J. Mechanisms of fluoroquinolone transport by human 
neutrophils. Antimicrob. Agents Chemother. 43, 2710–2715 (1999). 
622. Hotta, K. Regulation of fluoroquinolone uptake by human neutrophils: involvement of 
mitogen-activated protein kinase. J. Antimicrob. Chemother. 49, 953–959 (2002). 
623. Hartkoorn, R. C. et al. Differential drug susceptibility of intracellular and extracellular 
tuberculosis, and the impact of P-glycoprotein. Tuberculosis 87, 248–255 (2007). 
624. Mirnejad, R. et al. Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomed. 
Pharmacother. 105, 1353–1359 (2018). 
219 
 
625. Ammerman, N. C. et al. Clofazimine has delayed antimicrobial activity against Mycobacterium 
tuberculosis both in vitro and in vivo. J. Antimicrob. Chemother. dkw417 (2016). 
626. Angiolini, L., Valetti, S., Cohen, B., Feiler, A. & Douhal, A. Fluorescence imaging of antibiotic 
clofazimine encapsulated within mesoporous silica particle carriers: relevance to drug delivery 
and the effect on its release kinetics. Phys. Chem. Chem. Phys. 20, 11899–11911 (2018). 
627. Sherman, D. B., Pitner, J. B., Ambroise, A. & Thomas, K. J. Synthesis of Thiol-Reactive, Long-
Wavelength Fluorescent Phenoxazine Derivatives for Biosensor Applications. Bioconjug. Chem. 
17, 387–392 (2006). 
628. Smith, J. L. On the simultaneous staining of neutral fat and fatty acid by oxazine dyes. J. Pathol. 
Bacteriol. 12, 1–4 (1908). 
629. Zhu, W.-J., Niu, J.-Y., Sun, R., Xu, Y.-J. & Ge, J.-F. The improvement of lysosome targetability 
with oligoethyleneoxy chains linked benzo [a] phenoxazine. Bioorg. Med. Chem. Lett. 28, 2953–
2956 (2018). 
630. Knorr, G., Kozma, E., Herner, A., Lemke, E. A. & Kele, P. New Red‐Emitting Tetrazine‐
Phenoxazine Fluorogenic Labels for Live‐Cell Intracellular Bioorthogonal Labeling Schemes. 
Chem. Eur. J. 22, 8972–8979 (2016). 
631. Schnappinger, D. et al. Transcriptional Adaptation of Mycobacterium tuberculosis within 
Macrophages: Insights into the Phagosomal Environment. J. Exp. Med. J. Exp. Med 98, 693–704 
(2003). 
632. Zhang, Y., Yew, W. W. & Barer, M. R. Targeting persisters for tuberculosis control. Antimicrob. 
Agents Chemother. 56, 2223–2230 (2012). 
633. Cai, H., Rose, K., Liang, L. H., Dunham, S. & Stover, C. Development of a liquid 
chromatography/mass spectrometry-based drug accumulation assay in Pseudomonas 
aeruginosa. Anal. Biochem. 385, 321–325 (2009). 
634. Bitto, N. J. et al. Membrane vesicles from Pseudomonas aeruginosa activate the non‐canonical 
inflammasome through caspase‐5 in human monocytes. Immunol. Cell Biol. (2018). 
635. Raffetseder, J. et al. Replication Rates of Mycobacterium tuberculosis in Human Macrophages 
Do Not Correlate with Mycobacterial Antibiotic Susceptibility. PLoS One 9, e112426 (2014). 
636. Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M.-P., Tulkens, P. M. & Van Bambeke, F. 
Pharmacodynamic evaluation of the intracellular activities of antibiotics against 
Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50, 
841–851 (2006). 
637. Hand, W. L., Corwin, R. W., Steinberg, T. H. & Grossman, G. D. Uptake of antibiotics by human 
alveolar macrophages. Am. Rev. Respir. Dis. 129, 933–7 (1984). 
638. Lemaire, S., Mingeot-Leclercq, M.-P., Tulkens, P. M. & Van Bambeke, F. Study of macrophage 
functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a 
lipoglycopeptide with high cellular accumulation. Antimicrob. Agents Chemother. 58, 2059–
2066 (2014). 
639. Carolina, R. D., Marisol, O., Mary, S. L. & Alfonso, P. M. Quantifying intracellular Mycobacterium 
tuberculosis: An essential issue for in vitro assays. Microbiologyopen 7, e00588 (2018). 
640. Nazarova, E. V & Russell, D. G. in Phagocytosis and Phagosomes 325–331 (Springer, 2017). 
641. Lee, J., Remold, H. G., Ieong, M. H. & Kornfeld, H. Macrophage apoptosis in response to high 
220 
 
intracellular burden of Mycobacterium tuberculosis is mediated by a novel caspase-
independent pathway. J. Immunol. 176, 4267–4274 (2006). 
642. Molloy, A., Laochumroonvorapong, P. & Kaplan, G. Apoptosis, but not necrosis, of infected 
monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J. Exp. Med. 180, 
1499–1509 (1994). 
643. Kornfeld, H., Mancino, G. & Colizzi, V. The role of macrophage cell death in tuberculosis. Cell 
Death Differ 6, 71–78 (1999). 
644. Lee, J., Hartman, M. & Kornfeld, H. Macrophage apoptosis in tuberculosis. Yonsei Med. J. 50, 
1–11 (2009). 
645. Goutelle, S. et al. Population modeling and Monte Carlo simulation study of the 
pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. 
Agents Chemother. 53, 2974–2981 (2009). 
646. Breilh, D. et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung 
tissue at pharmacokinetic steady-state. J. Chemother. 15, 558–562 (2003). 
647. Stass, H., Kubitza, D. & Schühly, U. Pharmacokinetics, safety and tolerability of moxifloxacin, a 
novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin. Pharmacokinet. 40, 
1–9 (2001). 
648. Müller, M. et al. Penetration of moxifloxacin into peripheral compartments in humans. 
Antimicrob. Agents Chemother. 43, 2345–2349 (1999). 
649. Gillespie, S. H. The role of moxifloxacin in tuberculosis therapy. Eur. Respir. Rev. 25, 19 LP-28 
(2016). 
650. van Heeswijk, R. P. G., Dannemann, B. & Hoetelmans, R. M. W. Bedaquiline: A review of human 
pharmacokinetics and drug-drug interactions. J. Antimicrob. Chemother. 69, 2310–2318 
(2014). 
651. Diacon, A. H. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment 
for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence 
of drug resistance. Antimicrob. Agents Chemother. 56, 3271–3276 (2012). 
652. Hara, T., Takemura, H., Kanemitsu, K., Yamamoto, H. & Shimada, J. Comparative uptake of 
grepafloxacin and ciprofloxacin by a human monocytic cell line, THP-1. J. Infect. Chemother. 6, 
162–167 (2000). 
653. Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M. P. & Tulkens, P. M. Modulation of the 
cellular accumulation and intracellular activity of daptomycin towards phagocytized 
Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 
macrophages and madin-darby canine kidney cells. Antimicrob. Agents Chemother. 51, 2748–
2757 (2007). 
654. Peyrusson, F., Tulkens, P. M. & Van Bambeke, F. Cellular pharmacokinetics and intracellular 
activity of gepotidacin against Staphylococcus aureus with different resistance phenotypes in 
models of cultured phagocytic cells. Antimicrob. Agents Chemother. 62, e02245-17 (2018). 
655. Van de Velde, S. et al. Contrasting effects of human THP-1 cell differentiation on levofloxacin 
and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and 
Listeria monocytogenes. J. Antimicrob. Chemother. 62, 518–521 (2008). 
656. Tulkens, P. M. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 
10, 100–106 (1991). 
221 
 
657. Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M.-P., Tulkens, P. M. & Van Bambeke, F. 
Pharmacodynamic evaluation of the intracellular activities of antibiotics against 
Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50, 
841–851 (2006). 
658. Benmerzoug, S. & Quesniaux, V. F. J. Bioengineered 3D Models for Studying Human Cell-
Tuberculosis Interactions. Trends Microbiol. 25, 245–246 (2017). 
659. Bielecka, M. K. & Elkington, P. Advanced cellular systems to study tuberculosis treatment. Curr. 
Opin. Pharmacol. 42, 16–21 (2018). 
660. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 
10, 1093–1095 (1993). 
661. Anderson, B. J. & Holford, N. H. G. Mechanism-based concepts of size and maturity in 







Appendix A presents the modelling approach used in both Chapter 4 and Chapter 6, displaying the 
representative data sets and equations used to generate human dose predictions in this study. 
Introduction 
PK Tool is a freeware package validated by a team of internationally recognized scientists. The PK Tool 
methodology was previously validated using a retrospective approach by including data from 
proprietary compounds.482 The PK Tool was used in this study to determine predicted human dose 
values from in vitro data, as in Chapter 4, or a combination of in vitro in and vivo data, as in Chapter 6.  
Data input and processing for PK Tool 
Data input for the PK tool for in vitro derived human dose prediction involved the following procedure. 
Initial data processing involved the input of several in vitro derived parameters including with 
parameter abbreviation in brackets: 
(i) plasma protein binding data (fu_plasma), (ii) microsomal protein binding data (fu_mic), (iii) 
microsomal half-life (in vitro t ½ (mic)), (iv) microsomal protein concentration (Mic.Prot. Conc.), (v) 
blood to plasma partitioning ratio (blood/plasma ratio), and (vi) estimated microsomal intrinsic 
clearance (Clint (mic)) 
 




Figure 12.2. Representative human predicted dose for PHX 1 showing mouse in vitro data 
 
 
Figure 12.3. Representative human dose prediction for PHX 1 showing human in vitro data 
 
The next data input step involved the use of in vitro efficacy (MIC90) and in vitro cytotoxicity (IC50) data, 
along with the simulated dosing interval (time between doses, 24 h in this study), route of 




Figure 12.4. In vitro efficacy, cytotoxicity and other simulation parameters included for PHX 1 
 
The PK Tool program then used all of the relevant data points to calculate predicted in vivo clearance, 
blood clearance rate values are calculated for each species using the equations below: 
 




Equation 12.2. Predicted in vivo clearance equation 
         
Where QH is hepatic blood flow obtained from literature660, fup is the unbound compound fraction in 








Equation 12.3. Blood clearance rate              
 
Where blood clearance (CLblood), blood flow (Q), fraction unbound in blood (fu(blood)), and               
fraction unbound in microsomes (fu(mic)) are presented               
 
Following these calculations, the rates of clearance are Log/Log transformed and scaled according to 
the body weight of each animal using the allometric scaling equation below: 
 
Equation 12.4. Single species allometric scaling between species 
 
Where P is the physiological parameter being scaled, a is the allometric coefficient (species specific), 
W is the bodyweight of the animal in kilograms, and b is exponent describing how the metabolic rate 
changes with body weight, thus accounting for the difference in body size between different species. 
The exponent b is set to 0.75 for CL, 1 for Vdss, and the elimination rate constant (Ka) is set to 0 in the 
in vitro prediction.661 The slope drawn using the different log transformed species values (Figure 12.5) 
is calculated from the Log transformed species body weight which was set at 0.025, 0.3, 10, and 70 kg 





Figure 12.5. Representative graph of multiple species allometric calculation for PHX 1 clearance 
 
In vivo human dose prediction 
In the in vivo prediction scenario, concentration-time data from the in vivo murine experiments was 
used to determine the PK parameters of CL, Vdss, absorption rate constant (Ka), and bioavailability 
(BA) as determined in Chapter 6 using NCA analyses.  
Then, Ka and BA are assumed to have the same values in mice and in humans, while in vivo CL and 
Vdss were allometrically scaled with body weight using in vivo murine PK data and the same approach 
as in Figure 12.5.  
The predicted PK curve for both the in vitro and in vivo datasets can then be modelled using a one 
compartment model. The one compartment model assumes that the human body behaves as a single 
compartment for which absorbtion is determined by Ka and elimination from this compartment is 
determined by the elimination rate constant (Ke), where Ke is calculated by dividing the scaled CL by 
the scaled Vdss value. These values are then used in the one compartment model below to calculate 
predicted plasma concentrations in humans (Cp). 
 




[e-Ket - e-Kat] 
Where Cp is the predicted concentration in human plasma given a specific dose of compound (D) in 
























Log body weight (Kg)
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The predicted human dose is then calculated as the dose which maintains a drug concentration above 
the efficacy value for the specified duration (24 h in this study). This is calculated using equation 
Equation 12.6. This equation is used to predict the human dose values in Chapter 4 and Chapter 6. 
 
Equation 12.6 Predicted effective human dose (ED) calculation 
ED= 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 ℎ𝑢𝑚𝑎𝑛 𝐶𝐿 𝑥 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑒𝑑 𝑀𝐼𝐶 𝑣𝑎𝑙𝑢𝑒
𝐵𝐴
      
 
Limitations of the PK Tool include: 
1) Enzyme activity is not maintained across species and may lead to interspecies differences in 
metabolic clearance rates 
2) A one compartmental model is used by the PK Tool for all compounds which may not be the case 
for many situations 
3) The scaling of BA across species provides a weak correlation 
4) Food effects such as gastric emptying rate and GIT blood flow are not considered 
5) Biliary excretion of compounds is not considered in this model which could have an effect 
particularly if enterohepatic recirculation is involved 
         
Human predicted concentration time versus time curves (in vitro data) 
 
 
Figure 12.6. Predicted human concentration versus time curve for PHX 1, with the therapeutic window 





Figure 12.7. Predicted human concentration versus time curve for DPINH, with the therapeutic 
window (cytotoxicity shown in red and in vitro efficacy shown in blue) presented in the log scale 
 
Figure 12.8. Predicted human concentration versus time curve for RMB 041, with the therapeutic 
window (cytotoxicity shown in red and in vitro efficacy shown in blue) presented in the log scale 
 
 
Figure 12.9. Predicted human concentration versus time curve for RMB 043, with the therapeutic 





Figure 12.10. Predicted human concentration versus time curve for RMB 073, with the therapeutic 
window (cytotoxicity shown in red and in vitro efficacy shown in blue) presented in the log scale 
 
Figure 12.11. Predicted human concentration versus time curve for Coco-296, with the therapeutic 
window (cytotoxicity shown in red and in vitro efficacy shown in blue) presented in the log scale 
 
Figure 12.12. Predicted human concentration versus time curve for Coco-298, with the therapeutic 




Appendix B presents calibration curves and representative chromatograms from Chapter 5 and 
Chapter 6 for each compound. Representative highest standard, lowest standard, blank, double blank, 
calibration curve, and murine PK samples are presented for RMB 041, RMB 043, RMB 073, PHX 1, 
DPINH. Representative highest standard, lowest standard, blank, and double blank samples are 
presented for Coco 296 and Coco 298. 
RMB 041 representative chromatograms 
 
Figure 12.13. RMB 041 highest standard (4000ng/mL) extracted from murine whole-blood 
 
Figure 12.14. Lowest standard (0.98 ng/mL) for RMB 041 extracted from murine whole-blood 
 




Figure 12.16. Double blank extracted sample RMB 041 
 
Figure 12.17. Calibration curve RMB 041 
 
Figure 12.18. Representative murine sample IV (Mouse 1 T1) administration RMB 041 (RMB 041- Left 
and IS- Right) 
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RMB 043 representative chromatograms 
 
Figure 12.19. RMB 043 highest standard (4000ng/mL) extracted from murine whole-blood 
 
 
Figure 12.20. RMB 043 lowest standard (0.98 ng/mL) extracted from murine whole-blood 
 





Figure 12.22. Double blank RMB 043 sample extracted from murine whole-blood 
 
Figure 12.23. Calibration curve RMB 043 
 
 
Figure 12.24. Representative murine sample IV (Mouse 1 T1) administration RMB 043 (RMB 043- Left 




RMB 073 representative chromatograms 
 
Figure 12.25. RMB 073 highest standard (4000ng/mL) extracted from murine whole-blood 
 
Figure 12.26. Lowest standard (0.98 ng/mL) for RMB 073 extracted from murine whole-blood 
 




Figure 12.28. Double blank extracted sample RMB 073 
 





Figure 12.30. Representative murine sample IV (Mouse 1 T1) administration RMB 073 (RMB 073- Left 




PHX 1 representative chromatograms 
 
Figure 12.31. PHX 1 highest standard (4000ng/mL) extracted from murine whole-blood 
 
Figure 12.32. Lowest standard (0.25 ng/mL) for PHX 1 extracted from murine whole-blood 
 
Figure 12.33. Blank extracted sample PHX 1 
 




Figure 12.35. Calibration curve PHX 1 
 
Figure 12.36. Representative murine sample IV (Mouse 1 T1) administration PHX 1 (RMB PHX 1- Left 
and IS- Right) 
 
DPINH representative chromatograms 
 
 








Figure 12.39. Blank extracted sample DPINH 
 
Figure 12.40. Double blank extracted sample DPINH 
 
 
Figure 12.41. Calibration curve DPINH 
 





 Coco 298 representative chromatograms 
 
Figure 12.43. Coco 298 highest standard (4000ng/mL) extracted from murine whole-blood 
 
Figure 12.44. Lowest standard (0.98 ng/mL) for Coco 298 extracted from murine whole-blood 
 
 
Figure 12.45. Blank extracted sample Coco 298 
 
 
Figure 12.46. Double blank extracted sample Coco 298 
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 Coco 296 representative chromatograms 
 
 
Figure 12.47. Coco 296 highest standard (4000ng/mL) extracted from murine whole-blood 
 
 














Appendix C presents representative calibration curves and chromatograms associated with work 
presented in Chapter 7 for PHX 1 and RMB 041. Representative calibration curves, lowest standard, 
murine organ, and blank samples for each organ are presented. 
 














Figure 12.53. Representative murine brain sample 
 




Figure 12.55. Standard curve for PHX 1 in murine heart 
 
 




Figure 12.57. Representative murine heart sample 
 
 








Figure 12.60. Lowest standard (3.9 ng/mL) 
 
 
Figure 12.61. Representative murine lung sample 
 






Figure 12.63. Standard curve for PHX 1 in murine spleen 
 
Figure 12.64. Lowest standard (3.9 ng/mL) 
 

















Figure 12.69. Representative murine kidney sample 
 
Figure 12.70. Blank extracted sample 
Liver 
 
Figure 12.71. Standard curve for PHX 1 in murine liver 
 





Figure 12.73. Representative murine liver sample 
 










Figure 12.76. Lowest standard (3.9 ng/mL) 
 
Figure 12.77. Representative murine brain sample 
 
 









Figure 12.80. Lowest standard (3.9 ng/mL)  
 
 
Figure 12.81. Blank sample 
 
 







Figure 12.83. Standard curve for RMB 041 in murine kidney 
 
 
Figure 12.84. Lowest standard (3.9 ng/mL) 
 
Figure 12.85. Blank sample 
 







Figure 12.87. Standard curve for PHX 1 in murine lung 
 
Figure 12.88. Lowest standard (3.9 ng/mL) 
 
 










Figure 12.91. Standard curve for RMB 041 in murine liver 
 





Figure 12.93. Blank sample 
 
Figure 12.94. Representative murine liver sample 
Spleen 
 
Figure 12.95. Standard curve for RMB 041 in murine spleen 
 





Figure 12.97. Blank sample 
 
 





Appendix D presents representative calibration curves and chromatograms associated with work 
presented in Chapter 8 for PHX 1. Representative calibration curves, lowest standards, murine 
representative PK samples, and blank samples for alveolar, plasma, ELF matrices are presented. 
 
Alveolar cell samples 
 
Figure 12.99. Standard curve for PHX 1 in murine alveolar cells 
 
Figure 12.100. Lowest standard (3.9 ng/mL) 
 









Figure 12.103. Standard curve for PHX 1 in murine plasma 
 
Figure 12.104. Lowest standard for murine plasma (3.9 ng/mL) 
 




Figure 12.106. Blank murine plasma sample 
ELF samples 
 
Figure 12.107. Standard curve for PHX 1 in murine ELF 
 
Figure 12.108. Lowest standard (3.9 ng/mL) 
 
 








Appendix E presents representative calibration curves and chromatograms associated with work 
presented in Chapter 9 for PHX 1, RMB 041, MXF, BDQ, RIF, and PHX 1/ Coco 296 combination. 
Representative high standard, low standard, blank, double blank, extracellular, intracellular, and 
calibration curves for each compound are presented. 
 
PHX 1-infected macrophage samples 
 
Figure 12.111. Highest standard 2000 ng/mL 
 





Figure 12.113. Blank sample 
 
Figure 12.114. Double blank sample 
 
Figure 12.115. Extracellular representative sample 
 








RMB 041-infected macrophage samples 
 
Figure 12.118. Highest standard 10 000 ng/mL 
 




Figure 12.120. Blank sample 
 
 
Figure 12.121. Double blank sample 
 




Figure 12.123. Extracellular representative sample 
 
 
Figure 12.124. Intracellular representative sample 
MXF-infected macrophage samples 
 
 





Figure 12.126. Lowest standard 7.8 ng/mL 
 
Figure 12.127. Blank sample 
 
 
Figure 12.128. Double blank sample 
 




Figure 12.130. Intracellular representative sample 
 




BDQ-infected macrophage samples 
 
 
Figure 12.132. Highest standard 2000 ng/mL 
 
Figure 12.133. Lowest standard 62.5 ng/mL 
 
Figure 12.134. Blank sample 
 
 




Figure 12.136. Extracellular representative sample 
 
Figure 12.137. Intracellular representative sample 
 




RIF-infected macrophage samples 
 
 
Figure 12.139. Highest standard 8000 ng/mL 
 
 
Figure 12.140. Lowest standard 3.2 ng/mL 
 
 





Figure 12.142. Double blank sample 
 
Figure 12.143. Intracellular sample RIF 
 
Figure 12.144. Extracellular RIF sample 
 
 




Coco 296/PHX 1-infected macrophage samples 
 
Coco 296-infected macrophage samples 
 
 
Figure 12.146. Highest standard 16000 ng/mL 
 
Figure 12.147. Lowest standard 156 ng/mL 
 





Figure 12.149. Double blank sample 
 
Figure 12.150. Intracellular representative sample 
 
Figure 12.151. Extracellular representative sample 
 




PHX 1-infected macrophage samples 
 
 
Figure 12.153. Highest standard 2000 ng/mL 
 
Figure 12.154. Lowest standard 31.2 ng/mL 
 
Figure 12.155. Blank sample 
 




Figure 12.157. Representative extracellular sample 
 
Figure 12.158. Intracellular representative sample 
 
Figure 12.159. Calibration curve PHX 1 
 
